<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Prophylactic use of inotropic agents for the prevention of low cardiac output syndrome and mortality in adults undergoing cardiac surgery - Gayatri, D - 2024 | Cochrane Library</title> <meta content="Prophylactic use of inotropic agents for the prevention of low cardiac output syndrome and mortality in adults undergoing cardiac surgery - Gayatri, D - 2024 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013781.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Prophylactic use of inotropic agents for the prevention of low cardiac output syndrome and mortality in adults undergoing cardiac surgery - Gayatri, D - 2024 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013781.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013781.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Prophylactic use of inotropic agents for the prevention of low cardiac output syndrome and mortality in adults undergoing cardiac surgery" name="citation_title"/> <meta content="Dwi Gayatri" name="citation_author"/> <meta content="Jörn Tongers" name="citation_author"/> <meta content="University Hospital Halle" name="citation_author_institution"/> <meta content="Ljupcho Efremov" name="citation_author"/> <meta content="Medical School of the Martin-Luther-University Halle-Wittenberg" name="citation_author_institution"/> <meta content="Rafael Mikolajczyk" name="citation_author"/> <meta content="Medical School of the Martin-Luther-University Halle-Wittenberg" name="citation_author_institution"/> <meta content="Daniel Sedding" name="citation_author"/> <meta content="University Hospital Halle" name="citation_author_institution"/> <meta content="Julia Schumann" name="citation_author"/> <meta content="University Medicine Halle" name="citation_author_institution"/> <meta content="julia.schumann@uk-halle.de" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD013781.pub2" name="citation_doi"/> <meta content="2024" name="citation_date"/> <meta content="2024/11/27" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013781.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013781.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013781.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Bias; *Cardiac Output, Low [mortality, prevention &amp; control]; *Cardiac Surgical Procedures [adverse effects, mortality]; *Cardiotonic Agents [therapeutic use]; Dobutamine [therapeutic use]; Hydrazones [therapeutic use]; Milrinone [therapeutic use]; Postoperative Complications [mortality, prevention &amp; control]; *Randomized Controlled Trials as Topic; *Simendan [therapeutic use]" name="citation_keywords"/> <meta content="" name="citation_fulltext_world_readable"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013781.pub2&amp;doi=10.1002/14651858.CD013781.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013781.pub2&amp;doi=10.1002/14651858.CD013781.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013781.pub2&amp;doi=10.1002/14651858.CD013781.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013781.pub2&amp;doi=10.1002/14651858.CD013781.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013781.pub2&amp;doi=10.1002/14651858.CD013781.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013781.pub2&amp;doi=10.1002/14651858.CD013781.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013781.pub2&amp;doi=10.1002/14651858.CD013781.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013781.pub2&amp;doi=10.1002/14651858.CD013781.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013781.pub2&amp;doi=10.1002/14651858.CD013781.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013781.pub2&amp;doi=10.1002/14651858.CD013781.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013781.pub2&amp;doi=10.1002/14651858.CD013781.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013781.pub2&amp;doi=10.1002/14651858.CD013781.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013781.pub2&amp;doi=10.1002/14651858.CD013781.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013781.pub2&amp;doi=10.1002/14651858.CD013781.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013781.pub2&amp;doi=10.1002/14651858.CD013781.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013781.pub2&amp;doi=10.1002/14651858.CD013781.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013781.pub2&amp;doi=10.1002/14651858.CD013781.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013781.pub2&amp;doi=10.1002/14651858.CD013781.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013781.pub2&amp;doi=10.1002/14651858.CD013781.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013781.pub2&amp;doi=10.1002/14651858.CD013781.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013781.pub2&amp;doi=10.1002/14651858.CD013781.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013781.pub2&amp;doi=10.1002/14651858.CD013781.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013781.pub2&amp;doi=10.1002/14651858.CD013781.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="xNbeAU8n";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013781\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013781\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013781\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013781\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANT","ru","fa","fr"],languageCode:"en",accessStatus:"open-access",doi:"10.1002/14651858.CD013781.pub2",title:"Prophylactic use of inotropic agents for the prevention of low cardiac output syndrome and mortality in adults undergoing cardiac surgery",firstPublishedDate:"Nov 27, 2024 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Central Editorial Service",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=xNbeAU8n&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013781.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013781.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013781.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013781.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013781.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013781.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013781.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013781.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013781.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013781.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1069 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013781.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013781.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013781.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013781.pub2/full#CD013781-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013781.pub2/full#CD013781-sec-0173"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013781.pub2/full#CD013781-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013781.pub2/full#CD013781-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013781.pub2/full#CD013781-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013781.pub2/full#CD013781-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013781.pub2/full#CD013781-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013781.pub2/full#CD013781-sec-0167"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013781.pub2/appendices#CD013781-sec-0179"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/supinfo/CD013781-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/supinfo/CD013781-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013781.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013781.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013781.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013781.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013781.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013781.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2024 The Authors. Cochrane Database of Systematic Reviews published by John Wiley &amp; Sons, Ltd. on behalf of The Cochrane Collaboration." data-creative-commons="true" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Prophylactic use of inotropic agents for the prevention of low cardiac output syndrome and mortality in adults undergoing cardiac surgery </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013781.pub2/information#CD013781-cr-0004">Dwi Gayatri</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013781.pub2/information#CD013781-cr-0005">Jörn Tongers</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013781.pub2/information#CD013781-cr-0006">Ljupcho Efremov</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013781.pub2/information#CD013781-cr-0007">Rafael Mikolajczyk</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013781.pub2/information#CD013781-cr-0008">Daniel Sedding</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013781.pub2/information#CD013781-cr-0009"><i class="icon corresponding-author fa fa-envelope"></i>Julia Schumann</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/information/en#CD013781-sec-0183">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 27 November 2024 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013781.pub2">https://doi.org/10.1002/14651858.CD013781.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013781-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013781-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013781-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013781-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013781-abs-0008">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013781-abs-0001" lang="en"> <section id="CD013781-sec-0001"> <h3 class="title" id="CD013781-sec-0001">Background</h3> <p>As the burden of cardiovascular disease grows, so does the number of cardiac surgeries. Surgery is increasingly performed on older people with comorbidities who are at higher risk of developing perioperative complications such as low cardiac output state (LCOS). Surgery‐associated LCOS represents a serious pathology responsible for substantial morbidity and mortality. Prevention of LCOS is a critical and worthwhile aim to further improve the outcome and effectiveness of cardiac surgery. However, guidelines consistently report a lack of evidence for pharmacological LCOS prophylaxis. </p> </section> <section id="CD013781-sec-0002"> <h3 class="title" id="CD013781-sec-0002">Objectives</h3> <p>To assess the benefits and harms of the prophylactic use of any inotropic agent to prevent low cardiac output and associated morbidity and mortality in adults undergoing cardiac surgery. </p> </section> <section id="CD013781-sec-0003"> <h3 class="title" id="CD013781-sec-0003">Search methods</h3> <p>We identified trials (without language restrictions) via systematic searches of CENTRAL<i>,</i> MEDLINE, Embase, and CPCI‐S Web of Science in October 2022. We checked reference lists from primary studies and review articles for additional references. We also searched two registers of ongoing trials. </p> </section> <section id="CD013781-sec-0004"> <h3 class="title" id="CD013781-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) enrolling adults who underwent cardiac surgery and were prophylactically treated with one or multiple inotropic agent(s) in comparison to any type of control (i.e. standard cardiac care, placebo, other inotropic agents). </p> </section> <section id="CD013781-sec-0005"> <h3 class="title" id="CD013781-sec-0005">Data collection and analysis</h3> <p>We used established methodological procedures according to Cochrane standards. Two review authors independently extracted data and assessed risk of bias according to a pre‐defined protocol. On request, we obtained a reply and additional information from only one of the included study authors. We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the certainty of evidence from the studies that contributed data to the meta‐analyses for the pre‐specified outcomes. Based on the identified studies, there were seven comparison groups: amrinone versus placebo, dopamine versus placebo, milrinone versus placebo, levosimendan versus dobutamine, levosimendan versus milrinone, levosimendan versus standard cardiac care, and levosimendan versus placebo. </p> </section> <section id="CD013781-sec-0006"> <h3 class="title" id="CD013781-sec-0006">Main results</h3> <p>We identified 29 eligible studies, including 3307 individuals, and four ongoing studies. In general, confidence in the results of the analysed studies was reduced due to relevant study limitations, imprecision, or inconsistency. Domains of concern encompassed inadequate methods of sequence generation and lack of blinding. The majority of trials were small, with only a few included participants, and investigated the prophylactic use of levosimendan. </p> <p>Our meta‐analyses showed that levosimendan as compared to placebo may reduce the risk of LCOS (risk ratio (RR) 0.43, 95% confidence interval (CI) 0.25 to 0.74; I<sup>2</sup> = 66%; 1724 participants, 6 studies; GRADE: low) and probably reduces all‐cause mortality (RR 0.65, 95% CI 0.43 to 0.97; I<sup>2</sup> = 11%; 2347 participants, 14 studies; GRADE: moderate). This translates into a number needed to treat for an additional beneficial outcome (NNTB) of 8 to prevent one event of LCOS post surgery and of 44 to prevent one death at 30 days. Subgroup analyses revealed that the beneficial effects of levosimendan were predominantly observed in preoperative drug administration. Our meta‐analyses further indicated that levosimendan as compared to placebo may shorten the length of intensive care unit (ICU) stay (mean difference ‐1.00 days, 95% CI ‐1.63 to ‐0.37; 572 participants, 7 studies; GRADE: very low) and the duration of mechanical ventilation (mean difference ‐8.03 hours, 95% CI ‐13.17 to ‐2.90; 572 participants, 7 studies; GRADE: very low) but the evidence is very uncertain. The risk of adverse events did not clearly differ between levosimendan and placebo groups (cardiogenic shock: RR 0.65, 95% CI 0.40 to 1.05; I<sup>2</sup> = 0%; 1212 participants, 3 studies; GRADE: high; atrial fibrillation: RR 1.02, 95% CI 0.82 to 1.27; I<sup>2</sup> = 60%; 1934 participants, 11 studies; GRADE: very low; perioperative myocardial infarction: RR 0.89, 95% CI 0.61 to 1.31; I<sup>2</sup> = 13%; 1838 participants, 8 studies; GRADE: moderate; non‐embolic stroke or transient ischaemic attack: RR 0.89, 95% CI 0.58 to 1.38; I<sup>2</sup> = 0%; 1786 participants, 8 studies; GRADE: moderate). However, levosimendan as compared to placebo might reduce the number of participants requiring mechanical circulatory support (RR 0.47, 95% CI 0.24 to 0.91; I<sup>2</sup> = 74%; 1881 participants, 10 studies; GRADE: low). </p> <p>There was no conclusive evidence on the effect of levosimendan compared to standard cardiac care on LCOS (RR 0.49, 95% CI 0.14 to 1.73; I<sup>2</sup> = 59%; 208 participants, 3 studies; GRADE: very low), all‐cause mortality (RR 0.37, 95% CI 0.13 to 1.04; I<sup>2</sup> = 0%; 208 participants, 3 studies; GRADE: low), adverse events (cardiogenic shock: RR 0.62, 95% CI 0.22 to 1.81; 128 participants, 1 study; GRADE: very low; atrial fibrillation: RR 0.40, 95% CI 0.11 to 1.41; I<sup>2</sup> = 60%; 188 participants, 2 studies; GRADE: very low; perioperative myocardial infarction: RR 0.62, 95% CI 0.22 to 1.81; 128 participants, 1 study; GRADE: very low; non‐embolic stroke or transient ischaemic attack: RR 0.56, 95% CI 0.27 to 1.18; 128 participants, 1 study; GRADE: very low), length of ICU stay (mean difference 0.33 days, 95% CI ‐1.16 to 1.83; 80 participants, 2 studies; GRADE: very low), the duration of mechanical ventilation (mean difference ‐3.40 hours, 95% CI ‐11.50 to 4.70; 128 participants, 1 study; GRADE: very low), and the number of participants requiring mechanical circulatory support (RR 0.88, 95% CI 0.50 to 1.55; I<sup>2</sup> = 0%; 208 participants, 3 studies; GRADE: low). </p> </section> <section id="CD013781-sec-0007"> <h3 class="title" id="CD013781-sec-0007">Authors' conclusions</h3> <p>Prophylactic treatment with levosimendan may reduce the incidence of LCOS and probably reduces associated mortality in adult patients undergoing cardiac surgery when compared to placebo only. Conclusions on the benefits and harms of other inotropic agents cannot be drawn due to limited study data. Given the limited evidence available, there is an unmet need for large‐scale, well‐designed randomised trials. Future studies of levosimendan ought to be designed to derive potential benefit in specific patient groups and surgery types, and the optimal administration protocol. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013781-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013781-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD013781-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD013781-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013781-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013781-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/ru#CD013781-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013781-abs-0004">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013781-abs-0002" lang="en"> <h3>Do heart surgery patients benefit from preventive treatment with inotropic drugs?</h3> <p><b>Key messages</b> </p> <p>• Treatment of heart surgery patients with the drug ‘levosimendan’ before surgery may be beneficial. </p> <p>• However, the current evidence is limited, and more studies are needed before definitive recommendations can be made. </p> <p><b>Rationale</b> </p> <p>Reduced heart function is a potentially fatal complication after heart surgery. A possible approach to prevent this complication is treatment with drugs that stimulate the contraction of the heart (so‐called inotropic agents). </p> <p><b>What did we want to find out?</b> </p> <p>We assessed whether the use of inotropic agents before or during the surgical procedure prevented reduced heart function and death in adults after heart surgery. </p> <p><b>What did we do?</b> </p> <p>We searched different medical literature databases and trial registers that collect information about planned, ongoing, and completed clinical studies. We considered studies in which one group had received an inotropic agent and a second group had received another inotropic drug or a sham medication or standard care. Two review authors independently screened and collected the data. </p> <p><b>What did we find?</b> </p> <p><b><i>Study characteristics</i> </b> </p> <p>We identified 29 studies that had a total of 3307 adult patients of both sexes who had heart surgery. The studies were conducted in different hospitals in Europe, Israel, Japan, Korea, Turkey, Canada, and the USA. Nine studies were funded by the manufacturer of the investigated drug. In 10 studies, the relationship to the pharmaceutical industry was not determined. When we asked all of the study authors for additional information about their studies, only one author responded. </p> <p>The majority of the studies (24 in total) dealt with the inotropic drug levosimendan. So, the available data did not allow us to judge agents other than levosimendan. The participants were given the drug before, during, or immediately after heart surgery. They were monitored for up to 30 days. </p> <p><b><i>Main results</i> </b> </p> <p>Patients treated with levosimendan prior to heart surgery possibly have a lower risk of reduced heart function and death and may spend less time in intensive care compared to patients receiving a sham medication. However, the available data revealed no clear difference between levosimendan and standard care or treatment with another inotropic drug in preventing reduced heart function and death and reducing time spent in intensive care after heart surgery. The available data also showed no clear differences in the prevention of adverse events between levosimendan and comparator treatment. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>We have little confidence in the evidence, mainly because of the small number of included participants (the results are very imprecise). Thus, most results of the review must be viewed with caution. </p> <p><b>How up‐to‐date is this evidence?</b> </p> <p>This evidence is up‐to‐date to October 2022.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013781-sec-0173" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013781-sec-0173"></div> <h3 class="title" id="CD013781-sec-0174">Implications for practice</h3> <section id="CD013781-sec-0174"> <p>At present, the data regarding whether a (specific) pre‐operative inotropic drug therapy could affect mortality in haemodynamically unstable patients before cardiac surgery is not robust. </p> <p>Most importantly, our meta‐analyses show that levosimendan probably reduces the risk of all‐cause mortality and may reduce low cardiac output state (LCOS) compared to placebo. However, when compared to either standard cardiac care, dobutamine, or milrinone, there was no benefit in regard to all‐cause mortality or LCOS. These data indicate that any of these strategies, including the use of levosimendan, might be similar in performance in pre‐operative treatment. </p> <p>Compared to placebo or even to the other inotropic drugs evaluated, our analyses indicate that levosimendan may shorten the length of intensive care unit (ICU) stay and the duration of mechanical ventilation. </p> <p>Our analysis did not compare combinations of the above‐mentioned treatment modalities and thus does not provide any data on the effects of such combined treatments. </p> </section> <h3 class="title" id="CD013781-sec-0175">Implications for research</h3> <section id="CD013781-sec-0175"> <p>Considering the limited evidence derived from the present body of evidence, due to a generally high risk of bias and imprecision because of few events and small numbers of participants and trials, it should be emphasised that there remains a great need for large‐scale, well‐designed randomised controlled trials to precisely decipher different drug, dosing, and timing regimens in order to show significant changes in hard endpoints like mortality or safety. </p> <p>Further prospective studies will be necessary to determine if levosimendan indeed proves to be superior in reducing ventilation time and ICU stay as compared to dopamine, milrinone, or placebo. In addition, the timing and duration of a pre‐operative inotropic drug therapy has to be evaluated in more detail and might hold the potential for further improvement using optimised protocols. Importantly, further analyses will also have to more clearly define which patient subgroups will benefit the most from a pre‐operative inotropic drug therapy and which parameters will be suitable to identify the respective patients. </p> <p>As reported above, there were essential differences in baseline parameters and coexisting therapeutic interventions among the trials. Therefore, better comparability of baseline conditions, especially with regard to haemodynamic parameters and the management of inotropics (i.e. standardised protocols for titration and dosing), is necessary in future controlled, prospective studies. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013781-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013781-sec-0008"></div> <div class="table" id="CD013781-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Levosimendan compared to standard cardiac care</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patients/population:</b> adults (&gt; 18 years) undergoing cardiac surgery </p> <p><b>Intervention:</b> levosimendan (started for preventive reasons) </p> <p><b>Comparison:</b> standard cardiac care </p> <p><b>Setting of interest:</b> hospital‐based randomised controlled trials conducted in Turkey or India </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with standard cardiac care</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with levosimendan</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> (number of deaths within 30 days) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>115 per 1000<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>42 per 1000</b> </p> <p>(15 to 120)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.37</b><br/>(0.13 to 1.04) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>208 (3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>low<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of LCOS</b> (number of events within 48 hours post surgery) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>192 per 1000<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>94 per 1000</b> </p> <p>(27 to 332)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.49</b><br/>(0.14 to 1.73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>208 (3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>very low<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events: cardiogenic shock</b> (number of events within hospital stay) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>125 per 1000<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>79 per 1000</b> </p> <p>(27 to 226)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.62</b><br/>(0.22 to 1.81) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>128 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>very low<sup>e</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Length of ICU stay</b> (in days within ICU care) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean length of ICU stay across control groups was from 1.40 to 3.67 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean length of ICU stay in the intervention group was 0.33 higher (1.16 lower to 1.83 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>very low<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of mechanical ventilation</b> (in hours within ICU care) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean duration of mechanical ventilation in the control group was 83.2 hours</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean duration of mechanical ventilation in the intervention group was 3.40 hours lower (11.50 lower to 4.70 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>128 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>very low<sup>e</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants requiring mechanical circulatory support</b> (number of events within hospital stay) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>192 per 1000<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>169 per 1000</b> </p> <p>(96 to 298)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.88</b><br/>(0.50 to 1.55) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>208 (3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>low<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI</b> : confidence interval; <b>LCOS:</b> low cardiac output syndrome; <b>ICU:</b> intensive care unit; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE working group grades of evidence</p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Control group risk estimate comes from the control group risk in included studies.<br/><sup>b</sup>Control group risk estimate comes from the control group risk in a small included study.<br/><sup>c</sup>Downgraded 1 level for risk of bias due to inadequate methods of sequence generation and lack of blinding, and 1 level for imprecision due to the optimal information size criterion not being met.<br/><sup>d</sup>Downgraded 1 level for risk of bias due to inadequate methods of sequence generation and lack of blinding, 1 level for imprecision due to the optimal information size criterion not being met, and 1 level for inconsistency due to heterogeneity according to the I<sup>2</sup> statistic.<br/><sup>e</sup>Downgraded 1 level for risk of bias due to inadequate methods of sequence generation and lack of blinding, and 2 levels for imprecision due to the optimal information size criterion not being met (data based on a single small study). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013781-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Levosimendan compared to placebo</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="bottom"> <p><b>Patients/population:</b> adults (&gt; 18 years) undergoing cardiac surgery </p> <p><b>Intervention:</b> levosimendan (started for preventive reasons) </p> <p><b>Comparison:</b> placebo </p> <p><b>Setting of interest:</b> hospital‐based randomised controlled trials conducted in Europe, China, or India </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with levosimendan</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> (number of deaths within 30 days) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66 per 1000<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>43 per 1000</b> </p> <p>(28 to 64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.65</b><br/>(0.43 to 0.97) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2347 (14 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>moderate<sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of LCOS</b> (number of events within 48 hours post surgery) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>238 per 1000<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>102 per 1000</b> </p> <p>(60 to 176)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.43</b><br/>(0.25 to 0.74) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1724 (6 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>low<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events: cardiogenic shock</b> (number of events within hospital stay) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>63 per 1000<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>41 per 1000</b> </p> <p>(25 to 66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.65</b><br/>(0.40 to 1.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1212 (3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>high</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Length of ICU stay</b> (in days within ICU care) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean length of ICU stay across control groups was from 1.07 to 8.15 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean length of ICU stay in the intervention group was 1.00 lower (1.63 lower to 0.37 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>572 (7 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>very low<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of mechanical ventilation</b> (in hours within ICU care) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean duration of mechanical ventilation across control groups was between 5.67 and 157.44 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean duration of mechanical ventilation in the intervention group was 8.03 lower (13.17 lower to 2.90 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>572 (7 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>very low<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants requiring mechanical circulatory support</b> (number of events within hospital stay) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>145 per 1000<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>68 per 1000</b> (35 to 132) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.47</b><br/>(0.24 to 0.91) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1881 (10 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>low<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI</b> : confidence interval; <b>LCOS:</b> low cardiac output syndrome; <b>ICU:</b> intensive care unit; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE working group grades of evidence</p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Control group risk estimate comes from the control group risk in included studies.<br/><sup>b</sup>Downgraded 1 level for risk of bias due to inadequate methods of sequence generation and lack of blinding.<br/><sup>c</sup>Downgraded 1 level for risk of bias due to inadequate methods of sequence generation and 1 level for inconsistency due to heterogeneity according to the I<sup>2</sup> statistic.<br/><sup>d</sup>Downgraded 1 level for risk of bias due to inadequate methods of sequence generation and lack of blinding, and 2 levels for inconsistency due to heterogeneity according to the I<sup>2</sup> statistic. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013781-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013781-sec-0009"></div> <section id="CD013781-sec-0010"> <h3 class="title" id="CD013781-sec-0010">Description of the condition</h3> <p>The worldwide increasing number of individuals with cardiovascular disease results in a steadily rising number of patients undergoing heart surgery. Globally, more than 1.5 million individuals undergo heart surgery in about 4000 centres annually; the vast majority of surgeries are performed in high‐income countries (<a href="./references#CD013781-bbs2-0092" title="VervoortD , SwainJD , PezzellaAT , KpodonuJ . Cardiac surgery in low- and middle-income countries: a state-of-the-art review. Annals of Thoracic Surgery2020;6(20):31293-5.">Vervoort 2020</a>). </p> <p>The state of low cardiac output (LCOS) represents a potential complication of heart surgery, and is associated with a marked increase in morbidity and mortality. It is characterised mainly by a spontaneous drop of systolic cardiac function and a reduction of circulatory capacity, resulting in cardio‐circulatory insufficiency; perfusion of the microcirculation and oxygen supply of end organ tissue cannot be maintained. However, there is no standardised definition of LCOS. For the purpose of this review, we will consider the most widely used definition of cardio‐circulatory insufficiency (cardiac index (CI) &lt; 2.2 L/min/m²; mean arterial pressure (MAP) &lt; 60 mmHg; mixed venous oxygen saturation (SvO2) &lt; 60 %) despite optimal therapy including euvolaemia within two hours after completion of the index procedure (<a href="./references#CD013781-bbs2-0078" title='Pérez VelaJL , Martín BenitezJC , Carrasco GonzalezM , La Cal LópezMA , Hinojosa PérezR , Sagredo MenesesV , et al. Resumen del documento de consenso: "Guías de práctica clínica para el manejo del síndrome de bajo gasto cardiaco en el postoperatorio de cirugía cardiaca". Medicina Intensiva2012;36(4):277-87.'>Pérez 2012</a>). This haemodynamic state must be associated with clinical signs and symptoms of malperfusion, or end‐organ hypoperfusion (e.g. cumulating lactate levels &gt; 2.0 mmol/L; cool extremities, oliguria or anuria, with a diuresis &lt; 0.5 mL/kg/h; <a href="./references#CD013781-bbs2-0078" title='Pérez VelaJL , Martín BenitezJC , Carrasco GonzalezM , La Cal LópezMA , Hinojosa PérezR , Sagredo MenesesV , et al. Resumen del documento de consenso: "Guías de práctica clínica para el manejo del síndrome de bajo gasto cardiaco en el postoperatorio de cirugía cardiaca". Medicina Intensiva2012;36(4):277-87.'>Pérez 2012</a>). The state of LCOS can further destabilise into cardiogenic shock (CS), when systolic blood pressure (SBP) falls below 90 mmHg, or catecholamines are required for a duration of at least 15 minutes, or both (<a href="./references#CD013781-bbs2-0078" title='Pérez VelaJL , Martín BenitezJC , Carrasco GonzalezM , La Cal LópezMA , Hinojosa PérezR , Sagredo MenesesV , et al. Resumen del documento de consenso: "Guías de práctica clínica para el manejo del síndrome de bajo gasto cardiaco en el postoperatorio de cirugía cardiaca". Medicina Intensiva2012;36(4):277-87.'>Pérez 2012</a>; <a href="./references#CD013781-bbs2-0090" title="vanDiepenS , KatzJN , AlbertNM , HenryTD , JacobsAK , KapurNK , et al. Contemporary management of cardiogenic shock. Circulation2017;136(16):e232-68.">van Diepen 2017</a>). Following the adverse spiral of shock, subsequent peripheral malperfusion can culminate in multi‐organ dysfunction (<a href="./references#CD013781-bbs2-0090" title="vanDiepenS , KatzJN , AlbertNM , HenryTD , JacobsAK , KapurNK , et al. Contemporary management of cardiogenic shock. Circulation2017;136(16):e232-68.">van Diepen 2017</a>). LCOS related to cardiac surgery can have a variety of causes. Both worsening of pre‐existing heart disease and the adverse impact of cardiac surgery may contribute to the development of LCOS (<a href="./references#CD013781-bbs2-0054" title="CarlM , AlmsA , BraunJ , DongasA , ErbJ , GoetzA , et al. S3 guidelines for intensive care in cardiac surgery patients. German Medical Science2010;8:Doc12.">Carl 2010</a>; <a href="./references#CD013781-bbs2-0061" title="HabicherM , ZajonzT , HeringlakeM , BöningA , TreskatschS , SchirmerU , et al. S3-Leitlinie zur intensivmedizinischen versorgung herzchirurgischer patienten. Der Anaesthesist2018;67(5):375-9.">Habicher 2018</a>). </p> </section> <section id="CD013781-sec-0011"> <h3 class="title" id="CD013781-sec-0011">Description of the intervention</h3> <p>To maintain a physiological haemodynamic state during cardiac surgery can be challenging, and frequently requires pharmacological interventions or mechanical circulatory support. This might be even more challenging in light of the growing population of the elderly and people with multiple comorbidities who are currently undergoing heart surgery. The drugs predominantly used for haemodynamic stabilisation in LCOS are inotropes. Inotropes restore adequate perfusion by increasing systolic cardiac function. </p> <p>More traditional inotropes, such as catecholamines (e.g. dopamine, epinephrine, norepinephrine, dobutamine, dopexamine) and phosphodiesterase (PDE)‐III‐inhibitors (e.g. milrinone, enoximone, amrinone), act by increasing the calcium influx of cardiomyocytes in different ways, thereby enhancing contractility (<a href="./references#CD013781-bbs2-0061" title="HabicherM , ZajonzT , HeringlakeM , BöningA , TreskatschS , SchirmerU , et al. S3-Leitlinie zur intensivmedizinischen versorgung herzchirurgischer patienten. Der Anaesthesist2018;67(5):375-9.">Habicher 2018</a>). To some degree, this comes with a risk of arrhythmias (<a href="./references#CD013781-bbs2-0054" title="CarlM , AlmsA , BraunJ , DongasA , ErbJ , GoetzA , et al. S3 guidelines for intensive care in cardiac surgery patients. German Medical Science2010;8:Doc12.">Carl 2010</a>; <a href="./references#CD013781-bbs2-0061" title="HabicherM , ZajonzT , HeringlakeM , BöningA , TreskatschS , SchirmerU , et al. S3-Leitlinie zur intensivmedizinischen versorgung herzchirurgischer patienten. Der Anaesthesist2018;67(5):375-9.">Habicher 2018</a>). </p> <p>As an established alternative, myocardial contractility can also be increased by triggering myocardial coupling to a given calcium concentration. This can be addressed pharmacologically with calcium sensitisers (<a href="./references#CD013781-bbs2-0054" title="CarlM , AlmsA , BraunJ , DongasA , ErbJ , GoetzA , et al. S3 guidelines for intensive care in cardiac surgery patients. German Medical Science2010;8:Doc12.">Carl 2010</a>; <a href="./references#CD013781-bbs2-0061" title="HabicherM , ZajonzT , HeringlakeM , BöningA , TreskatschS , SchirmerU , et al. S3-Leitlinie zur intensivmedizinischen versorgung herzchirurgischer patienten. Der Anaesthesist2018;67(5):375-9.">Habicher 2018</a>). Out of the drug class of calcium sensitisers, the broadest body of evidence exists for levosimendan. Levosimendan acts by enhancing the responsiveness of myofilaments to calcium and, thereby, increasing cardiac output without elevating myocardial oxygen consumption (<a href="./references#CD013781-bbs2-0061" title="HabicherM , ZajonzT , HeringlakeM , BöningA , TreskatschS , SchirmerU , et al. S3-Leitlinie zur intensivmedizinischen versorgung herzchirurgischer patienten. Der Anaesthesist2018;67(5):375-9.">Habicher 2018</a>; <a href="./references#CD013781-bbs2-0075" title="PathakA , LebrinM , VaccaroA , SenardJM , DespasF . Pharmacology of levosimendan. Journal of Clinical Pharmacy and Therapeutics2013;38(5):341-9.">Pathak 2013</a>). Therefore, it is considered to be fairly safe and effective in the prevention or treatment of surgery‐related LCOS (<a href="./references#CD013781-bbs2-0054" title="CarlM , AlmsA , BraunJ , DongasA , ErbJ , GoetzA , et al. S3 guidelines for intensive care in cardiac surgery patients. German Medical Science2010;8:Doc12.">Carl 2010</a>; <a href="./references#CD013781-bbs2-0061" title="HabicherM , ZajonzT , HeringlakeM , BöningA , TreskatschS , SchirmerU , et al. S3-Leitlinie zur intensivmedizinischen versorgung herzchirurgischer patienten. Der Anaesthesist2018;67(5):375-9.">Habicher 2018</a>). Similarly to other inotropes, levosimendan is administered intravenously, with an option to start with a bolus prior to continuous infusion. For prophylactic use, levosimendan is applied before, during, or after the person is weaned from cardiopulmonary bypass. Since its active metabolite, OR‐1896, has a half‐life of 70 to 80 hours, it is thought that levosimendan provides prolonged haemodynamic benefit (<a href="./references#CD013781-bbs2-0075" title="PathakA , LebrinM , VaccaroA , SenardJM , DespasF . Pharmacology of levosimendan. Journal of Clinical Pharmacy and Therapeutics2013;38(5):341-9.">Pathak 2013</a>). Levosimendan is a widely studied calcium sensitiser. In addition to many small‐scale studies, several randomised controlled trials (RCTs) and meta‐analyses generating heterogenous data have recently been published (<a href="./references#CD013781-bbs2-0055" title="ChenQH , ZhengRQ , LinH , ShaoJ , YuJQ , WangHL . Effect of levosimendan on prognosis in adult patients undergoing cardiac surgery. Critical Care2017;21:253.">Chen 2017</a>; <a href="./references#CD013781-bbs2-0056" title="ChenP , WuX , WangZ , LiZ , TianX , WangJ , et al. Effects of levosimendan on mortality in patients undergoing cardiac surgery. Journal of Cardiac Surgery2018;33(6):322-9.">Chen 2018</a>; <a href="./references#CD013781-bbs2-0057" title="CholleyB , CarubaT , GrosjeanS , AmourJ , OuattaraA , VillacortaJ , et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass. JAMA2017;318(6):548-56.">Cholley 2017</a>; <a href="./references#CD013781-bbs2-0058" title="ConteSM , FlorissonDS , BonoJA , DaviesRA , NewcombAE . Levosimendan following cardiac surgery. Heart Lung and Circulation2019;28(3):E19-20.">Conte 2019</a>; <a href="./references#CD013781-bbs2-0059" title="DesaiPM , SarkarMS , UmbarkarSR . Prophylactic preoperative levosimendan for off-pump coronary artery bypass grafting in patients with left ventricular dysfunction. Annals of Cardiac Anaesthesia2018;21(2):123-8.">Desai 2018</a>; <a href="./references#CD013781-bbs2-0060" title="ElbadawiA , ElgendyIY , SaadM , MegalyM , MentiasA , AbuzaidAS , et al. Meta-analysis of trials on prophylactic use of levosimendan in patients undergoing cardiac surgery. Annals of Thoracic Surgery2018;105(5):1403-10.">Elbadawi 2018</a>; <a href="./references#CD013781-bbs2-0067" title="LandoniG , LomivorotovVV , AlvaroG , LobreglioR , PisanoA , GuarracinoF , et al. Levosimendan for hemodynamic support after cardiac surgery. New England Journal of Medicine2017;376(21):2021-31.">Landoni 2017</a>; <a href="./references#CD013781-bbs2-0068" title="LeeCT , LinYC , YehYC , ChenTL , ChenCY . Effects of levosimendan for perioperative cardiovascular dysfunction in patients receiving cardiac surgery. Intensive Care Medicine2017;43(12):1929-30. [DOI: 10.1007/s00134-017-4927-5]">Lee 2017</a>; <a href="./references#CD013781-bbs2-0072" title="MehtaRH , LeimbergerJD , vanDiepenS , MezaJ , WangA , JankowichR , et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. New England Journal of Medicine2017;376(21):2032-42.">Mehta 2017</a>; <a href="./references#CD013781-bbs2-0073" title="NgKT , ChanXL , TanW , WangCY . Levosimendan use in patients with preoperative low ejection fraction undergoing cardiac surgery: a systematic review with meta-analysis and trial sequential analysis. Journal of Clinical Anesthesia2019;52:37-47.">Ng 2019</a>; <a href="./references#CD013781-bbs2-0077" title="PutzuA , ClivioS , BellettiA , CassinaT . Perioperative levosimendan in cardiac surgery: a systematic review with meta-analysis and trial sequential analysis. International Journal of Cardiology2018;251:22-31.">Putzu 2018</a>; <a href="./references#CD013781-bbs2-0079" title="QiangH , LuoX , Huo J-H, Wang Z-Q. Perioperative use of levosimendan improves clinical outcomes in patients after cardiac surgery: a systematic review and meta-analysis. Journal of Cardiovascular Pharmacology2018;72(1):11-8.">Qiang 2018</a>; <a href="./references#CD013781-bbs2-0083" title="SanfilippoF , KnightJB , ScollettaS , SantonocitoC , PastoreF , LoriniFL , et al. Levosimendan for patients with severely reduced left ventricular systolic function and/or low cardiac output syndrome undergoing cardiac surgery. Critical Care2017;21(1):252.">Sanfilippo 2017</a>; <a href="./references#CD013781-bbs2-0084" title="SchumannJ , HenrichEC , StroblH , ProndzinskyR , WeicheS , ThieleH , et al. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome. Cochrane Database of Systematic Reviews2018, Issue 1. Art. No: CD009669. [DOI: 10.1002/14651858.CD009669.pub3]">Schumann 2018</a>; <a href="./references#CD013781-bbs2-0088" title="TenaMA , UrsoS , GonzálezJM , SantanaL , SadabaR , JuarezP , et al. Levosimendan versus placebo in cardiac surgery: a systematic review and meta-analysis. Interactive Cardiovascular and Thoracic Surgery2018;27(5):677-85.">Tena 2018</a>; <a href="./references#CD013781-bbs2-0091" title="vanDiepenS , MehtaRH , LeimbergerJD , GoodmanSG , FremesS , JankowichR , et al. Levosimendan in patients with reduced left ventricular function undergoing isolated coronary or valve surgery. Journal of Thoracic and Cardiovascular Surgery2020;159(6):2302-9.e6.">van Diepen 2020</a>; <a href="./references#CD013781-bbs2-0093" title="WangB , HeX , GongY , ChengB . Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery: an update meta-analysis and trial sequential analysis. BioMed Research International2018;2018:7563083.">Wang 2018</a>; <a href="./references#CD013781-bbs2-0094" title="WangA , CuiC , FanY , ZiJ , ZhangJ , WangG , et al. Prophylactic use of levosimendan in pediatric patients undergoing cardiac surgery. Critical Care2019;23(1):428.">Wang 2019</a>; <a href="./references#CD013781-bbs2-0095" title="WangW , ZhouX , LiaoX , LiuB , YuH . The efficacy and safety of prophylactic use of levosimendan on patients undergoing coronary artery bypass graft. Journal of Anesthesia2019;33(4):543-50.">Wang 2019a</a>; <a href="./references#CD013781-bbs2-0097" title="WeberC , EsserM , EghbalzadehK , SabashnikovA , DjordjevicI , MaierJ , et al. Levosimendan reduces mortality and low cardiac output syndrome in cardiac surgery. Thoracic and Cardiovascular Surgeon2020;68(5):401-9. [DOI: 10.1055/s-0039-3400496]">Weber 2020</a>; <a href="./references#CD013781-bbs2-0099" title="YanSB , WangXY , ShangGK , WangZH , DengQM , SongJW , et al. Impact of perioperative levosimendan administration on risk of bleeding after cardiac surgery. American Journal of Cardiovascular Drugs2020;20(2):149-60.">Yan 2020</a>; <a href="./references#CD013781-bbs2-0103" title="ZhouX , HuC , XuZ , LiuP , ZhangY , SunL , et al. Effect of levosimendan on clinical outcomes in adult patients undergoing cardiac surgery: a meta-analysis of randomized controlled trials. Interactive Cardiovascular and Thoracic Surgery2018;26(6):1016-26.">Zhou 2018</a>; <a href="./references#CD013781-bbs2-0104" title="ZhuJ , ZhangY , ChenL , HeY , QingX . Levosimendan in patients with low cardiac output syndrome undergoing cardiac surgery. Anaesthesia, Critical Care and Pain Medicine2019;38(3):243-9.">Zhu 2019</a>). </p> </section> <section id="CD013781-sec-0012"> <h3 class="title" id="CD013781-sec-0012">How the intervention might work</h3> <p>The outcome of people undergoing cardiac surgery is critically dependent on minimising or avoiding functional or morphological cell damage of the myocardium which, in turn, would alter contractility. People are even more at risk for a negative haemodynamic cascade if left ventricular function was impaired beforehand (<a href="./references#CD013781-bbs2-0054" title="CarlM , AlmsA , BraunJ , DongasA , ErbJ , GoetzA , et al. S3 guidelines for intensive care in cardiac surgery patients. German Medical Science2010;8:Doc12.">Carl 2010</a>; <a href="./references#CD013781-bbs2-0061" title="HabicherM , ZajonzT , HeringlakeM , BöningA , TreskatschS , SchirmerU , et al. S3-Leitlinie zur intensivmedizinischen versorgung herzchirurgischer patienten. Der Anaesthesist2018;67(5):375-9.">Habicher 2018</a>). The main treatment strategies in LCOS aim to prevent or to improve impaired macro‐ and microcirculatory perfusion, in order to maintain oxygen supply at the cellular level and to modulate local and systemic inflammatory responses (<a href="./references#CD013781-bbs2-0090" title="vanDiepenS , KatzJN , AlbertNM , HenryTD , JacobsAK , KapurNK , et al. Contemporary management of cardiogenic shock. Circulation2017;136(16):e232-68.">van Diepen 2017</a>). These mechanistic leverages are intended to prevent or minimise secondary multi‐organ dysfunction, or failure. </p> <p>Classic inotropic agents (catecholamines, PDE‐III‐inhibitors) increase cardiac contractility and reduce systemic vascular resistance (SVR), thereby attenuating left ventricular afterload via activation of the cAMP pathway (<a href="./references#CD013781-bbs2-0061" title="HabicherM , ZajonzT , HeringlakeM , BöningA , TreskatschS , SchirmerU , et al. S3-Leitlinie zur intensivmedizinischen versorgung herzchirurgischer patienten. Der Anaesthesist2018;67(5):375-9.">Habicher 2018</a>). The resulting increase in myocardial performance and haemodynamic improvement is accompanied by intensified myocardial oxygen consumption, a relevant consequence of inotropic support (<a href="./references#CD013781-bbs2-0054" title="CarlM , AlmsA , BraunJ , DongasA , ErbJ , GoetzA , et al. S3 guidelines for intensive care in cardiac surgery patients. German Medical Science2010;8:Doc12.">Carl 2010</a>; <a href="./references#CD013781-bbs2-0061" title="HabicherM , ZajonzT , HeringlakeM , BöningA , TreskatschS , SchirmerU , et al. S3-Leitlinie zur intensivmedizinischen versorgung herzchirurgischer patienten. Der Anaesthesist2018;67(5):375-9.">Habicher 2018</a>). Therefore, if clinically required, the use of inotropes should be restricted to a limited duration. </p> <p>Calcium sensitisers have been extensively studied in an attempt to prevent LCOS. The effect of calcium sensitisers, such as levosimendan, is based on a dual mechanism. First, the pharmacological agent binds to troponin C, increasing the stability of the tropomyosin molecule (<a href="./references#CD013781-bbs2-0061" title="HabicherM , ZajonzT , HeringlakeM , BöningA , TreskatschS , SchirmerU , et al. S3-Leitlinie zur intensivmedizinischen versorgung herzchirurgischer patienten. Der Anaesthesist2018;67(5):375-9.">Habicher 2018</a>; <a href="./references#CD013781-bbs2-0075" title="PathakA , LebrinM , VaccaroA , SenardJM , DespasF . Pharmacology of levosimendan. Journal of Clinical Pharmacy and Therapeutics2013;38(5):341-9.">Pathak 2013</a>). This results in enhanced myocardial contractility. The presence of calcium is a prerequisite for the binding of levosimendan to troponin C. As levosimendan does not negatively affect unbound intracellular calcium levels, it does not influence the relaxation of the myocardium (<a href="./references#CD013781-bbs2-0061" title="HabicherM , ZajonzT , HeringlakeM , BöningA , TreskatschS , SchirmerU , et al. S3-Leitlinie zur intensivmedizinischen versorgung herzchirurgischer patienten. Der Anaesthesist2018;67(5):375-9.">Habicher 2018</a>; <a href="./references#CD013781-bbs2-0075" title="PathakA , LebrinM , VaccaroA , SenardJM , DespasF . Pharmacology of levosimendan. Journal of Clinical Pharmacy and Therapeutics2013;38(5):341-9.">Pathak 2013</a>). Second, levosimendan causes relaxation of smooth muscles by opening ATP‐sensitive potassium channels in the vasculature (<a href="./references#CD013781-bbs2-0061" title="HabicherM , ZajonzT , HeringlakeM , BöningA , TreskatschS , SchirmerU , et al. S3-Leitlinie zur intensivmedizinischen versorgung herzchirurgischer patienten. Der Anaesthesist2018;67(5):375-9.">Habicher 2018</a>; <a href="./references#CD013781-bbs2-0075" title="PathakA , LebrinM , VaccaroA , SenardJM , DespasF . Pharmacology of levosimendan. Journal of Clinical Pharmacy and Therapeutics2013;38(5):341-9.">Pathak 2013</a>). This facilitates coronary blood flow and myocardial perfusion. Similarly, levosimendan elicits vasodilatation of peripheral arteries which, in turn, reduces left ventricular afterload (<a href="./references#CD013781-bbs2-0061" title="HabicherM , ZajonzT , HeringlakeM , BöningA , TreskatschS , SchirmerU , et al. S3-Leitlinie zur intensivmedizinischen versorgung herzchirurgischer patienten. Der Anaesthesist2018;67(5):375-9.">Habicher 2018</a>; <a href="./references#CD013781-bbs2-0075" title="PathakA , LebrinM , VaccaroA , SenardJM , DespasF . Pharmacology of levosimendan. Journal of Clinical Pharmacy and Therapeutics2013;38(5):341-9.">Pathak 2013</a>). So, levosimendan exerts both inotropic and vasodilatory effects. </p> <p>This review will focus on all inotropic agents that are being used to prophylactically minimise the incidence of LCOS in adults undergoing cardiac surgery. </p> </section> <section id="CD013781-sec-0013"> <h3 class="title" id="CD013781-sec-0013">Why it is important to do this review</h3> <p>As the burden of cardiovascular disease grows in western society, so does the number of cardiac surgeries. Due to medical progress and refinements of care at all healthcare levels, i.e. perioperative myocardial protection, specialised cardio‐anaesthesia, haemodynamic monitoring, surgical techniques, intraoperative perfusion, and postoperative management, the morbidity and mortality of people undergoing cardiovascular surgery have decreased overall. Against this background, surgical procedures are performed in increasingly elderly and comorbid people, who are already at a higher risk of developing perioperative complications, such as LCOS. LCOS represents a serious pathology that accounts for substantial morbidity and mortality following cardiac surgery. Beyond its prognostic impact, LCOS can increase the length of stay in the intensive care unit (ICU) and in the hospital overall. As a result of a complicated postoperative course, LCOS increases the use of medical resources (e.g. ventilators, extracorporeal membrane oxygenation (ECMO) circuits, dialysis) and ultimately increases medical costs. Hence, the prevention of LCOS is a critical and worthwhile aim to further improve the outcome and effectiveness of cardiac surgery. </p> <p>Notwithstanding the relevance described above, research on the prophylactic use of inotropic agents in cardiac surgery has not resulted in high‐quality evidence in support of the concept (<a href="./references#CD013781-bbs2-0060" title="ElbadawiA , ElgendyIY , SaadM , MegalyM , MentiasA , AbuzaidAS , et al. Meta-analysis of trials on prophylactic use of levosimendan in patients undergoing cardiac surgery. Annals of Thoracic Surgery2018;105(5):1403-10.">Elbadawi 2018</a>; <a href="./references#CD013781-bbs2-0073" title="NgKT , ChanXL , TanW , WangCY . Levosimendan use in patients with preoperative low ejection fraction undergoing cardiac surgery: a systematic review with meta-analysis and trial sequential analysis. Journal of Clinical Anesthesia2019;52:37-47.">Ng 2019</a>; <a href="./references#CD013781-bbs2-0095" title="WangW , ZhouX , LiaoX , LiuB , YuH . The efficacy and safety of prophylactic use of levosimendan on patients undergoing coronary artery bypass graft. Journal of Anesthesia2019;33(4):543-50.">Wang 2019a</a>). Based on heterogenous original data, national and international guidelines consistently state a lack of evidence for pharmacological treatment of LCOS, and do not recommend it (<a href="./references#CD013781-bbs2-0057" title="CholleyB , CarubaT , GrosjeanS , AmourJ , OuattaraA , VillacortaJ , et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass. JAMA2017;318(6):548-56.">Cholley 2017</a>; <a href="./references#CD013781-bbs2-0059" title="DesaiPM , SarkarMS , UmbarkarSR . Prophylactic preoperative levosimendan for off-pump coronary artery bypass grafting in patients with left ventricular dysfunction. Annals of Cardiac Anaesthesia2018;21(2):123-8.">Desai 2018</a>; <a href="./references#CD013781-bbs2-0072" title="MehtaRH , LeimbergerJD , vanDiepenS , MezaJ , WangA , JankowichR , et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. New England Journal of Medicine2017;376(21):2032-42.">Mehta 2017</a>; <a href="./references#CD013781-bbs2-0094" title="WangA , CuiC , FanY , ZiJ , ZhangJ , WangG , et al. Prophylactic use of levosimendan in pediatric patients undergoing cardiac surgery. Critical Care2019;23(1):428.">Wang 2019</a>). This is especially true for its prophylactic use (<a href="./references#CD013781-bbs2-0054" title="CarlM , AlmsA , BraunJ , DongasA , ErbJ , GoetzA , et al. S3 guidelines for intensive care in cardiac surgery patients. German Medical Science2010;8:Doc12.">Carl 2010</a>; <a href="./references#CD013781-bbs2-0061" title="HabicherM , ZajonzT , HeringlakeM , BöningA , TreskatschS , SchirmerU , et al. S3-Leitlinie zur intensivmedizinischen versorgung herzchirurgischer patienten. Der Anaesthesist2018;67(5):375-9.">Habicher 2018</a>; <a href="./references#CD013781-bbs2-0076" title="PonikowskiP , VoorsAA , AnkerSD , BuenoH , ClelandJG , CoatsAJ , et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Revista Espanola de Cardiologia (English ed.)2016;69(12):1167.">Ponikowski 2016</a>; <a href="./references#CD013781-bbs2-0078" title='Pérez VelaJL , Martín BenitezJC , Carrasco GonzalezM , La Cal LópezMA , Hinojosa PérezR , Sagredo MenesesV , et al. Resumen del documento de consenso: "Guías de práctica clínica para el manejo del síndrome de bajo gasto cardiaco en el postoperatorio de cirugía cardiaca". Medicina Intensiva2012;36(4):277-87.'>Pérez 2012</a>; <a href="./references#CD013781-bbs2-0090" title="vanDiepenS , KatzJN , AlbertNM , HenryTD , JacobsAK , KapurNK , et al. Contemporary management of cardiogenic shock. Circulation2017;136(16):e232-68.">van Diepen 2017</a>). It remains uncertain whether people with specific disorders do better, or if certain surgical methods, drugs or administration protocols provide better outcomes. </p> <p>In light of the growing number of people undergoing heart surgery, and the critical impact on clinical practice, this review will assess the efficacy and safety of a precautionary administration of inotropes, by analysing available randomised controlled trials. This review aims to generate a basis for evidence‐based decision‐making in future clinical practice, improving perioperative morbidity and mortality. The evaluation of current evidence and the identification of persistent knowledge gaps may contribute to the conception and design of future clinical trials. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013781-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013781-sec-0014"></div> <p>To assess the benefits and harms of the prophylactic use of any inotropic agent to prevent low cardiac output and associated morbidity and mortality in adults undergoing cardiac surgery. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013781-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013781-sec-0015"></div> <section id="CD013781-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013781-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) of parallel or multi‐arm design with randomisation at the level of the participant, regardless of the study publication status. We excluded studies that aimed to evaluate interventions but did not use randomisation for participant allocation to different study arms (quasi‐randomised trials), due to concerns regarding internal validity, as well as cross‐over trials, due to the investigation of all‐cause mortality as the primary outcome. We excluded RCTs whose unit of allocation was not the individual participant (cluster‐RCTs), due to our interest in the individual effect of an intervention. </p> </section> <section id="CD013781-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included RCTs that investigated the prophylactic administration of inotropic agents, enrolling adults (≥ 18 years of age) undergoing cardiac surgery, without signs of low cardiac output (LCOS) at the time of inclusion, with a follow‐up period spanning at least the hospitalisation phase. We considered any type of cardiac surgery, with the exception of complex heart defects, which require several operations in succession. We considered procedures with and without cardiopulmonary bypass (CPB). Participants were included regardless of clinical heart failure state or pre‐existing left ventricular (LV) dysfunction. We assessed the aspects of 'type of cardiac surgery' and 'pre‐existing LV dysfunction' by subgroup analyses. Studies including only a subset of relevant participants were also considered. </p> </section> <section id="CD013781-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included trials investigating the use of inotropic agents (i.e. dopamine, epinephrine, norepinephrine, dobutamine, dopexamine, milrinone, enoximone, amrinone, levosimendan), either alone or in combination, started for preventive reasons before, during, or after the surgical intervention. There were no restrictions in terms of delivery or dosage. We considered the comparison of (i) inotropic agent(s) to treatments without specific experimental single drugs (standard cardiac care), or (ii) inotropic agent(s) to placebo or (iii) inotropic agents(s) to other inotropic agent(s). </p> </section> <section id="CD013781-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>Reporting in the trial of one or more of the outcomes listed here was not an inclusion criterion for the review. When a published report did not appear to report one of these outcomes, we accessed the trial protocol and contacted the trial authors to ascertain whether the outcomes were measured but not reported. We used quantitative data provided by the study authors. We included relevant trials, which measured these outcomes but did not report the data at all or not in a usable format, as part of the narrative in the review. </p> <p>Given the clinical relevance of LCOS during the acute perioperative and immediate postoperative period, we focused on the short‐term course (intensive care unit (ICU) and hospital stay). We also examined data at the longest follow‐up given in each study. </p> <section id="CD013781-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD013781-list-0001"> <li> <p>All‐cause mortality (within 30 days)</p> </li> <li> <p>Incidence of LCOS, as defined in the background section (perioperatively until 48 hours after the completion of the procedure) </p> </li> <li> <p>Adverse events (number or proportion of participants)</p> <ol id="CD013781-list-0002"> <li> <p>Cardiogenic shock (mean arterial pressure (MAP) &lt; 60 mmHg or requirement of catecholamines for more than 15 minutes; cardiac index (CI) &lt; 2.2 L/min/m²; pulmonary capillary wedge pressure (PCWP) &gt; 18 mmHg; lactate level &gt; 2.0 mmol/L; venous oxygen saturation (SvO2) &lt; 60%; clinical signs of malperfusion) </p> </li> <li> <p>Arrhythmia (atrial fibrillation, supraventricular tachycardia, ventricular arrhythmia of new onset) </p> </li> <li> <p>Perioperative myocardial infarction (increasing troponin and creatine kinase‐MB (CK‐MB) levels of more than 50% relative to baseline; electrocardiogram (ECG) changes, or regional wall motion abnormalities, or angiographic changes, or a combination) </p> </li> <li> <p>Non‐embolic stroke or transient ischaemic attack</p> </li> </ol> </li> </ol> </p> </section> <section id="CD013781-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD013781-list-0003"> <li> <p>Length of hospital stay (days)</p> </li> <li> <p>Length of intensive care unit (ICU) stay (days)</p> </li> <li> <p>CI (L/min/m²) in ICU</p> </li> <li> <p>MAP pressure (mmHg) in ICU</p> </li> <li> <p>PCWP (mmHg) in ICU</p> </li> <li> <p>Duration of mechanical ventilation (hours)</p> </li> <li> <p>Proportion of weaning failure within 48 hours of extubation (objective (e.g. tachypnoea, hypertension, hypoxaemia, acidosis) or subjective (e.g. agitation, distress, diaphoresis, increased respiratory efforts), or both), signs of respiratory insufficiency; unsuccessful permanent discontinuation of mechanical ventilation </p> </li> <li> <p>Number of participants requiring mechanical circulatory support</p> </li> <li> <p>Number of participants requiring additional inotropic drugs</p> </li> <li> <p>Number of participants requiring cardiac transplantation or ventricular assist device implantation of any bridging strategy </p> </li> <li> <p>Number of participants requiring cardiopulmonary resuscitation</p> </li> <li> <p>Proportion of renal failure (increase of serum creatinine of at least 0.3 mg/dL, oliguria or anuria with diuresis &lt; 0.5 mL/kg/h for at least six hours, or requirement of renal replacement therapy, or a combination) </p> </li> </ol> </p> <p>We included any data on participants' quality of life or medical cost in the analysed studies as part of the narrative in the review. </p> </section> </section> </section> <section id="CD013781-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD013781-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We identified trials through systematic searches of the following bibliographic databases on 17 October 2022: </p> <p> <ul id="CD013781-list-0004"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2022, Issue 10) in the Cochrane Library; </p> </li> <li> <p>MEDLINE All (Ovid, 1946 to 14 October 2022);</p> </li> <li> <p>Embase (Ovid, 1980 to 2022 week 41);</p> </li> <li> <p>Conference Proceedings Citation Index ‐ Science (CPCI‐S) on the Web of Science (Clarivate Analytics, 1990 to 17 October 2022). </p> </li> </ul> </p> <p>We adapted the search strategy for MEDLINE Ovid for use in the other databases (<a href="./appendices#CD013781-sec-0180">Appendix 1</a>). We applied the Cochrane sensitivity and precision‐maximising RCT filter to MEDLINE Ovid, and adapted it to the other databases, except CENTRAL (<a href="./references#CD013781-bbs2-0069" title="LefebvreC , GlanvilleJ , BriscoeS , LittlewoodA , MarshallC , Metzendorf M-I, et al. Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">Lefebvre 2019</a>). </p> <p>We also conducted a search of ClinicalTrials.gov (<a href="http://www.ClinicalTrials.gov" target="_blank">www.ClinicalTrials.gov</a>) and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) Search Portal (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>) for ongoing or unpublished trials on 17 October 2022. </p> <p>We searched all databases from their inception to the present, with no restriction on language or status of publication. </p> </section> <section id="CD013781-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We checked the reference lists of all included studies and relevant systematic reviews identified for additional references of interest. We also examined any relevant retraction statements and errata for included studies. </p> </section> </section> <section id="CD013781-sec-0026"> <h3 class="title" id="CD013781-sec-0026">Data collection and analysis</h3> <section id="CD013781-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (DG and JS) independently screened titles and abstracts of all the potential studies we identified in our search, and coded them as 'retrieve' (eligible, potentially eligible, or unclear) or 'do not retrieve'. Disagreements were resolved by consensus. We retrieved the full‐text study reports or publication, and two review authors (DG and JS) independently screened the full text, identified studies for inclusion, and identified and recorded reasons for excluding the ineligible studies. Any disagreement was resolved by discussion. We identified and excluded duplicates and collated multiple reports of the same study, so that each study was the unit of interest in the review process. We recorded the selection process in sufficient detail to complete a PRISMA flow diagram (<a href="#CD013781-fig-0001">Figure 1</a>) and 'Characteristics of excluded studies' table (<a href="./references#CD013781-bbs2-0070" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GøtzschePC , IoannidisJP , et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLOS Medicine2009;6(7):e1000100.">Liberati 2009</a>). </p> <div class="figure" id="CD013781-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA study flow diagram" data-id="CD013781-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA study flow diagram</p> </div> </div> </div> </section> <section id="CD013781-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>We used a data collection form for study characteristics and outcome data, which had been piloted on at least one study in the review process. Two review authors (DG and JS) extracted study characteristics from the included studies. We extracted the following study characteristics. </p> <p> <ol id="CD013781-list-0005"> <li> <p>Methods: study design, total duration of enrolment and follow‐up, number and location of study centres, study setting, and period of study. </p> </li> <li> <p>Participants: N randomised, N lost to follow‐up or withdrawn, N analysed, mean age, age range, gender, participant with or without pre‐existing LV dysfunction, type of cardiac surgery, inclusion criteria, and exclusion criteria. </p> </li> <li> <p>Interventions: intervention, comparison, concomitant medications, excluded medications, timing of the administration, and in the case of levosimendan, the administration protocol (with or without bolus). </p> </li> <li> <p>Outcomes: primary and secondary outcomes specified and collected, and time points reported. </p> </li> <li> <p>Notes: funding for the trial and notable conflicts of interest of trial authors.</p> </li> </ol> </p> <p>Two review authors (DG and JS) independently extracted outcome data from the included studies. Disagreements were resolved by consensus. One review author (JS) transferred data into the Review Manager 5 file (<a href="./references#CD013781-bbs2-0081" title="Review Manager 5 (RevMan 5). Version 5.4.1. Copenhagen: The Cochrane Collaboration, 2020.">Review Manager 2020</a>). We double‐checked whether data were entered correctly by comparing the data presented in the review with the data extraction form. A second review author (DG) spot‐checked study characteristics for accuracy in comparison to the trial reports. </p> <p>No transformations of reported data were made before presentation in the review article and no numerical data were extracted from graphs. </p> </section> <section id="CD013781-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (DG and JS) independently assessed risk of bias for each study using Cochrane RoB 1, as outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013781-bbs2-0063" title="HigginsJP , AltmanDG , SterneJA , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). Cochrane, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). Disagreements were resolved by consensus. We assessed the risk of bias in trial results according to the following domains: </p> <p> <ol id="CD013781-list-0006"> <li> <p>random sequence generation;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding of participants, personnel, and outcome assessment;</p> </li> <li> <p>incomplete outcome data;</p> </li> <li> <p>selective reporting;</p> </li> <li> <p>other sources of bias (cross‐over design, baseline differences, conduct of the study affected by interim results, deviation from the study protocol not reflecting clinical practice, inappropriate administration of an intervention, contra‐active or similar pre‐randomisation intervention). </p> </li> </ol> </p> <p>We assessed the risk of bias for the outcomes of the included studies that are included in our summary of findings tables. The effect of interest was that of assignment to intervention, and assessment for risk of bias was the result corresponding to a full intention‐to‐treat (ITT) analysis. </p> <p>We rated each domain as low, unclear, or high risk of bias. We summarised the risk of bias judgements across different studies for each of the domains listed, and for each outcome. The overall risk of bias is the least favourable assessment across the domains of bias. </p> <p>When considering treatment effects, we took the risk of bias for the contributing outcome data into account. </p> </section> <section id="CD013781-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed dichotomous data as risk ratios (RR) with 95% confidence intervals (CI), and continuous data as mean difference (MD) with 95% CIs. We entered data presented as a scale with a consistent direction of effect. </p> <p>We narratively described skewed data reported as medians and interquartile ranges.</p> </section> <section id="CD013781-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>We included RCTs with a parallel design, as well as multi‐arm studies. For outcomes measured at multiple time points, we performed separate analyses, with time frames that reflected short‐term and longest follow‐up. In the case where a study contributed multiple, correlated comparisons, we combined groups to create a single pair‐wise comparison as outlined in the <i>Cochrane</i> <i>Handbook</i> (<a href="./references#CD013781-bbs2-0064" title="HigginsJP , LiT , DeeksJJ , editor(s). Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpson M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">Higgins 2019</a>). We analysed groups in an appropriate way, which avoided arbitrary omission or double counting of participants. </p> </section> <section id="CD013781-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We contacted investigators or study sponsors to verify key study characteristics, and obtain missing numerical outcome data, when possible (e.g. when a study was identified as an abstract only). Wherever possible, we used the Review Manager 5 calculator to calculate missing standard deviations (SD), using other data from the trial, such as confidence intervals, based on methods outlined in the <i>Cochrane</i> <i>Handbook</i> (<a href="./references#CD013781-bbs2-0064" title="HigginsJP , LiT , DeeksJJ , editor(s). Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpson M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">Higgins 2019</a>)<i>.</i> Whenever this was not possible, and we thought missing data may introduce serious bias, we explored the impact of including such studies in the overall assessment of results with a sensitivity analysis. </p> </section> <section id="CD013781-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We inspected forest plots visually to consider the direction and magnitude of effects and the degree of overlap between confidence intervals. We used the I² statistic to measure heterogeneity among the trials in each analysis, but acknowledge that there is substantial uncertainty in the value of I² if there are only a small number of studies available. We also considered the P value from the Chi² test. If we identified substantial heterogeneity (I² ≥ 50%), or we suspected heterogeneity from the confidence intervals in the forest plots, we reported it, and explored possible causes by prespecified subgroup analyses. </p> </section> <section id="CD013781-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>If we were able to pool more than 10 trials, we created and examined a funnel plot, to explore possible small study biases for the primary outcomes (<a href="./references#CD013781-bbs2-0087" title="SterneJA , SuttonAJ , IoannidisJP , TerrinN , JonesDR , LauJ , et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ2011;e343:d4002.">Sterne 2011</a>). To assess asymmetry, we performed the Habord test, as implemented in the statistical software Stata 15 (<a href="./references#CD013781-bbs2-0086" title="Stata. Version 15. College Station, TX, USA: StataCorp, 2017. Available from www.stata.com.">Stata</a>). </p> </section> <section id="CD013781-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We performed a meta‐analysis only where it was meaningful, i.e. if treatments, participants, and the underlying clinical question were similar enough for pooling to make sense. </p> <p>In the primary analysis, we included all studies. We assessed the potential effects of studies at high risk, or unclear risk of bias in sensitivity analyses. </p> <p>We used a random‐effects model, because we expected clinical heterogeneity to arise from differences in study characteristics, and the associated assumption that the effects being estimated in the different studies are not identical, but follow a similar distribution. </p> </section> <section id="CD013781-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We carried out the following subgroup analyses for any outcomes with substantial heterogeneity.</p> <p> <ol id="CD013781-list-0007"> <li> <p>Regimen of the control group (placebo‐controlled versus active control).</p> </li> <li> <p>Timing of the administration (preoperative versus perioperative versus postoperative).</p> </li> <li> <p>Administration protocol for levosimendan (with versus without bolus).</p> </li> <li> <p>Type of cardiac surgery (single versus combined structural procedures, procedures with versus without bypass). </p> </li> <li> <p>Participants with versus without pre‐existing LV dysfunction, i.e. heart failure with preserved ejection fraction (HFpEF; LVEF &gt; 50%), heart failure with mid‐range ejection fraction (HFmEF; LVEF 41% to 49%), and heart failure with reduced ejection fraction (HFrEF; LVEF &lt; 40%). </p> </li> </ol> </p> <p>We used the formal test for subgroup differences in Review Manager 5, and based our interpretation on this. </p> </section> <section id="CD013781-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>Depending on the number of included studies, we planned to carry out the following sensitivity analyses, to test whether key methodological factors or decisions had affected the main result. </p> <p> <ul id="CD013781-list-0008"> <li> <p>Primary analyses including all studies and sensitivity analysis including only studies judged to be at an overall low risk of bias. </p> </li> <li> <p>Primary analysis using the random‐effects model, due to expected heterogeneity between studies; we also explored a fixed‐effect model if the I² statistic value was &lt; 50%. </p> </li> </ul> </p> </section> <section id="CD013781-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We created summary of findings tables using the following outcomes:</p> <p> <ul id="CD013781-list-0009"> <li> <p>All‐cause mortality</p> </li> <li> <p>Incidence of LCOS</p> </li> <li> <p>Adverse events</p> </li> <li> <p>Length of ICU stay</p> </li> <li> <p>Duration of mechanical ventilation</p> </li> <li> <p>Number of participants requiring mechanical circulatory support</p> </li> </ul> </p> <p>In clinical practice, the debate on prophylactic medication mainly relates to the use of the calcium sensitiser levosimendan. Most RCTs on this topic therefore focus on the efficacy and safety of this specific drug. For this reason, the summary of findings tables were restricted to the comparisons of levosimendan with placebo or standard care. </p> <p>Two review authors (DG and JS) independently judged the certainty of the evidence, with disagreements resolved by discussion. We justified judgements by documenting decisions and incorporating them into the results for each outcome. We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the certainty of the body of evidence as it relates to the studies that contribute data to the meta‐analyses for the prespecified outcomes. We used the overall risk of bias judgement for the GRADE assessment, as described in <a href="https://training.cochrane.org/handbook/current/chapter-14" target="_blank">Chapter 14</a> of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013781-bbs2-0085" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston MS, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">Schünemann 2019</a>). We justified all decisions to downgrade the certainty of studies using footnotes, and we made comments to aid the reader's understanding of the review, where necessary. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013781-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013781-sec-0039"></div> <section id="CD013781-sec-0040"> <h3 class="title">Description of studies</h3> <p>Randomised controlled trials (RCTs) in individuals undergoing cardiac surgery and treated prophylactically with inotropic drugs. </p> <section id="CD013781-sec-0041"> <h4 class="title">Results of the search</h4> <p>After removing duplicates, we identified a total of 6416 references. By screening the titles and abstracts, we ascertained 49 references of potential relevance, whose full texts we assessed by applying our inclusion and exclusion criteria. This resulted in the inclusion of 29 studies (see <a href="./references#CD013781-sec-0189" title="">Characteristics of included studies</a>). Furthermore, we identified four ongoing studies (see <a href="./references#CD013781-sec-0191" title="">Characteristics of ongoing studies</a>). Details of the remaining studies can be found in <a href="./references#CD013781-sec-0190" title="">Characteristics of excluded studies</a>. The overall process is recorded in the PRISMA flowchart (<a href="#CD013781-fig-0001">Figure 1</a>). </p> </section> <section id="CD013781-sec-0042"> <h4 class="title">Included studies</h4> <p>The inclusion criteria were met by 29 randomised controlled studies. Each study characteristic is presented briefly in the table <a href="./references#CD013781-sec-0189" title="">Characteristics of included studies</a>. The qualitative and quantitative analysis of the included studies is based on published information. Contacting the authors of the included studies resulted in feedback and additional information only from the corresponding author of the study <a href="./references#CD013781-bbs2-0003" title="BaysalA , YanartasM , DogukanM , GundogusN , KocakT , Koksal C. Levosimendan improves renal outcome in cardiac surgery: a randomized trial. Journal of Cardiothoracic and Vascular Anesthesia2014;28:586-94. [DOI: 10.1053/j.jvca.2013.09.004]">Baysal 2014</a>, which was included in the analysis. </p> </section> <section id="CD013781-sec-0043"> <h4 class="title">Study size and location</h4> <p>Twenty‐four studies were conducted as single‐centre trials in Belgium (<a href="./references#CD013781-bbs2-0005" title="De HertSG , LorsomradeeS , CromheeckeS , Van der LindenPJ . The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesthesia and Analgesia2007;104:766-73. [DOI: 10.1213/01.ane.0000256863.92050.d3]">De Hert 2007</a>), China (<a href="./references#CD013781-bbs2-0014" title="HuX , XuQ . Application of levosimendan in severe patients after cardiac surgery. Chinese Journal of Clinical Pharmacology and Therapeutics2020;25:1027-32. [DOI: 10.12092/j.issn.1009-2501.2020.09.010]">Hu 2020</a>), Denmark (<a href="./references#CD013781-bbs2-0017" title="Juhl-OlsenP , Jakobsen C-J, RasmussenLA , BhavsarR , Klaaborg K-E, FrederiksenCA , et al. Effects of levosimendan in patients with left ventricular hypertrophy undergoing aortic valve replacement. Acta Anaesthesiologica Scandinavica2015;59:65-77. [DOI: 10.1111/aas.12425]">Juhl‐Olsen 2015</a>), Egypt (<a href="./references#CD013781-bbs2-0001" title="AminSW , Abd-ElgalilSM , MohamedSA , AhmedMM , HamawyTY , FathiLM . Levosimendan versus milrinone in the management of impaired left ventricular function in patients undergoing coronary artery bypass graft surgery. Open Anesthesia Journal2019;13:59-67. [DOI: 10.2174/2589645801913010059]">Amin 2019</a>), Finland (<a href="./references#CD013781-bbs2-0015" title="JärveläK , MaaranenP , SistoT , RuokonenE . Levosimendan in aortic valve surgery: cardiac performance and recovery. Journal of Cardiothoracic and Vascular Anesthesia2008;22:693-8. [DOI: 10.1053/j.jvca.2008.01.024]">Jävelä 2008</a>; <a href="./references#CD013781-bbs2-0021" title="LahtinenP , PitkänenO , PölönenP , TurpeinenA , KiviniemiV , UusaroA . Levosimendan reduces heart failure after cardiac surgery: a prospective, randomized, placebo-controlled trial. Criítical Care Medicine2011;39:2263-70. [DOI: 10.1097/CCM.0b013e3182227b97]">Lahtinen 2011</a>; <a href="./references#CD013781-bbs2-0022" title="LeppikangasH , JärveläK , SistoT , MaaranenP , VirtanenM , LehtoP , et al. Preoperative levosimendan infusion in combined aortic valve and coronary bypass surgery. British Journal of Anaesthesia2011;106:298-304. [DOI: 10.1093/bja/aeq402]">Leppikangas 2011</a>), Germany (<a href="./references#CD013781-bbs2-0008" title="ErbJ , BeutlhauserT , FeldheiserA , SchusterB , TreskatschS , GrubitzschH , et al. Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery. Journal of International Medical Research2014;42:750-64. [DOI: 10.1177/0300060513516293]">Erb 2014</a>), Greece (<a href="./references#CD013781-bbs2-0002" title="AnastasiadisK , AntonitsisP , VranisK , KleontasA , AsteriouC , GrosomanidisV , et al. Effectiveness of prophylactic levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting: a randomized pilot study. Interactive Cardiovascular and Thoracic Surgery2016;23:740-8. [DOI: 10.1093/icvts/ivw213]">Anastasiadis 2016</a>), India (<a href="./references#CD013781-bbs2-0007" title="DesaiPM , SarkarMS , UmbarkarSR . Prophylactic preoperative levosimendan for off-pump coronary artery bypass grafting in patients with left ventricular dysfunction: single-centered randomized prospective study. Annals of Cardiac Anaesthesia2018;21:123-8. [DOI: 10.4103/aca.ACA_178_17]">Desai 2018</a>; <a href="./references#CD013781-bbs2-0011" title="GandhamR , SyamasundarA , RavulapalliH , KarthekeyanRB , VakamudiM , KodalliR , et al. A comparison of hemodynamic effects of levosimendan and dobutamine in patients undergoing mitral valve repair / replacement for severe mitral stenosis. Annals of Cardiac Anaesthesia2013;16:11-5. [DOI: 10.4103/0971-9784.105363]">Gandham 2013</a>; <a href="./references#CD013781-bbs2-0018" title="KandasamyA , SimonHA , MurthyP , AnnaduraiM , AliMM , RamanathanG . Comparison of levosimendan versus dobutamine in patients with moderate to severe left ventricular dysfunction undergoing off-pump coronary artery bypass grafting: a randomized prospective study. Annals of Cardiac Anaesthesia2017;20:200-6. [DOI: 10.4103/aca.ACA_195_16]">Kandasamy 2017</a>; <a href="./references#CD013781-bbs2-0020" title="KodalliRK , SundarAS , VakamudiM , RavulapaliH , NandipatiS , ChandrasekaranN , et al. Effect of levosimendan on hemodynamic changes in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled study. Annals of Cardiac Anaesthesia2013;16:94-9. [DOI: 10.4103/0971-9784.109737]">Kodalli 2013</a>; <a href="./references#CD013781-bbs2-0025" title="MishraA , KumarB , DuttaV , AryaVK , MishraAK . Comparative effect of levosimendan and milrinone in cardiac surgery patients with pulmonary hypertension and left ventricular dysfunction. Journal of Cardiothoracic and Vascular Anesthesia2016;30:639-46. [DOI: 10.1053/j.jvca.2016.01.015]">Mishra 2016</a>; <a href="./references#CD013781-bbs2-0026" title="ShahB , SharmaP , BrahmbhattA , ShahR , RathodB , ShastriN , et al. Study of levosimendan during off-pump coronary artery bypass grafting in patients with LV dysfunction: a double-blind randomized study. Indian Journal of Pharmacology2014;46:29-34. [DOI: 10.4103/0253-7613.125161]">Shah 2014</a>; <a href="./references#CD013781-bbs2-0027" title="SharmaP , MalhotraA , GandhiS , GargP , BishnoiA , GandhiH . Preoperative levosimendan in ischemic mitral valve repair. Asian Cardiovascular and Thoracic Annals2014;22:539-45. [DOI: 10.1177/0218492313499352]">Sharma 2014</a>), Iran (<a href="./references#CD013781-bbs2-0013" title="HadadzadehM , HosseiniSH , Mostafavi-Pour-ManshadiSM , NaderiN , Emami-MeybodiM . Effect of milrinone on short term outcome of patients with myocardial dysfunction undergoing off-pump coronary artery bypass graft: a randomized clinical trial. Acta Medica Iranica2013;51:681-6. [PMID: 24338139]">Hadadzadeh 2013</a>), Israel (<a href="./references#CD013781-bbs2-0012" title="GatotI , AbramovD , TsodikovV , YeshayahuM , OrmanS , GavrielA , et al. Should we give prophylactic renal-dose dopamine after coronary artery bypass surgery?Journal of Cardiac Surgery2004;19:128-33. [DOI: 10.1111/j.0886-0440.2004.04044.x]">Gatot 2004</a>), Italy (<a href="./references#CD013781-bbs2-0028" title="TritapepeL , De SantisV , VitaleD , SantulliM , MorelliA , NofroniI , et al. Preconditioning effects of levosimendan in coronary artery bypass grafting - a pilot study. British Journal of Anaesthesia2006;96:694-700. [DOI: 10.1093/bja/ael082]">Tritapepe 2006</a>; <a href="./references#CD013781-bbs2-0029" title="TritapepeL , De SantisV , VitaleD , GuarracinoF , PellegriniF , PietropaoliP , et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. British Journal of Anaesthesia2009;102:198-204. [DOI: 10.1093/bja/aen367]">Tritapepe 2009</a>), Japan (<a href="./references#CD013781-bbs2-0019" title="KikuraM , SatoS . The efficacy of preemptive milrinone or amrinone therapy in patients undergoing coronary artery bypass grafting. Anesthesia and Analgesia2002;94:22-30. [DOI: 10.1097/00000539-200201000-00005]">Kikura 2002</a>), Korea (<a href="./references#CD013781-bbs2-0016" title="JoHR , LeeWK , KimYH , MinJH , ChaeYK , ChoiIG , et al. The effect of milrinone infusion on right ventricular function during coronary anastomosis and early outcomes in patients undergoing off-pump coronary artery bypass surgery. Korean Journal of Anesthesiology2010;59:92-8. [DOI: 10.4097/kjae.2010.59.2.92]">Jo 2010</a>), or Turkey (<a href="./references#CD013781-bbs2-0003" title="BaysalA , YanartasM , DogukanM , GundogusN , KocakT , Koksal C. Levosimendan improves renal outcome in cardiac surgery: a randomized trial. Journal of Cardiothoracic and Vascular Anesthesia2014;28:586-94. [DOI: 10.1053/j.jvca.2013.09.004]">Baysal 2014</a>; <a href="./references#CD013781-bbs2-0010" title="ErsoyO , BoysanE , UnalEU , YayK , YenerU , CicekciogluF , et al. Effectiveness of prophylactic levosimendan in high-risk valve surgery patients. Cardiovascular Journal of Africa2013;24:260-4. [DOI: 10.5830/CVJA-2013-047]">Ersoy 2013</a>). In these studies, the number of enrolled study participants varied from 20 to 207. </p> <p>Five studies were conducted as multicentre trials in Canada (125 participants enrolled; <a href="./references#CD013781-bbs2-0006" title="DenaultAY , BussièresJS , ArellanoR , FineganB , GavraP , HaddadF , et al. A multicentre randomized-controlled trial of inhaled milrinone in high-risk cardiac surgical patients. Canadian Journal of Anesthesia2016;63:1140-53. [DOI: 10.1007/s12630-016-0709-8]">Denault 2016</a>), Finland (60 participants enrolled; <a href="./references#CD013781-bbs2-0009" title="RikssonHI , JalonenJR , HeikkinenLO , KivikkoM , LaineM , LeinoKA , et al. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Cardiothoracic Anesthesiology2009;87:448-54. [DOI: 10.1016/j.athoracsur.2008.10.029]">Eriksson 2009</a>), France (336 participants enrolled; <a href="./references#CD013781-bbs2-0004" title="CholleyB , CarubaT , GrosjeanS , AmourJ , OuattaraA , VillacortaJ , et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA2017;318:548-56. [DOI: 10.1001/jama.2017.9973]">Cholley 2017</a>), the USA (252 participants enrolled; <a href="./references#CD013781-bbs2-0023" title="LevinR , DegrangeM , Del MazoC , TanusE , PorcileR . Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Experimental and Clinical Cardiology2012;17:125-30. [PMID: 23620700]">Levin 2012</a>), or the USA plus Canada (882 participants enrolled; <a href="./references#CD013781-bbs2-0024" title="MehtaRH , LeimbergerJD , vanDiepenS , MezaJ , WangA , JankowichR , et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. New England Journal of Medicine2017;376:2032-42. [DOI: 10.1056/NEJMoa1616218]">Mehta 2017</a>). </p> </section> <section id="CD013781-sec-0044"> <h4 class="title">Examined surgical interventions</h4> <p>The types of surgery assessed included coronary artery bypass graft (CABG), off‐pump coronary artery bypass graft (OPCABG), and valve surgery. In one study, there was no detailed description of the cardiac surgery performed (<a href="./references#CD013781-bbs2-0005" title="De HertSG , LorsomradeeS , CromheeckeS , Van der LindenPJ . The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesthesia and Analgesia2007;104:766-73. [DOI: 10.1213/01.ane.0000256863.92050.d3]">De Hert 2007</a>). Only CABG (<a href="./references#CD013781-bbs2-0002" title="AnastasiadisK , AntonitsisP , VranisK , KleontasA , AsteriouC , GrosomanidisV , et al. Effectiveness of prophylactic levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting: a randomized pilot study. Interactive Cardiovascular and Thoracic Surgery2016;23:740-8. [DOI: 10.1093/icvts/ivw213]">Anastasiadis 2016</a>; <a href="./references#CD013781-bbs2-0009" title="RikssonHI , JalonenJR , HeikkinenLO , KivikkoM , LaineM , LeinoKA , et al. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Cardiothoracic Anesthesiology2009;87:448-54. [DOI: 10.1016/j.athoracsur.2008.10.029]">Eriksson 2009</a>; <a href="./references#CD013781-bbs2-0012" title="GatotI , AbramovD , TsodikovV , YeshayahuM , OrmanS , GavrielA , et al. Should we give prophylactic renal-dose dopamine after coronary artery bypass surgery?Journal of Cardiac Surgery2004;19:128-33. [DOI: 10.1111/j.0886-0440.2004.04044.x]">Gatot 2004</a>; <a href="./references#CD013781-bbs2-0019" title="KikuraM , SatoS . The efficacy of preemptive milrinone or amrinone therapy in patients undergoing coronary artery bypass grafting. Anesthesia and Analgesia2002;94:22-30. [DOI: 10.1097/00000539-200201000-00005]">Kikura 2002</a>; <a href="./references#CD013781-bbs2-0023" title="LevinR , DegrangeM , Del MazoC , TanusE , PorcileR . Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Experimental and Clinical Cardiology2012;17:125-30. [PMID: 23620700]">Levin 2012</a>; <a href="./references#CD013781-bbs2-0028" title="TritapepeL , De SantisV , VitaleD , SantulliM , MorelliA , NofroniI , et al. Preconditioning effects of levosimendan in coronary artery bypass grafting - a pilot study. British Journal of Anaesthesia2006;96:694-700. [DOI: 10.1093/bja/ael082]">Tritapepe 2006</a>; <a href="./references#CD013781-bbs2-0029" title="TritapepeL , De SantisV , VitaleD , GuarracinoF , PellegriniF , PietropaoliP , et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. British Journal of Anaesthesia2009;102:198-204. [DOI: 10.1093/bja/aen367]">Tritapepe 2009</a>) and OPCABG (<a href="./references#CD013781-bbs2-0001" title="AminSW , Abd-ElgalilSM , MohamedSA , AhmedMM , HamawyTY , FathiLM . Levosimendan versus milrinone in the management of impaired left ventricular function in patients undergoing coronary artery bypass graft surgery. Open Anesthesia Journal2019;13:59-67. [DOI: 10.2174/2589645801913010059]">Amin 2019</a>; <a href="./references#CD013781-bbs2-0007" title="DesaiPM , SarkarMS , UmbarkarSR . Prophylactic preoperative levosimendan for off-pump coronary artery bypass grafting in patients with left ventricular dysfunction: single-centered randomized prospective study. Annals of Cardiac Anaesthesia2018;21:123-8. [DOI: 10.4103/aca.ACA_178_17]">Desai 2018</a>; <a href="./references#CD013781-bbs2-0013" title="HadadzadehM , HosseiniSH , Mostafavi-Pour-ManshadiSM , NaderiN , Emami-MeybodiM . Effect of milrinone on short term outcome of patients with myocardial dysfunction undergoing off-pump coronary artery bypass graft: a randomized clinical trial. Acta Medica Iranica2013;51:681-6. [PMID: 24338139]">Hadadzadeh 2013</a>; <a href="./references#CD013781-bbs2-0016" title="JoHR , LeeWK , KimYH , MinJH , ChaeYK , ChoiIG , et al. The effect of milrinone infusion on right ventricular function during coronary anastomosis and early outcomes in patients undergoing off-pump coronary artery bypass surgery. Korean Journal of Anesthesiology2010;59:92-8. [DOI: 10.4097/kjae.2010.59.2.92]">Jo 2010</a>; <a href="./references#CD013781-bbs2-0018" title="KandasamyA , SimonHA , MurthyP , AnnaduraiM , AliMM , RamanathanG . Comparison of levosimendan versus dobutamine in patients with moderate to severe left ventricular dysfunction undergoing off-pump coronary artery bypass grafting: a randomized prospective study. Annals of Cardiac Anaesthesia2017;20:200-6. [DOI: 10.4103/aca.ACA_195_16]">Kandasamy 2017</a>; <a href="./references#CD013781-bbs2-0020" title="KodalliRK , SundarAS , VakamudiM , RavulapaliH , NandipatiS , ChandrasekaranN , et al. Effect of levosimendan on hemodynamic changes in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled study. Annals of Cardiac Anaesthesia2013;16:94-9. [DOI: 10.4103/0971-9784.109737]">Kodalli 2013</a>; <a href="./references#CD013781-bbs2-0026" title="ShahB , SharmaP , BrahmbhattA , ShahR , RathodB , ShastriN , et al. Study of levosimendan during off-pump coronary artery bypass grafting in patients with LV dysfunction: a double-blind randomized study. Indian Journal of Pharmacology2014;46:29-34. [DOI: 10.4103/0253-7613.125161]">Shah 2014</a>) participants were included in seven studies each; five trials were limited to participants with valve surgery (<a href="./references#CD013781-bbs2-0003" title="BaysalA , YanartasM , DogukanM , GundogusN , KocakT , Koksal C. Levosimendan improves renal outcome in cardiac surgery: a randomized trial. Journal of Cardiothoracic and Vascular Anesthesia2014;28:586-94. [DOI: 10.1053/j.jvca.2013.09.004]">Baysal 2014</a>; <a href="./references#CD013781-bbs2-0010" title="ErsoyO , BoysanE , UnalEU , YayK , YenerU , CicekciogluF , et al. Effectiveness of prophylactic levosimendan in high-risk valve surgery patients. Cardiovascular Journal of Africa2013;24:260-4. [DOI: 10.5830/CVJA-2013-047]">Ersoy 2013</a>; <a href="./references#CD013781-bbs2-0011" title="GandhamR , SyamasundarA , RavulapalliH , KarthekeyanRB , VakamudiM , KodalliR , et al. A comparison of hemodynamic effects of levosimendan and dobutamine in patients undergoing mitral valve repair / replacement for severe mitral stenosis. Annals of Cardiac Anaesthesia2013;16:11-5. [DOI: 10.4103/0971-9784.105363]">Gandham 2013</a>; <a href="./references#CD013781-bbs2-0017" title="Juhl-OlsenP , Jakobsen C-J, RasmussenLA , BhavsarR , Klaaborg K-E, FrederiksenCA , et al. Effects of levosimendan in patients with left ventricular hypertrophy undergoing aortic valve replacement. Acta Anaesthesiologica Scandinavica2015;59:65-77. [DOI: 10.1111/aas.12425]">Juhl‐Olsen 2015</a>; <a href="./references#CD013781-bbs2-0025" title="MishraA , KumarB , DuttaV , AryaVK , MishraAK . Comparative effect of levosimendan and milrinone in cardiac surgery patients with pulmonary hypertension and left ventricular dysfunction. Journal of Cardiothoracic and Vascular Anesthesia2016;30:639-46. [DOI: 10.1053/j.jvca.2016.01.015]">Mishra 2016</a>). In one study, both patients with CABG and patients with valve surgery were included (<a href="./references#CD013781-bbs2-0014" title="HuX , XuQ . Application of levosimendan in severe patients after cardiac surgery. Chinese Journal of Clinical Pharmacology and Therapeutics2020;25:1027-32. [DOI: 10.12092/j.issn.1009-2501.2020.09.010]">Hu 2020</a>). Also, eight studies included participants with combined procedures, i.e. CABG with valve surgery or valve surgery with CABG (<a href="./references#CD013781-bbs2-0004" title="CholleyB , CarubaT , GrosjeanS , AmourJ , OuattaraA , VillacortaJ , et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA2017;318:548-56. [DOI: 10.1001/jama.2017.9973]">Cholley 2017</a>; <a href="./references#CD013781-bbs2-0006" title="DenaultAY , BussièresJS , ArellanoR , FineganB , GavraP , HaddadF , et al. A multicentre randomized-controlled trial of inhaled milrinone in high-risk cardiac surgical patients. Canadian Journal of Anesthesia2016;63:1140-53. [DOI: 10.1007/s12630-016-0709-8]">Denault 2016</a>; <a href="./references#CD013781-bbs2-0008" title="ErbJ , BeutlhauserT , FeldheiserA , SchusterB , TreskatschS , GrubitzschH , et al. Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery. Journal of International Medical Research2014;42:750-64. [DOI: 10.1177/0300060513516293]">Erb 2014</a>; <a href="./references#CD013781-bbs2-0015" title="JärveläK , MaaranenP , SistoT , RuokonenE . Levosimendan in aortic valve surgery: cardiac performance and recovery. Journal of Cardiothoracic and Vascular Anesthesia2008;22:693-8. [DOI: 10.1053/j.jvca.2008.01.024]">Jävelä 2008</a>; <a href="./references#CD013781-bbs2-0021" title="LahtinenP , PitkänenO , PölönenP , TurpeinenA , KiviniemiV , UusaroA . Levosimendan reduces heart failure after cardiac surgery: a prospective, randomized, placebo-controlled trial. Criítical Care Medicine2011;39:2263-70. [DOI: 10.1097/CCM.0b013e3182227b97]">Lahtinen 2011</a>; <a href="./references#CD013781-bbs2-0022" title="LeppikangasH , JärveläK , SistoT , MaaranenP , VirtanenM , LehtoP , et al. Preoperative levosimendan infusion in combined aortic valve and coronary bypass surgery. British Journal of Anaesthesia2011;106:298-304. [DOI: 10.1093/bja/aeq402]">Leppikangas 2011</a>; <a href="./references#CD013781-bbs2-0024" title="MehtaRH , LeimbergerJD , vanDiepenS , MezaJ , WangA , JankowichR , et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. New England Journal of Medicine2017;376:2032-42. [DOI: 10.1056/NEJMoa1616218]">Mehta 2017</a>; <a href="./references#CD013781-bbs2-0027" title="SharmaP , MalhotraA , GandhiS , GargP , BishnoiA , GandhiH . Preoperative levosimendan in ischemic mitral valve repair. Asian Cardiovascular and Thoracic Annals2014;22:539-45. [DOI: 10.1177/0218492313499352]">Sharma 2014</a>). </p> <p>Emergency surgery was an exclusion criterion in 13 studies (<a href="./references#CD013781-bbs2-0002" title="AnastasiadisK , AntonitsisP , VranisK , KleontasA , AsteriouC , GrosomanidisV , et al. Effectiveness of prophylactic levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting: a randomized pilot study. Interactive Cardiovascular and Thoracic Surgery2016;23:740-8. [DOI: 10.1093/icvts/ivw213]">Anastasiadis 2016</a>; <a href="./references#CD013781-bbs2-0003" title="BaysalA , YanartasM , DogukanM , GundogusN , KocakT , Koksal C. Levosimendan improves renal outcome in cardiac surgery: a randomized trial. Journal of Cardiothoracic and Vascular Anesthesia2014;28:586-94. [DOI: 10.1053/j.jvca.2013.09.004]">Baysal 2014</a>; <a href="./references#CD013781-bbs2-0004" title="CholleyB , CarubaT , GrosjeanS , AmourJ , OuattaraA , VillacortaJ , et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA2017;318:548-56. [DOI: 10.1001/jama.2017.9973]">Cholley 2017</a>; <a href="./references#CD013781-bbs2-0006" title="DenaultAY , BussièresJS , ArellanoR , FineganB , GavraP , HaddadF , et al. A multicentre randomized-controlled trial of inhaled milrinone in high-risk cardiac surgical patients. Canadian Journal of Anesthesia2016;63:1140-53. [DOI: 10.1007/s12630-016-0709-8]">Denault 2016</a>; <a href="./references#CD013781-bbs2-0007" title="DesaiPM , SarkarMS , UmbarkarSR . Prophylactic preoperative levosimendan for off-pump coronary artery bypass grafting in patients with left ventricular dysfunction: single-centered randomized prospective study. Annals of Cardiac Anaesthesia2018;21:123-8. [DOI: 10.4103/aca.ACA_178_17]">Desai 2018</a>; <a href="./references#CD013781-bbs2-0013" title="HadadzadehM , HosseiniSH , Mostafavi-Pour-ManshadiSM , NaderiN , Emami-MeybodiM . Effect of milrinone on short term outcome of patients with myocardial dysfunction undergoing off-pump coronary artery bypass graft: a randomized clinical trial. Acta Medica Iranica2013;51:681-6. [PMID: 24338139]">Hadadzadeh 2013</a>; <a href="./references#CD013781-bbs2-0016" title="JoHR , LeeWK , KimYH , MinJH , ChaeYK , ChoiIG , et al. The effect of milrinone infusion on right ventricular function during coronary anastomosis and early outcomes in patients undergoing off-pump coronary artery bypass surgery. Korean Journal of Anesthesiology2010;59:92-8. [DOI: 10.4097/kjae.2010.59.2.92]">Jo 2010</a>; <a href="./references#CD013781-bbs2-0018" title="KandasamyA , SimonHA , MurthyP , AnnaduraiM , AliMM , RamanathanG . Comparison of levosimendan versus dobutamine in patients with moderate to severe left ventricular dysfunction undergoing off-pump coronary artery bypass grafting: a randomized prospective study. Annals of Cardiac Anaesthesia2017;20:200-6. [DOI: 10.4103/aca.ACA_195_16]">Kandasamy 2017</a>; <a href="./references#CD013781-bbs2-0019" title="KikuraM , SatoS . The efficacy of preemptive milrinone or amrinone therapy in patients undergoing coronary artery bypass grafting. Anesthesia and Analgesia2002;94:22-30. [DOI: 10.1097/00000539-200201000-00005]">Kikura 2002</a>; <a href="./references#CD013781-bbs2-0023" title="LevinR , DegrangeM , Del MazoC , TanusE , PorcileR . Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Experimental and Clinical Cardiology2012;17:125-30. [PMID: 23620700]">Levin 2012</a>; <a href="./references#CD013781-bbs2-0025" title="MishraA , KumarB , DuttaV , AryaVK , MishraAK . Comparative effect of levosimendan and milrinone in cardiac surgery patients with pulmonary hypertension and left ventricular dysfunction. Journal of Cardiothoracic and Vascular Anesthesia2016;30:639-46. [DOI: 10.1053/j.jvca.2016.01.015]">Mishra 2016</a>; <a href="./references#CD013781-bbs2-0026" title="ShahB , SharmaP , BrahmbhattA , ShahR , RathodB , ShastriN , et al. Study of levosimendan during off-pump coronary artery bypass grafting in patients with LV dysfunction: a double-blind randomized study. Indian Journal of Pharmacology2014;46:29-34. [DOI: 10.4103/0253-7613.125161]">Shah 2014</a>; <a href="./references#CD013781-bbs2-0027" title="SharmaP , MalhotraA , GandhiS , GargP , BishnoiA , GandhiH . Preoperative levosimendan in ischemic mitral valve repair. Asian Cardiovascular and Thoracic Annals2014;22:539-45. [DOI: 10.1177/0218492313499352]">Sharma 2014</a>). A total of 12 studies excluded participants with a history of heart surgery (<a href="./references#CD013781-bbs2-0002" title="AnastasiadisK , AntonitsisP , VranisK , KleontasA , AsteriouC , GrosomanidisV , et al. Effectiveness of prophylactic levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting: a randomized pilot study. Interactive Cardiovascular and Thoracic Surgery2016;23:740-8. [DOI: 10.1093/icvts/ivw213]">Anastasiadis 2016</a>; <a href="./references#CD013781-bbs2-0003" title="BaysalA , YanartasM , DogukanM , GundogusN , KocakT , Koksal C. Levosimendan improves renal outcome in cardiac surgery: a randomized trial. Journal of Cardiothoracic and Vascular Anesthesia2014;28:586-94. [DOI: 10.1053/j.jvca.2013.09.004]">Baysal 2014</a>; <a href="./references#CD013781-bbs2-0007" title="DesaiPM , SarkarMS , UmbarkarSR . Prophylactic preoperative levosimendan for off-pump coronary artery bypass grafting in patients with left ventricular dysfunction: single-centered randomized prospective study. Annals of Cardiac Anaesthesia2018;21:123-8. [DOI: 10.4103/aca.ACA_178_17]">Desai 2018</a>; <a href="./references#CD013781-bbs2-0009" title="RikssonHI , JalonenJR , HeikkinenLO , KivikkoM , LaineM , LeinoKA , et al. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Cardiothoracic Anesthesiology2009;87:448-54. [DOI: 10.1016/j.athoracsur.2008.10.029]">Eriksson 2009</a>; <a href="./references#CD013781-bbs2-0011" title="GandhamR , SyamasundarA , RavulapalliH , KarthekeyanRB , VakamudiM , KodalliR , et al. A comparison of hemodynamic effects of levosimendan and dobutamine in patients undergoing mitral valve repair / replacement for severe mitral stenosis. Annals of Cardiac Anaesthesia2013;16:11-5. [DOI: 10.4103/0971-9784.105363]">Gandham 2013</a>; <a href="./references#CD013781-bbs2-0012" title="GatotI , AbramovD , TsodikovV , YeshayahuM , OrmanS , GavrielA , et al. Should we give prophylactic renal-dose dopamine after coronary artery bypass surgery?Journal of Cardiac Surgery2004;19:128-33. [DOI: 10.1111/j.0886-0440.2004.04044.x]">Gatot 2004</a>; <a href="./references#CD013781-bbs2-0018" title="KandasamyA , SimonHA , MurthyP , AnnaduraiM , AliMM , RamanathanG . Comparison of levosimendan versus dobutamine in patients with moderate to severe left ventricular dysfunction undergoing off-pump coronary artery bypass grafting: a randomized prospective study. Annals of Cardiac Anaesthesia2017;20:200-6. [DOI: 10.4103/aca.ACA_195_16]">Kandasamy 2017</a>; <a href="./references#CD013781-bbs2-0020" title="KodalliRK , SundarAS , VakamudiM , RavulapaliH , NandipatiS , ChandrasekaranN , et al. Effect of levosimendan on hemodynamic changes in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled study. Annals of Cardiac Anaesthesia2013;16:94-9. [DOI: 10.4103/0971-9784.109737]">Kodalli 2013</a>; <a href="./references#CD013781-bbs2-0026" title="ShahB , SharmaP , BrahmbhattA , ShahR , RathodB , ShastriN , et al. Study of levosimendan during off-pump coronary artery bypass grafting in patients with LV dysfunction: a double-blind randomized study. Indian Journal of Pharmacology2014;46:29-34. [DOI: 10.4103/0253-7613.125161]">Shah 2014</a>; <a href="./references#CD013781-bbs2-0027" title="SharmaP , MalhotraA , GandhiS , GargP , BishnoiA , GandhiH . Preoperative levosimendan in ischemic mitral valve repair. Asian Cardiovascular and Thoracic Annals2014;22:539-45. [DOI: 10.1177/0218492313499352]">Sharma 2014</a>; <a href="./references#CD013781-bbs2-0028" title="TritapepeL , De SantisV , VitaleD , SantulliM , MorelliA , NofroniI , et al. Preconditioning effects of levosimendan in coronary artery bypass grafting - a pilot study. British Journal of Anaesthesia2006;96:694-700. [DOI: 10.1093/bja/ael082]">Tritapepe 2006</a>; <a href="./references#CD013781-bbs2-0029" title="TritapepeL , De SantisV , VitaleD , GuarracinoF , PellegriniF , PietropaoliP , et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. British Journal of Anaesthesia2009;102:198-204. [DOI: 10.1093/bja/aen367]">Tritapepe 2009</a>). </p> </section> <section id="CD013781-sec-0045"> <h4 class="title">Examined prophylactic medication</h4> <p>The majority of trials investigated the prophylactic usage of levosimendan compared to placebo (<a href="./references#CD013781-bbs2-0002" title="AnastasiadisK , AntonitsisP , VranisK , KleontasA , AsteriouC , GrosomanidisV , et al. Effectiveness of prophylactic levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting: a randomized pilot study. Interactive Cardiovascular and Thoracic Surgery2016;23:740-8. [DOI: 10.1093/icvts/ivw213]">Anastasiadis 2016</a>; <a href="./references#CD013781-bbs2-0004" title="CholleyB , CarubaT , GrosjeanS , AmourJ , OuattaraA , VillacortaJ , et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA2017;318:548-56. [DOI: 10.1001/jama.2017.9973]">Cholley 2017</a>; <a href="./references#CD013781-bbs2-0008" title="ErbJ , BeutlhauserT , FeldheiserA , SchusterB , TreskatschS , GrubitzschH , et al. Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery. Journal of International Medical Research2014;42:750-64. [DOI: 10.1177/0300060513516293]">Erb 2014</a>; <a href="./references#CD013781-bbs2-0009" title="RikssonHI , JalonenJR , HeikkinenLO , KivikkoM , LaineM , LeinoKA , et al. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Cardiothoracic Anesthesiology2009;87:448-54. [DOI: 10.1016/j.athoracsur.2008.10.029]">Eriksson 2009</a>; <a href="./references#CD013781-bbs2-0014" title="HuX , XuQ . Application of levosimendan in severe patients after cardiac surgery. Chinese Journal of Clinical Pharmacology and Therapeutics2020;25:1027-32. [DOI: 10.12092/j.issn.1009-2501.2020.09.010]">Hu 2020</a>; <a href="./references#CD013781-bbs2-0015" title="JärveläK , MaaranenP , SistoT , RuokonenE . Levosimendan in aortic valve surgery: cardiac performance and recovery. Journal of Cardiothoracic and Vascular Anesthesia2008;22:693-8. [DOI: 10.1053/j.jvca.2008.01.024]">Jävelä 2008</a>; <a href="./references#CD013781-bbs2-0017" title="Juhl-OlsenP , Jakobsen C-J, RasmussenLA , BhavsarR , Klaaborg K-E, FrederiksenCA , et al. Effects of levosimendan in patients with left ventricular hypertrophy undergoing aortic valve replacement. Acta Anaesthesiologica Scandinavica2015;59:65-77. [DOI: 10.1111/aas.12425]">Juhl‐Olsen 2015</a>; <a href="./references#CD013781-bbs2-0020" title="KodalliRK , SundarAS , VakamudiM , RavulapaliH , NandipatiS , ChandrasekaranN , et al. Effect of levosimendan on hemodynamic changes in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled study. Annals of Cardiac Anaesthesia2013;16:94-9. [DOI: 10.4103/0971-9784.109737]">Kodalli 2013</a>; <a href="./references#CD013781-bbs2-0021" title="LahtinenP , PitkänenO , PölönenP , TurpeinenA , KiviniemiV , UusaroA . Levosimendan reduces heart failure after cardiac surgery: a prospective, randomized, placebo-controlled trial. Criítical Care Medicine2011;39:2263-70. [DOI: 10.1097/CCM.0b013e3182227b97]">Lahtinen 2011</a>; <a href="./references#CD013781-bbs2-0022" title="LeppikangasH , JärveläK , SistoT , MaaranenP , VirtanenM , LehtoP , et al. Preoperative levosimendan infusion in combined aortic valve and coronary bypass surgery. British Journal of Anaesthesia2011;106:298-304. [DOI: 10.1093/bja/aeq402]">Leppikangas 2011</a>; <a href="./references#CD013781-bbs2-0023" title="LevinR , DegrangeM , Del MazoC , TanusE , PorcileR . Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Experimental and Clinical Cardiology2012;17:125-30. [PMID: 23620700]">Levin 2012</a>; <a href="./references#CD013781-bbs2-0024" title="MehtaRH , LeimbergerJD , vanDiepenS , MezaJ , WangA , JankowichR , et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. New England Journal of Medicine2017;376:2032-42. [DOI: 10.1056/NEJMoa1616218]">Mehta 2017</a>; <a href="./references#CD013781-bbs2-0026" title="ShahB , SharmaP , BrahmbhattA , ShahR , RathodB , ShastriN , et al. Study of levosimendan during off-pump coronary artery bypass grafting in patients with LV dysfunction: a double-blind randomized study. Indian Journal of Pharmacology2014;46:29-34. [DOI: 10.4103/0253-7613.125161]">Shah 2014</a>; <a href="./references#CD013781-bbs2-0027" title="SharmaP , MalhotraA , GandhiS , GargP , BishnoiA , GandhiH . Preoperative levosimendan in ischemic mitral valve repair. Asian Cardiovascular and Thoracic Annals2014;22:539-45. [DOI: 10.1177/0218492313499352]">Sharma 2014</a>; <a href="./references#CD013781-bbs2-0028" title="TritapepeL , De SantisV , VitaleD , SantulliM , MorelliA , NofroniI , et al. Preconditioning effects of levosimendan in coronary artery bypass grafting - a pilot study. British Journal of Anaesthesia2006;96:694-700. [DOI: 10.1093/bja/ael082]">Tritapepe 2006</a>; <a href="./references#CD013781-bbs2-0029" title="TritapepeL , De SantisV , VitaleD , GuarracinoF , PellegriniF , PietropaoliP , et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. British Journal of Anaesthesia2009;102:198-204. [DOI: 10.1093/bja/aen367]">Tritapepe 2009</a>), standard cardiac care (<a href="./references#CD013781-bbs2-0003" title="BaysalA , YanartasM , DogukanM , GundogusN , KocakT , Koksal C. Levosimendan improves renal outcome in cardiac surgery: a randomized trial. Journal of Cardiothoracic and Vascular Anesthesia2014;28:586-94. [DOI: 10.1053/j.jvca.2013.09.004]">Baysal 2014</a>; <a href="./references#CD013781-bbs2-0007" title="DesaiPM , SarkarMS , UmbarkarSR . Prophylactic preoperative levosimendan for off-pump coronary artery bypass grafting in patients with left ventricular dysfunction: single-centered randomized prospective study. Annals of Cardiac Anaesthesia2018;21:123-8. [DOI: 10.4103/aca.ACA_178_17]">Desai 2018</a>; <a href="./references#CD013781-bbs2-0010" title="ErsoyO , BoysanE , UnalEU , YayK , YenerU , CicekciogluF , et al. Effectiveness of prophylactic levosimendan in high-risk valve surgery patients. Cardiovascular Journal of Africa2013;24:260-4. [DOI: 10.5830/CVJA-2013-047]">Ersoy 2013</a>), or another inotropic agent (either milrinone (<a href="./references#CD013781-bbs2-0001" title="AminSW , Abd-ElgalilSM , MohamedSA , AhmedMM , HamawyTY , FathiLM . Levosimendan versus milrinone in the management of impaired left ventricular function in patients undergoing coronary artery bypass graft surgery. Open Anesthesia Journal2019;13:59-67. [DOI: 10.2174/2589645801913010059]">Amin 2019</a>; <a href="./references#CD013781-bbs2-0005" title="De HertSG , LorsomradeeS , CromheeckeS , Van der LindenPJ . The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesthesia and Analgesia2007;104:766-73. [DOI: 10.1213/01.ane.0000256863.92050.d3]">De Hert 2007</a>; <a href="./references#CD013781-bbs2-0025" title="MishraA , KumarB , DuttaV , AryaVK , MishraAK . Comparative effect of levosimendan and milrinone in cardiac surgery patients with pulmonary hypertension and left ventricular dysfunction. Journal of Cardiothoracic and Vascular Anesthesia2016;30:639-46. [DOI: 10.1053/j.jvca.2016.01.015]">Mishra 2016</a>) or dobutamine (<a href="./references#CD013781-bbs2-0011" title="GandhamR , SyamasundarA , RavulapalliH , KarthekeyanRB , VakamudiM , KodalliR , et al. A comparison of hemodynamic effects of levosimendan and dobutamine in patients undergoing mitral valve repair / replacement for severe mitral stenosis. Annals of Cardiac Anaesthesia2013;16:11-5. [DOI: 10.4103/0971-9784.105363]">Gandham 2013</a>; <a href="./references#CD013781-bbs2-0018" title="KandasamyA , SimonHA , MurthyP , AnnaduraiM , AliMM , RamanathanG . Comparison of levosimendan versus dobutamine in patients with moderate to severe left ventricular dysfunction undergoing off-pump coronary artery bypass grafting: a randomized prospective study. Annals of Cardiac Anaesthesia2017;20:200-6. [DOI: 10.4103/aca.ACA_195_16]">Kandasamy 2017</a>)). Altogether, 2290 participants were enrolled in the studies on levosimendan compared to placebo, 208 participants in the studies on levosimendan compared to standard cardiac care, 100 participants in the studies on levosimendan compared to milrinone, and 140 participants in the studies on levosimendan compared to dobutamine. There were only four trials investigating milrinone versus placebo (<a href="./references#CD013781-bbs2-0006" title="DenaultAY , BussièresJS , ArellanoR , FineganB , GavraP , HaddadF , et al. A multicentre randomized-controlled trial of inhaled milrinone in high-risk cardiac surgical patients. Canadian Journal of Anesthesia2016;63:1140-53. [DOI: 10.1007/s12630-016-0709-8]">Denault 2016</a>; <a href="./references#CD013781-bbs2-0013" title="HadadzadehM , HosseiniSH , Mostafavi-Pour-ManshadiSM , NaderiN , Emami-MeybodiM . Effect of milrinone on short term outcome of patients with myocardial dysfunction undergoing off-pump coronary artery bypass graft: a randomized clinical trial. Acta Medica Iranica2013;51:681-6. [PMID: 24338139]">Hadadzadeh 2013</a>; <a href="./references#CD013781-bbs2-0016" title="JoHR , LeeWK , KimYH , MinJH , ChaeYK , ChoiIG , et al. The effect of milrinone infusion on right ventricular function during coronary anastomosis and early outcomes in patients undergoing off-pump coronary artery bypass surgery. Korean Journal of Anesthesiology2010;59:92-8. [DOI: 10.4097/kjae.2010.59.2.92]">Jo 2010</a>; <a href="./references#CD013781-bbs2-0019" title="KikuraM , SatoS . The efficacy of preemptive milrinone or amrinone therapy in patients undergoing coronary artery bypass grafting. Anesthesia and Analgesia2002;94:22-30. [DOI: 10.1097/00000539-200201000-00005]">Kikura 2002</a>), one trial investigating dopamine versus placebo (<a href="./references#CD013781-bbs2-0012" title="GatotI , AbramovD , TsodikovV , YeshayahuM , OrmanS , GavrielA , et al. Should we give prophylactic renal-dose dopamine after coronary artery bypass surgery?Journal of Cardiac Surgery2004;19:128-33. [DOI: 10.1111/j.0886-0440.2004.04044.x]">Gatot 2004</a>), and one trial investigating amrinone versus milrinone or placebo (<a href="./references#CD013781-bbs2-0019" title="KikuraM , SatoS . The efficacy of preemptive milrinone or amrinone therapy in patients undergoing coronary artery bypass grafting. Anesthesia and Analgesia2002;94:22-30. [DOI: 10.1097/00000539-200201000-00005]">Kikura 2002</a>). The number of enrolled participants was 275 for the comparison of milrinone versus placebo, 89 for the comparison of dopamine versus placebo, and 45 for the comparison of amrinone versus milrinone or placebo. </p> <p>Levosimendan was administered as a continuous infusion without loading dose in 15 studies (<a href="./references#CD013781-bbs2-0001" title="AminSW , Abd-ElgalilSM , MohamedSA , AhmedMM , HamawyTY , FathiLM . Levosimendan versus milrinone in the management of impaired left ventricular function in patients undergoing coronary artery bypass graft surgery. Open Anesthesia Journal2019;13:59-67. [DOI: 10.2174/2589645801913010059]">Amin 2019</a>; <a href="./references#CD013781-bbs2-0002" title="AnastasiadisK , AntonitsisP , VranisK , KleontasA , AsteriouC , GrosomanidisV , et al. Effectiveness of prophylactic levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting: a randomized pilot study. Interactive Cardiovascular and Thoracic Surgery2016;23:740-8. [DOI: 10.1093/icvts/ivw213]">Anastasiadis 2016</a>; <a href="./references#CD013781-bbs2-0004" title="CholleyB , CarubaT , GrosjeanS , AmourJ , OuattaraA , VillacortaJ , et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA2017;318:548-56. [DOI: 10.1001/jama.2017.9973]">Cholley 2017</a>; <a href="./references#CD013781-bbs2-0005" title="De HertSG , LorsomradeeS , CromheeckeS , Van der LindenPJ . The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesthesia and Analgesia2007;104:766-73. [DOI: 10.1213/01.ane.0000256863.92050.d3]">De Hert 2007</a>; <a href="./references#CD013781-bbs2-0007" title="DesaiPM , SarkarMS , UmbarkarSR . Prophylactic preoperative levosimendan for off-pump coronary artery bypass grafting in patients with left ventricular dysfunction: single-centered randomized prospective study. Annals of Cardiac Anaesthesia2018;21:123-8. [DOI: 10.4103/aca.ACA_178_17]">Desai 2018</a>; <a href="./references#CD013781-bbs2-0008" title="ErbJ , BeutlhauserT , FeldheiserA , SchusterB , TreskatschS , GrubitzschH , et al. Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery. Journal of International Medical Research2014;42:750-64. [DOI: 10.1177/0300060513516293]">Erb 2014</a>; <a href="./references#CD013781-bbs2-0011" title="GandhamR , SyamasundarA , RavulapalliH , KarthekeyanRB , VakamudiM , KodalliR , et al. A comparison of hemodynamic effects of levosimendan and dobutamine in patients undergoing mitral valve repair / replacement for severe mitral stenosis. Annals of Cardiac Anaesthesia2013;16:11-5. [DOI: 10.4103/0971-9784.105363]">Gandham 2013</a>; <a href="./references#CD013781-bbs2-0014" title="HuX , XuQ . Application of levosimendan in severe patients after cardiac surgery. Chinese Journal of Clinical Pharmacology and Therapeutics2020;25:1027-32. [DOI: 10.12092/j.issn.1009-2501.2020.09.010]">Hu 2020</a>; <a href="./references#CD013781-bbs2-0015" title="JärveläK , MaaranenP , SistoT , RuokonenE . Levosimendan in aortic valve surgery: cardiac performance and recovery. Journal of Cardiothoracic and Vascular Anesthesia2008;22:693-8. [DOI: 10.1053/j.jvca.2008.01.024]">Jävelä 2008</a>; <a href="./references#CD013781-bbs2-0017" title="Juhl-OlsenP , Jakobsen C-J, RasmussenLA , BhavsarR , Klaaborg K-E, FrederiksenCA , et al. Effects of levosimendan in patients with left ventricular hypertrophy undergoing aortic valve replacement. Acta Anaesthesiologica Scandinavica2015;59:65-77. [DOI: 10.1111/aas.12425]">Juhl‐Olsen 2015</a>; <a href="./references#CD013781-bbs2-0018" title="KandasamyA , SimonHA , MurthyP , AnnaduraiM , AliMM , RamanathanG . Comparison of levosimendan versus dobutamine in patients with moderate to severe left ventricular dysfunction undergoing off-pump coronary artery bypass grafting: a randomized prospective study. Annals of Cardiac Anaesthesia2017;20:200-6. [DOI: 10.4103/aca.ACA_195_16]">Kandasamy 2017</a>; <a href="./references#CD013781-bbs2-0020" title="KodalliRK , SundarAS , VakamudiM , RavulapaliH , NandipatiS , ChandrasekaranN , et al. Effect of levosimendan on hemodynamic changes in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled study. Annals of Cardiac Anaesthesia2013;16:94-9. [DOI: 10.4103/0971-9784.109737]">Kodalli 2013</a>; <a href="./references#CD013781-bbs2-0024" title="MehtaRH , LeimbergerJD , vanDiepenS , MezaJ , WangA , JankowichR , et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. New England Journal of Medicine2017;376:2032-42. [DOI: 10.1056/NEJMoa1616218]">Mehta 2017</a>; <a href="./references#CD013781-bbs2-0026" title="ShahB , SharmaP , BrahmbhattA , ShahR , RathodB , ShastriN , et al. Study of levosimendan during off-pump coronary artery bypass grafting in patients with LV dysfunction: a double-blind randomized study. Indian Journal of Pharmacology2014;46:29-34. [DOI: 10.4103/0253-7613.125161]">Shah 2014</a>; <a href="./references#CD013781-bbs2-0027" title="SharmaP , MalhotraA , GandhiS , GargP , BishnoiA , GandhiH . Preoperative levosimendan in ischemic mitral valve repair. Asian Cardiovascular and Thoracic Annals2014;22:539-45. [DOI: 10.1177/0218492313499352]">Sharma 2014</a>). In seven studies, the continuous administration was preceded by a bolus (<a href="./references#CD013781-bbs2-0003" title="BaysalA , YanartasM , DogukanM , GundogusN , KocakT , Koksal C. Levosimendan improves renal outcome in cardiac surgery: a randomized trial. Journal of Cardiothoracic and Vascular Anesthesia2014;28:586-94. [DOI: 10.1053/j.jvca.2013.09.004]">Baysal 2014</a>; <a href="./references#CD013781-bbs2-0009" title="RikssonHI , JalonenJR , HeikkinenLO , KivikkoM , LaineM , LeinoKA , et al. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Cardiothoracic Anesthesiology2009;87:448-54. [DOI: 10.1016/j.athoracsur.2008.10.029]">Eriksson 2009</a>; <a href="./references#CD013781-bbs2-0010" title="ErsoyO , BoysanE , UnalEU , YayK , YenerU , CicekciogluF , et al. Effectiveness of prophylactic levosimendan in high-risk valve surgery patients. Cardiovascular Journal of Africa2013;24:260-4. [DOI: 10.5830/CVJA-2013-047]">Ersoy 2013</a>; <a href="./references#CD013781-bbs2-0021" title="LahtinenP , PitkänenO , PölönenP , TurpeinenA , KiviniemiV , UusaroA . Levosimendan reduces heart failure after cardiac surgery: a prospective, randomized, placebo-controlled trial. Criítical Care Medicine2011;39:2263-70. [DOI: 10.1097/CCM.0b013e3182227b97]">Lahtinen 2011</a>; <a href="./references#CD013781-bbs2-0022" title="LeppikangasH , JärveläK , SistoT , MaaranenP , VirtanenM , LehtoP , et al. Preoperative levosimendan infusion in combined aortic valve and coronary bypass surgery. British Journal of Anaesthesia2011;106:298-304. [DOI: 10.1093/bja/aeq402]">Leppikangas 2011</a>; <a href="./references#CD013781-bbs2-0023" title="LevinR , DegrangeM , Del MazoC , TanusE , PorcileR . Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Experimental and Clinical Cardiology2012;17:125-30. [PMID: 23620700]">Levin 2012</a>; <a href="./references#CD013781-bbs2-0025" title="MishraA , KumarB , DuttaV , AryaVK , MishraAK . Comparative effect of levosimendan and milrinone in cardiac surgery patients with pulmonary hypertension and left ventricular dysfunction. Journal of Cardiothoracic and Vascular Anesthesia2016;30:639-46. [DOI: 10.1053/j.jvca.2016.01.015]">Mishra 2016</a>). In two studies, levosimendan was administered by bolus only (<a href="./references#CD013781-bbs2-0028" title="TritapepeL , De SantisV , VitaleD , SantulliM , MorelliA , NofroniI , et al. Preconditioning effects of levosimendan in coronary artery bypass grafting - a pilot study. British Journal of Anaesthesia2006;96:694-700. [DOI: 10.1093/bja/ael082]">Tritapepe 2006</a>; <a href="./references#CD013781-bbs2-0029" title="TritapepeL , De SantisV , VitaleD , GuarracinoF , PellegriniF , PietropaoliP , et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. British Journal of Anaesthesia2009;102:198-204. [DOI: 10.1093/bja/aen367]">Tritapepe 2009</a>). The majority of studies used a dose of 0.1 µg/kg/min for continuous administration (<a href="./references#CD013781-bbs2-0001" title="AminSW , Abd-ElgalilSM , MohamedSA , AhmedMM , HamawyTY , FathiLM . Levosimendan versus milrinone in the management of impaired left ventricular function in patients undergoing coronary artery bypass graft surgery. Open Anesthesia Journal2019;13:59-67. [DOI: 10.2174/2589645801913010059]">Amin 2019</a>; <a href="./references#CD013781-bbs2-0002" title="AnastasiadisK , AntonitsisP , VranisK , KleontasA , AsteriouC , GrosomanidisV , et al. Effectiveness of prophylactic levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting: a randomized pilot study. Interactive Cardiovascular and Thoracic Surgery2016;23:740-8. [DOI: 10.1093/icvts/ivw213]">Anastasiadis 2016</a>; <a href="./references#CD013781-bbs2-0003" title="BaysalA , YanartasM , DogukanM , GundogusN , KocakT , Koksal C. Levosimendan improves renal outcome in cardiac surgery: a randomized trial. Journal of Cardiothoracic and Vascular Anesthesia2014;28:586-94. [DOI: 10.1053/j.jvca.2013.09.004]">Baysal 2014</a>; <a href="./references#CD013781-bbs2-0004" title="CholleyB , CarubaT , GrosjeanS , AmourJ , OuattaraA , VillacortaJ , et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA2017;318:548-56. [DOI: 10.1001/jama.2017.9973]">Cholley 2017</a>; <a href="./references#CD013781-bbs2-0005" title="De HertSG , LorsomradeeS , CromheeckeS , Van der LindenPJ . The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesthesia and Analgesia2007;104:766-73. [DOI: 10.1213/01.ane.0000256863.92050.d3]">De Hert 2007</a>; <a href="./references#CD013781-bbs2-0007" title="DesaiPM , SarkarMS , UmbarkarSR . Prophylactic preoperative levosimendan for off-pump coronary artery bypass grafting in patients with left ventricular dysfunction: single-centered randomized prospective study. Annals of Cardiac Anaesthesia2018;21:123-8. [DOI: 10.4103/aca.ACA_178_17]">Desai 2018</a>; <a href="./references#CD013781-bbs2-0008" title="ErbJ , BeutlhauserT , FeldheiserA , SchusterB , TreskatschS , GrubitzschH , et al. Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery. Journal of International Medical Research2014;42:750-64. [DOI: 10.1177/0300060513516293]">Erb 2014</a>; <a href="./references#CD013781-bbs2-0010" title="ErsoyO , BoysanE , UnalEU , YayK , YenerU , CicekciogluF , et al. Effectiveness of prophylactic levosimendan in high-risk valve surgery patients. Cardiovascular Journal of Africa2013;24:260-4. [DOI: 10.5830/CVJA-2013-047]">Ersoy 2013</a>; <a href="./references#CD013781-bbs2-0011" title="GandhamR , SyamasundarA , RavulapalliH , KarthekeyanRB , VakamudiM , KodalliR , et al. A comparison of hemodynamic effects of levosimendan and dobutamine in patients undergoing mitral valve repair / replacement for severe mitral stenosis. Annals of Cardiac Anaesthesia2013;16:11-5. [DOI: 10.4103/0971-9784.105363]">Gandham 2013</a>; <a href="./references#CD013781-bbs2-0017" title="Juhl-OlsenP , Jakobsen C-J, RasmussenLA , BhavsarR , Klaaborg K-E, FrederiksenCA , et al. Effects of levosimendan in patients with left ventricular hypertrophy undergoing aortic valve replacement. Acta Anaesthesiologica Scandinavica2015;59:65-77. [DOI: 10.1111/aas.12425]">Juhl‐Olsen 2015</a>; <a href="./references#CD013781-bbs2-0018" title="KandasamyA , SimonHA , MurthyP , AnnaduraiM , AliMM , RamanathanG . Comparison of levosimendan versus dobutamine in patients with moderate to severe left ventricular dysfunction undergoing off-pump coronary artery bypass grafting: a randomized prospective study. Annals of Cardiac Anaesthesia2017;20:200-6. [DOI: 10.4103/aca.ACA_195_16]">Kandasamy 2017</a>; <a href="./references#CD013781-bbs2-0020" title="KodalliRK , SundarAS , VakamudiM , RavulapaliH , NandipatiS , ChandrasekaranN , et al. Effect of levosimendan on hemodynamic changes in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled study. Annals of Cardiac Anaesthesia2013;16:94-9. [DOI: 10.4103/0971-9784.109737]">Kodalli 2013</a>; <a href="./references#CD013781-bbs2-0023" title="LevinR , DegrangeM , Del MazoC , TanusE , PorcileR . Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Experimental and Clinical Cardiology2012;17:125-30. [PMID: 23620700]">Levin 2012</a>; <a href="./references#CD013781-bbs2-0025" title="MishraA , KumarB , DuttaV , AryaVK , MishraAK . Comparative effect of levosimendan and milrinone in cardiac surgery patients with pulmonary hypertension and left ventricular dysfunction. Journal of Cardiothoracic and Vascular Anesthesia2016;30:639-46. [DOI: 10.1053/j.jvca.2016.01.015]">Mishra 2016</a>). In four studies, a dose of 0.1 to 0.2 µg/kg/min was used (<a href="./references#CD013781-bbs2-0014" title="HuX , XuQ . Application of levosimendan in severe patients after cardiac surgery. Chinese Journal of Clinical Pharmacology and Therapeutics2020;25:1027-32. [DOI: 10.12092/j.issn.1009-2501.2020.09.010]">Hu 2020</a>; <a href="./references#CD013781-bbs2-0024" title="MehtaRH , LeimbergerJD , vanDiepenS , MezaJ , WangA , JankowichR , et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. New England Journal of Medicine2017;376:2032-42. [DOI: 10.1056/NEJMoa1616218]">Mehta 2017</a>; <a href="./references#CD013781-bbs2-0026" title="ShahB , SharmaP , BrahmbhattA , ShahR , RathodB , ShastriN , et al. Study of levosimendan during off-pump coronary artery bypass grafting in patients with LV dysfunction: a double-blind randomized study. Indian Journal of Pharmacology2014;46:29-34. [DOI: 10.4103/0253-7613.125161]">Shah 2014</a>; <a href="./references#CD013781-bbs2-0027" title="SharmaP , MalhotraA , GandhiS , GargP , BishnoiA , GandhiH . Preoperative levosimendan in ischemic mitral valve repair. Asian Cardiovascular and Thoracic Annals2014;22:539-45. [DOI: 10.1177/0218492313499352]">Sharma 2014</a>) and in another four studies a dose of 0.2 µg/kg/min was administered (<a href="./references#CD013781-bbs2-0009" title="RikssonHI , JalonenJR , HeikkinenLO , KivikkoM , LaineM , LeinoKA , et al. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Cardiothoracic Anesthesiology2009;87:448-54. [DOI: 10.1016/j.athoracsur.2008.10.029]">Eriksson 2009</a>; <a href="./references#CD013781-bbs2-0015" title="JärveläK , MaaranenP , SistoT , RuokonenE . Levosimendan in aortic valve surgery: cardiac performance and recovery. Journal of Cardiothoracic and Vascular Anesthesia2008;22:693-8. [DOI: 10.1053/j.jvca.2008.01.024]">Jävelä 2008</a>; <a href="./references#CD013781-bbs2-0021" title="LahtinenP , PitkänenO , PölönenP , TurpeinenA , KiviniemiV , UusaroA . Levosimendan reduces heart failure after cardiac surgery: a prospective, randomized, placebo-controlled trial. Criítical Care Medicine2011;39:2263-70. [DOI: 10.1097/CCM.0b013e3182227b97]">Lahtinen 2011</a>; <a href="./references#CD013781-bbs2-0022" title="LeppikangasH , JärveläK , SistoT , MaaranenP , VirtanenM , LehtoP , et al. Preoperative levosimendan infusion in combined aortic valve and coronary bypass surgery. British Journal of Anaesthesia2011;106:298-304. [DOI: 10.1093/bja/aeq402]">Leppikangas 2011</a>). </p> <p>In 15 studies, continuous levosimendan administration was maintained for 24 hours. In <a href="./references#CD013781-bbs2-0001" title="AminSW , Abd-ElgalilSM , MohamedSA , AhmedMM , HamawyTY , FathiLM . Levosimendan versus milrinone in the management of impaired left ventricular function in patients undergoing coronary artery bypass graft surgery. Open Anesthesia Journal2019;13:59-67. [DOI: 10.2174/2589645801913010059]">Amin 2019</a> and <a href="./references#CD013781-bbs2-0017" title="Juhl-OlsenP , Jakobsen C-J, RasmussenLA , BhavsarR , Klaaborg K-E, FrederiksenCA , et al. Effects of levosimendan in patients with left ventricular hypertrophy undergoing aortic valve replacement. Acta Anaesthesiologica Scandinavica2015;59:65-77. [DOI: 10.1111/aas.12425]">Juhl‐Olsen 2015</a>, the administration was limited to the entire duration of surgery and in <a href="./references#CD013781-bbs2-0011" title="GandhamR , SyamasundarA , RavulapalliH , KarthekeyanRB , VakamudiM , KodalliR , et al. A comparison of hemodynamic effects of levosimendan and dobutamine in patients undergoing mitral valve repair / replacement for severe mitral stenosis. Annals of Cardiac Anaesthesia2013;16:11-5. [DOI: 10.4103/0971-9784.105363]">Gandham 2013</a> for the duration of weaning. <a href="./references#CD013781-bbs2-0008" title="ErbJ , BeutlhauserT , FeldheiserA , SchusterB , TreskatschS , GrubitzschH , et al. Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery. Journal of International Medical Research2014;42:750-64. [DOI: 10.1177/0300060513516293]">Erb 2014</a> and <a href="./references#CD013781-bbs2-0014" title="HuX , XuQ . Application of levosimendan in severe patients after cardiac surgery. Chinese Journal of Clinical Pharmacology and Therapeutics2020;25:1027-32. [DOI: 10.12092/j.issn.1009-2501.2020.09.010]">Hu 2020</a> limited the administration to a total dose of 12.5 µg. In <a href="./references#CD013781-bbs2-0005" title="De HertSG , LorsomradeeS , CromheeckeS , Van der LindenPJ . The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesthesia and Analgesia2007;104:766-73. [DOI: 10.1213/01.ane.0000256863.92050.d3]">De Hert 2007</a> and <a href="./references#CD013781-bbs2-0020" title="KodalliRK , SundarAS , VakamudiM , RavulapaliH , NandipatiS , ChandrasekaranN , et al. Effect of levosimendan on hemodynamic changes in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled study. Annals of Cardiac Anaesthesia2013;16:94-9. [DOI: 10.4103/0971-9784.109737]">Kodalli 2013</a>, levosimendan administration ended in the ICU according to the physician's decision to wean from inotropics. </p> <p>Differences were also seen in the timing of levosimendan administration. In seven studies, levosimendan was administered preoperatively (on the day before surgery (<a href="./references#CD013781-bbs2-0022" title="LeppikangasH , JärveläK , SistoT , MaaranenP , VirtanenM , LehtoP , et al. Preoperative levosimendan infusion in combined aortic valve and coronary bypass surgery. British Journal of Anaesthesia2011;106:298-304. [DOI: 10.1093/bja/aeq402]">Leppikangas 2011</a>), 24 hours before surgery (<a href="./references#CD013781-bbs2-0002" title="AnastasiadisK , AntonitsisP , VranisK , KleontasA , AsteriouC , GrosomanidisV , et al. Effectiveness of prophylactic levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting: a randomized pilot study. Interactive Cardiovascular and Thoracic Surgery2016;23:740-8. [DOI: 10.1093/icvts/ivw213]">Anastasiadis 2016</a>; <a href="./references#CD013781-bbs2-0023" title="LevinR , DegrangeM , Del MazoC , TanusE , PorcileR . Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Experimental and Clinical Cardiology2012;17:125-30. [PMID: 23620700]">Levin 2012</a>; <a href="./references#CD013781-bbs2-0026" title="ShahB , SharmaP , BrahmbhattA , ShahR , RathodB , ShastriN , et al. Study of levosimendan during off-pump coronary artery bypass grafting in patients with LV dysfunction: a double-blind randomized study. Indian Journal of Pharmacology2014;46:29-34. [DOI: 10.4103/0253-7613.125161]">Shah 2014</a>; <a href="./references#CD013781-bbs2-0027" title="SharmaP , MalhotraA , GandhiS , GargP , BishnoiA , GandhiH . Preoperative levosimendan in ischemic mitral valve repair. Asian Cardiovascular and Thoracic Annals2014;22:539-45. [DOI: 10.1177/0218492313499352]">Sharma 2014</a>), 12 hours before surgery (<a href="./references#CD013781-bbs2-0007" title="DesaiPM , SarkarMS , UmbarkarSR . Prophylactic preoperative levosimendan for off-pump coronary artery bypass grafting in patients with left ventricular dysfunction: single-centered randomized prospective study. Annals of Cardiac Anaesthesia2018;21:123-8. [DOI: 10.4103/aca.ACA_178_17]">Desai 2018</a>), or 4 hours before surgery (<a href="./references#CD013781-bbs2-0017" title="Juhl-OlsenP , Jakobsen C-J, RasmussenLA , BhavsarR , Klaaborg K-E, FrederiksenCA , et al. Effects of levosimendan in patients with left ventricular hypertrophy undergoing aortic valve replacement. Acta Anaesthesiologica Scandinavica2015;59:65-77. [DOI: 10.1111/aas.12425]">Juhl‐Olsen 2015</a>)). In 12 studies, administration occurred at the start of surgery, i.e. with induction of anaesthesia (<a href="./references#CD013781-bbs2-0001" title="AminSW , Abd-ElgalilSM , MohamedSA , AhmedMM , HamawyTY , FathiLM . Levosimendan versus milrinone in the management of impaired left ventricular function in patients undergoing coronary artery bypass graft surgery. Open Anesthesia Journal2019;13:59-67. [DOI: 10.2174/2589645801913010059]">Amin 2019</a>; <a href="./references#CD013781-bbs2-0004" title="CholleyB , CarubaT , GrosjeanS , AmourJ , OuattaraA , VillacortaJ , et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA2017;318:548-56. [DOI: 10.1001/jama.2017.9973]">Cholley 2017</a>; <a href="./references#CD013781-bbs2-0008" title="ErbJ , BeutlhauserT , FeldheiserA , SchusterB , TreskatschS , GrubitzschH , et al. Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery. Journal of International Medical Research2014;42:750-64. [DOI: 10.1177/0300060513516293]">Erb 2014</a>; <a href="./references#CD013781-bbs2-0009" title="RikssonHI , JalonenJR , HeikkinenLO , KivikkoM , LaineM , LeinoKA , et al. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Cardiothoracic Anesthesiology2009;87:448-54. [DOI: 10.1016/j.athoracsur.2008.10.029]">Eriksson 2009</a>; <a href="./references#CD013781-bbs2-0010" title="ErsoyO , BoysanE , UnalEU , YayK , YenerU , CicekciogluF , et al. Effectiveness of prophylactic levosimendan in high-risk valve surgery patients. Cardiovascular Journal of Africa2013;24:260-4. [DOI: 10.5830/CVJA-2013-047]">Ersoy 2013</a>; <a href="./references#CD013781-bbs2-0015" title="JärveläK , MaaranenP , SistoT , RuokonenE . Levosimendan in aortic valve surgery: cardiac performance and recovery. Journal of Cardiothoracic and Vascular Anesthesia2008;22:693-8. [DOI: 10.1053/j.jvca.2008.01.024]">Jävelä 2008</a>; <a href="./references#CD013781-bbs2-0018" title="KandasamyA , SimonHA , MurthyP , AnnaduraiM , AliMM , RamanathanG . Comparison of levosimendan versus dobutamine in patients with moderate to severe left ventricular dysfunction undergoing off-pump coronary artery bypass grafting: a randomized prospective study. Annals of Cardiac Anaesthesia2017;20:200-6. [DOI: 10.4103/aca.ACA_195_16]">Kandasamy 2017</a>; <a href="./references#CD013781-bbs2-0020" title="KodalliRK , SundarAS , VakamudiM , RavulapaliH , NandipatiS , ChandrasekaranN , et al. Effect of levosimendan on hemodynamic changes in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled study. Annals of Cardiac Anaesthesia2013;16:94-9. [DOI: 10.4103/0971-9784.109737]">Kodalli 2013</a>; <a href="./references#CD013781-bbs2-0021" title="LahtinenP , PitkänenO , PölönenP , TurpeinenA , KiviniemiV , UusaroA . Levosimendan reduces heart failure after cardiac surgery: a prospective, randomized, placebo-controlled trial. Criítical Care Medicine2011;39:2263-70. [DOI: 10.1097/CCM.0b013e3182227b97]">Lahtinen 2011</a>), before skin incision (<a href="./references#CD013781-bbs2-0024" title="MehtaRH , LeimbergerJD , vanDiepenS , MezaJ , WangA , JankowichR , et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. New England Journal of Medicine2017;376:2032-42. [DOI: 10.1056/NEJMoa1616218]">Mehta 2017</a>), or before cardiopulmonary bypass (CPB) (<a href="./references#CD013781-bbs2-0028" title="TritapepeL , De SantisV , VitaleD , SantulliM , MorelliA , NofroniI , et al. Preconditioning effects of levosimendan in coronary artery bypass grafting - a pilot study. British Journal of Anaesthesia2006;96:694-700. [DOI: 10.1093/bja/ael082]">Tritapepe 2006</a>; <a href="./references#CD013781-bbs2-0029" title="TritapepeL , De SantisV , VitaleD , GuarracinoF , PellegriniF , PietropaoliP , et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. British Journal of Anaesthesia2009;102:198-204. [DOI: 10.1093/bja/aen367]">Tritapepe 2009</a>). In four studies, levosimendan administration started at weaning from CPB (<a href="./references#CD013781-bbs2-0003" title="BaysalA , YanartasM , DogukanM , GundogusN , KocakT , Koksal C. Levosimendan improves renal outcome in cardiac surgery: a randomized trial. Journal of Cardiothoracic and Vascular Anesthesia2014;28:586-94. [DOI: 10.1053/j.jvca.2013.09.004]">Baysal 2014</a>; <a href="./references#CD013781-bbs2-0005" title="De HertSG , LorsomradeeS , CromheeckeS , Van der LindenPJ . The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesthesia and Analgesia2007;104:766-73. [DOI: 10.1213/01.ane.0000256863.92050.d3]">De Hert 2007</a>; <a href="./references#CD013781-bbs2-0011" title="GandhamR , SyamasundarA , RavulapalliH , KarthekeyanRB , VakamudiM , KodalliR , et al. A comparison of hemodynamic effects of levosimendan and dobutamine in patients undergoing mitral valve repair / replacement for severe mitral stenosis. Annals of Cardiac Anaesthesia2013;16:11-5. [DOI: 10.4103/0971-9784.105363]">Gandham 2013</a>; <a href="./references#CD013781-bbs2-0025" title="MishraA , KumarB , DuttaV , AryaVK , MishraAK . Comparative effect of levosimendan and milrinone in cardiac surgery patients with pulmonary hypertension and left ventricular dysfunction. Journal of Cardiothoracic and Vascular Anesthesia2016;30:639-46. [DOI: 10.1053/j.jvca.2016.01.015]">Mishra 2016</a>). In one study, levosimendan was administered only after the surgical procedure (<a href="./references#CD013781-bbs2-0014" title="HuX , XuQ . Application of levosimendan in severe patients after cardiac surgery. Chinese Journal of Clinical Pharmacology and Therapeutics2020;25:1027-32. [DOI: 10.12092/j.issn.1009-2501.2020.09.010]">Hu 2020</a>). </p> <p>The studies investigating milrinone were also characterised by a wide variety of timing, dosage, duration, and route of drug administration. <a href="./references#CD013781-bbs2-0006" title="DenaultAY , BussièresJS , ArellanoR , FineganB , GavraP , HaddadF , et al. A multicentre randomized-controlled trial of inhaled milrinone in high-risk cardiac surgical patients. Canadian Journal of Anesthesia2016;63:1140-53. [DOI: 10.1007/s12630-016-0709-8]">Denault 2016</a> used a single dose as an inhalant at the time of induction of anaesthesia. <a href="./references#CD013781-bbs2-0016" title="JoHR , LeeWK , KimYH , MinJH , ChaeYK , ChoiIG , et al. The effect of milrinone infusion on right ventricular function during coronary anastomosis and early outcomes in patients undergoing off-pump coronary artery bypass surgery. Korean Journal of Anesthesiology2010;59:92-8. [DOI: 10.4097/kjae.2010.59.2.92]">Jo 2010</a> administered milrinone perioperatively at a dose of 0.5 µg/kg/min. <a href="./references#CD013781-bbs2-0019" title="KikuraM , SatoS . The efficacy of preemptive milrinone or amrinone therapy in patients undergoing coronary artery bypass grafting. Anesthesia and Analgesia2002;94:22-30. [DOI: 10.1097/00000539-200201000-00005]">Kikura 2002</a> initiated milrinone at weaning from CPB and continued for 10 hours. <a href="./references#CD013781-bbs2-0013" title="HadadzadehM , HosseiniSH , Mostafavi-Pour-ManshadiSM , NaderiN , Emami-MeybodiM . Effect of milrinone on short term outcome of patients with myocardial dysfunction undergoing off-pump coronary artery bypass graft: a randomized clinical trial. Acta Medica Iranica2013;51:681-6. [PMID: 24338139]">Hadadzadeh 2013</a> started milrinone for a period of 24 hours after completion of the surgical procedure. Both <a href="./references#CD013781-bbs2-0019" title="KikuraM , SatoS . The efficacy of preemptive milrinone or amrinone therapy in patients undergoing coronary artery bypass grafting. Anesthesia and Analgesia2002;94:22-30. [DOI: 10.1097/00000539-200201000-00005]">Kikura 2002</a> and <a href="./references#CD013781-bbs2-0013" title="HadadzadehM , HosseiniSH , Mostafavi-Pour-ManshadiSM , NaderiN , Emami-MeybodiM . Effect of milrinone on short term outcome of patients with myocardial dysfunction undergoing off-pump coronary artery bypass graft: a randomized clinical trial. Acta Medica Iranica2013;51:681-6. [PMID: 24338139]">Hadadzadeh 2013</a> initially gave a bolus of 50 µg/kg followed by a continuous dose of 0.5 µg/kg/min. </p> </section> <section id="CD013781-sec-0046"> <h4 class="title">Participants</h4> <p>The mean age varied between 52.5 and 76 years, with the exception of three studies that were characterised by a more juvenile age structure (<a href="./references#CD013781-bbs2-0010" title="ErsoyO , BoysanE , UnalEU , YayK , YenerU , CicekciogluF , et al. Effectiveness of prophylactic levosimendan in high-risk valve surgery patients. Cardiovascular Journal of Africa2013;24:260-4. [DOI: 10.5830/CVJA-2013-047]">Ersoy 2013</a>; <a href="./references#CD013781-bbs2-0011" title="GandhamR , SyamasundarA , RavulapalliH , KarthekeyanRB , VakamudiM , KodalliR , et al. A comparison of hemodynamic effects of levosimendan and dobutamine in patients undergoing mitral valve repair / replacement for severe mitral stenosis. Annals of Cardiac Anaesthesia2013;16:11-5. [DOI: 10.4103/0971-9784.105363]">Gandham 2013</a>; <a href="./references#CD013781-bbs2-0025" title="MishraA , KumarB , DuttaV , AryaVK , MishraAK . Comparative effect of levosimendan and milrinone in cardiac surgery patients with pulmonary hypertension and left ventricular dysfunction. Journal of Cardiothoracic and Vascular Anesthesia2016;30:639-46. [DOI: 10.1053/j.jvca.2016.01.015]">Mishra 2016</a>). In six studies, inclusion was restricted to adult patients (at least 18 years) (<a href="./references#CD013781-bbs2-0004" title="CholleyB , CarubaT , GrosjeanS , AmourJ , OuattaraA , VillacortaJ , et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA2017;318:548-56. [DOI: 10.1001/jama.2017.9973]">Cholley 2017</a>; <a href="./references#CD013781-bbs2-0006" title="DenaultAY , BussièresJS , ArellanoR , FineganB , GavraP , HaddadF , et al. A multicentre randomized-controlled trial of inhaled milrinone in high-risk cardiac surgical patients. Canadian Journal of Anesthesia2016;63:1140-53. [DOI: 10.1007/s12630-016-0709-8]">Denault 2016</a>; <a href="./references#CD013781-bbs2-0008" title="ErbJ , BeutlhauserT , FeldheiserA , SchusterB , TreskatschS , GrubitzschH , et al. Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery. Journal of International Medical Research2014;42:750-64. [DOI: 10.1177/0300060513516293]">Erb 2014</a>; <a href="./references#CD013781-bbs2-0021" title="LahtinenP , PitkänenO , PölönenP , TurpeinenA , KiviniemiV , UusaroA . Levosimendan reduces heart failure after cardiac surgery: a prospective, randomized, placebo-controlled trial. Criítical Care Medicine2011;39:2263-70. [DOI: 10.1097/CCM.0b013e3182227b97]">Lahtinen 2011</a>; <a href="./references#CD013781-bbs2-0024" title="MehtaRH , LeimbergerJD , vanDiepenS , MezaJ , WangA , JankowichR , et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. New England Journal of Medicine2017;376:2032-42. [DOI: 10.1056/NEJMoa1616218]">Mehta 2017</a>; <a href="./references#CD013781-bbs2-0029" title="TritapepeL , De SantisV , VitaleD , GuarracinoF , PellegriniF , PietropaoliP , et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. British Journal of Anaesthesia2009;102:198-204. [DOI: 10.1093/bja/aen367]">Tritapepe 2009</a>). Other age restrictions described were: 25 to 70 years (<a href="./references#CD013781-bbs2-0014" title="HuX , XuQ . Application of levosimendan in severe patients after cardiac surgery. Chinese Journal of Clinical Pharmacology and Therapeutics2020;25:1027-32. [DOI: 10.12092/j.issn.1009-2501.2020.09.010]">Hu 2020</a>), 30 to 65 years (<a href="./references#CD013781-bbs2-0018" title="KandasamyA , SimonHA , MurthyP , AnnaduraiM , AliMM , RamanathanG . Comparison of levosimendan versus dobutamine in patients with moderate to severe left ventricular dysfunction undergoing off-pump coronary artery bypass grafting: a randomized prospective study. Annals of Cardiac Anaesthesia2017;20:200-6. [DOI: 10.4103/aca.ACA_195_16]">Kandasamy 2017</a>), 35 to 75 years (<a href="./references#CD013781-bbs2-0007" title="DesaiPM , SarkarMS , UmbarkarSR . Prophylactic preoperative levosimendan for off-pump coronary artery bypass grafting in patients with left ventricular dysfunction: single-centered randomized prospective study. Annals of Cardiac Anaesthesia2018;21:123-8. [DOI: 10.4103/aca.ACA_178_17]">Desai 2018</a>), 40 to 70 years (<a href="./references#CD013781-bbs2-0001" title="AminSW , Abd-ElgalilSM , MohamedSA , AhmedMM , HamawyTY , FathiLM . Levosimendan versus milrinone in the management of impaired left ventricular function in patients undergoing coronary artery bypass graft surgery. Open Anesthesia Journal2019;13:59-67. [DOI: 10.2174/2589645801913010059]">Amin 2019</a>), &lt; 60 years (<a href="./references#CD013781-bbs2-0011" title="GandhamR , SyamasundarA , RavulapalliH , KarthekeyanRB , VakamudiM , KodalliR , et al. A comparison of hemodynamic effects of levosimendan and dobutamine in patients undergoing mitral valve repair / replacement for severe mitral stenosis. Annals of Cardiac Anaesthesia2013;16:11-5. [DOI: 10.4103/0971-9784.105363]">Gandham 2013</a>), and &lt; 80 years (<a href="./references#CD013781-bbs2-0002" title="AnastasiadisK , AntonitsisP , VranisK , KleontasA , AsteriouC , GrosomanidisV , et al. Effectiveness of prophylactic levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting: a randomized pilot study. Interactive Cardiovascular and Thoracic Surgery2016;23:740-8. [DOI: 10.1093/icvts/ivw213]">Anastasiadis 2016</a>). No age restriction was documented in the remaining 17 studies. </p> <p>The proportion of male participants ranged from 40% (<a href="./references#CD013781-bbs2-0010" title="ErsoyO , BoysanE , UnalEU , YayK , YenerU , CicekciogluF , et al. Effectiveness of prophylactic levosimendan in high-risk valve surgery patients. Cardiovascular Journal of Africa2013;24:260-4. [DOI: 10.5830/CVJA-2013-047]">Ersoy 2013</a>) to 93.75% (<a href="./references#CD013781-bbs2-0002" title="AnastasiadisK , AntonitsisP , VranisK , KleontasA , AsteriouC , GrosomanidisV , et al. Effectiveness of prophylactic levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting: a randomized pilot study. Interactive Cardiovascular and Thoracic Surgery2016;23:740-8. [DOI: 10.1093/icvts/ivw213]">Anastasiadis 2016</a>) between studies. </p> <p>A total of 17 studies focused on the examination of patients with left ventricular (LV) dysfunction (<a href="./references#CD013781-bbs2-0001" title="AminSW , Abd-ElgalilSM , MohamedSA , AhmedMM , HamawyTY , FathiLM . Levosimendan versus milrinone in the management of impaired left ventricular function in patients undergoing coronary artery bypass graft surgery. Open Anesthesia Journal2019;13:59-67. [DOI: 10.2174/2589645801913010059]">Amin 2019</a>; <a href="./references#CD013781-bbs2-0002" title="AnastasiadisK , AntonitsisP , VranisK , KleontasA , AsteriouC , GrosomanidisV , et al. Effectiveness of prophylactic levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting: a randomized pilot study. Interactive Cardiovascular and Thoracic Surgery2016;23:740-8. [DOI: 10.1093/icvts/ivw213]">Anastasiadis 2016</a>; <a href="./references#CD013781-bbs2-0003" title="BaysalA , YanartasM , DogukanM , GundogusN , KocakT , Koksal C. Levosimendan improves renal outcome in cardiac surgery: a randomized trial. Journal of Cardiothoracic and Vascular Anesthesia2014;28:586-94. [DOI: 10.1053/j.jvca.2013.09.004]">Baysal 2014</a>; <a href="./references#CD013781-bbs2-0004" title="CholleyB , CarubaT , GrosjeanS , AmourJ , OuattaraA , VillacortaJ , et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA2017;318:548-56. [DOI: 10.1001/jama.2017.9973]">Cholley 2017</a>; <a href="./references#CD013781-bbs2-0005" title="De HertSG , LorsomradeeS , CromheeckeS , Van der LindenPJ . The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesthesia and Analgesia2007;104:766-73. [DOI: 10.1213/01.ane.0000256863.92050.d3]">De Hert 2007</a>; <a href="./references#CD013781-bbs2-0007" title="DesaiPM , SarkarMS , UmbarkarSR . Prophylactic preoperative levosimendan for off-pump coronary artery bypass grafting in patients with left ventricular dysfunction: single-centered randomized prospective study. Annals of Cardiac Anaesthesia2018;21:123-8. [DOI: 10.4103/aca.ACA_178_17]">Desai 2018</a>; <a href="./references#CD013781-bbs2-0008" title="ErbJ , BeutlhauserT , FeldheiserA , SchusterB , TreskatschS , GrubitzschH , et al. Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery. Journal of International Medical Research2014;42:750-64. [DOI: 10.1177/0300060513516293]">Erb 2014</a>; <a href="./references#CD013781-bbs2-0009" title="RikssonHI , JalonenJR , HeikkinenLO , KivikkoM , LaineM , LeinoKA , et al. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Cardiothoracic Anesthesiology2009;87:448-54. [DOI: 10.1016/j.athoracsur.2008.10.029]">Eriksson 2009</a>; <a href="./references#CD013781-bbs2-0010" title="ErsoyO , BoysanE , UnalEU , YayK , YenerU , CicekciogluF , et al. Effectiveness of prophylactic levosimendan in high-risk valve surgery patients. Cardiovascular Journal of Africa2013;24:260-4. [DOI: 10.5830/CVJA-2013-047]">Ersoy 2013</a>; <a href="./references#CD013781-bbs2-0013" title="HadadzadehM , HosseiniSH , Mostafavi-Pour-ManshadiSM , NaderiN , Emami-MeybodiM . Effect of milrinone on short term outcome of patients with myocardial dysfunction undergoing off-pump coronary artery bypass graft: a randomized clinical trial. Acta Medica Iranica2013;51:681-6. [PMID: 24338139]">Hadadzadeh 2013</a>; <a href="./references#CD013781-bbs2-0014" title="HuX , XuQ . Application of levosimendan in severe patients after cardiac surgery. Chinese Journal of Clinical Pharmacology and Therapeutics2020;25:1027-32. [DOI: 10.12092/j.issn.1009-2501.2020.09.010]">Hu 2020</a>; <a href="./references#CD013781-bbs2-0018" title="KandasamyA , SimonHA , MurthyP , AnnaduraiM , AliMM , RamanathanG . Comparison of levosimendan versus dobutamine in patients with moderate to severe left ventricular dysfunction undergoing off-pump coronary artery bypass grafting: a randomized prospective study. Annals of Cardiac Anaesthesia2017;20:200-6. [DOI: 10.4103/aca.ACA_195_16]">Kandasamy 2017</a>; <a href="./references#CD013781-bbs2-0023" title="LevinR , DegrangeM , Del MazoC , TanusE , PorcileR . Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Experimental and Clinical Cardiology2012;17:125-30. [PMID: 23620700]">Levin 2012</a>; <a href="./references#CD013781-bbs2-0024" title="MehtaRH , LeimbergerJD , vanDiepenS , MezaJ , WangA , JankowichR , et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. New England Journal of Medicine2017;376:2032-42. [DOI: 10.1056/NEJMoa1616218]">Mehta 2017</a>; <a href="./references#CD013781-bbs2-0025" title="MishraA , KumarB , DuttaV , AryaVK , MishraAK . Comparative effect of levosimendan and milrinone in cardiac surgery patients with pulmonary hypertension and left ventricular dysfunction. Journal of Cardiothoracic and Vascular Anesthesia2016;30:639-46. [DOI: 10.1053/j.jvca.2016.01.015]">Mishra 2016</a>; <a href="./references#CD013781-bbs2-0026" title="ShahB , SharmaP , BrahmbhattA , ShahR , RathodB , ShastriN , et al. Study of levosimendan during off-pump coronary artery bypass grafting in patients with LV dysfunction: a double-blind randomized study. Indian Journal of Pharmacology2014;46:29-34. [DOI: 10.4103/0253-7613.125161]">Shah 2014</a>; <a href="./references#CD013781-bbs2-0027" title="SharmaP , MalhotraA , GandhiS , GargP , BishnoiA , GandhiH . Preoperative levosimendan in ischemic mitral valve repair. Asian Cardiovascular and Thoracic Annals2014;22:539-45. [DOI: 10.1177/0218492313499352]">Sharma 2014</a>). In contrast, five studies exclusively included participants without LV dysfunction (<a href="./references#CD013781-bbs2-0011" title="GandhamR , SyamasundarA , RavulapalliH , KarthekeyanRB , VakamudiM , KodalliR , et al. A comparison of hemodynamic effects of levosimendan and dobutamine in patients undergoing mitral valve repair / replacement for severe mitral stenosis. Annals of Cardiac Anaesthesia2013;16:11-5. [DOI: 10.4103/0971-9784.105363]">Gandham 2013</a>; <a href="./references#CD013781-bbs2-0015" title="JärveläK , MaaranenP , SistoT , RuokonenE . Levosimendan in aortic valve surgery: cardiac performance and recovery. Journal of Cardiothoracic and Vascular Anesthesia2008;22:693-8. [DOI: 10.1053/j.jvca.2008.01.024]">Jävelä 2008</a>; <a href="./references#CD013781-bbs2-0017" title="Juhl-OlsenP , Jakobsen C-J, RasmussenLA , BhavsarR , Klaaborg K-E, FrederiksenCA , et al. Effects of levosimendan in patients with left ventricular hypertrophy undergoing aortic valve replacement. Acta Anaesthesiologica Scandinavica2015;59:65-77. [DOI: 10.1111/aas.12425]">Juhl‐Olsen 2015</a>; <a href="./references#CD013781-bbs2-0019" title="KikuraM , SatoS . The efficacy of preemptive milrinone or amrinone therapy in patients undergoing coronary artery bypass grafting. Anesthesia and Analgesia2002;94:22-30. [DOI: 10.1097/00000539-200201000-00005]">Kikura 2002</a>; <a href="./references#CD013781-bbs2-0020" title="KodalliRK , SundarAS , VakamudiM , RavulapaliH , NandipatiS , ChandrasekaranN , et al. Effect of levosimendan on hemodynamic changes in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled study. Annals of Cardiac Anaesthesia2013;16:94-9. [DOI: 10.4103/0971-9784.109737]">Kodalli 2013</a>). In seven studies, both participants with and without LV dysfunction were enrolled (<a href="./references#CD013781-bbs2-0006" title="DenaultAY , BussièresJS , ArellanoR , FineganB , GavraP , HaddadF , et al. A multicentre randomized-controlled trial of inhaled milrinone in high-risk cardiac surgical patients. Canadian Journal of Anesthesia2016;63:1140-53. [DOI: 10.1007/s12630-016-0709-8]">Denault 2016</a>; <a href="./references#CD013781-bbs2-0012" title="GatotI , AbramovD , TsodikovV , YeshayahuM , OrmanS , GavrielA , et al. Should we give prophylactic renal-dose dopamine after coronary artery bypass surgery?Journal of Cardiac Surgery2004;19:128-33. [DOI: 10.1111/j.0886-0440.2004.04044.x]">Gatot 2004</a>; <a href="./references#CD013781-bbs2-0016" title="JoHR , LeeWK , KimYH , MinJH , ChaeYK , ChoiIG , et al. The effect of milrinone infusion on right ventricular function during coronary anastomosis and early outcomes in patients undergoing off-pump coronary artery bypass surgery. Korean Journal of Anesthesiology2010;59:92-8. [DOI: 10.4097/kjae.2010.59.2.92]">Jo 2010</a>; <a href="./references#CD013781-bbs2-0021" title="LahtinenP , PitkänenO , PölönenP , TurpeinenA , KiviniemiV , UusaroA . Levosimendan reduces heart failure after cardiac surgery: a prospective, randomized, placebo-controlled trial. Criítical Care Medicine2011;39:2263-70. [DOI: 10.1097/CCM.0b013e3182227b97]">Lahtinen 2011</a>; <a href="./references#CD013781-bbs2-0022" title="LeppikangasH , JärveläK , SistoT , MaaranenP , VirtanenM , LehtoP , et al. Preoperative levosimendan infusion in combined aortic valve and coronary bypass surgery. British Journal of Anaesthesia2011;106:298-304. [DOI: 10.1093/bja/aeq402]">Leppikangas 2011</a>; <a href="./references#CD013781-bbs2-0028" title="TritapepeL , De SantisV , VitaleD , SantulliM , MorelliA , NofroniI , et al. Preconditioning effects of levosimendan in coronary artery bypass grafting - a pilot study. British Journal of Anaesthesia2006;96:694-700. [DOI: 10.1093/bja/ael082]">Tritapepe 2006</a>; <a href="./references#CD013781-bbs2-0029" title="TritapepeL , De SantisV , VitaleD , GuarracinoF , PellegriniF , PietropaoliP , et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. British Journal of Anaesthesia2009;102:198-204. [DOI: 10.1093/bja/aen367]">Tritapepe 2009</a>). </p> </section> <section id="CD013781-sec-0047"> <h4 class="title">Funding by pharmaceutical industry</h4> <p>Trials that acknowledged funding by the pharmaceutical industry were: <a href="./references#CD013781-bbs2-0002" title="AnastasiadisK , AntonitsisP , VranisK , KleontasA , AsteriouC , GrosomanidisV , et al. Effectiveness of prophylactic levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting: a randomized pilot study. Interactive Cardiovascular and Thoracic Surgery2016;23:740-8. [DOI: 10.1093/icvts/ivw213]">Anastasiadis 2016</a> (supported by Orion Pharma), <a href="./references#CD013781-bbs2-0004" title="CholleyB , CarubaT , GrosjeanS , AmourJ , OuattaraA , VillacortaJ , et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA2017;318:548-56. [DOI: 10.1001/jama.2017.9973]">Cholley 2017</a> (supported by Orion Pharma), <a href="./references#CD013781-bbs2-0009" title="RikssonHI , JalonenJR , HeikkinenLO , KivikkoM , LaineM , LeinoKA , et al. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Cardiothoracic Anesthesiology2009;87:448-54. [DOI: 10.1016/j.athoracsur.2008.10.029]">Eriksson 2009</a> (supported by Orion Pharma), <a href="./references#CD013781-bbs2-0017" title="Juhl-OlsenP , Jakobsen C-J, RasmussenLA , BhavsarR , Klaaborg K-E, FrederiksenCA , et al. Effects of levosimendan in patients with left ventricular hypertrophy undergoing aortic valve replacement. Acta Anaesthesiologica Scandinavica2015;59:65-77. [DOI: 10.1111/aas.12425]">Juhl‐Olsen 2015</a> (supported by Orion Pharma; author associated with BK medical and GE Healthcare), <a href="./references#CD013781-bbs2-0021" title="LahtinenP , PitkänenO , PölönenP , TurpeinenA , KiviniemiV , UusaroA . Levosimendan reduces heart failure after cardiac surgery: a prospective, randomized, placebo-controlled trial. Criítical Care Medicine2011;39:2263-70. [DOI: 10.1097/CCM.0b013e3182227b97]">Lahtinen 2011</a> (supported by and authors associated with Orion Pharma), <a href="./references#CD013781-bbs2-0022" title="LeppikangasH , JärveläK , SistoT , MaaranenP , VirtanenM , LehtoP , et al. Preoperative levosimendan infusion in combined aortic valve and coronary bypass surgery. British Journal of Anaesthesia2011;106:298-304. [DOI: 10.1093/bja/aeq402]">Leppikangas 2011</a> (supported by and authors associated with Orion Pharma), <a href="./references#CD013781-bbs2-0024" title="MehtaRH , LeimbergerJD , vanDiepenS , MezaJ , WangA , JankowichR , et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. New England Journal of Medicine2017;376:2032-42. [DOI: 10.1056/NEJMoa1616218]">Mehta 2017</a> (supported by Tenax Therapeutics; authors associated with Orion Pharma and Tenax Therapeutics), and <a href="./references#CD013781-bbs2-0028" title="TritapepeL , De SantisV , VitaleD , SantulliM , MorelliA , NofroniI , et al. Preconditioning effects of levosimendan in coronary artery bypass grafting - a pilot study. British Journal of Anaesthesia2006;96:694-700. [DOI: 10.1093/bja/ael082]">Tritapepe 2006</a>; <a href="./references#CD013781-bbs2-0029" title="TritapepeL , De SantisV , VitaleD , GuarracinoF , PellegriniF , PietropaoliP , et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. British Journal of Anaesthesia2009;102:198-204. [DOI: 10.1093/bja/aen367]">Tritapepe 2009</a> (authors associated with Orion Pharma and Abbott). No information was given by <a href="./references#CD013781-bbs2-0003" title="BaysalA , YanartasM , DogukanM , GundogusN , KocakT , Koksal C. Levosimendan improves renal outcome in cardiac surgery: a randomized trial. Journal of Cardiothoracic and Vascular Anesthesia2014;28:586-94. [DOI: 10.1053/j.jvca.2013.09.004]">Baysal 2014</a>, <a href="./references#CD013781-bbs2-0005" title="De HertSG , LorsomradeeS , CromheeckeS , Van der LindenPJ . The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesthesia and Analgesia2007;104:766-73. [DOI: 10.1213/01.ane.0000256863.92050.d3]">De Hert 2007</a>, <a href="./references#CD013781-bbs2-0010" title="ErsoyO , BoysanE , UnalEU , YayK , YenerU , CicekciogluF , et al. Effectiveness of prophylactic levosimendan in high-risk valve surgery patients. Cardiovascular Journal of Africa2013;24:260-4. [DOI: 10.5830/CVJA-2013-047]">Ersoy 2013</a>, <a href="./references#CD013781-bbs2-0012" title="GatotI , AbramovD , TsodikovV , YeshayahuM , OrmanS , GavrielA , et al. Should we give prophylactic renal-dose dopamine after coronary artery bypass surgery?Journal of Cardiac Surgery2004;19:128-33. [DOI: 10.1111/j.0886-0440.2004.04044.x]">Gatot 2004</a>, <a href="./references#CD013781-bbs2-0013" title="HadadzadehM , HosseiniSH , Mostafavi-Pour-ManshadiSM , NaderiN , Emami-MeybodiM . Effect of milrinone on short term outcome of patients with myocardial dysfunction undergoing off-pump coronary artery bypass graft: a randomized clinical trial. Acta Medica Iranica2013;51:681-6. [PMID: 24338139]">Hadadzadeh 2013</a>, <a href="./references#CD013781-bbs2-0014" title="HuX , XuQ . Application of levosimendan in severe patients after cardiac surgery. Chinese Journal of Clinical Pharmacology and Therapeutics2020;25:1027-32. [DOI: 10.12092/j.issn.1009-2501.2020.09.010]">Hu 2020</a>, <a href="./references#CD013781-bbs2-0015" title="JärveläK , MaaranenP , SistoT , RuokonenE . Levosimendan in aortic valve surgery: cardiac performance and recovery. Journal of Cardiothoracic and Vascular Anesthesia2008;22:693-8. [DOI: 10.1053/j.jvca.2008.01.024]">Jävelä 2008</a>, <a href="./references#CD013781-bbs2-0016" title="JoHR , LeeWK , KimYH , MinJH , ChaeYK , ChoiIG , et al. The effect of milrinone infusion on right ventricular function during coronary anastomosis and early outcomes in patients undergoing off-pump coronary artery bypass surgery. Korean Journal of Anesthesiology2010;59:92-8. [DOI: 10.4097/kjae.2010.59.2.92]">Jo 2010</a>, <a href="./references#CD013781-bbs2-0023" title="LevinR , DegrangeM , Del MazoC , TanusE , PorcileR . Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Experimental and Clinical Cardiology2012;17:125-30. [PMID: 23620700]">Levin 2012</a>, or <a href="./references#CD013781-bbs2-0025" title="MishraA , KumarB , DuttaV , AryaVK , MishraAK . Comparative effect of levosimendan and milrinone in cardiac surgery patients with pulmonary hypertension and left ventricular dysfunction. Journal of Cardiothoracic and Vascular Anesthesia2016;30:639-46. [DOI: 10.1053/j.jvca.2016.01.015]">Mishra 2016</a>. </p> </section> <section id="CD013781-sec-0048"> <h4 class="title">Excluded studies</h4> <p>We excluded 20 trials for at least one of the following reasons: limited to perioperative evaluation, treatment not prophylaxis of LCOS, no randomisation, no assessment of LCOS, goal‐directed dosing of study drugs, exclusion of participants with postoperative LCOS, inclusion of participants with complex heart defects, cross‐over design, post hoc analysis of an included study. Details for each study can be found in the table <a href="./references#CD013781-sec-0190" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD013781-sec-0049"> <h3 class="title">Risk of bias in included studies</h3> <p>A summary of all investigated sources of bias in the 29 eligible studies is presented in <a href="#CD013781-fig-0002">Figure 2</a> and <a href="#CD013781-fig-0003">Figure 3</a>. The risk of bias tables for the individual trials are given in <a href="./references#CD013781-sec-0189" title="">Characteristics of included studies</a>. </p> <div class="figure" id="CD013781-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD013781-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD013781-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013781-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <p>All included studies used intention‐to‐treat analysis and were published in peer‐reviewed journals. The studies were small, with the exception of <a href="./references#CD013781-bbs2-0024" title="MehtaRH , LeimbergerJD , vanDiepenS , MezaJ , WangA , JankowichR , et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. New England Journal of Medicine2017;376:2032-42. [DOI: 10.1056/NEJMoa1616218]">Mehta 2017</a>, which enrolled 882 participants. Due to the small number of participants included (high imprecision of results), the evidence is considered limited. Other issues identified in the risk of bias review include inappropriate sequencing methods (selection bias) and lack of blinding (performance and detection bias). Funding from the pharmaceutical industry was acknowledged or conflicts of interest were not disclosed in 19 of the 29 studies. </p> <section id="CD013781-sec-0050"> <h4 class="title">Allocation</h4> <p>We rated the risk of bias for random sequence generation as well as allocation concealment as low for 14 studies (<a href="./references#CD013781-bbs2-0004" title="CholleyB , CarubaT , GrosjeanS , AmourJ , OuattaraA , VillacortaJ , et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA2017;318:548-56. [DOI: 10.1001/jama.2017.9973]">Cholley 2017</a>; <a href="./references#CD013781-bbs2-0005" title="De HertSG , LorsomradeeS , CromheeckeS , Van der LindenPJ . The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesthesia and Analgesia2007;104:766-73. [DOI: 10.1213/01.ane.0000256863.92050.d3]">De Hert 2007</a>; <a href="./references#CD013781-bbs2-0006" title="DenaultAY , BussièresJS , ArellanoR , FineganB , GavraP , HaddadF , et al. A multicentre randomized-controlled trial of inhaled milrinone in high-risk cardiac surgical patients. Canadian Journal of Anesthesia2016;63:1140-53. [DOI: 10.1007/s12630-016-0709-8]">Denault 2016</a>; <a href="./references#CD013781-bbs2-0008" title="ErbJ , BeutlhauserT , FeldheiserA , SchusterB , TreskatschS , GrubitzschH , et al. Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery. Journal of International Medical Research2014;42:750-64. [DOI: 10.1177/0300060513516293]">Erb 2014</a>; <a href="./references#CD013781-bbs2-0009" title="RikssonHI , JalonenJR , HeikkinenLO , KivikkoM , LaineM , LeinoKA , et al. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Cardiothoracic Anesthesiology2009;87:448-54. [DOI: 10.1016/j.athoracsur.2008.10.029]">Eriksson 2009</a>; <a href="./references#CD013781-bbs2-0011" title="GandhamR , SyamasundarA , RavulapalliH , KarthekeyanRB , VakamudiM , KodalliR , et al. A comparison of hemodynamic effects of levosimendan and dobutamine in patients undergoing mitral valve repair / replacement for severe mitral stenosis. Annals of Cardiac Anaesthesia2013;16:11-5. [DOI: 10.4103/0971-9784.105363]">Gandham 2013</a>; <a href="./references#CD013781-bbs2-0015" title="JärveläK , MaaranenP , SistoT , RuokonenE . Levosimendan in aortic valve surgery: cardiac performance and recovery. Journal of Cardiothoracic and Vascular Anesthesia2008;22:693-8. [DOI: 10.1053/j.jvca.2008.01.024]">Jävelä 2008</a>; <a href="./references#CD013781-bbs2-0017" title="Juhl-OlsenP , Jakobsen C-J, RasmussenLA , BhavsarR , Klaaborg K-E, FrederiksenCA , et al. Effects of levosimendan in patients with left ventricular hypertrophy undergoing aortic valve replacement. Acta Anaesthesiologica Scandinavica2015;59:65-77. [DOI: 10.1111/aas.12425]">Juhl‐Olsen 2015</a>; <a href="./references#CD013781-bbs2-0018" title="KandasamyA , SimonHA , MurthyP , AnnaduraiM , AliMM , RamanathanG . Comparison of levosimendan versus dobutamine in patients with moderate to severe left ventricular dysfunction undergoing off-pump coronary artery bypass grafting: a randomized prospective study. Annals of Cardiac Anaesthesia2017;20:200-6. [DOI: 10.4103/aca.ACA_195_16]">Kandasamy 2017</a>; <a href="./references#CD013781-bbs2-0021" title="LahtinenP , PitkänenO , PölönenP , TurpeinenA , KiviniemiV , UusaroA . Levosimendan reduces heart failure after cardiac surgery: a prospective, randomized, placebo-controlled trial. Criítical Care Medicine2011;39:2263-70. [DOI: 10.1097/CCM.0b013e3182227b97]">Lahtinen 2011</a>; <a href="./references#CD013781-bbs2-0024" title="MehtaRH , LeimbergerJD , vanDiepenS , MezaJ , WangA , JankowichR , et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. New England Journal of Medicine2017;376:2032-42. [DOI: 10.1056/NEJMoa1616218]">Mehta 2017</a>; <a href="./references#CD013781-bbs2-0025" title="MishraA , KumarB , DuttaV , AryaVK , MishraAK . Comparative effect of levosimendan and milrinone in cardiac surgery patients with pulmonary hypertension and left ventricular dysfunction. Journal of Cardiothoracic and Vascular Anesthesia2016;30:639-46. [DOI: 10.1053/j.jvca.2016.01.015]">Mishra 2016</a>; <a href="./references#CD013781-bbs2-0028" title="TritapepeL , De SantisV , VitaleD , SantulliM , MorelliA , NofroniI , et al. Preconditioning effects of levosimendan in coronary artery bypass grafting - a pilot study. British Journal of Anaesthesia2006;96:694-700. [DOI: 10.1093/bja/ael082]">Tritapepe 2006</a>; <a href="./references#CD013781-bbs2-0029" title="TritapepeL , De SantisV , VitaleD , GuarracinoF , PellegriniF , PietropaoliP , et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. British Journal of Anaesthesia2009;102:198-204. [DOI: 10.1093/bja/aen367]">Tritapepe 2009</a>). For <a href="./references#CD013781-bbs2-0002" title="AnastasiadisK , AntonitsisP , VranisK , KleontasA , AsteriouC , GrosomanidisV , et al. Effectiveness of prophylactic levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting: a randomized pilot study. Interactive Cardiovascular and Thoracic Surgery2016;23:740-8. [DOI: 10.1093/icvts/ivw213]">Anastasiadis 2016</a>, <a href="./references#CD013781-bbs2-0007" title="DesaiPM , SarkarMS , UmbarkarSR . Prophylactic preoperative levosimendan for off-pump coronary artery bypass grafting in patients with left ventricular dysfunction: single-centered randomized prospective study. Annals of Cardiac Anaesthesia2018;21:123-8. [DOI: 10.4103/aca.ACA_178_17]">Desai 2018</a>, and <a href="./references#CD013781-bbs2-0014" title="HuX , XuQ . Application of levosimendan in severe patients after cardiac surgery. Chinese Journal of Clinical Pharmacology and Therapeutics2020;25:1027-32. [DOI: 10.12092/j.issn.1009-2501.2020.09.010]">Hu 2020</a>, we also assessed the risk of random sequence generation to be low, but there was no information regarding allocation concealment. For <a href="./references#CD013781-bbs2-0012" title="GatotI , AbramovD , TsodikovV , YeshayahuM , OrmanS , GavrielA , et al. Should we give prophylactic renal-dose dopamine after coronary artery bypass surgery?Journal of Cardiac Surgery2004;19:128-33. [DOI: 10.1111/j.0886-0440.2004.04044.x]">Gatot 2004</a>, <a href="./references#CD013781-bbs2-0013" title="HadadzadehM , HosseiniSH , Mostafavi-Pour-ManshadiSM , NaderiN , Emami-MeybodiM . Effect of milrinone on short term outcome of patients with myocardial dysfunction undergoing off-pump coronary artery bypass graft: a randomized clinical trial. Acta Medica Iranica2013;51:681-6. [PMID: 24338139]">Hadadzadeh 2013</a>, <a href="./references#CD013781-bbs2-0019" title="KikuraM , SatoS . The efficacy of preemptive milrinone or amrinone therapy in patients undergoing coronary artery bypass grafting. Anesthesia and Analgesia2002;94:22-30. [DOI: 10.1097/00000539-200201000-00005]">Kikura 2002</a>, and <a href="./references#CD013781-bbs2-0022" title="LeppikangasH , JärveläK , SistoT , MaaranenP , VirtanenM , LehtoP , et al. Preoperative levosimendan infusion in combined aortic valve and coronary bypass surgery. British Journal of Anaesthesia2011;106:298-304. [DOI: 10.1093/bja/aeq402]">Leppikangas 2011</a>, we rated the risk of allocation concealment as low, but no information was available regarding random sequence generation. We judged a high risk of bias for random sequence generation in five studies, with a low risk of bias for allocation concealment in <a href="./references#CD013781-bbs2-0003" title="BaysalA , YanartasM , DogukanM , GundogusN , KocakT , Koksal C. Levosimendan improves renal outcome in cardiac surgery: a randomized trial. Journal of Cardiothoracic and Vascular Anesthesia2014;28:586-94. [DOI: 10.1053/j.jvca.2013.09.004]">Baysal 2014</a>, <a href="./references#CD013781-bbs2-0023" title="LevinR , DegrangeM , Del MazoC , TanusE , PorcileR . Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Experimental and Clinical Cardiology2012;17:125-30. [PMID: 23620700]">Levin 2012</a>, <a href="./references#CD013781-bbs2-0026" title="ShahB , SharmaP , BrahmbhattA , ShahR , RathodB , ShastriN , et al. Study of levosimendan during off-pump coronary artery bypass grafting in patients with LV dysfunction: a double-blind randomized study. Indian Journal of Pharmacology2014;46:29-34. [DOI: 10.4103/0253-7613.125161]">Shah 2014</a>, and <a href="./references#CD013781-bbs2-0027" title="SharmaP , MalhotraA , GandhiS , GargP , BishnoiA , GandhiH . Preoperative levosimendan in ischemic mitral valve repair. Asian Cardiovascular and Thoracic Annals2014;22:539-45. [DOI: 10.1177/0218492313499352]">Sharma 2014</a>, whereas no information regarding allocation concealment was available for <a href="./references#CD013781-bbs2-0010" title="ErsoyO , BoysanE , UnalEU , YayK , YenerU , CicekciogluF , et al. Effectiveness of prophylactic levosimendan in high-risk valve surgery patients. Cardiovascular Journal of Africa2013;24:260-4. [DOI: 10.5830/CVJA-2013-047]">Ersoy 2013</a>. Entirely no information regarding allocation was given in <a href="./references#CD013781-bbs2-0001" title="AminSW , Abd-ElgalilSM , MohamedSA , AhmedMM , HamawyTY , FathiLM . Levosimendan versus milrinone in the management of impaired left ventricular function in patients undergoing coronary artery bypass graft surgery. Open Anesthesia Journal2019;13:59-67. [DOI: 10.2174/2589645801913010059]">Amin 2019</a>, <a href="./references#CD013781-bbs2-0016" title="JoHR , LeeWK , KimYH , MinJH , ChaeYK , ChoiIG , et al. The effect of milrinone infusion on right ventricular function during coronary anastomosis and early outcomes in patients undergoing off-pump coronary artery bypass surgery. Korean Journal of Anesthesiology2010;59:92-8. [DOI: 10.4097/kjae.2010.59.2.92]">Jo 2010</a>, or <a href="./references#CD013781-bbs2-0020" title="KodalliRK , SundarAS , VakamudiM , RavulapaliH , NandipatiS , ChandrasekaranN , et al. Effect of levosimendan on hemodynamic changes in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled study. Annals of Cardiac Anaesthesia2013;16:94-9. [DOI: 10.4103/0971-9784.109737]">Kodalli 2013</a>. </p> </section> <section id="CD013781-sec-0051"> <h4 class="title">Blinding</h4> <p>We rated the risk of bias for blinding of participants and personnel (performance bias), as well as blinding of outcome assessment (detection bias), as low for 22 studies (<a href="./references#CD013781-bbs2-0002" title="AnastasiadisK , AntonitsisP , VranisK , KleontasA , AsteriouC , GrosomanidisV , et al. Effectiveness of prophylactic levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting: a randomized pilot study. Interactive Cardiovascular and Thoracic Surgery2016;23:740-8. [DOI: 10.1093/icvts/ivw213]">Anastasiadis 2016</a>; <a href="./references#CD013781-bbs2-0004" title="CholleyB , CarubaT , GrosjeanS , AmourJ , OuattaraA , VillacortaJ , et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA2017;318:548-56. [DOI: 10.1001/jama.2017.9973]">Cholley 2017</a>; <a href="./references#CD013781-bbs2-0006" title="DenaultAY , BussièresJS , ArellanoR , FineganB , GavraP , HaddadF , et al. A multicentre randomized-controlled trial of inhaled milrinone in high-risk cardiac surgical patients. Canadian Journal of Anesthesia2016;63:1140-53. [DOI: 10.1007/s12630-016-0709-8]">Denault 2016</a>; <a href="./references#CD013781-bbs2-0008" title="ErbJ , BeutlhauserT , FeldheiserA , SchusterB , TreskatschS , GrubitzschH , et al. Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery. Journal of International Medical Research2014;42:750-64. [DOI: 10.1177/0300060513516293]">Erb 2014</a>; <a href="./references#CD013781-bbs2-0009" title="RikssonHI , JalonenJR , HeikkinenLO , KivikkoM , LaineM , LeinoKA , et al. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Cardiothoracic Anesthesiology2009;87:448-54. [DOI: 10.1016/j.athoracsur.2008.10.029]">Eriksson 2009</a>; <a href="./references#CD013781-bbs2-0011" title="GandhamR , SyamasundarA , RavulapalliH , KarthekeyanRB , VakamudiM , KodalliR , et al. A comparison of hemodynamic effects of levosimendan and dobutamine in patients undergoing mitral valve repair / replacement for severe mitral stenosis. Annals of Cardiac Anaesthesia2013;16:11-5. [DOI: 10.4103/0971-9784.105363]">Gandham 2013</a>; <a href="./references#CD013781-bbs2-0012" title="GatotI , AbramovD , TsodikovV , YeshayahuM , OrmanS , GavrielA , et al. Should we give prophylactic renal-dose dopamine after coronary artery bypass surgery?Journal of Cardiac Surgery2004;19:128-33. [DOI: 10.1111/j.0886-0440.2004.04044.x]">Gatot 2004</a>; <a href="./references#CD013781-bbs2-0013" title="HadadzadehM , HosseiniSH , Mostafavi-Pour-ManshadiSM , NaderiN , Emami-MeybodiM . Effect of milrinone on short term outcome of patients with myocardial dysfunction undergoing off-pump coronary artery bypass graft: a randomized clinical trial. Acta Medica Iranica2013;51:681-6. [PMID: 24338139]">Hadadzadeh 2013</a>; <a href="./references#CD013781-bbs2-0015" title="JärveläK , MaaranenP , SistoT , RuokonenE . Levosimendan in aortic valve surgery: cardiac performance and recovery. Journal of Cardiothoracic and Vascular Anesthesia2008;22:693-8. [DOI: 10.1053/j.jvca.2008.01.024]">Jävelä 2008</a>; <a href="./references#CD013781-bbs2-0016" title="JoHR , LeeWK , KimYH , MinJH , ChaeYK , ChoiIG , et al. The effect of milrinone infusion on right ventricular function during coronary anastomosis and early outcomes in patients undergoing off-pump coronary artery bypass surgery. Korean Journal of Anesthesiology2010;59:92-8. [DOI: 10.4097/kjae.2010.59.2.92]">Jo 2010</a>; <a href="./references#CD013781-bbs2-0017" title="Juhl-OlsenP , Jakobsen C-J, RasmussenLA , BhavsarR , Klaaborg K-E, FrederiksenCA , et al. Effects of levosimendan in patients with left ventricular hypertrophy undergoing aortic valve replacement. Acta Anaesthesiologica Scandinavica2015;59:65-77. [DOI: 10.1111/aas.12425]">Juhl‐Olsen 2015</a>; <a href="./references#CD013781-bbs2-0018" title="KandasamyA , SimonHA , MurthyP , AnnaduraiM , AliMM , RamanathanG . Comparison of levosimendan versus dobutamine in patients with moderate to severe left ventricular dysfunction undergoing off-pump coronary artery bypass grafting: a randomized prospective study. Annals of Cardiac Anaesthesia2017;20:200-6. [DOI: 10.4103/aca.ACA_195_16]">Kandasamy 2017</a>; <a href="./references#CD013781-bbs2-0019" title="KikuraM , SatoS . The efficacy of preemptive milrinone or amrinone therapy in patients undergoing coronary artery bypass grafting. Anesthesia and Analgesia2002;94:22-30. [DOI: 10.1097/00000539-200201000-00005]">Kikura 2002</a>; <a href="./references#CD013781-bbs2-0020" title="KodalliRK , SundarAS , VakamudiM , RavulapaliH , NandipatiS , ChandrasekaranN , et al. Effect of levosimendan on hemodynamic changes in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled study. Annals of Cardiac Anaesthesia2013;16:94-9. [DOI: 10.4103/0971-9784.109737]">Kodalli 2013</a>; <a href="./references#CD013781-bbs2-0021" title="LahtinenP , PitkänenO , PölönenP , TurpeinenA , KiviniemiV , UusaroA . Levosimendan reduces heart failure after cardiac surgery: a prospective, randomized, placebo-controlled trial. Criítical Care Medicine2011;39:2263-70. [DOI: 10.1097/CCM.0b013e3182227b97]">Lahtinen 2011</a>; <a href="./references#CD013781-bbs2-0022" title="LeppikangasH , JärveläK , SistoT , MaaranenP , VirtanenM , LehtoP , et al. Preoperative levosimendan infusion in combined aortic valve and coronary bypass surgery. British Journal of Anaesthesia2011;106:298-304. [DOI: 10.1093/bja/aeq402]">Leppikangas 2011</a>; <a href="./references#CD013781-bbs2-0023" title="LevinR , DegrangeM , Del MazoC , TanusE , PorcileR . Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Experimental and Clinical Cardiology2012;17:125-30. [PMID: 23620700]">Levin 2012</a>; <a href="./references#CD013781-bbs2-0024" title="MehtaRH , LeimbergerJD , vanDiepenS , MezaJ , WangA , JankowichR , et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. New England Journal of Medicine2017;376:2032-42. [DOI: 10.1056/NEJMoa1616218]">Mehta 2017</a>; <a href="./references#CD013781-bbs2-0026" title="ShahB , SharmaP , BrahmbhattA , ShahR , RathodB , ShastriN , et al. Study of levosimendan during off-pump coronary artery bypass grafting in patients with LV dysfunction: a double-blind randomized study. Indian Journal of Pharmacology2014;46:29-34. [DOI: 10.4103/0253-7613.125161]">Shah 2014</a>; <a href="./references#CD013781-bbs2-0027" title="SharmaP , MalhotraA , GandhiS , GargP , BishnoiA , GandhiH . Preoperative levosimendan in ischemic mitral valve repair. Asian Cardiovascular and Thoracic Annals2014;22:539-45. [DOI: 10.1177/0218492313499352]">Sharma 2014</a>; <a href="./references#CD013781-bbs2-0028" title="TritapepeL , De SantisV , VitaleD , SantulliM , MorelliA , NofroniI , et al. Preconditioning effects of levosimendan in coronary artery bypass grafting - a pilot study. British Journal of Anaesthesia2006;96:694-700. [DOI: 10.1093/bja/ael082]">Tritapepe 2006</a>; <a href="./references#CD013781-bbs2-0029" title="TritapepeL , De SantisV , VitaleD , GuarracinoF , PellegriniF , PietropaoliP , et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. British Journal of Anaesthesia2009;102:198-204. [DOI: 10.1093/bja/aen367]">Tritapepe 2009</a>). We judged a high risk of performance bias due to missing blinding of caregivers, yet low detection bias, for <a href="./references#CD013781-bbs2-0003" title="BaysalA , YanartasM , DogukanM , GundogusN , KocakT , Koksal C. Levosimendan improves renal outcome in cardiac surgery: a randomized trial. Journal of Cardiothoracic and Vascular Anesthesia2014;28:586-94. [DOI: 10.1053/j.jvca.2013.09.004]">Baysal 2014</a>, <a href="./references#CD013781-bbs2-0005" title="De HertSG , LorsomradeeS , CromheeckeS , Van der LindenPJ . The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesthesia and Analgesia2007;104:766-73. [DOI: 10.1213/01.ane.0000256863.92050.d3]">De Hert 2007</a>, and <a href="./references#CD013781-bbs2-0025" title="MishraA , KumarB , DuttaV , AryaVK , MishraAK . Comparative effect of levosimendan and milrinone in cardiac surgery patients with pulmonary hypertension and left ventricular dysfunction. Journal of Cardiothoracic and Vascular Anesthesia2016;30:639-46. [DOI: 10.1053/j.jvca.2016.01.015]">Mishra 2016</a>. In three studies, blinding was not possible due to different administration of the study drugs (<a href="./references#CD013781-bbs2-0007" title="DesaiPM , SarkarMS , UmbarkarSR . Prophylactic preoperative levosimendan for off-pump coronary artery bypass grafting in patients with left ventricular dysfunction: single-centered randomized prospective study. Annals of Cardiac Anaesthesia2018;21:123-8. [DOI: 10.4103/aca.ACA_178_17]">Desai 2018</a>; <a href="./references#CD013781-bbs2-0010" title="ErsoyO , BoysanE , UnalEU , YayK , YenerU , CicekciogluF , et al. Effectiveness of prophylactic levosimendan in high-risk valve surgery patients. Cardiovascular Journal of Africa2013;24:260-4. [DOI: 10.5830/CVJA-2013-047]">Ersoy 2013</a>; <a href="./references#CD013781-bbs2-0014" title="HuX , XuQ . Application of levosimendan in severe patients after cardiac surgery. Chinese Journal of Clinical Pharmacology and Therapeutics2020;25:1027-32. [DOI: 10.12092/j.issn.1009-2501.2020.09.010]">Hu 2020</a>). No information regarding blinding was given in <a href="./references#CD013781-bbs2-0001" title="AminSW , Abd-ElgalilSM , MohamedSA , AhmedMM , HamawyTY , FathiLM . Levosimendan versus milrinone in the management of impaired left ventricular function in patients undergoing coronary artery bypass graft surgery. Open Anesthesia Journal2019;13:59-67. [DOI: 10.2174/2589645801913010059]">Amin 2019</a>. </p> </section> <section id="CD013781-sec-0052"> <h4 class="title">Incomplete outcome data</h4> <p>We rated the risk of bias for incomplete outcome data as low for all studies.</p> </section> <section id="CD013781-sec-0053"> <h4 class="title">Selective reporting</h4> <p>We rated the risk of bias for selective reporting as low for 12 studies (<a href="./references#CD013781-bbs2-0002" title="AnastasiadisK , AntonitsisP , VranisK , KleontasA , AsteriouC , GrosomanidisV , et al. Effectiveness of prophylactic levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting: a randomized pilot study. Interactive Cardiovascular and Thoracic Surgery2016;23:740-8. [DOI: 10.1093/icvts/ivw213]">Anastasiadis 2016</a>; <a href="./references#CD013781-bbs2-0003" title="BaysalA , YanartasM , DogukanM , GundogusN , KocakT , Koksal C. Levosimendan improves renal outcome in cardiac surgery: a randomized trial. Journal of Cardiothoracic and Vascular Anesthesia2014;28:586-94. [DOI: 10.1053/j.jvca.2013.09.004]">Baysal 2014</a>; <a href="./references#CD013781-bbs2-0004" title="CholleyB , CarubaT , GrosjeanS , AmourJ , OuattaraA , VillacortaJ , et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA2017;318:548-56. [DOI: 10.1001/jama.2017.9973]">Cholley 2017</a>; <a href="./references#CD013781-bbs2-0006" title="DenaultAY , BussièresJS , ArellanoR , FineganB , GavraP , HaddadF , et al. A multicentre randomized-controlled trial of inhaled milrinone in high-risk cardiac surgical patients. Canadian Journal of Anesthesia2016;63:1140-53. [DOI: 10.1007/s12630-016-0709-8]">Denault 2016</a>; <a href="./references#CD013781-bbs2-0008" title="ErbJ , BeutlhauserT , FeldheiserA , SchusterB , TreskatschS , GrubitzschH , et al. Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery. Journal of International Medical Research2014;42:750-64. [DOI: 10.1177/0300060513516293]">Erb 2014</a>; <a href="./references#CD013781-bbs2-0009" title="RikssonHI , JalonenJR , HeikkinenLO , KivikkoM , LaineM , LeinoKA , et al. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Cardiothoracic Anesthesiology2009;87:448-54. [DOI: 10.1016/j.athoracsur.2008.10.029]">Eriksson 2009</a>; <a href="./references#CD013781-bbs2-0011" title="GandhamR , SyamasundarA , RavulapalliH , KarthekeyanRB , VakamudiM , KodalliR , et al. A comparison of hemodynamic effects of levosimendan and dobutamine in patients undergoing mitral valve repair / replacement for severe mitral stenosis. Annals of Cardiac Anaesthesia2013;16:11-5. [DOI: 10.4103/0971-9784.105363]">Gandham 2013</a>; <a href="./references#CD013781-bbs2-0017" title="Juhl-OlsenP , Jakobsen C-J, RasmussenLA , BhavsarR , Klaaborg K-E, FrederiksenCA , et al. Effects of levosimendan in patients with left ventricular hypertrophy undergoing aortic valve replacement. Acta Anaesthesiologica Scandinavica2015;59:65-77. [DOI: 10.1111/aas.12425]">Juhl‐Olsen 2015</a>; <a href="./references#CD013781-bbs2-0021" title="LahtinenP , PitkänenO , PölönenP , TurpeinenA , KiviniemiV , UusaroA . Levosimendan reduces heart failure after cardiac surgery: a prospective, randomized, placebo-controlled trial. Criítical Care Medicine2011;39:2263-70. [DOI: 10.1097/CCM.0b013e3182227b97]">Lahtinen 2011</a>; <a href="./references#CD013781-bbs2-0023" title="LevinR , DegrangeM , Del MazoC , TanusE , PorcileR . Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Experimental and Clinical Cardiology2012;17:125-30. [PMID: 23620700]">Levin 2012</a>; <a href="./references#CD013781-bbs2-0024" title="MehtaRH , LeimbergerJD , vanDiepenS , MezaJ , WangA , JankowichR , et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. New England Journal of Medicine2017;376:2032-42. [DOI: 10.1056/NEJMoa1616218]">Mehta 2017</a>; <a href="./references#CD013781-bbs2-0029" title="TritapepeL , De SantisV , VitaleD , GuarracinoF , PellegriniF , PietropaoliP , et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. British Journal of Anaesthesia2009;102:198-204. [DOI: 10.1093/bja/aen367]">Tritapepe 2009</a>). In <a href="./references#CD013781-bbs2-0005" title="De HertSG , LorsomradeeS , CromheeckeS , Van der LindenPJ . The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesthesia and Analgesia2007;104:766-73. [DOI: 10.1213/01.ane.0000256863.92050.d3]">De Hert 2007</a>, prespecified secondary endpoints were missing, and neither primary nor secondary endpoints were defined in the remaining studies. However, in these studies, the measures listed in the methods section were reported in full. </p> </section> <section id="CD013781-sec-0054"> <h4 class="title">Other potential sources of bias</h4> <p>We rated the risk of bias for other potential sources of bias as low for 18 studies (<a href="./references#CD013781-bbs2-0002" title="AnastasiadisK , AntonitsisP , VranisK , KleontasA , AsteriouC , GrosomanidisV , et al. Effectiveness of prophylactic levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting: a randomized pilot study. Interactive Cardiovascular and Thoracic Surgery2016;23:740-8. [DOI: 10.1093/icvts/ivw213]">Anastasiadis 2016</a>; <a href="./references#CD013781-bbs2-0004" title="CholleyB , CarubaT , GrosjeanS , AmourJ , OuattaraA , VillacortaJ , et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA2017;318:548-56. [DOI: 10.1001/jama.2017.9973]">Cholley 2017</a>; <a href="./references#CD013781-bbs2-0005" title="De HertSG , LorsomradeeS , CromheeckeS , Van der LindenPJ . The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesthesia and Analgesia2007;104:766-73. [DOI: 10.1213/01.ane.0000256863.92050.d3]">De Hert 2007</a>; <a href="./references#CD013781-bbs2-0007" title="DesaiPM , SarkarMS , UmbarkarSR . Prophylactic preoperative levosimendan for off-pump coronary artery bypass grafting in patients with left ventricular dysfunction: single-centered randomized prospective study. Annals of Cardiac Anaesthesia2018;21:123-8. [DOI: 10.4103/aca.ACA_178_17]">Desai 2018</a>; <a href="./references#CD013781-bbs2-0008" title="ErbJ , BeutlhauserT , FeldheiserA , SchusterB , TreskatschS , GrubitzschH , et al. Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery. Journal of International Medical Research2014;42:750-64. [DOI: 10.1177/0300060513516293]">Erb 2014</a>; <a href="./references#CD013781-bbs2-0009" title="RikssonHI , JalonenJR , HeikkinenLO , KivikkoM , LaineM , LeinoKA , et al. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Cardiothoracic Anesthesiology2009;87:448-54. [DOI: 10.1016/j.athoracsur.2008.10.029]">Eriksson 2009</a>; <a href="./references#CD013781-bbs2-0011" title="GandhamR , SyamasundarA , RavulapalliH , KarthekeyanRB , VakamudiM , KodalliR , et al. A comparison of hemodynamic effects of levosimendan and dobutamine in patients undergoing mitral valve repair / replacement for severe mitral stenosis. Annals of Cardiac Anaesthesia2013;16:11-5. [DOI: 10.4103/0971-9784.105363]">Gandham 2013</a>; <a href="./references#CD013781-bbs2-0012" title="GatotI , AbramovD , TsodikovV , YeshayahuM , OrmanS , GavrielA , et al. Should we give prophylactic renal-dose dopamine after coronary artery bypass surgery?Journal of Cardiac Surgery2004;19:128-33. [DOI: 10.1111/j.0886-0440.2004.04044.x]">Gatot 2004</a>; <a href="./references#CD013781-bbs2-0014" title="HuX , XuQ . Application of levosimendan in severe patients after cardiac surgery. Chinese Journal of Clinical Pharmacology and Therapeutics2020;25:1027-32. [DOI: 10.12092/j.issn.1009-2501.2020.09.010]">Hu 2020</a>; <a href="./references#CD013781-bbs2-0015" title="JärveläK , MaaranenP , SistoT , RuokonenE . Levosimendan in aortic valve surgery: cardiac performance and recovery. Journal of Cardiothoracic and Vascular Anesthesia2008;22:693-8. [DOI: 10.1053/j.jvca.2008.01.024]">Jävelä 2008</a>; <a href="./references#CD013781-bbs2-0016" title="JoHR , LeeWK , KimYH , MinJH , ChaeYK , ChoiIG , et al. The effect of milrinone infusion on right ventricular function during coronary anastomosis and early outcomes in patients undergoing off-pump coronary artery bypass surgery. Korean Journal of Anesthesiology2010;59:92-8. [DOI: 10.4097/kjae.2010.59.2.92]">Jo 2010</a>; <a href="./references#CD013781-bbs2-0018" title="KandasamyA , SimonHA , MurthyP , AnnaduraiM , AliMM , RamanathanG . Comparison of levosimendan versus dobutamine in patients with moderate to severe left ventricular dysfunction undergoing off-pump coronary artery bypass grafting: a randomized prospective study. Annals of Cardiac Anaesthesia2017;20:200-6. [DOI: 10.4103/aca.ACA_195_16]">Kandasamy 2017</a>; <a href="./references#CD013781-bbs2-0019" title="KikuraM , SatoS . The efficacy of preemptive milrinone or amrinone therapy in patients undergoing coronary artery bypass grafting. Anesthesia and Analgesia2002;94:22-30. [DOI: 10.1097/00000539-200201000-00005]">Kikura 2002</a>; <a href="./references#CD013781-bbs2-0021" title="LahtinenP , PitkänenO , PölönenP , TurpeinenA , KiviniemiV , UusaroA . Levosimendan reduces heart failure after cardiac surgery: a prospective, randomized, placebo-controlled trial. Criítical Care Medicine2011;39:2263-70. [DOI: 10.1097/CCM.0b013e3182227b97]">Lahtinen 2011</a>; <a href="./references#CD013781-bbs2-0023" title="LevinR , DegrangeM , Del MazoC , TanusE , PorcileR . Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Experimental and Clinical Cardiology2012;17:125-30. [PMID: 23620700]">Levin 2012</a>; <a href="./references#CD013781-bbs2-0024" title="MehtaRH , LeimbergerJD , vanDiepenS , MezaJ , WangA , JankowichR , et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. New England Journal of Medicine2017;376:2032-42. [DOI: 10.1056/NEJMoa1616218]">Mehta 2017</a>; <a href="./references#CD013781-bbs2-0028" title="TritapepeL , De SantisV , VitaleD , SantulliM , MorelliA , NofroniI , et al. Preconditioning effects of levosimendan in coronary artery bypass grafting - a pilot study. British Journal of Anaesthesia2006;96:694-700. [DOI: 10.1093/bja/ael082]">Tritapepe 2006</a>; <a href="./references#CD013781-bbs2-0029" title="TritapepeL , De SantisV , VitaleD , GuarracinoF , PellegriniF , PietropaoliP , et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. British Journal of Anaesthesia2009;102:198-204. [DOI: 10.1093/bja/aen367]">Tritapepe 2009</a>) and unclear for 10 studies due to baseline differences in gender (<a href="./references#CD013781-bbs2-0001" title="AminSW , Abd-ElgalilSM , MohamedSA , AhmedMM , HamawyTY , FathiLM . Levosimendan versus milrinone in the management of impaired left ventricular function in patients undergoing coronary artery bypass graft surgery. Open Anesthesia Journal2019;13:59-67. [DOI: 10.2174/2589645801913010059]">Amin 2019</a>; <a href="./references#CD013781-bbs2-0003" title="BaysalA , YanartasM , DogukanM , GundogusN , KocakT , Koksal C. Levosimendan improves renal outcome in cardiac surgery: a randomized trial. Journal of Cardiothoracic and Vascular Anesthesia2014;28:586-94. [DOI: 10.1053/j.jvca.2013.09.004]">Baysal 2014</a>; <a href="./references#CD013781-bbs2-0006" title="DenaultAY , BussièresJS , ArellanoR , FineganB , GavraP , HaddadF , et al. A multicentre randomized-controlled trial of inhaled milrinone in high-risk cardiac surgical patients. Canadian Journal of Anesthesia2016;63:1140-53. [DOI: 10.1007/s12630-016-0709-8]">Denault 2016</a>; <a href="./references#CD013781-bbs2-0010" title="ErsoyO , BoysanE , UnalEU , YayK , YenerU , CicekciogluF , et al. Effectiveness of prophylactic levosimendan in high-risk valve surgery patients. Cardiovascular Journal of Africa2013;24:260-4. [DOI: 10.5830/CVJA-2013-047]">Ersoy 2013</a>; <a href="./references#CD013781-bbs2-0013" title="HadadzadehM , HosseiniSH , Mostafavi-Pour-ManshadiSM , NaderiN , Emami-MeybodiM . Effect of milrinone on short term outcome of patients with myocardial dysfunction undergoing off-pump coronary artery bypass graft: a randomized clinical trial. Acta Medica Iranica2013;51:681-6. [PMID: 24338139]">Hadadzadeh 2013</a>; <a href="./references#CD013781-bbs2-0017" title="Juhl-OlsenP , Jakobsen C-J, RasmussenLA , BhavsarR , Klaaborg K-E, FrederiksenCA , et al. Effects of levosimendan in patients with left ventricular hypertrophy undergoing aortic valve replacement. Acta Anaesthesiologica Scandinavica2015;59:65-77. [DOI: 10.1111/aas.12425]">Juhl‐Olsen 2015</a>; <a href="./references#CD013781-bbs2-0020" title="KodalliRK , SundarAS , VakamudiM , RavulapaliH , NandipatiS , ChandrasekaranN , et al. Effect of levosimendan on hemodynamic changes in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled study. Annals of Cardiac Anaesthesia2013;16:94-9. [DOI: 10.4103/0971-9784.109737]">Kodalli 2013</a>; <a href="./references#CD013781-bbs2-0022" title="LeppikangasH , JärveläK , SistoT , MaaranenP , VirtanenM , LehtoP , et al. Preoperative levosimendan infusion in combined aortic valve and coronary bypass surgery. British Journal of Anaesthesia2011;106:298-304. [DOI: 10.1093/bja/aeq402]">Leppikangas 2011</a>; <a href="./references#CD013781-bbs2-0027" title="SharmaP , MalhotraA , GandhiS , GargP , BishnoiA , GandhiH . Preoperative levosimendan in ischemic mitral valve repair. Asian Cardiovascular and Thoracic Annals2014;22:539-45. [DOI: 10.1177/0218492313499352]">Sharma 2014</a>) or baseline differences in age and missing information on gender (<a href="./references#CD013781-bbs2-0025" title="MishraA , KumarB , DuttaV , AryaVK , MishraAK . Comparative effect of levosimendan and milrinone in cardiac surgery patients with pulmonary hypertension and left ventricular dysfunction. Journal of Cardiothoracic and Vascular Anesthesia2016;30:639-46. [DOI: 10.1053/j.jvca.2016.01.015]">Mishra 2016</a>). Although the title and inclusion criteria of the study <a href="./references#CD013781-bbs2-0026" title="ShahB , SharmaP , BrahmbhattA , ShahR , RathodB , ShastriN , et al. Study of levosimendan during off-pump coronary artery bypass grafting in patients with LV dysfunction: a double-blind randomized study. Indian Journal of Pharmacology2014;46:29-34. [DOI: 10.4103/0253-7613.125161]">Shah 2014</a> implied that the enrolled participants underwent OPCABG, surgery was completed with the help of CPB for 1 of 25 participants from the intervention group and 8 of 25 participants from the comparison group. </p> <p>None of the included trials reported any cross‐over or were affected by interim results.</p> </section> </section> <section id="CD013781-sec-0055"> <h3 class="title" id="CD013781-sec-0055">Effects of interventions</h3> <p>See: <a href="./full#CD013781-tbl-0001"><b>Summary of findings 1</b> Levosimendan compared to standard cardiac care</a>; <a href="./full#CD013781-tbl-0002"><b>Summary of findings 2</b> Levosimendan compared to placebo</a> </p> <section id="CD013781-sec-0056"> <h4 class="title">Amrinone versus placebo</h4> <p>There was only one single‐centre study with 30 participants investigating amrinone compared to placebo (<a href="./references#CD013781-bbs2-0019" title="KikuraM , SatoS . The efficacy of preemptive milrinone or amrinone therapy in patients undergoing coronary artery bypass grafting. Anesthesia and Analgesia2002;94:22-30. [DOI: 10.1097/00000539-200201000-00005]">Kikura 2002</a>). All that the authors reported were haemodynamic parameters and the need for additional inotropics. </p> <section id="CD013781-sec-0057"> <h5 class="title">Primary outcomes</h5> <section id="CD013781-sec-0058"> <h6 class="title">All‐cause mortality (within 30 days)</h6> <p>This outcome was not reported in the included study.</p> </section> <section id="CD013781-sec-0059"> <h6 class="title">Incidence of LCOS</h6> <p>This outcome was not reported in the included study.</p> </section> <section id="CD013781-sec-0060"> <h6 class="title">Adverse events</h6> <p>This outcome was not reported in the included study.</p> </section> </section> <section id="CD013781-sec-0061"> <h5 class="title">Secondary outcomes</h5> <section id="CD013781-sec-0062"> <h6 class="title">Length of in‐hospital and intensive care unit stay</h6> <p>These outcomes were not reported in the included study.</p> </section> <section id="CD013781-sec-0063"> <h6 class="title">Haemodynamics (cardiac index, MAP, PCWP)</h6> <p>Cardiac index was increased in the amrinone‐treated group compared to the placebo group during this period (2.5 ± 0.2 versus 1.9 ± 0.5 l/min/m<sup>2</sup>) (<a href="./references#CD013781-fig-0006" title="">Analysis 1.1</a>). With regard to MAP, the study authors reportedly observed no differences between the study groups (observation period: 7 to 10 hours after CPB; no quantitative data available). Information on PCWP was not reported. </p> </section> <section id="CD013781-sec-0064"> <h6 class="title">Duration of mechanical ventilation</h6> <p>This outcome was not reported in the included study.</p> </section> <section id="CD013781-sec-0065"> <h6 class="title">Proportion of weaning failure within 48 hours of extubation</h6> <p>This outcome was not reported in the included study.</p> </section> <section id="CD013781-sec-0066"> <h6 class="title">Number of patients requiring mechanical circulatory support (IABP)</h6> <p>This outcome was not reported in the included study.</p> </section> <section id="CD013781-sec-0067"> <h6 class="title">Number of patients requiring additional inotropic drugs</h6> <p>Dopamine was administered when needed. The authors claimed that the mean total dose of dopamine administered in the first 24 hours after surgery was lower in the amrinone group than in the placebo group. This was said to be due to a slower rate of dopamine infusion in the period 7 to 10 hours after CPB. Quantitative data were not available. No information was given on the number of patients who received additional dopamine. </p> </section> <section id="CD013781-sec-0068"> <h6 class="title">Number of patients requiring cardiac transplantation, ventricular assist device (VAD) implantation or cardiopulmonary resuscitation </h6> <p>These outcomes were not reported in the included study.</p> </section> <section id="CD013781-sec-0069"> <h6 class="title">Proportion of renal failure</h6> <p>This outcome was not reported in the included study.</p> </section> <section id="CD013781-sec-0070"> <h6 class="title">Quality of life</h6> <p>This outcome was not reported in the included study.</p> </section> </section> </section> <section id="CD013781-sec-0071"> <h4 class="title">Dopamine versus placebo</h4> <p>There was only one single‐centre study with 81 participants investigating dopamine compared to placebo (<a href="./references#CD013781-bbs2-0012" title="GatotI , AbramovD , TsodikovV , YeshayahuM , OrmanS , GavrielA , et al. Should we give prophylactic renal-dose dopamine after coronary artery bypass surgery?Journal of Cardiac Surgery2004;19:128-33. [DOI: 10.1111/j.0886-0440.2004.04044.x]">Gatot 2004</a>). </p> <section id="CD013781-sec-0072"> <h5 class="title">Primary outcomes</h5> <section id="CD013781-sec-0073"> <h6 class="title">All‐cause mortality (within 30 days)</h6> <p>This outcome was not reported in the included study.</p> </section> <section id="CD013781-sec-0074"> <h6 class="title">Incidence of LCOS</h6> <p>No RR and resulting estimations of absolute effect were possible since no events were observed in either group (<a href="./references#CD013781-fig-0007" title="">Analysis 2.1</a>). </p> </section> <section id="CD013781-sec-0075"> <h6 class="title">Adverse events</h6> <p>Information on cardiogenic shock or non‐embolic stroke/transient ischaemic attack was not reported. There was no evidence of a difference in atrial fibrillation with 15 out of 41 participants (36.6%) suffering atrial fibrillation in the dopamine intervention group compared with 20 out of 40 participants (50.0%) in the placebo control group (RR 0.73, 95% CI 0.44 to 1.22; 81 participants, 1 study; very low‐certainty evidence; heterogeneity was not applicable) (<a href="./references#CD013781-fig-0008" title="">Analysis 2.2</a>). No RR and resulting estimations of absolute effect on perioperative myocardial infarction were possible since no events were observed in either group (<a href="./references#CD013781-fig-0009" title="">Analysis 2.3</a>). </p> </section> </section> <section id="CD013781-sec-0076"> <h5 class="title">Secondary outcomes</h5> <section id="CD013781-sec-0077"> <h6 class="title">Length of in‐hospital and intensive care unit stay</h6> <p>The mean length of in‐hospital stay was similar between study groups, with 10 ± 3 days in the dopamine intervention group compared with 10 ± 4 days in the placebo control group (<a href="./references#CD013781-fig-0010" title="">Analysis 2.4</a>). The length of intensive care unit stay was not reported in the included study. </p> </section> <section id="CD013781-sec-0078"> <h6 class="title">Haemodynamics (cardiac index, MAP, PCWP)</h6> <p>While information on cardiac index and PCWP was not reported in the included study, MAP showed little to no difference between groups (87 ± 10 versus 84 ± 10 mmHg at 24 hours after surgery) (<a href="./references#CD013781-fig-0011" title="">Analysis 2.5</a>). </p> </section> <section id="CD013781-sec-0079"> <h6 class="title">Duration of mechanical ventilation</h6> <p>The mean duration of mechanical ventilation in the dopamine intervention group (10 hours) was similar to the placebo control group (mean difference 0.00, 95% CI ‐1.11 to 1.11; 81 participants, 1 study; very low‐certainty evidence; heterogeneity was not applicable) (<a href="./references#CD013781-fig-0012" title="">Analysis 2.6</a>). </p> </section> <section id="CD013781-sec-0080"> <h6 class="title">Proportion of weaning failure within 48 hours of extubation</h6> <p>This outcome was not reported in the included study.</p> </section> <section id="CD013781-sec-0081"> <h6 class="title">Number of patients requiring mechanical circulatory support (IABP)</h6> <p>This outcome was not reported in the included study.</p> </section> <section id="CD013781-sec-0082"> <h6 class="title">Number of patients requiring additional inotropic drugs</h6> <p>While no participants in the dopamine intervention group (n = 41) did require additional inotropic drugs, 4 out of 40 participants in the placebo control group required additional inotropic drugs (dopamine). However, the risk ratio showed no evidence of a difference between groups (RR 0.11, 95% CI 0.01 to 1.95) (<a href="./references#CD013781-fig-0013" title="">Analysis 2.7</a>). </p> </section> <section id="CD013781-sec-0083"> <h6 class="title">Number of patients requiring cardiac transplantation, ventricular assist device (VAD) implantation or cardiopulmonary resuscitation </h6> <p>These outcomes were not reported in the included study.</p> </section> <section id="CD013781-sec-0084"> <h6 class="title">Proportion of renal failure</h6> <p>No participant suffered from renal failure in the dopamine intervention group (n = 41) compared to 4 out of 40 participants in the placebo control group. However, the risk ratio demonstrated no evidence of a difference between groups (RR 0.11, 95% CI 0.01 to 1.95) (<a href="./references#CD013781-fig-0014" title="">Analysis 2.8</a>). </p> </section> <section id="CD013781-sec-0085"> <h6 class="title">Quality of life</h6> <p>This outcome was not reported in the included study.</p> </section> </section> </section> <section id="CD013781-sec-0086"> <h4 class="title">Milrinone versus placebo</h4> <p>Three small, single‐centre trials covering 150 participants (<a href="./references#CD013781-bbs2-0013" title="HadadzadehM , HosseiniSH , Mostafavi-Pour-ManshadiSM , NaderiN , Emami-MeybodiM . Effect of milrinone on short term outcome of patients with myocardial dysfunction undergoing off-pump coronary artery bypass graft: a randomized clinical trial. Acta Medica Iranica2013;51:681-6. [PMID: 24338139]">Hadadzadeh 2013</a>; <a href="./references#CD013781-bbs2-0016" title="JoHR , LeeWK , KimYH , MinJH , ChaeYK , ChoiIG , et al. The effect of milrinone infusion on right ventricular function during coronary anastomosis and early outcomes in patients undergoing off-pump coronary artery bypass surgery. Korean Journal of Anesthesiology2010;59:92-8. [DOI: 10.4097/kjae.2010.59.2.92]">Jo 2010</a>; <a href="./references#CD013781-bbs2-0019" title="KikuraM , SatoS . The efficacy of preemptive milrinone or amrinone therapy in patients undergoing coronary artery bypass grafting. Anesthesia and Analgesia2002;94:22-30. [DOI: 10.1097/00000539-200201000-00005]">Kikura 2002</a>) and one multicentre trial with 124 participants (<a href="./references#CD013781-bbs2-0006" title="DenaultAY , BussièresJS , ArellanoR , FineganB , GavraP , HaddadF , et al. A multicentre randomized-controlled trial of inhaled milrinone in high-risk cardiac surgical patients. Canadian Journal of Anesthesia2016;63:1140-53. [DOI: 10.1007/s12630-016-0709-8]">Denault 2016</a>) investigated milrinone compared to placebo. </p> <section id="CD013781-sec-0087"> <h5 class="title">Primary outcomes</h5> <section id="CD013781-sec-0088"> <h6 class="title">All‐cause mortality (within 30 days)</h6> <p>Information on mortality within 30 days was restricted to two studies (<a href="./references#CD013781-bbs2-0013" title="HadadzadehM , HosseiniSH , Mostafavi-Pour-ManshadiSM , NaderiN , Emami-MeybodiM . Effect of milrinone on short term outcome of patients with myocardial dysfunction undergoing off-pump coronary artery bypass graft: a randomized clinical trial. Acta Medica Iranica2013;51:681-6. [PMID: 24338139]">Hadadzadeh 2013</a>; <a href="./references#CD013781-bbs2-0016" title="JoHR , LeeWK , KimYH , MinJH , ChaeYK , ChoiIG , et al. The effect of milrinone infusion on right ventricular function during coronary anastomosis and early outcomes in patients undergoing off-pump coronary artery bypass surgery. Korean Journal of Anesthesiology2010;59:92-8. [DOI: 10.4097/kjae.2010.59.2.92]">Jo 2010</a>). However, the relative effect was only generated from one trial (<a href="./references#CD013781-bbs2-0013" title="HadadzadehM , HosseiniSH , Mostafavi-Pour-ManshadiSM , NaderiN , Emami-MeybodiM . Effect of milrinone on short term outcome of patients with myocardial dysfunction undergoing off-pump coronary artery bypass graft: a randomized clinical trial. Acta Medica Iranica2013;51:681-6. [PMID: 24338139]">Hadadzadeh 2013</a>), while the relative effect from <a href="./references#CD013781-bbs2-0016" title="JoHR , LeeWK , KimYH , MinJH , ChaeYK , ChoiIG , et al. The effect of milrinone infusion on right ventricular function during coronary anastomosis and early outcomes in patients undergoing off-pump coronary artery bypass surgery. Korean Journal of Anesthesiology2010;59:92-8. [DOI: 10.4097/kjae.2010.59.2.92]">Jo 2010</a> was not estimable since no events were observed in either group. When milrinone was compared to the placebo group, there was no evidence of a difference in all‐cause mortality within 30 days (RR 1.00, 95% CI 0.06 to 15.44; 40 participants, 1 study; low‐certainty evidence; heterogeneity was not applicable) (<a href="./references#CD013781-fig-0015" title="">Analysis 3.1</a>). </p> </section> <section id="CD013781-sec-0089"> <h6 class="title">Incidence of LCOS</h6> <p>This outcome was not reported in any of the included studies.</p> </section> <section id="CD013781-sec-0090"> <h6 class="title">Adverse events</h6> <p>For adverse events, there was only one study with limited quantitative data for each outcome: non‐embolic stroke/transient ischaemic attack data were provided by <a href="./references#CD013781-bbs2-0016" title="JoHR , LeeWK , KimYH , MinJH , ChaeYK , ChoiIG , et al. The effect of milrinone infusion on right ventricular function during coronary anastomosis and early outcomes in patients undergoing off-pump coronary artery bypass surgery. Korean Journal of Anesthesiology2010;59:92-8. [DOI: 10.4097/kjae.2010.59.2.92]">Jo 2010</a>, and cardiogenic shock, atrial fibrillation, and perioperative myocardial infarction data were contributed by <a href="./references#CD013781-bbs2-0013" title="HadadzadehM , HosseiniSH , Mostafavi-Pour-ManshadiSM , NaderiN , Emami-MeybodiM . Effect of milrinone on short term outcome of patients with myocardial dysfunction undergoing off-pump coronary artery bypass graft: a randomized clinical trial. Acta Medica Iranica2013;51:681-6. [PMID: 24338139]">Hadadzadeh 2013</a>. </p> <p>All four adverse event outcomes showed little to no difference between groups. For example, 1 out of 40 participants experienced a cardiogenic shock in both the milrinone (2.5%) and placebo groups (2.5%) with a risk ratio of 1.00 (95% CI 0.06 to 15.44; 80 participants, 1 study; low‐certainty evidence; heterogeneity was not applicable) (<a href="./references#CD013781-fig-0016" title="">Analysis 3.2</a>). Moreover, 2 out of 40 participants (5%) suffered atrial fibrillation in the milrinone group compared with 3 out of 40 participants (7.5%) in the placebo group (RR 0.67, 95% CI 0.12 to 3.78; 80 participants, 1 study; low‐certainty evidence; heterogeneity was not applicable) (<a href="./references#CD013781-fig-0017" title="">Analysis 3.3</a>). For perioperative myocardial infarction, 4 out of 40 patients (10%) had this event in the milrinone intervention group compared with 9 out of 40 patients (22.5%) in the placebo control group (RR 0.44, 95% CI 0.15 to 1.33; 80 participants, 1 study; low‐certainty evidence; heterogeneity was not applicable) (<a href="./references#CD013781-fig-0018" title="">Analysis 3.4</a>). Similarly, <a href="./references#CD013781-bbs2-0016" title="JoHR , LeeWK , KimYH , MinJH , ChaeYK , ChoiIG , et al. The effect of milrinone infusion on right ventricular function during coronary anastomosis and early outcomes in patients undergoing off-pump coronary artery bypass surgery. Korean Journal of Anesthesiology2010;59:92-8. [DOI: 10.4097/kjae.2010.59.2.92]">Jo 2010</a> narratively reported similar rates of perioperative myocardial infarction between the study groups. Lastly, there was no participant who suffered from non‐embolic stroke/transient ischaemic attack in the milrinone group compared with 1 out of 20 participants (5%) in the placebo group (RR 0.33, 95% CI 0.01 to 7.72; 40 participants, 1 study; low‐certainty evidence; heterogeneity was not applicable) (<a href="./references#CD013781-fig-0019" title="">Analysis 3.5</a>). </p> </section> </section> <section id="CD013781-sec-0091"> <h5 class="title">Secondary outcomes</h5> <section id="CD013781-sec-0092"> <h6 class="title">Length of in‐hospital and intensive care unit stay</h6> <p>Information on the length of in‐hospital stay was restricted to <a href="./references#CD013781-bbs2-0006" title="DenaultAY , BussièresJS , ArellanoR , FineganB , GavraP , HaddadF , et al. A multicentre randomized-controlled trial of inhaled milrinone in high-risk cardiac surgical patients. Canadian Journal of Anesthesia2016;63:1140-53. [DOI: 10.1007/s12630-016-0709-8]">Denault 2016</a> (8 (IQR 6 to 11) versus 7 (IQR 5 to 10) days). Information on the length of intensive care unit stay was restricted to <a href="./references#CD013781-bbs2-0013" title="HadadzadehM , HosseiniSH , Mostafavi-Pour-ManshadiSM , NaderiN , Emami-MeybodiM . Effect of milrinone on short term outcome of patients with myocardial dysfunction undergoing off-pump coronary artery bypass graft: a randomized clinical trial. Acta Medica Iranica2013;51:681-6. [PMID: 24338139]">Hadadzadeh 2013</a> and <a href="./references#CD013781-bbs2-0006" title="DenaultAY , BussièresJS , ArellanoR , FineganB , GavraP , HaddadF , et al. A multicentre randomized-controlled trial of inhaled milrinone in high-risk cardiac surgical patients. Canadian Journal of Anesthesia2016;63:1140-53. [DOI: 10.1007/s12630-016-0709-8]">Denault 2016</a>. <a href="./references#CD013781-bbs2-0013" title="HadadzadehM , HosseiniSH , Mostafavi-Pour-ManshadiSM , NaderiN , Emami-MeybodiM . Effect of milrinone on short term outcome of patients with myocardial dysfunction undergoing off-pump coronary artery bypass graft: a randomized clinical trial. Acta Medica Iranica2013;51:681-6. [PMID: 24338139]">Hadadzadeh 2013</a> reported that the mean length of stay in intensive care in the placebo control group was 2.5 ± 0.59 days. In the milrinone intervention group, the mean length of intensive care stay was 0.15 days shorter (mean difference ‐0.15, 95% CI ‐0.40 to 0.10) (<a href="./references#CD013781-fig-0020" title="">Analysis 3.6</a>). <a href="./references#CD013781-bbs2-0006" title="DenaultAY , BussièresJS , ArellanoR , FineganB , GavraP , HaddadF , et al. A multicentre randomized-controlled trial of inhaled milrinone in high-risk cardiac surgical patients. Canadian Journal of Anesthesia2016;63:1140-53. [DOI: 10.1007/s12630-016-0709-8]">Denault 2016</a> reported similar median durations of intensive care in both study groups (1.79 (IQR 0.89 to 3.15) versus 1.09 (IQR 0.90 to 2.95) days). </p> </section> <section id="CD013781-sec-0093"> <h6 class="title">Haemodynamics (cardiac index, MAP, PCWP)</h6> <p>Information on cardiac index was restricted to two studies (<a href="./references#CD013781-bbs2-0016" title="JoHR , LeeWK , KimYH , MinJH , ChaeYK , ChoiIG , et al. The effect of milrinone infusion on right ventricular function during coronary anastomosis and early outcomes in patients undergoing off-pump coronary artery bypass surgery. Korean Journal of Anesthesiology2010;59:92-8. [DOI: 10.4097/kjae.2010.59.2.92]">Jo 2010</a>; <a href="./references#CD013781-bbs2-0019" title="KikuraM , SatoS . The efficacy of preemptive milrinone or amrinone therapy in patients undergoing coronary artery bypass grafting. Anesthesia and Analgesia2002;94:22-30. [DOI: 10.1097/00000539-200201000-00005]">Kikura 2002</a>). There was little to no difference in mean cardiac index at end of surgery with a mean difference of 0.10 (95% CI ‐0.22 to 0.42; 40 participants, 1 study; heterogeneity was not applicable) (<a href="./references#CD013781-fig-0021" title="">Analysis 3.7</a>). However, at 6 hours after surgery and 12 hours after surgery, the mean cardiac index differed between groups with mean differences of 0.50 (95% CI 0.29 to 0.71; 70 participants, 2 studies; low heterogeneity) and 0.50 (95% CI 0.25 to 0.75; 40 participants, 1 study; heterogeneity was not applicable), respectively (<a href="./references#CD013781-fig-0021" title="">Analysis 3.7</a>). </p> <p>For MAP, there were two included studies that reported quantitative data (<a href="./references#CD013781-bbs2-0006" title="DenaultAY , BussièresJS , ArellanoR , FineganB , GavraP , HaddadF , et al. A multicentre randomized-controlled trial of inhaled milrinone in high-risk cardiac surgical patients. Canadian Journal of Anesthesia2016;63:1140-53. [DOI: 10.1007/s12630-016-0709-8]">Denault 2016</a>; <a href="./references#CD013781-bbs2-0016" title="JoHR , LeeWK , KimYH , MinJH , ChaeYK , ChoiIG , et al. The effect of milrinone infusion on right ventricular function during coronary anastomosis and early outcomes in patients undergoing off-pump coronary artery bypass surgery. Korean Journal of Anesthesiology2010;59:92-8. [DOI: 10.4097/kjae.2010.59.2.92]">Jo 2010</a>). <a href="./references#CD013781-bbs2-0006" title="DenaultAY , BussièresJS , ArellanoR , FineganB , GavraP , HaddadF , et al. A multicentre randomized-controlled trial of inhaled milrinone in high-risk cardiac surgical patients. Canadian Journal of Anesthesia2016;63:1140-53. [DOI: 10.1007/s12630-016-0709-8]">Denault 2016</a> focussed on the perioperative period until the end of surgery. <a href="./references#CD013781-bbs2-0016" title="JoHR , LeeWK , KimYH , MinJH , ChaeYK , ChoiIG , et al. The effect of milrinone infusion on right ventricular function during coronary anastomosis and early outcomes in patients undergoing off-pump coronary artery bypass surgery. Korean Journal of Anesthesiology2010;59:92-8. [DOI: 10.4097/kjae.2010.59.2.92]">Jo 2010</a> covered the postoperative period from the end of surgery until 12 hours after surgery. There was little to no difference in mean MAP between groups at baseline (mean difference 2.00, 95% CI ‐2.23 to 6.23; 124 participants, 1 study; heterogeneity was not applicable), at end of surgery (mean difference ‐1.66, 95% CI ‐5.43 to 2.12; 164 participants, 2 studies; low heterogeneity), 6 hours after surgery (mean difference ‐3.00, 95% CI ‐9.82 to 3.82; 40 participants, 1 study; heterogeneity was not applicable), and 12 hours after surgery (mean difference ‐1.00, 95% CI ‐8.19 to 6.19; 40 participants, 1 study; heterogeneity was not applicable) (<a href="./references#CD013781-fig-0022" title="">Analysis 3.8</a>). <a href="./references#CD013781-bbs2-0019" title="KikuraM , SatoS . The efficacy of preemptive milrinone or amrinone therapy in patients undergoing coronary artery bypass grafting. Anesthesia and Analgesia2002;94:22-30. [DOI: 10.1097/00000539-200201000-00005]">Kikura 2002</a> reported no quantitative data but claimed no differences between the study groups in the observation period 7 to 10 hours after CPB. </p> <p>There was only one included study providing means of PCWP at three time points (at end of surgery, 6 and 12 hours after surgery) (<a href="./references#CD013781-bbs2-0016" title="JoHR , LeeWK , KimYH , MinJH , ChaeYK , ChoiIG , et al. The effect of milrinone infusion on right ventricular function during coronary anastomosis and early outcomes in patients undergoing off-pump coronary artery bypass surgery. Korean Journal of Anesthesiology2010;59:92-8. [DOI: 10.4097/kjae.2010.59.2.92]">Jo 2010</a>). There was little to no difference in mean PCWP between groups at the end of surgery and at 12 hours after surgery with mean differences of ‐3.00 (95% CI ‐6.74 to 0.74) and ‐3.00 (95% CI ‐8.00 to 2.00), respectively (<a href="./references#CD013781-fig-0023" title="">Analysis 3.9</a>). However, at 6 hours after surgery, the mean PCWP differed between groups (mean differences ‐4.00, 95% CI ‐7.16 to ‐0.84; 40 participants, 1 study; heterogeneity was not applicable) (<a href="./references#CD013781-fig-0023" title="">Analysis 3.9</a>). </p> </section> <section id="CD013781-sec-0094"> <h6 class="title">Duration of mechanical ventilation</h6> <p>Information on this outcome was provided by <a href="./references#CD013781-bbs2-0013" title="HadadzadehM , HosseiniSH , Mostafavi-Pour-ManshadiSM , NaderiN , Emami-MeybodiM . Effect of milrinone on short term outcome of patients with myocardial dysfunction undergoing off-pump coronary artery bypass graft: a randomized clinical trial. Acta Medica Iranica2013;51:681-6. [PMID: 24338139]">Hadadzadeh 2013</a> and <a href="./references#CD013781-bbs2-0006" title="DenaultAY , BussièresJS , ArellanoR , FineganB , GavraP , HaddadF , et al. A multicentre randomized-controlled trial of inhaled milrinone in high-risk cardiac surgical patients. Canadian Journal of Anesthesia2016;63:1140-53. [DOI: 10.1007/s12630-016-0709-8]">Denault 2016</a>. <a href="./references#CD013781-bbs2-0013" title="HadadzadehM , HosseiniSH , Mostafavi-Pour-ManshadiSM , NaderiN , Emami-MeybodiM . Effect of milrinone on short term outcome of patients with myocardial dysfunction undergoing off-pump coronary artery bypass graft: a randomized clinical trial. Acta Medica Iranica2013;51:681-6. [PMID: 24338139]">Hadadzadeh 2013</a> showed that the mean duration of mechanical ventilation in the placebo control group was 14.3 hours. The mean duration of mechanical ventilation in the milrinone intervention group was 3.98 hours lower (95% CI ‐7.28 to ‐0.68) (<a href="./references#CD013781-fig-0024" title="">Analysis 3.10</a>). <a href="./references#CD013781-bbs2-0006" title="DenaultAY , BussièresJS , ArellanoR , FineganB , GavraP , HaddadF , et al. A multicentre randomized-controlled trial of inhaled milrinone in high-risk cardiac surgical patients. Canadian Journal of Anesthesia2016;63:1140-53. [DOI: 10.1007/s12630-016-0709-8]">Denault 2016</a> reported a median duration of mechanical ventilation of 8.5 (IQR 5.3 to 18.2) days in the milrinone intervention group compared with 6.8 (IQR 4.4 to 17) days in the placebo control group. </p> </section> <section id="CD013781-sec-0095"> <h6 class="title">Proportion of weaning failure within 48 hours of extubation</h6> <p>Information on the proportion of weaning failure was reported by <a href="./references#CD013781-bbs2-0006" title="DenaultAY , BussièresJS , ArellanoR , FineganB , GavraP , HaddadF , et al. A multicentre randomized-controlled trial of inhaled milrinone in high-risk cardiac surgical patients. Canadian Journal of Anesthesia2016;63:1140-53. [DOI: 10.1007/s12630-016-0709-8]">Denault 2016</a> and <a href="./references#CD013781-bbs2-0016" title="JoHR , LeeWK , KimYH , MinJH , ChaeYK , ChoiIG , et al. The effect of milrinone infusion on right ventricular function during coronary anastomosis and early outcomes in patients undergoing off-pump coronary artery bypass surgery. Korean Journal of Anesthesiology2010;59:92-8. [DOI: 10.4097/kjae.2010.59.2.92]">Jo 2010</a>, covering 164 participants. The risk ratio demonstrated no evidence of a difference between the milrinone intervention group and the placebo control group (RR 1.17, 95% CI 0.37 to 3.69) (<a href="./references#CD013781-fig-0025" title="">Analysis 3.11</a>). </p> </section> <section id="CD013781-sec-0096"> <h6 class="title">Number of patients requiring mechanical circulatory support (IABP)</h6> <p>Information on the number of patients requiring mechanical circulatory support was provided by two studies (<a href="./references#CD013781-bbs2-0006" title="DenaultAY , BussièresJS , ArellanoR , FineganB , GavraP , HaddadF , et al. A multicentre randomized-controlled trial of inhaled milrinone in high-risk cardiac surgical patients. Canadian Journal of Anesthesia2016;63:1140-53. [DOI: 10.1007/s12630-016-0709-8]">Denault 2016</a>; <a href="./references#CD013781-bbs2-0013" title="HadadzadehM , HosseiniSH , Mostafavi-Pour-ManshadiSM , NaderiN , Emami-MeybodiM . Effect of milrinone on short term outcome of patients with myocardial dysfunction undergoing off-pump coronary artery bypass graft: a randomized clinical trial. Acta Medica Iranica2013;51:681-6. [PMID: 24338139]">Hadadzadeh 2013</a>). In the milrinone group, 3 out of 103 participants required mechanical circulatory support compared to 8 out of 101 participants in the control group. However, no evidence of a difference was found in the risk ratio between groups (RR 0.41, 95% CI 0.13 to 1.35; 204 participants, 2 studies; moderate‐certainty evidence; low heterogeneity) (<a href="./references#CD013781-fig-0026" title="">Analysis 3.12</a>). </p> </section> <section id="CD013781-sec-0097"> <h6 class="title">Number of patients requiring additional inotropic drugs</h6> <p>For overall additional inotropic drugs (without reporting a specific drug type or name), two studies reported that 36 out of 103 patients required additional inotropic drugs in the milrinone intervention group compared to 38 out of 101 patients in the placebo control group (<a href="./references#CD013781-bbs2-0006" title="DenaultAY , BussièresJS , ArellanoR , FineganB , GavraP , HaddadF , et al. A multicentre randomized-controlled trial of inhaled milrinone in high-risk cardiac surgical patients. Canadian Journal of Anesthesia2016;63:1140-53. [DOI: 10.1007/s12630-016-0709-8]">Denault 2016</a>; <a href="./references#CD013781-bbs2-0013" title="HadadzadehM , HosseiniSH , Mostafavi-Pour-ManshadiSM , NaderiN , Emami-MeybodiM . Effect of milrinone on short term outcome of patients with myocardial dysfunction undergoing off-pump coronary artery bypass graft: a randomized clinical trial. Acta Medica Iranica2013;51:681-6. [PMID: 24338139]">Hadadzadeh 2013</a>). Little to no difference was found between groups (RR 0.93, 95% CI 0.65 to 1.31; 204 participants, 2 studies; low heterogeneity) (<a href="./references#CD013781-fig-0027" title="">Analysis 3.13</a>). </p> <p>Within this outcome category, <a href="./references#CD013781-bbs2-0006" title="DenaultAY , BussièresJS , ArellanoR , FineganB , GavraP , HaddadF , et al. A multicentre randomized-controlled trial of inhaled milrinone in high-risk cardiac surgical patients. Canadian Journal of Anesthesia2016;63:1140-53. [DOI: 10.1007/s12630-016-0709-8]">Denault 2016</a> also reported on specific inotropic drugs, i.e. epinephrine, norepinephrine, dobutamine, phenylephrine, and additional milrinone. In detail, 9 out of 63 participants in the milrinone group required additional epinephrine compared to 7 out of 61 participants in the control group (RR 1.24, 95% CI 0.49 to 3.13) (<a href="./references#CD013781-fig-0028" title="">Analysis 3.14</a>), and 8 out of 63 participants in the milrinone group required additional norepinephrine compared to 8 out of 61 participants in the placebo control group (RR 0.97, 95% CI 0.39 to 2.42) (<a href="./references#CD013781-fig-0029" title="">Analysis 3.15</a>). In addition, <a href="./references#CD013781-bbs2-0006" title="DenaultAY , BussièresJS , ArellanoR , FineganB , GavraP , HaddadF , et al. A multicentre randomized-controlled trial of inhaled milrinone in high-risk cardiac surgical patients. Canadian Journal of Anesthesia2016;63:1140-53. [DOI: 10.1007/s12630-016-0709-8]">Denault 2016</a> stated that 2 out of 63 participants required additional dobutamine in the milrinone group compared to 1 out of 61 participants in the control group and little to no difference was found between groups (RR 1.94, 95% CI 0.18 to 20.81) (<a href="./references#CD013781-fig-0030" title="">Analysis 3.16</a>). <a href="./references#CD013781-bbs2-0006" title="DenaultAY , BussièresJS , ArellanoR , FineganB , GavraP , HaddadF , et al. A multicentre randomized-controlled trial of inhaled milrinone in high-risk cardiac surgical patients. Canadian Journal of Anesthesia2016;63:1140-53. [DOI: 10.1007/s12630-016-0709-8]">Denault 2016</a> also provided information on the number of patients that required additional phenylephrine. While no participants required additional phenylephrine in the milrinone group (n = 63), 1 out of 61 participants was in need of phenylephrine in the control group (RR 0.32, 95% CI 0.01 to 7.78) (<a href="./references#CD013781-fig-0031" title="">Analysis 3.17</a>). Notably, in each case, 8 participants in the intervention group (n = 63) and the control group (n = 61) received additional milrinone. </p> <p><a href="./references#CD013781-bbs2-0019" title="KikuraM , SatoS . The efficacy of preemptive milrinone or amrinone therapy in patients undergoing coronary artery bypass grafting. Anesthesia and Analgesia2002;94:22-30. [DOI: 10.1097/00000539-200201000-00005]">Kikura 2002</a> reported that dopamine was administered when needed with the mean total dose of dopamine given in the first 24 hours after surgery being significantly lower in the milrinone intervention group compared to the placebo control group. No information was given on the number of patients who received additional dopamine. </p> </section> <section id="CD013781-sec-0098"> <h6 class="title">Number of patients requiring cardiac transplantation, ventricular assist device (VAD) implantation or cardiopulmonary resuscitation </h6> <p>These outcomes were not reported in any of the included studies.</p> </section> <section id="CD013781-sec-0099"> <h6 class="title">Proportion of renal failure</h6> <p>Information on the proportion of renal failure was restricted to two included studies with 120 participants (<a href="./references#CD013781-bbs2-0013" title="HadadzadehM , HosseiniSH , Mostafavi-Pour-ManshadiSM , NaderiN , Emami-MeybodiM . Effect of milrinone on short term outcome of patients with myocardial dysfunction undergoing off-pump coronary artery bypass graft: a randomized clinical trial. Acta Medica Iranica2013;51:681-6. [PMID: 24338139]">Hadadzadeh 2013</a>; <a href="./references#CD013781-bbs2-0016" title="JoHR , LeeWK , KimYH , MinJH , ChaeYK , ChoiIG , et al. The effect of milrinone infusion on right ventricular function during coronary anastomosis and early outcomes in patients undergoing off-pump coronary artery bypass surgery. Korean Journal of Anesthesiology2010;59:92-8. [DOI: 10.4097/kjae.2010.59.2.92]">Jo 2010</a>). There were 2 out of 60 patients suffering from renal failure in the milrinone group compared to 5 out of 60 patients in the control group. However, no evidence of a difference in risk ratio was found between groups (RR 0.40, 95% CI 0.08 to 2.01) (<a href="./references#CD013781-fig-0032" title="">Analysis 3.18</a>). </p> </section> <section id="CD013781-sec-0100"> <h6 class="title">Quality of life</h6> <p>This outcome was not reported in any of the included studies.</p> </section> </section> </section> <section id="CD013781-sec-0101"> <h4 class="title">Levosimendan versus dobutamine</h4> <p>Two small, single‐centre trials with 140 participants investigated levosimendan compared to dobutamine (<a href="./references#CD013781-bbs2-0011" title="GandhamR , SyamasundarA , RavulapalliH , KarthekeyanRB , VakamudiM , KodalliR , et al. A comparison of hemodynamic effects of levosimendan and dobutamine in patients undergoing mitral valve repair / replacement for severe mitral stenosis. Annals of Cardiac Anaesthesia2013;16:11-5. [DOI: 10.4103/0971-9784.105363]">Gandham 2013</a>; <a href="./references#CD013781-bbs2-0018" title="KandasamyA , SimonHA , MurthyP , AnnaduraiM , AliMM , RamanathanG . Comparison of levosimendan versus dobutamine in patients with moderate to severe left ventricular dysfunction undergoing off-pump coronary artery bypass grafting: a randomized prospective study. Annals of Cardiac Anaesthesia2017;20:200-6. [DOI: 10.4103/aca.ACA_195_16]">Kandasamy 2017</a>). </p> <section id="CD013781-sec-0102"> <h5 class="title">Primary outcomes</h5> <section id="CD013781-sec-0103"> <h6 class="title">All‐cause mortality (within 30 days)</h6> <p>This outcome was not reported in any of the included studies.</p> </section> <section id="CD013781-sec-0104"> <h6 class="title">Incidence of LCOS</h6> <p>This outcome was not reported in any of the included studies.</p> </section> <section id="CD013781-sec-0105"> <h6 class="title">Adverse events</h6> <p>Information in both included studies was restricted to atrial fibrillation (<a href="./references#CD013781-bbs2-0011" title="GandhamR , SyamasundarA , RavulapalliH , KarthekeyanRB , VakamudiM , KodalliR , et al. A comparison of hemodynamic effects of levosimendan and dobutamine in patients undergoing mitral valve repair / replacement for severe mitral stenosis. Annals of Cardiac Anaesthesia2013;16:11-5. [DOI: 10.4103/0971-9784.105363]">Gandham 2013</a>; <a href="./references#CD013781-bbs2-0018" title="KandasamyA , SimonHA , MurthyP , AnnaduraiM , AliMM , RamanathanG . Comparison of levosimendan versus dobutamine in patients with moderate to severe left ventricular dysfunction undergoing off-pump coronary artery bypass grafting: a randomized prospective study. Annals of Cardiac Anaesthesia2017;20:200-6. [DOI: 10.4103/aca.ACA_195_16]">Kandasamy 2017</a>). The study authors did not report on cardiogenic shock, non‐embolic stroke/transient ischaemic attack or perioperative myocardial infarction. There were 8 out of 70 patients suffering from atrial fibrillation in the levosimendan intervention group compared with 15 out of 70 patients in the dobutamine control group and little to no difference in risk ratio was found between groups (RR 0.53, 95% CI 0.16 to 1.75; 140 participants, 2 studies; low‐certainty evidence; moderate heterogeneity) (<a href="./references#CD013781-fig-0033" title="">Analysis 4.1</a>). </p> </section> </section> <section id="CD013781-sec-0106"> <h5 class="title">Secondary outcomes</h5> <section id="CD013781-sec-0107"> <h6 class="title">Length of in‐hospital and intensive care unit stay</h6> <p>Information on the length of in‐hospital stay was restricted to <a href="./references#CD013781-bbs2-0018" title="KandasamyA , SimonHA , MurthyP , AnnaduraiM , AliMM , RamanathanG . Comparison of levosimendan versus dobutamine in patients with moderate to severe left ventricular dysfunction undergoing off-pump coronary artery bypass grafting: a randomized prospective study. Annals of Cardiac Anaesthesia2017;20:200-6. [DOI: 10.4103/aca.ACA_195_16]">Kandasamy 2017</a>. The mean stay in hospital in the control group with dobutamine was 6.85 days. The mean length of in‐hospital stay in the levosimendan group was 0.97 days shorter (95% CI ‐1.28 to ‐0.66) (<a href="./references#CD013781-fig-0034" title="">Analysis 4.2</a>). </p> <p>Information on the length of intensive care stay was reported by both included studies. The mean length of stay in intensive care in the control group with dobutamine was 2.8 to 3.2 days. The mean length of intensive care stay in the levosimendan group was 0.29 days shorter (95% CI ‐0.51 to ‐0.08; 140 participants, 2 studies; moderate‐certainty evidence; low heterogeneity) (<a href="./references#CD013781-fig-0035" title="">Analysis 4.3</a>). </p> </section> <section id="CD013781-sec-0108"> <h6 class="title">Haemodynamics (cardiac index, MAP, PCWP)</h6> <p>Information on cardiac index was restricted to <a href="./references#CD013781-bbs2-0011" title="GandhamR , SyamasundarA , RavulapalliH , KarthekeyanRB , VakamudiM , KodalliR , et al. A comparison of hemodynamic effects of levosimendan and dobutamine in patients undergoing mitral valve repair / replacement for severe mitral stenosis. Annals of Cardiac Anaesthesia2013;16:11-5. [DOI: 10.4103/0971-9784.105363]">Gandham 2013</a>, which showed little to no difference at baseline, 6 hours and 12 hours after surgery (<a href="./references#CD013781-fig-0036" title="">Analysis 4.4</a>). However, there was a difference at 24 hours after surgery between groups and this outcome was favourable to the levosimendan group compared to the dobutamine group (mean difference 0.46, 95% CI 0.35 to 0.57; 60 participants, 1 study; heterogeneity was not applicable) (<a href="./references#CD013781-fig-0036" title="">Analysis 4.4</a>). </p> <p>MAP was reported by both included studies (<a href="./references#CD013781-bbs2-0011" title="GandhamR , SyamasundarA , RavulapalliH , KarthekeyanRB , VakamudiM , KodalliR , et al. A comparison of hemodynamic effects of levosimendan and dobutamine in patients undergoing mitral valve repair / replacement for severe mitral stenosis. Annals of Cardiac Anaesthesia2013;16:11-5. [DOI: 10.4103/0971-9784.105363]">Gandham 2013</a>; <a href="./references#CD013781-bbs2-0018" title="KandasamyA , SimonHA , MurthyP , AnnaduraiM , AliMM , RamanathanG . Comparison of levosimendan versus dobutamine in patients with moderate to severe left ventricular dysfunction undergoing off-pump coronary artery bypass grafting: a randomized prospective study. Annals of Cardiac Anaesthesia2017;20:200-6. [DOI: 10.4103/aca.ACA_195_16]">Kandasamy 2017</a>). No evidence of a difference in mean MAP between the levosimendan intervention group and the dobutamine control group was observed at baseline with ‐0.06 (95% CI ‐2.11 to 2.00) and at 24 hours after surgery with ‐5.42 (95% CI ‐12.52 to 1.68). Instead, at 6 hours and 12 hours after surgery, the mean MAP was lower in the levosimendan intervention group compared with the dopamine control group (mean difference at 6 hours post‐surgery ‐9.27, 95% CI ‐14.18 to ‐4.36; mean difference at 12 hours post‐surgery ‐9.17, 95% CI ‐10.85 to ‐7.50) (<a href="./references#CD013781-fig-0037" title="">Analysis 4.5</a>). </p> <p>Information on PCWP was restricted to <a href="./references#CD013781-bbs2-0018" title="KandasamyA , SimonHA , MurthyP , AnnaduraiM , AliMM , RamanathanG . Comparison of levosimendan versus dobutamine in patients with moderate to severe left ventricular dysfunction undergoing off-pump coronary artery bypass grafting: a randomized prospective study. Annals of Cardiac Anaesthesia2017;20:200-6. [DOI: 10.4103/aca.ACA_195_16]">Kandasamy 2017</a>. There was little to no difference in mean PCWP between groups at baseline (mean difference 0.63, 95% CI ‐0.07 to 1.33). At 6 hours, 12 hours and 24 hours after surgery, however, the mean PCWP was reduced in the levosimendan group compared with control with ‐2.47 (95% CI ‐3.04 to ‐1.90), ‐2.42 (95% CI ‐2.90 to ‐1.94), and ‐1.45 (95% CI ‐1.92 to ‐0.98), respectively (<a href="./references#CD013781-fig-0038" title="">Analysis 4.6</a>). </p> </section> <section id="CD013781-sec-0109"> <h6 class="title">Duration of mechanical ventilation</h6> <p>Information on this outcome was provided by both included studies, which reported that the mean of duration of mechanical ventilation was lower (mean difference ‐1.04, 95% CI ‐1.72 to ‐0.35) in the intervention group with levosimendan compared to 5.97 to 7.40 hours in the control group with dobutamine (140 participants, 2 studies; low‐certainty evidence; low heterogeneity) (<a href="./references#CD013781-fig-0039" title="">Analysis 4.7</a>). </p> </section> <section id="CD013781-sec-0110"> <h6 class="title">Proportion of weaning failure within 48 hours of extubation</h6> <p>This outcome was not reported in any of the included studies.</p> </section> <section id="CD013781-sec-0111"> <h6 class="title">Number of patients requiring mechanical circulatory support (IABP)</h6> <p>Only one study provided this outcome (<a href="./references#CD013781-bbs2-0018" title="KandasamyA , SimonHA , MurthyP , AnnaduraiM , AliMM , RamanathanG . Comparison of levosimendan versus dobutamine in patients with moderate to severe left ventricular dysfunction undergoing off-pump coronary artery bypass grafting: a randomized prospective study. Annals of Cardiac Anaesthesia2017;20:200-6. [DOI: 10.4103/aca.ACA_195_16]">Kandasamy 2017</a>), and reported that 1 out of 40 participants required mechanical circulatory support in both intervention and control groups (<a href="./references#CD013781-fig-0040" title="">Analysis 4.8</a>). Accordingly, no evidence of a difference was found in the risk ratio for this outcome between groups (RR 1.00, 95% CI 0.06 to 15.44; 80 participants, 1 study; low‐certainty evidence; heterogeneity was not applicable) (<a href="./references#CD013781-fig-0040" title="">Analysis 4.8</a>). </p> </section> <section id="CD013781-sec-0112"> <h6 class="title">Number of patients requiring additional inotropic drugs</h6> <p>The need for overall additional inotropic drugs was restricted to <a href="./references#CD013781-bbs2-0011" title="GandhamR , SyamasundarA , RavulapalliH , KarthekeyanRB , VakamudiM , KodalliR , et al. A comparison of hemodynamic effects of levosimendan and dobutamine in patients undergoing mitral valve repair / replacement for severe mitral stenosis. Annals of Cardiac Anaesthesia2013;16:11-5. [DOI: 10.4103/0971-9784.105363]">Gandham 2013</a>, who reported that 21 out of 30 patients required additional inotropic drugs in the intervention group with levosimendan compared to 4 out of 30 patients in the dobutamine control group. There was a difference in risk ratio between groups favouring dobutamine (RR 5.25, 95% CI 2.05 to 13.47; 60 participants, 1 study; heterogeneity not applicable) (<a href="./references#CD013781-fig-0041" title="">Analysis 4.9</a>). </p> <p>Within this outcome category, both included studies reported on specific inotropic drugs, i.e. epinephrine and norepinephrine. Regarding epinephrine, 9 out of 70 participants in the levosimendan group compared to 5 out of 70 participants in the control group received this additional inotropic support (RR 1.63, 95% CI 0.32 to 8.23) (<a href="./references#CD013781-fig-0042" title="">Analysis 4.10</a>). In addition, it was stated that 28 out of 70 participants in the levosimendan group and 8 out of 70 participants in the dobutamine control group required additional norepinephrine (RR 3.52, 95% CI 1.21 to 10.24) (<a href="./references#CD013781-fig-0043" title="">Analysis 4.11</a>). </p> </section> <section id="CD013781-sec-0113"> <h6 class="title">Number of patients requiring cardiac transplantation, ventricular assist device (VAD) implantation or cardiopulmonary resuscitation </h6> <p>These outcomes were not reported in any of the included studies.</p> </section> <section id="CD013781-sec-0114"> <h6 class="title">Proportion of renal failure</h6> <p>This outcome was not reported in any of the included studies.</p> </section> <section id="CD013781-sec-0115"> <h6 class="title">Quality of life</h6> <p>This outcome was not reported in any of the included studies.</p> </section> </section> </section> <section id="CD013781-sec-0116"> <h4 class="title">Levosimendan versus standard cardiac care</h4> <p>Three small, single‐centre trials with 208 participants investigated the effect of levosimendan compared to standard cardiac care (<a href="./references#CD013781-bbs2-0003" title="BaysalA , YanartasM , DogukanM , GundogusN , KocakT , Koksal C. Levosimendan improves renal outcome in cardiac surgery: a randomized trial. Journal of Cardiothoracic and Vascular Anesthesia2014;28:586-94. [DOI: 10.1053/j.jvca.2013.09.004]">Baysal 2014</a>; <a href="./references#CD013781-bbs2-0007" title="DesaiPM , SarkarMS , UmbarkarSR . Prophylactic preoperative levosimendan for off-pump coronary artery bypass grafting in patients with left ventricular dysfunction: single-centered randomized prospective study. Annals of Cardiac Anaesthesia2018;21:123-8. [DOI: 10.4103/aca.ACA_178_17]">Desai 2018</a>; <a href="./references#CD013781-bbs2-0010" title="ErsoyO , BoysanE , UnalEU , YayK , YenerU , CicekciogluF , et al. Effectiveness of prophylactic levosimendan in high-risk valve surgery patients. Cardiovascular Journal of Africa2013;24:260-4. [DOI: 10.5830/CVJA-2013-047]">Ersoy 2013</a>). See <a href="./full#CD013781-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD013781-sec-0117"> <h5 class="title">Primary outcomes</h5> <section id="CD013781-sec-0118"> <h6 class="title">All‐cause mortality (within 30 days)</h6> <p>Information on mortality within 30 days was found in all three included studies. However, the relative effect was only generated from two trials (<a href="./references#CD013781-bbs2-0003" title="BaysalA , YanartasM , DogukanM , GundogusN , KocakT , Koksal C. Levosimendan improves renal outcome in cardiac surgery: a randomized trial. Journal of Cardiothoracic and Vascular Anesthesia2014;28:586-94. [DOI: 10.1053/j.jvca.2013.09.004]">Baysal 2014</a>; <a href="./references#CD013781-bbs2-0007" title="DesaiPM , SarkarMS , UmbarkarSR . Prophylactic preoperative levosimendan for off-pump coronary artery bypass grafting in patients with left ventricular dysfunction: single-centered randomized prospective study. Annals of Cardiac Anaesthesia2018;21:123-8. [DOI: 10.4103/aca.ACA_178_17]">Desai 2018</a>), while the relative risk from <a href="./references#CD013781-bbs2-0010" title="ErsoyO , BoysanE , UnalEU , YayK , YenerU , CicekciogluF , et al. Effectiveness of prophylactic levosimendan in high-risk valve surgery patients. Cardiovascular Journal of Africa2013;24:260-4. [DOI: 10.5830/CVJA-2013-047]">Ersoy 2013</a> was not estimable due to no events being observed in either group. When levosimendan was compared to the standard cardiac care group, there was no evidence of a difference in all‐cause mortality within 30 days (RR 0.37, 95% CI 0.13 to 1.04; 208 participants, 3 studies; low‐certainty evidence; low heterogeneity) (<a href="./references#CD013781-fig-0044" title="">Analysis 5.1</a>; <a href="./full#CD013781-tbl-0001">summary of findings Table 1</a>). </p> </section> <section id="CD013781-sec-0119"> <h6 class="title">Incidence of LCOS</h6> <p>Information on LCOS was reported by all three studies. As with 30‐day mortality, the relative effect was solely generated from two trials (<a href="./references#CD013781-bbs2-0003" title="BaysalA , YanartasM , DogukanM , GundogusN , KocakT , Koksal C. Levosimendan improves renal outcome in cardiac surgery: a randomized trial. Journal of Cardiothoracic and Vascular Anesthesia2014;28:586-94. [DOI: 10.1053/j.jvca.2013.09.004]">Baysal 2014</a>; <a href="./references#CD013781-bbs2-0007" title="DesaiPM , SarkarMS , UmbarkarSR . Prophylactic preoperative levosimendan for off-pump coronary artery bypass grafting in patients with left ventricular dysfunction: single-centered randomized prospective study. Annals of Cardiac Anaesthesia2018;21:123-8. [DOI: 10.4103/aca.ACA_178_17]">Desai 2018</a>), while the relative risk from <a href="./references#CD013781-bbs2-0010" title="ErsoyO , BoysanE , UnalEU , YayK , YenerU , CicekciogluF , et al. Effectiveness of prophylactic levosimendan in high-risk valve surgery patients. Cardiovascular Journal of Africa2013;24:260-4. [DOI: 10.5830/CVJA-2013-047]">Ersoy 2013</a> was not estimable since no events were observed in either group. When the levosimendan intervention group was compared to the control group receiving standard cardiac care, there was little to no difference in LCOS (RR 0.49, 95% CI 0.14 to 1.73; 208 participants, 3 studies; very low‐certainty evidence; moderate heterogeneity) (<a href="./references#CD013781-fig-0045" title="">Analysis 5.2</a>; <a href="./full#CD013781-tbl-0001">summary of findings Table 1</a>). </p> </section> <section id="CD013781-sec-0120"> <h6 class="title">Adverse events</h6> <p>Information on atrial fibrillation was restricted to two studies (<a href="./references#CD013781-bbs2-0003" title="BaysalA , YanartasM , DogukanM , GundogusN , KocakT , Koksal C. Levosimendan improves renal outcome in cardiac surgery: a randomized trial. Journal of Cardiothoracic and Vascular Anesthesia2014;28:586-94. [DOI: 10.1053/j.jvca.2013.09.004]">Baysal 2014</a>; <a href="./references#CD013781-bbs2-0007" title="DesaiPM , SarkarMS , UmbarkarSR . Prophylactic preoperative levosimendan for off-pump coronary artery bypass grafting in patients with left ventricular dysfunction: single-centered randomized prospective study. Annals of Cardiac Anaesthesia2018;21:123-8. [DOI: 10.4103/aca.ACA_178_17]">Desai 2018</a>). Only <a href="./references#CD013781-bbs2-0003" title="BaysalA , YanartasM , DogukanM , GundogusN , KocakT , Koksal C. Levosimendan improves renal outcome in cardiac surgery: a randomized trial. Journal of Cardiothoracic and Vascular Anesthesia2014;28:586-94. [DOI: 10.1053/j.jvca.2013.09.004]">Baysal 2014</a> reported on cardiogenic shock, perioperative myocardial infarction, and non‐embolic stroke/transient ischaemic attack. </p> <p>When levosimendan was compared to the standard cardiac care group, there was no evidence of a difference in any of the four adverse events. Five out of 64 patients suffered from cardiogenic shock in the levosimendan group compared to 8 out of 64 patients in the standard cardiac care group (RR 0.63, 95% CI 0.22 to 1.81; 128 participants, 1 study; very low‐certainty evidence; heterogeneity was not applicable) (<a href="./references#CD013781-fig-0046" title="">Analysis 5.3</a>; <a href="./full#CD013781-tbl-0001">summary of findings Table 1</a>). There were 10 out of 94 patients suffering from atrial fibrillation in the levosimendan intervention group compared with 23 out of 94 in the standard cardiac care group (RR 0.40, 95% CI 0.11 to 1.41; 188 participants, 2 studies; very low‐certainty evidence; moderate heterogeneity) (<a href="./references#CD013781-fig-0047" title="">Analysis 5.4</a>). Five out 64 participants were afflicted with perioperative myocardial infarction in the levosimendan group compared to 8 out of 64 participants in the standard cardiac care group (RR 0.63, 95% CI 0.22 to 1.81; 128 participants, 1 study; very low‐certainty evidence; heterogeneity was not applicable) (<a href="./references#CD013781-fig-0048" title="">Analysis 5.5</a>). There were 9 out of 64 participants suffering from non‐embolic stroke/transient ischaemic attack in the levosimendan group compared to 16 out of 64 participants in the standard cardiac care group (RR 0.56, 95% CI 0.27 to 1.18; 128 participants, 1 study; very low‐certainty evidence; heterogeneity was not applicable) (<a href="./references#CD013781-fig-0049" title="">Analysis 5.6</a>). </p> </section> </section> <section id="CD013781-sec-0121"> <h5 class="title">Secondary outcomes</h5> <section id="CD013781-sec-0122"> <h6 class="title">Length of in‐hospital and intensive care unit stay</h6> <p>There was little to no difference between the study groups in terms of mean length of in‐hospital stay as shown by <a href="./references#CD013781-fig-0050" title="">Analysis 5.7</a> based on data from <a href="./references#CD013781-bbs2-0007" title="DesaiPM , SarkarMS , UmbarkarSR . Prophylactic preoperative levosimendan for off-pump coronary artery bypass grafting in patients with left ventricular dysfunction: single-centered randomized prospective study. Annals of Cardiac Anaesthesia2018;21:123-8. [DOI: 10.4103/aca.ACA_178_17]">Desai 2018</a> and <a href="./references#CD013781-bbs2-0010" title="ErsoyO , BoysanE , UnalEU , YayK , YenerU , CicekciogluF , et al. Effectiveness of prophylactic levosimendan in high-risk valve surgery patients. Cardiovascular Journal of Africa2013;24:260-4. [DOI: 10.5830/CVJA-2013-047]">Ersoy 2013</a> (mean difference 0.70, 95% CI ‐1.50 to 2.91; 80 participants, 2 studies; substantial heterogeneity). Likewise, <a href="./references#CD013781-bbs2-0003" title="BaysalA , YanartasM , DogukanM , GundogusN , KocakT , Koksal C. Levosimendan improves renal outcome in cardiac surgery: a randomized trial. Journal of Cardiothoracic and Vascular Anesthesia2014;28:586-94. [DOI: 10.1053/j.jvca.2013.09.004]">Baysal 2014</a> documented related median durations of hospital care in both study groups with notable intra‐group variability (8.0 (IQR 7.0 to 38.0) versus 9.0 (IQR 7.0 to 37.0) days). </p> <p><a href="./references#CD013781-bbs2-0007" title="DesaiPM , SarkarMS , UmbarkarSR . Prophylactic preoperative levosimendan for off-pump coronary artery bypass grafting in patients with left ventricular dysfunction: single-centered randomized prospective study. Annals of Cardiac Anaesthesia2018;21:123-8. [DOI: 10.4103/aca.ACA_178_17]">Desai 2018</a> reported the mean length of stay in intensive care in the control group receiving standard cardiac care to be 3.67 ± 0.76 days. In the levosimendan group, the mean length of intensive care was 0.27 days shorter (95% CI ‐0.62 to 0.08). <a href="./references#CD013781-bbs2-0010" title="ErsoyO , BoysanE , UnalEU , YayK , YenerU , CicekciogluF , et al. Effectiveness of prophylactic levosimendan in high-risk valve surgery patients. Cardiovascular Journal of Africa2013;24:260-4. [DOI: 10.5830/CVJA-2013-047]">Ersoy 2013</a> reported that the mean length of stay in intensive care in the control group was 1.4 ± 1.3 days. In the levosimendan intervention group, the mean length of intensive care was 1.30 days longer (95% CI ‐0.23 to 2.83). Altogether, there was no evidence of a difference in the mean length of stay in the intensive care unit between groups (mean difference 0.33, 95% CI ‐1.16 to 1.83; 80 participants, 2 studies; very low‐certainty evidence; substantial heterogeneity) (<a href="./references#CD013781-fig-0051" title="">Analysis 5.8</a>; <a href="./full#CD013781-tbl-0001">summary of findings Table 1</a>). <a href="./references#CD013781-bbs2-0003" title="BaysalA , YanartasM , DogukanM , GundogusN , KocakT , Koksal C. Levosimendan improves renal outcome in cardiac surgery: a randomized trial. Journal of Cardiothoracic and Vascular Anesthesia2014;28:586-94. [DOI: 10.1053/j.jvca.2013.09.004]">Baysal 2014</a> reported similar median durations of intensive care in both study groups with wide intra‐group variability (4.0 (IQR 1.0 to 4.0) versus 5.0 (IQR 2.0 to 37.0) days). </p> </section> <section id="CD013781-sec-0123"> <h6 class="title">Haemodynamics (cardiac index, MAP, PCWP)</h6> <p>Information on cardiac index was provided by <a href="./references#CD013781-bbs2-0003" title="BaysalA , YanartasM , DogukanM , GundogusN , KocakT , Koksal C. Levosimendan improves renal outcome in cardiac surgery: a randomized trial. Journal of Cardiothoracic and Vascular Anesthesia2014;28:586-94. [DOI: 10.1053/j.jvca.2013.09.004]">Baysal 2014</a>, <a href="./references#CD013781-bbs2-0007" title="DesaiPM , SarkarMS , UmbarkarSR . Prophylactic preoperative levosimendan for off-pump coronary artery bypass grafting in patients with left ventricular dysfunction: single-centered randomized prospective study. Annals of Cardiac Anaesthesia2018;21:123-8. [DOI: 10.4103/aca.ACA_178_17]">Desai 2018</a>, and <a href="./references#CD013781-bbs2-0010" title="ErsoyO , BoysanE , UnalEU , YayK , YenerU , CicekciogluF , et al. Effectiveness of prophylactic levosimendan in high-risk valve surgery patients. Cardiovascular Journal of Africa2013;24:260-4. [DOI: 10.5830/CVJA-2013-047]">Ersoy 2013</a>. There was little to no difference at baseline (mean difference 0.00, 95% CI ‐0.10 to 0.10; 208 participants, 3 studies; low heterogeneity). However, there were differences at the end of surgery as well as 6 hours, 12 hours, and 24 hours after surgery between groups and this outcome was favourable to the levosimendan group compared to the standard cardiac care group (mean difference at end of surgery 0.52, 95% CI 0.32 to 0.73; 188 participants, 2 studies; moderate heterogeneity; mean difference at 6 hours post surgery 0.77, 95% CI 0.64 to 0.89; 188 participants, 2 studies; low heterogeneity; mean difference at 12 hours post surgery 0.55, 95% CI 0.34 to 0.76; 60 participants, 1 study; heterogeneity was not applicable; and mean difference at 24 hours post surgery 0.47, 95% CI 0.35 to 0.58; 188 participants, 2 studies; low heterogeneity) (<a href="./references#CD013781-fig-0052" title="">Analysis 5.9</a>). </p> <p>MAP was only reported by <a href="./references#CD013781-bbs2-0003" title="BaysalA , YanartasM , DogukanM , GundogusN , KocakT , Koksal C. Levosimendan improves renal outcome in cardiac surgery: a randomized trial. Journal of Cardiothoracic and Vascular Anesthesia2014;28:586-94. [DOI: 10.1053/j.jvca.2013.09.004]">Baysal 2014</a> and <a href="./references#CD013781-bbs2-0007" title="DesaiPM , SarkarMS , UmbarkarSR . Prophylactic preoperative levosimendan for off-pump coronary artery bypass grafting in patients with left ventricular dysfunction: single-centered randomized prospective study. Annals of Cardiac Anaesthesia2018;21:123-8. [DOI: 10.4103/aca.ACA_178_17]">Desai 2018</a>. Little to no difference in mean MAP between the levosimendan intervention group and the standard cardiac care control group was observed at the time points at which quantitative data were available from both studies, i.e. at baseline with 0.41 (95% CI ‐0.78 to 1.59), at end of surgery with 2.39 (95% CI ‐8.74 to 13.52), at 6 hours after surgery with ‐1.11 (95% CI ‐2.36 to 0.14), and at 24 hours after surgery with 3.54 (95% CI ‐0.06 to 7.15) (<a href="./references#CD013781-fig-0053" title="">Analysis 5.10</a>). However, at 12 hours after surgery (a time point that was only available for <a href="./references#CD013781-bbs2-0007" title="DesaiPM , SarkarMS , UmbarkarSR . Prophylactic preoperative levosimendan for off-pump coronary artery bypass grafting in patients with left ventricular dysfunction: single-centered randomized prospective study. Annals of Cardiac Anaesthesia2018;21:123-8. [DOI: 10.4103/aca.ACA_178_17]">Desai 2018</a>) the mean MAP was higher in the levosimendan intervention group compared with the standard cardiac care control group (mean difference 4.07, 95% CI 1.03 to 7.11) (<a href="./references#CD013781-fig-0053" title="">Analysis 5.10</a>). </p> <p>Information on PCWP was restricted to <a href="./references#CD013781-bbs2-0003" title="BaysalA , YanartasM , DogukanM , GundogusN , KocakT , Koksal C. Levosimendan improves renal outcome in cardiac surgery: a randomized trial. Journal of Cardiothoracic and Vascular Anesthesia2014;28:586-94. [DOI: 10.1053/j.jvca.2013.09.004]">Baysal 2014</a> and <a href="./references#CD013781-bbs2-0007" title="DesaiPM , SarkarMS , UmbarkarSR . Prophylactic preoperative levosimendan for off-pump coronary artery bypass grafting in patients with left ventricular dysfunction: single-centered randomized prospective study. Annals of Cardiac Anaesthesia2018;21:123-8. [DOI: 10.4103/aca.ACA_178_17]">Desai 2018</a>. <a href="./references#CD013781-bbs2-0003" title="BaysalA , YanartasM , DogukanM , GundogusN , KocakT , Koksal C. Levosimendan improves renal outcome in cardiac surgery: a randomized trial. Journal of Cardiothoracic and Vascular Anesthesia2014;28:586-94. [DOI: 10.1053/j.jvca.2013.09.004]">Baysal 2014</a> narratively reported no significant differences between study groups. In the study <a href="./references#CD013781-bbs2-0007" title="DesaiPM , SarkarMS , UmbarkarSR . Prophylactic preoperative levosimendan for off-pump coronary artery bypass grafting in patients with left ventricular dysfunction: single-centered randomized prospective study. Annals of Cardiac Anaesthesia2018;21:123-8. [DOI: 10.4103/aca.ACA_178_17]">Desai 2018</a> there was no evidence of a difference in mean PCWP between groups at baseline (mean difference 0.50, 95% CI ‐0.63 to 1.63) and 24 hours after surgery (mean difference ‐0.73, 95% CI ‐1.48 to 0.02) (<a href="./references#CD013781-fig-0054" title="">Analysis 5.11</a>). However, at the end of surgery, 6 hours and 12 hours after surgery, the mean PCWP was reduced in the levosimendan group compared with the standard cardiac care control group with ‐2.07 (95% CI ‐3.06 to ‐1.08), ‐1.21 (95% CI ‐2.22 to ‐0.20), and ‐1.04 (95% CI ‐1.69 to ‐0.39), respectively (<a href="./references#CD013781-fig-0054" title="">Analysis 5.11</a>). </p> </section> <section id="CD013781-sec-0124"> <h6 class="title">Duration of mechanical ventilation</h6> <p>Information on this outcome was provided only by <a href="./references#CD013781-bbs2-0003" title="BaysalA , YanartasM , DogukanM , GundogusN , KocakT , Koksal C. Levosimendan improves renal outcome in cardiac surgery: a randomized trial. Journal of Cardiothoracic and Vascular Anesthesia2014;28:586-94. [DOI: 10.1053/j.jvca.2013.09.004]">Baysal 2014</a>. The included study showed that the mean duration of mechanical ventilation in the standard cardiac care control group was 83.2 hours. The mean duration of mechanical ventilation in the levosimendan intervention group was 3.40 hours lower (95% CI ‐11.50 to 4.70; 128 participants, 1 study; very low‐certainty evidence; heterogeneity not applicable) (<a href="./references#CD013781-fig-0055" title="">Analysis 5.12</a>; <a href="./full#CD013781-tbl-0001">summary of findings Table 1</a>). </p> </section> <section id="CD013781-sec-0125"> <h6 class="title">Proportion of weaning failure within 48 hours of extubation</h6> <p>Information on the proportion of weaning failure was restricted to <a href="./references#CD013781-bbs2-0003" title="BaysalA , YanartasM , DogukanM , GundogusN , KocakT , Koksal C. Levosimendan improves renal outcome in cardiac surgery: a randomized trial. Journal of Cardiothoracic and Vascular Anesthesia2014;28:586-94. [DOI: 10.1053/j.jvca.2013.09.004]">Baysal 2014</a>, which found little to no difference between the levosimendan and standard cardiac care group (RR 0.82, 95% CI 0.36 to 1.84; 128 participants, 1 study; very low‐certainty evidence; heterogeneity was not applicable) (<a href="./references#CD013781-fig-0056" title="">Analysis 5.13</a>). </p> </section> <section id="CD013781-sec-0126"> <h6 class="title">Number of patients requiring mechanical circulatory support (IABP)</h6> <p>Information on the number of patients requiring mechanical circulatory support was given by all three included studies. However, the relative effect was only generated from two trials (<a href="./references#CD013781-bbs2-0003" title="BaysalA , YanartasM , DogukanM , GundogusN , KocakT , Koksal C. Levosimendan improves renal outcome in cardiac surgery: a randomized trial. Journal of Cardiothoracic and Vascular Anesthesia2014;28:586-94. [DOI: 10.1053/j.jvca.2013.09.004]">Baysal 2014</a>; <a href="./references#CD013781-bbs2-0007" title="DesaiPM , SarkarMS , UmbarkarSR . Prophylactic preoperative levosimendan for off-pump coronary artery bypass grafting in patients with left ventricular dysfunction: single-centered randomized prospective study. Annals of Cardiac Anaesthesia2018;21:123-8. [DOI: 10.4103/aca.ACA_178_17]">Desai 2018</a>), while the relative risk from <a href="./references#CD013781-bbs2-0010" title="ErsoyO , BoysanE , UnalEU , YayK , YenerU , CicekciogluF , et al. Effectiveness of prophylactic levosimendan in high-risk valve surgery patients. Cardiovascular Journal of Africa2013;24:260-4. [DOI: 10.5830/CVJA-2013-047]">Ersoy 2013</a> was not estimable due to no events being observed in either group. In the levosimendan intervention group, 17 out of 104 patients required mechanical circulatory support compared to 20 out of 104 patients in the standard cardiac care control group. However, no evidence of a difference was found in the risk ratio between groups (RR 0.88, 95% CI 0.50 to 1.55; 208 participants, 3 studies; low‐certainty evidence; low heterogeneity) (<a href="./references#CD013781-fig-0057" title="">Analysis 5.14</a>; <a href="./full#CD013781-tbl-0001">summary of findings Table 1</a>). </p> </section> <section id="CD013781-sec-0127"> <h6 class="title">Number of patients requiring additional inotropic drugs</h6> <p>The need for overall additional inotropic drugs was restricted to <a href="./references#CD013781-bbs2-0007" title="DesaiPM , SarkarMS , UmbarkarSR . Prophylactic preoperative levosimendan for off-pump coronary artery bypass grafting in patients with left ventricular dysfunction: single-centered randomized prospective study. Annals of Cardiac Anaesthesia2018;21:123-8. [DOI: 10.4103/aca.ACA_178_17]">Desai 2018</a> and <a href="./references#CD013781-bbs2-0010" title="ErsoyO , BoysanE , UnalEU , YayK , YenerU , CicekciogluF , et al. Effectiveness of prophylactic levosimendan in high-risk valve surgery patients. Cardiovascular Journal of Africa2013;24:260-4. [DOI: 10.5830/CVJA-2013-047]">Ersoy 2013</a>, who reported that 28 out of 40 patients required additional inotropic drugs in the intervention group with levosimendan compared to 16 out of 40 patients in the standard cardiac care control group. There was a difference in risk ratio between groups favouring standard cardiac care (RR 1.70, 95% CI 1.13 to 2.57; 80 participants, 2 studies; low heterogeneity) (<a href="./references#CD013781-fig-0058" title="">Analysis 5.15</a>). </p> <p>Within this outcome category, information on specific inotropic drugs, i.e. epinephrine, dopamine, and dobutamine, was reported by <a href="./references#CD013781-bbs2-0003" title="BaysalA , YanartasM , DogukanM , GundogusN , KocakT , Koksal C. Levosimendan improves renal outcome in cardiac surgery: a randomized trial. Journal of Cardiothoracic and Vascular Anesthesia2014;28:586-94. [DOI: 10.1053/j.jvca.2013.09.004]">Baysal 2014</a>, while information on norepinephrine was provided by <a href="./references#CD013781-bbs2-0003" title="BaysalA , YanartasM , DogukanM , GundogusN , KocakT , Koksal C. Levosimendan improves renal outcome in cardiac surgery: a randomized trial. Journal of Cardiothoracic and Vascular Anesthesia2014;28:586-94. [DOI: 10.1053/j.jvca.2013.09.004]">Baysal 2014</a> and <a href="./references#CD013781-bbs2-0007" title="DesaiPM , SarkarMS , UmbarkarSR . Prophylactic preoperative levosimendan for off-pump coronary artery bypass grafting in patients with left ventricular dysfunction: single-centered randomized prospective study. Annals of Cardiac Anaesthesia2018;21:123-8. [DOI: 10.4103/aca.ACA_178_17]">Desai 2018</a>. There was little to no difference in risk ratio between groups for all of these inotropic drugs. Regarding epinephrine, 16 out of 64 participants in the levosimendan group compared to 23 out of 64 participants in the standard cardiac care control group received this additional inotropic support (RR 0.70, 95% CI 0.41 to 1.19) (<a href="./references#CD013781-fig-0059" title="">Analysis 5.16</a>). Additional norepinephrine was required by 41 out of 94 patients in the levosimendan group and 36 out of 94 patients in the standard cardiac care group (RR 1.18, 95% CI 0.58 to 2.37) (<a href="./references#CD013781-fig-0060" title="">Analysis 5.17</a>). Moreover, 31 out of 64 participants in the levosimendan group and 40 out of 64 participants in the standard cardiac care control group required additional dopamine (RR 0.78, 95% CI 0.56 to 1.06) (<a href="./references#CD013781-fig-0061" title="">Analysis 5.18</a>). Lastly, 55 out of 64 participants in the levosimendan group compared to 53 out of 64 participants in the standard cardiac care control group required additional dobutamine (RR 1.04, 95% CI 0.89 to 1.20) (<a href="./references#CD013781-fig-0062" title="">Analysis 5.19</a>). </p> </section> <section id="CD013781-sec-0128"> <h6 class="title">Number of patients requiring cardiac transplantation, ventricular assist device (VAD) implantation or cardiopulmonary resuscitation </h6> <p>Information on these outcomes was restricted to <a href="./references#CD013781-bbs2-0003" title="BaysalA , YanartasM , DogukanM , GundogusN , KocakT , Koksal C. Levosimendan improves renal outcome in cardiac surgery: a randomized trial. Journal of Cardiothoracic and Vascular Anesthesia2014;28:586-94. [DOI: 10.1053/j.jvca.2013.09.004]">Baysal 2014</a>. The relative risk of cardiac transplantation or VAD implantation was not estimable since no events were observed in either group (<a href="./references#CD013781-fig-0063" title="">Analysis 5.20</a>). In the intervention group with levosimendan, 4 out of 64 patients required cardiopulmonary resuscitation compared to 10 out of 64 patients in the standard cardiac care control group. However, no evidence of a difference was found in the risk ratio between groups (RR 0.40, 95% CI 0.13 to 1.21; 128 participants, 1 study; heterogeneity was not applicable) (<a href="./references#CD013781-fig-0064" title="">Analysis 5.21</a>). </p> </section> <section id="CD013781-sec-0129"> <h6 class="title">Proportion of renal failure</h6> <p>All three studies reported on the proportion of renal failure. <a href="./references#CD013781-bbs2-0010" title="ErsoyO , BoysanE , UnalEU , YayK , YenerU , CicekciogluF , et al. Effectiveness of prophylactic levosimendan in high-risk valve surgery patients. Cardiovascular Journal of Africa2013;24:260-4. [DOI: 10.5830/CVJA-2013-047]">Ersoy 2013</a> observed no events in either group. Therefore, the relative effect was only generated from <a href="./references#CD013781-bbs2-0003" title="BaysalA , YanartasM , DogukanM , GundogusN , KocakT , Koksal C. Levosimendan improves renal outcome in cardiac surgery: a randomized trial. Journal of Cardiothoracic and Vascular Anesthesia2014;28:586-94. [DOI: 10.1053/j.jvca.2013.09.004]">Baysal 2014</a> and <a href="./references#CD013781-bbs2-0007" title="DesaiPM , SarkarMS , UmbarkarSR . Prophylactic preoperative levosimendan for off-pump coronary artery bypass grafting in patients with left ventricular dysfunction: single-centered randomized prospective study. Annals of Cardiac Anaesthesia2018;21:123-8. [DOI: 10.4103/aca.ACA_178_17]">Desai 2018</a>. In the levosimendan intervention group, 8 out of 104 patients suffered from renal failure compared with 17 out of 104 patients in the standard cardiac care control group. No evidence of a difference was found in the risk ratio between groups (RR 0.48, 95% CI 0.22 to 1.08; 208 participants, 3 studies; low heterogeneity) (<a href="./references#CD013781-fig-0065" title="">Analysis 5.22</a>). </p> </section> <section id="CD013781-sec-0130"> <h6 class="title">Quality of life</h6> <p>Only <a href="./references#CD013781-bbs2-0010" title="ErsoyO , BoysanE , UnalEU , YayK , YenerU , CicekciogluF , et al. Effectiveness of prophylactic levosimendan in high-risk valve surgery patients. Cardiovascular Journal of Africa2013;24:260-4. [DOI: 10.5830/CVJA-2013-047]">Ersoy 2013</a> narratively reported this outcome, while <a href="./references#CD013781-bbs2-0003" title="BaysalA , YanartasM , DogukanM , GundogusN , KocakT , Koksal C. Levosimendan improves renal outcome in cardiac surgery: a randomized trial. Journal of Cardiothoracic and Vascular Anesthesia2014;28:586-94. [DOI: 10.1053/j.jvca.2013.09.004]">Baysal 2014</a> and <a href="./references#CD013781-bbs2-0007" title="DesaiPM , SarkarMS , UmbarkarSR . Prophylactic preoperative levosimendan for off-pump coronary artery bypass grafting in patients with left ventricular dysfunction: single-centered randomized prospective study. Annals of Cardiac Anaesthesia2018;21:123-8. [DOI: 10.4103/aca.ACA_178_17]">Desai 2018</a> did not report it. <a href="./references#CD013781-bbs2-0010" title="ErsoyO , BoysanE , UnalEU , YayK , YenerU , CicekciogluF , et al. Effectiveness of prophylactic levosimendan in high-risk valve surgery patients. Cardiovascular Journal of Africa2013;24:260-4. [DOI: 10.5830/CVJA-2013-047]">Ersoy 2013</a> stated that no marked adverse reaction to the study drug was observed in the levosimendan group. </p> </section> </section> </section> <section id="CD013781-sec-0131"> <h4 class="title">Levosimendan versus milrinone</h4> <p>Three small, single‐centre trials with 130 participants investigated the effect of levosimendan compared to milrinone (<a href="./references#CD013781-bbs2-0001" title="AminSW , Abd-ElgalilSM , MohamedSA , AhmedMM , HamawyTY , FathiLM . Levosimendan versus milrinone in the management of impaired left ventricular function in patients undergoing coronary artery bypass graft surgery. Open Anesthesia Journal2019;13:59-67. [DOI: 10.2174/2589645801913010059]">Amin 2019</a>; <a href="./references#CD013781-bbs2-0005" title="De HertSG , LorsomradeeS , CromheeckeS , Van der LindenPJ . The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesthesia and Analgesia2007;104:766-73. [DOI: 10.1213/01.ane.0000256863.92050.d3]">De Hert 2007</a>; <a href="./references#CD013781-bbs2-0025" title="MishraA , KumarB , DuttaV , AryaVK , MishraAK . Comparative effect of levosimendan and milrinone in cardiac surgery patients with pulmonary hypertension and left ventricular dysfunction. Journal of Cardiothoracic and Vascular Anesthesia2016;30:639-46. [DOI: 10.1053/j.jvca.2016.01.015]">Mishra 2016</a>). </p> <section id="CD013781-sec-0132"> <h5 class="title">Primary outcomes</h5> <section id="CD013781-sec-0133"> <h6 class="title">All‐cause mortality (within 30 days)</h6> <p>Information on mortality within 30 days was restricted to two studies (<a href="./references#CD013781-bbs2-0005" title="De HertSG , LorsomradeeS , CromheeckeS , Van der LindenPJ . The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesthesia and Analgesia2007;104:766-73. [DOI: 10.1213/01.ane.0000256863.92050.d3]">De Hert 2007</a>; <a href="./references#CD013781-bbs2-0025" title="MishraA , KumarB , DuttaV , AryaVK , MishraAK . Comparative effect of levosimendan and milrinone in cardiac surgery patients with pulmonary hypertension and left ventricular dysfunction. Journal of Cardiothoracic and Vascular Anesthesia2016;30:639-46. [DOI: 10.1053/j.jvca.2016.01.015]">Mishra 2016</a>). However, the relative effect was only generated from <a href="./references#CD013781-bbs2-0005" title="De HertSG , LorsomradeeS , CromheeckeS , Van der LindenPJ . The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesthesia and Analgesia2007;104:766-73. [DOI: 10.1213/01.ane.0000256863.92050.d3]">De Hert 2007</a>, while the relative risk in <a href="./references#CD013781-bbs2-0025" title="MishraA , KumarB , DuttaV , AryaVK , MishraAK . Comparative effect of levosimendan and milrinone in cardiac surgery patients with pulmonary hypertension and left ventricular dysfunction. Journal of Cardiothoracic and Vascular Anesthesia2016;30:639-46. [DOI: 10.1053/j.jvca.2016.01.015]">Mishra 2016</a> was not estimable due to no events being observed in either group. When levosimendan was compared to milrinone, there was little to no difference in all‐cause mortality within 30 days (RR 0.14, 95% CI 0.01 to 2.55; 70 participants, 2 studies; low‐certainty evidence; heterogeneity was not applicable) (<a href="./references#CD013781-fig-0066" title="">Analysis 6.1</a>). </p> </section> <section id="CD013781-sec-0134"> <h6 class="title">Incidence of LCOS</h6> <p>This outcome was not reported in any of the included studies.</p> </section> <section id="CD013781-sec-0135"> <h6 class="title">Adverse events</h6> <p>While information on cardiogenic shock and non‐embolic stroke/transient ischaemic attack was not reported in any of the included studies, information on atrial fibrillation and perioperative myocardial infarction were restricted to one study (<a href="./references#CD013781-bbs2-0005" title="De HertSG , LorsomradeeS , CromheeckeS , Van der LindenPJ . The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesthesia and Analgesia2007;104:766-73. [DOI: 10.1213/01.ane.0000256863.92050.d3]">De Hert 2007</a>). In the levosimendan intervention group, 6 out of 15 participants suffered from atrial fibrillation compared to 7 out of 15 participants in the milrinone control group; no evidence of a difference was found in the risk ratio between groups (RR 0.86, 95% CI 0.38 to 1.95; 30 participants, 1 study; very low‐certainty evidence; heterogeneity was not applicable) (<a href="./references#CD013781-fig-0067" title="">Analysis 6.2</a>). The relative effect on perioperative myocardial infarction was not estimable due to no events being observed in either the levosimendan or milrinone groups (<a href="./references#CD013781-fig-0068" title="">Analysis 6.3</a>). </p> </section> </section> <section id="CD013781-sec-0136"> <h5 class="title">Secondary outcomes</h5> <section id="CD013781-sec-0137"> <h6 class="title">Length of in‐hospital and intensive care unit stay</h6> <p>Information on the length of in‐hospital stay was restricted to <a href="./references#CD013781-bbs2-0005" title="De HertSG , LorsomradeeS , CromheeckeS , Van der LindenPJ . The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesthesia and Analgesia2007;104:766-73. [DOI: 10.1213/01.ane.0000256863.92050.d3]">De Hert 2007</a> (10 (IQR 7 to 16) versus 12 (IQR 5 to 39) days). </p> <p><a href="./references#CD013781-bbs2-0001" title="AminSW , Abd-ElgalilSM , MohamedSA , AhmedMM , HamawyTY , FathiLM . Levosimendan versus milrinone in the management of impaired left ventricular function in patients undergoing coronary artery bypass graft surgery. Open Anesthesia Journal2019;13:59-67. [DOI: 10.2174/2589645801913010059]">Amin 2019</a> reported that the mean length of stay in intensive care in the control group receiving milrinone was 4.25 ± 1.75 days. In the levosimendan group, the mean length of intensive care was 0.90 days shorter (mean difference ‐0.90, 95% CI ‐1.67 to ‐0.13). <a href="./references#CD013781-bbs2-0025" title="MishraA , KumarB , DuttaV , AryaVK , MishraAK . Comparative effect of levosimendan and milrinone in cardiac surgery patients with pulmonary hypertension and left ventricular dysfunction. Journal of Cardiothoracic and Vascular Anesthesia2016;30:639-46. [DOI: 10.1053/j.jvca.2016.01.015]">Mishra 2016</a> reported that the mean length of stay in intensive care in the control group receiving milrinone was 4.56 ± 1.62 days. In the levosimendan intervention group, the mean length of intensive care was 0.31 days shorter (mean difference ‐0.31, 95% CI ‐1.34 to 0.72). Altogether, there was a difference in the mean length of stay in the intensive care unit between groups, favouring levosimendan (mean difference ‐0.69, 95% CI ‐1.31 to ‐0.07; 100 participants, 2 studies; low‐certainty evidence; low heterogeneity) (<a href="./references#CD013781-fig-0069" title="">Analysis 6.4</a>). In line with this, <a href="./references#CD013781-bbs2-0005" title="De HertSG , LorsomradeeS , CromheeckeS , Van der LindenPJ . The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesthesia and Analgesia2007;104:766-73. [DOI: 10.1213/01.ane.0000256863.92050.d3]">De Hert 2007</a> reported a similar length of stay in the intensive care unit (2.58 (IQR 1.17 to 5.04) versus 2.75 (IQR 1.42 to 39) days). </p> </section> <section id="CD013781-sec-0138"> <h6 class="title">Haemodynamics (cardiac index, MAP, PCWP)</h6> <p>The only available information regarding cardiac index was the narrative statement by <a href="./references#CD013781-bbs2-0025" title="MishraA , KumarB , DuttaV , AryaVK , MishraAK . Comparative effect of levosimendan and milrinone in cardiac surgery patients with pulmonary hypertension and left ventricular dysfunction. Journal of Cardiothoracic and Vascular Anesthesia2016;30:639-46. [DOI: 10.1053/j.jvca.2016.01.015]">Mishra 2016</a> that the cardiac index was comparable between groups during the study period, except at 6 hours of intensive care, when it was significantly higher in the levosimendan group compared with the milrinone group. </p> <p>Quantitative data on MAP was only reported by <a href="./references#CD013781-bbs2-0005" title="De HertSG , LorsomradeeS , CromheeckeS , Van der LindenPJ . The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesthesia and Analgesia2007;104:766-73. [DOI: 10.1213/01.ane.0000256863.92050.d3]">De Hert 2007</a> with 30 participants. No evidence of a difference in mean MAP between the levosimendan intervention group and the milrinone control group was observed at baseline with 2.00 (95% CI ‐4.60 to 8.60), at end‐of‐surgery with 3.00 (95% CI ‐1.53 to 7.53), at 6 hours after surgery with ‐3.00 (95% CI ‐10.16 to 4.16), at 12 hours after surgery with 0.00 (95% CI ‐6.48 to 6.48), and at 24 hours after surgery with ‐2.00 (95% CI ‐7.01 to 3.01) (<a href="./references#CD013781-fig-0070" title="">Analysis 6.5</a>). <a href="./references#CD013781-bbs2-0001" title="AminSW , Abd-ElgalilSM , MohamedSA , AhmedMM , HamawyTY , FathiLM . Levosimendan versus milrinone in the management of impaired left ventricular function in patients undergoing coronary artery bypass graft surgery. Open Anesthesia Journal2019;13:59-67. [DOI: 10.2174/2589645801913010059]">Amin 2019</a> narratively reported no significant differences in MAP from anaesthesia to the first 24 hours in intensive care. <a href="./references#CD013781-bbs2-0025" title="MishraA , KumarB , DuttaV , AryaVK , MishraAK . Comparative effect of levosimendan and milrinone in cardiac surgery patients with pulmonary hypertension and left ventricular dysfunction. Journal of Cardiothoracic and Vascular Anesthesia2016;30:639-46. [DOI: 10.1053/j.jvca.2016.01.015]">Mishra 2016</a> reported MAP to be comparable in both groups at all time points except at baseline when it was significantly lower in the levosimendan group. </p> <p>Information on PCWP was not reported in any of the included studies.</p> </section> <section id="CD013781-sec-0139"> <h6 class="title">Duration of mechanical ventilation</h6> <p>Information on this outcome was available in all three included studies. <a href="./references#CD013781-bbs2-0001" title="AminSW , Abd-ElgalilSM , MohamedSA , AhmedMM , HamawyTY , FathiLM . Levosimendan versus milrinone in the management of impaired left ventricular function in patients undergoing coronary artery bypass graft surgery. Open Anesthesia Journal2019;13:59-67. [DOI: 10.2174/2589645801913010059]">Amin 2019</a> reported the mean duration of mechanical ventilation in the milrinone group to be 18.76 ± 9.8 hours. The mean duration of mechanical ventilation in the intervention group receiving levosimendan was 6.50 hours lower (mean difference ‐6.50, 95% CI ‐10.65 to ‐2.35). <a href="./references#CD013781-bbs2-0005" title="De HertSG , LorsomradeeS , CromheeckeS , Van der LindenPJ . The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesthesia and Analgesia2007;104:766-73. [DOI: 10.1213/01.ane.0000256863.92050.d3]">De Hert 2007</a> reported the mean duration of mechanical ventilation in the milrinone group to be 20 ± 11 hours, whereas in the intervention group receiving levosimendan it was 9 hours lower (mean difference ‐9.00, 95% CI ‐15.60 to ‐2.40). Similarly, <a href="./references#CD013781-bbs2-0025" title="MishraA , KumarB , DuttaV , AryaVK , MishraAK . Comparative effect of levosimendan and milrinone in cardiac surgery patients with pulmonary hypertension and left ventricular dysfunction. Journal of Cardiothoracic and Vascular Anesthesia2016;30:639-46. [DOI: 10.1053/j.jvca.2016.01.015]">Mishra 2016</a> reported a shorter mean duration of mechanical ventilation in the levosimendan group compared with the milrinone group (15.36 ± 3.32 hours versus 21.87 ± 15.38 hours). In summary, there was a difference in the mean duration of mechanical ventilation between groups, favouring the levosimendan intervention group (mean difference ‐7.06, 95% CI ‐10.19 to ‐3.93; 130 participants, 3 studies; low‐certainty evidence; low heterogeneity) (<a href="./references#CD013781-fig-0071" title="">Analysis 6.6</a>). </p> </section> <section id="CD013781-sec-0140"> <h6 class="title">Proportion of weaning failure within 48 hours of extubation</h6> <p>This outcome was not reported in any of the included studies.</p> </section> <section id="CD013781-sec-0141"> <h6 class="title">Number of patients requiring mechanical circulatory support (IABP)</h6> <p>Information on the number of patients requiring mechanical circulatory support was restricted to <a href="./references#CD013781-bbs2-0001" title="AminSW , Abd-ElgalilSM , MohamedSA , AhmedMM , HamawyTY , FathiLM . Levosimendan versus milrinone in the management of impaired left ventricular function in patients undergoing coronary artery bypass graft surgery. Open Anesthesia Journal2019;13:59-67. [DOI: 10.2174/2589645801913010059]">Amin 2019</a> and <a href="./references#CD013781-bbs2-0005" title="De HertSG , LorsomradeeS , CromheeckeS , Van der LindenPJ . The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesthesia and Analgesia2007;104:766-73. [DOI: 10.1213/01.ane.0000256863.92050.d3]">De Hert 2007</a>. <a href="./references#CD013781-bbs2-0001" title="AminSW , Abd-ElgalilSM , MohamedSA , AhmedMM , HamawyTY , FathiLM . Levosimendan versus milrinone in the management of impaired left ventricular function in patients undergoing coronary artery bypass graft surgery. Open Anesthesia Journal2019;13:59-67. [DOI: 10.2174/2589645801913010059]">Amin 2019</a> reported that of 30 patients in the levosimendan intervention group, no patient required mechanical circulatory support compared to 3 out of 30 patients in the milrinone control group (RR 0.14, 95% CI 0.01 to 2.65). <a href="./references#CD013781-bbs2-0005" title="De HertSG , LorsomradeeS , CromheeckeS , Van der LindenPJ . The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesthesia and Analgesia2007;104:766-73. [DOI: 10.1213/01.ane.0000256863.92050.d3]">De Hert 2007</a> reported that 4 out of 15 patients in both the levosimendan and milrinone groups required mechanical circulatory support (RR 1.00, 95% CI 0.31 to 3.28). Altogether, there was little to no difference in the number of patients requiring mechanical circulatory support (RR 0.58, 95% CI 0.09 to 3.55; 90 participants, 2 studies; low‐certainty evidence; low heterogeneity) (<a href="./references#CD013781-fig-0072" title="">Analysis 6.7</a>). </p> </section> <section id="CD013781-sec-0142"> <h6 class="title">Number of patients requiring additional inotropic drugs</h6> <p>For this outcome, quantitative data on specific inotropic drugs, i.e. norepinephrine and dobutamine, were only reported by <a href="./references#CD013781-bbs2-0005" title="De HertSG , LorsomradeeS , CromheeckeS , Van der LindenPJ . The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesthesia and Analgesia2007;104:766-73. [DOI: 10.1213/01.ane.0000256863.92050.d3]">De Hert 2007</a>. There was no evidence of a difference in risk ratio between groups for both specific inotropic drugs. Regarding norepinephrine, all 15 participants in both the levosimendan and milrinone groups received this additional inotropic support (RR 1.00, 95% CI 0.88 to 1.13) (<a href="./references#CD013781-fig-0073" title="">Analysis 6.8</a>). Similarly, 15 out of 15 participants in levosimendan and milrinone groups required additional dobutamine (RR 1.00, 95% CI 0.88 to 1.13) (<a href="./references#CD013781-fig-0074" title="">Analysis 6.9</a>). <a href="./references#CD013781-bbs2-0025" title="MishraA , KumarB , DuttaV , AryaVK , MishraAK . Comparative effect of levosimendan and milrinone in cardiac surgery patients with pulmonary hypertension and left ventricular dysfunction. Journal of Cardiothoracic and Vascular Anesthesia2016;30:639-46. [DOI: 10.1053/j.jvca.2016.01.015]">Mishra 2016</a> narratively reported that at several time points after termination of cardiopulmonary bypass, more patients in the levosimendan group required significantly higher doses of norepinephrine infusion compared with those in the milrinone group. </p> </section> <section id="CD013781-sec-0143"> <h6 class="title">Number of patients requiring cardiac transplantation, ventricular assist device (VAD) implantation or cardiopulmonary resuscitation </h6> <p>This outcome was not reported in any of the included studies.</p> </section> <section id="CD013781-sec-0144"> <h6 class="title">Proportion of renal failure</h6> <p>This outcome was not reported in any of the included studies.</p> </section> <section id="CD013781-sec-0145"> <h6 class="title">Quality of life</h6> <p>This outcome was not reported in any of the included studies.</p> </section> </section> </section> <section id="CD013781-sec-0146"> <h4 class="title">Levosimendan versus placebo</h4> <p>Twelve small, single‐centre trials with 869 participants (<a href="./references#CD013781-bbs2-0002" title="AnastasiadisK , AntonitsisP , VranisK , KleontasA , AsteriouC , GrosomanidisV , et al. Effectiveness of prophylactic levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting: a randomized pilot study. Interactive Cardiovascular and Thoracic Surgery2016;23:740-8. [DOI: 10.1093/icvts/ivw213]">Anastasiadis 2016</a>; <a href="./references#CD013781-bbs2-0008" title="ErbJ , BeutlhauserT , FeldheiserA , SchusterB , TreskatschS , GrubitzschH , et al. Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery. Journal of International Medical Research2014;42:750-64. [DOI: 10.1177/0300060513516293]">Erb 2014</a>; <a href="./references#CD013781-bbs2-0014" title="HuX , XuQ . Application of levosimendan in severe patients after cardiac surgery. Chinese Journal of Clinical Pharmacology and Therapeutics2020;25:1027-32. [DOI: 10.12092/j.issn.1009-2501.2020.09.010]">Hu 2020</a>; <a href="./references#CD013781-bbs2-0015" title="JärveläK , MaaranenP , SistoT , RuokonenE . Levosimendan in aortic valve surgery: cardiac performance and recovery. Journal of Cardiothoracic and Vascular Anesthesia2008;22:693-8. [DOI: 10.1053/j.jvca.2008.01.024]">Jävelä 2008</a>; <a href="./references#CD013781-bbs2-0017" title="Juhl-OlsenP , Jakobsen C-J, RasmussenLA , BhavsarR , Klaaborg K-E, FrederiksenCA , et al. Effects of levosimendan in patients with left ventricular hypertrophy undergoing aortic valve replacement. Acta Anaesthesiologica Scandinavica2015;59:65-77. [DOI: 10.1111/aas.12425]">Juhl‐Olsen 2015</a>; <a href="./references#CD013781-bbs2-0020" title="KodalliRK , SundarAS , VakamudiM , RavulapaliH , NandipatiS , ChandrasekaranN , et al. Effect of levosimendan on hemodynamic changes in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled study. Annals of Cardiac Anaesthesia2013;16:94-9. [DOI: 10.4103/0971-9784.109737]">Kodalli 2013</a>; <a href="./references#CD013781-bbs2-0021" title="LahtinenP , PitkänenO , PölönenP , TurpeinenA , KiviniemiV , UusaroA . Levosimendan reduces heart failure after cardiac surgery: a prospective, randomized, placebo-controlled trial. Criítical Care Medicine2011;39:2263-70. [DOI: 10.1097/CCM.0b013e3182227b97]">Lahtinen 2011</a>; <a href="./references#CD013781-bbs2-0022" title="LeppikangasH , JärveläK , SistoT , MaaranenP , VirtanenM , LehtoP , et al. Preoperative levosimendan infusion in combined aortic valve and coronary bypass surgery. British Journal of Anaesthesia2011;106:298-304. [DOI: 10.1093/bja/aeq402]">Leppikangas 2011</a>; <a href="./references#CD013781-bbs2-0026" title="ShahB , SharmaP , BrahmbhattA , ShahR , RathodB , ShastriN , et al. Study of levosimendan during off-pump coronary artery bypass grafting in patients with LV dysfunction: a double-blind randomized study. Indian Journal of Pharmacology2014;46:29-34. [DOI: 10.4103/0253-7613.125161]">Shah 2014</a>; <a href="./references#CD013781-bbs2-0027" title="SharmaP , MalhotraA , GandhiS , GargP , BishnoiA , GandhiH . Preoperative levosimendan in ischemic mitral valve repair. Asian Cardiovascular and Thoracic Annals2014;22:539-45. [DOI: 10.1177/0218492313499352]">Sharma 2014</a>; <a href="./references#CD013781-bbs2-0028" title="TritapepeL , De SantisV , VitaleD , SantulliM , MorelliA , NofroniI , et al. Preconditioning effects of levosimendan in coronary artery bypass grafting - a pilot study. British Journal of Anaesthesia2006;96:694-700. [DOI: 10.1093/bja/ael082]">Tritapepe 2006</a>; <a href="./references#CD013781-bbs2-0029" title="TritapepeL , De SantisV , VitaleD , GuarracinoF , PellegriniF , PietropaoliP , et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. British Journal of Anaesthesia2009;102:198-204. [DOI: 10.1093/bja/aen367]">Tritapepe 2009</a>), three small, multicentre trials with 645 participants (<a href="./references#CD013781-bbs2-0004" title="CholleyB , CarubaT , GrosjeanS , AmourJ , OuattaraA , VillacortaJ , et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA2017;318:548-56. [DOI: 10.1001/jama.2017.9973]">Cholley 2017</a>; <a href="./references#CD013781-bbs2-0009" title="RikssonHI , JalonenJR , HeikkinenLO , KivikkoM , LaineM , LeinoKA , et al. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Cardiothoracic Anesthesiology2009;87:448-54. [DOI: 10.1016/j.athoracsur.2008.10.029]">Eriksson 2009</a>; <a href="./references#CD013781-bbs2-0023" title="LevinR , DegrangeM , Del MazoC , TanusE , PorcileR . Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Experimental and Clinical Cardiology2012;17:125-30. [PMID: 23620700]">Levin 2012</a>), and one large, multicentre trial with 849 participants (<a href="./references#CD013781-bbs2-0024" title="MehtaRH , LeimbergerJD , vanDiepenS , MezaJ , WangA , JankowichR , et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. New England Journal of Medicine2017;376:2032-42. [DOI: 10.1056/NEJMoa1616218]">Mehta 2017</a>) investigated levosimendan compared to placebo. See <a href="./full#CD013781-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD013781-sec-0147"> <h5 class="title">Primary outcomes</h5> <section id="CD013781-sec-0148"> <h6 class="title">All‐cause mortality (within 30 days)</h6> <p>Information on mortality within 30 days was found in 14 included studies (<a href="./references#CD013781-bbs2-0002" title="AnastasiadisK , AntonitsisP , VranisK , KleontasA , AsteriouC , GrosomanidisV , et al. Effectiveness of prophylactic levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting: a randomized pilot study. Interactive Cardiovascular and Thoracic Surgery2016;23:740-8. [DOI: 10.1093/icvts/ivw213]">Anastasiadis 2016</a>; <a href="./references#CD013781-bbs2-0004" title="CholleyB , CarubaT , GrosjeanS , AmourJ , OuattaraA , VillacortaJ , et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA2017;318:548-56. [DOI: 10.1001/jama.2017.9973]">Cholley 2017</a>; <a href="./references#CD013781-bbs2-0008" title="ErbJ , BeutlhauserT , FeldheiserA , SchusterB , TreskatschS , GrubitzschH , et al. Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery. Journal of International Medical Research2014;42:750-64. [DOI: 10.1177/0300060513516293]">Erb 2014</a>; <a href="./references#CD013781-bbs2-0009" title="RikssonHI , JalonenJR , HeikkinenLO , KivikkoM , LaineM , LeinoKA , et al. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Cardiothoracic Anesthesiology2009;87:448-54. [DOI: 10.1016/j.athoracsur.2008.10.029]">Eriksson 2009</a>; <a href="./references#CD013781-bbs2-0014" title="HuX , XuQ . Application of levosimendan in severe patients after cardiac surgery. Chinese Journal of Clinical Pharmacology and Therapeutics2020;25:1027-32. [DOI: 10.12092/j.issn.1009-2501.2020.09.010]">Hu 2020</a>; <a href="./references#CD013781-bbs2-0015" title="JärveläK , MaaranenP , SistoT , RuokonenE . Levosimendan in aortic valve surgery: cardiac performance and recovery. Journal of Cardiothoracic and Vascular Anesthesia2008;22:693-8. [DOI: 10.1053/j.jvca.2008.01.024]">Jävelä 2008</a>; <a href="./references#CD013781-bbs2-0017" title="Juhl-OlsenP , Jakobsen C-J, RasmussenLA , BhavsarR , Klaaborg K-E, FrederiksenCA , et al. Effects of levosimendan in patients with left ventricular hypertrophy undergoing aortic valve replacement. Acta Anaesthesiologica Scandinavica2015;59:65-77. [DOI: 10.1111/aas.12425]">Juhl‐Olsen 2015</a>; <a href="./references#CD013781-bbs2-0020" title="KodalliRK , SundarAS , VakamudiM , RavulapaliH , NandipatiS , ChandrasekaranN , et al. Effect of levosimendan on hemodynamic changes in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled study. Annals of Cardiac Anaesthesia2013;16:94-9. [DOI: 10.4103/0971-9784.109737]">Kodalli 2013</a>; <a href="./references#CD013781-bbs2-0021" title="LahtinenP , PitkänenO , PölönenP , TurpeinenA , KiviniemiV , UusaroA . Levosimendan reduces heart failure after cardiac surgery: a prospective, randomized, placebo-controlled trial. Criítical Care Medicine2011;39:2263-70. [DOI: 10.1097/CCM.0b013e3182227b97]">Lahtinen 2011</a>; <a href="./references#CD013781-bbs2-0023" title="LevinR , DegrangeM , Del MazoC , TanusE , PorcileR . Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Experimental and Clinical Cardiology2012;17:125-30. [PMID: 23620700]">Levin 2012</a>; <a href="./references#CD013781-bbs2-0024" title="MehtaRH , LeimbergerJD , vanDiepenS , MezaJ , WangA , JankowichR , et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. New England Journal of Medicine2017;376:2032-42. [DOI: 10.1056/NEJMoa1616218]">Mehta 2017</a>; <a href="./references#CD013781-bbs2-0026" title="ShahB , SharmaP , BrahmbhattA , ShahR , RathodB , ShastriN , et al. Study of levosimendan during off-pump coronary artery bypass grafting in patients with LV dysfunction: a double-blind randomized study. Indian Journal of Pharmacology2014;46:29-34. [DOI: 10.4103/0253-7613.125161]">Shah 2014</a>; <a href="./references#CD013781-bbs2-0027" title="SharmaP , MalhotraA , GandhiS , GargP , BishnoiA , GandhiH . Preoperative levosimendan in ischemic mitral valve repair. Asian Cardiovascular and Thoracic Annals2014;22:539-45. [DOI: 10.1177/0218492313499352]">Sharma 2014</a>; <a href="./references#CD013781-bbs2-0029" title="TritapepeL , De SantisV , VitaleD , GuarracinoF , PellegriniF , PietropaoliP , et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. British Journal of Anaesthesia2009;102:198-204. [DOI: 10.1093/bja/aen367]">Tritapepe 2009</a>). However, the relative effect was only generated from 11 included studies (<a href="./references#CD013781-bbs2-0002" title="AnastasiadisK , AntonitsisP , VranisK , KleontasA , AsteriouC , GrosomanidisV , et al. Effectiveness of prophylactic levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting: a randomized pilot study. Interactive Cardiovascular and Thoracic Surgery2016;23:740-8. [DOI: 10.1093/icvts/ivw213]">Anastasiadis 2016</a>; <a href="./references#CD013781-bbs2-0004" title="CholleyB , CarubaT , GrosjeanS , AmourJ , OuattaraA , VillacortaJ , et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA2017;318:548-56. [DOI: 10.1001/jama.2017.9973]">Cholley 2017</a>; <a href="./references#CD013781-bbs2-0008" title="ErbJ , BeutlhauserT , FeldheiserA , SchusterB , TreskatschS , GrubitzschH , et al. Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery. Journal of International Medical Research2014;42:750-64. [DOI: 10.1177/0300060513516293]">Erb 2014</a>; <a href="./references#CD013781-bbs2-0009" title="RikssonHI , JalonenJR , HeikkinenLO , KivikkoM , LaineM , LeinoKA , et al. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Cardiothoracic Anesthesiology2009;87:448-54. [DOI: 10.1016/j.athoracsur.2008.10.029]">Eriksson 2009</a>; <a href="./references#CD013781-bbs2-0014" title="HuX , XuQ . Application of levosimendan in severe patients after cardiac surgery. Chinese Journal of Clinical Pharmacology and Therapeutics2020;25:1027-32. [DOI: 10.12092/j.issn.1009-2501.2020.09.010]">Hu 2020</a>; <a href="./references#CD013781-bbs2-0015" title="JärveläK , MaaranenP , SistoT , RuokonenE . Levosimendan in aortic valve surgery: cardiac performance and recovery. Journal of Cardiothoracic and Vascular Anesthesia2008;22:693-8. [DOI: 10.1053/j.jvca.2008.01.024]">Jävelä 2008</a>; <a href="./references#CD013781-bbs2-0021" title="LahtinenP , PitkänenO , PölönenP , TurpeinenA , KiviniemiV , UusaroA . Levosimendan reduces heart failure after cardiac surgery: a prospective, randomized, placebo-controlled trial. Criítical Care Medicine2011;39:2263-70. [DOI: 10.1097/CCM.0b013e3182227b97]">Lahtinen 2011</a>; <a href="./references#CD013781-bbs2-0023" title="LevinR , DegrangeM , Del MazoC , TanusE , PorcileR . Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Experimental and Clinical Cardiology2012;17:125-30. [PMID: 23620700]">Levin 2012</a>; <a href="./references#CD013781-bbs2-0024" title="MehtaRH , LeimbergerJD , vanDiepenS , MezaJ , WangA , JankowichR , et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. New England Journal of Medicine2017;376:2032-42. [DOI: 10.1056/NEJMoa1616218]">Mehta 2017</a>; <a href="./references#CD013781-bbs2-0026" title="ShahB , SharmaP , BrahmbhattA , ShahR , RathodB , ShastriN , et al. Study of levosimendan during off-pump coronary artery bypass grafting in patients with LV dysfunction: a double-blind randomized study. Indian Journal of Pharmacology2014;46:29-34. [DOI: 10.4103/0253-7613.125161]">Shah 2014</a>; <a href="./references#CD013781-bbs2-0027" title="SharmaP , MalhotraA , GandhiS , GargP , BishnoiA , GandhiH . Preoperative levosimendan in ischemic mitral valve repair. Asian Cardiovascular and Thoracic Annals2014;22:539-45. [DOI: 10.1177/0218492313499352]">Sharma 2014</a>), while the relative risk in <a href="./references#CD013781-bbs2-0017" title="Juhl-OlsenP , Jakobsen C-J, RasmussenLA , BhavsarR , Klaaborg K-E, FrederiksenCA , et al. Effects of levosimendan in patients with left ventricular hypertrophy undergoing aortic valve replacement. Acta Anaesthesiologica Scandinavica2015;59:65-77. [DOI: 10.1111/aas.12425]">Juhl‐Olsen 2015</a>, <a href="./references#CD013781-bbs2-0020" title="KodalliRK , SundarAS , VakamudiM , RavulapaliH , NandipatiS , ChandrasekaranN , et al. Effect of levosimendan on hemodynamic changes in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled study. Annals of Cardiac Anaesthesia2013;16:94-9. [DOI: 10.4103/0971-9784.109737]">Kodalli 2013</a>, and <a href="./references#CD013781-bbs2-0029" title="TritapepeL , De SantisV , VitaleD , GuarracinoF , PellegriniF , PietropaoliP , et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. British Journal of Anaesthesia2009;102:198-204. [DOI: 10.1093/bja/aen367]">Tritapepe 2009</a> was not estimable due to no events being observed in either group. When levosimendan was compared to the control group, there was a small effect to no difference in all‐cause mortality within 30 days, favouring the levosimendan group (RR 0.65, 95% CI 0.43 to 0.97; 2347 participants, 14 studies; moderate‐certainty evidence; low heterogeneity; no indication of reporting bias) (<a href="./references#CD013781-fig-0075" title="">Analysis 7.1</a>; <a href="#CD013781-fig-0004">Figure 4</a>; <a href="./full#CD013781-tbl-0002">summary of findings Table 2</a>). Derived from that risk difference, the number needed to treat for an additional beneficial outcome (NNTB) is 44. </p> <div class="figure" id="CD013781-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="original image" data-id="CD013781-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> </section> <section id="CD013781-sec-0149"> <h6 class="title">Incidence of LCOS</h6> <p>Information on LCOS was reported by six studies (<a href="./references#CD013781-bbs2-0004" title="CholleyB , CarubaT , GrosjeanS , AmourJ , OuattaraA , VillacortaJ , et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA2017;318:548-56. [DOI: 10.1001/jama.2017.9973]">Cholley 2017</a>; <a href="./references#CD013781-bbs2-0021" title="LahtinenP , PitkänenO , PölönenP , TurpeinenA , KiviniemiV , UusaroA . Levosimendan reduces heart failure after cardiac surgery: a prospective, randomized, placebo-controlled trial. Criítical Care Medicine2011;39:2263-70. [DOI: 10.1097/CCM.0b013e3182227b97]">Lahtinen 2011</a>; <a href="./references#CD013781-bbs2-0023" title="LevinR , DegrangeM , Del MazoC , TanusE , PorcileR . Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Experimental and Clinical Cardiology2012;17:125-30. [PMID: 23620700]">Levin 2012</a>; <a href="./references#CD013781-bbs2-0024" title="MehtaRH , LeimbergerJD , vanDiepenS , MezaJ , WangA , JankowichR , et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. New England Journal of Medicine2017;376:2032-42. [DOI: 10.1056/NEJMoa1616218]">Mehta 2017</a>; <a href="./references#CD013781-bbs2-0026" title="ShahB , SharmaP , BrahmbhattA , ShahR , RathodB , ShastriN , et al. Study of levosimendan during off-pump coronary artery bypass grafting in patients with LV dysfunction: a double-blind randomized study. Indian Journal of Pharmacology2014;46:29-34. [DOI: 10.4103/0253-7613.125161]">Shah 2014</a>; <a href="./references#CD013781-bbs2-0027" title="SharmaP , MalhotraA , GandhiS , GargP , BishnoiA , GandhiH . Preoperative levosimendan in ischemic mitral valve repair. Asian Cardiovascular and Thoracic Annals2014;22:539-45. [DOI: 10.1177/0218492313499352]">Sharma 2014</a>). When the levosimendan intervention group was compared to the control group receiving placebo, there were differences in LCOS and this effect was favourable to the levosimendan group (RR 0.43, 95% CI 0.25 to 0.74; 1724 participants, 6 studies; low‐certainty evidence; substantial heterogeneity) (<a href="./references#CD013781-fig-0076" title="">Analysis 7.2</a>; <a href="./full#CD013781-tbl-0002">summary of findings Table 2</a>). Derived from that risk difference, the calculated NNTB is 8. </p> </section> <section id="CD013781-sec-0150"> <h6 class="title">Adverse events</h6> <p>Information on cardiogenic shock was restricted to <a href="./references#CD013781-bbs2-0004" title="CholleyB , CarubaT , GrosjeanS , AmourJ , OuattaraA , VillacortaJ , et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA2017;318:548-56. [DOI: 10.1001/jama.2017.9973]">Cholley 2017</a>, <a href="./references#CD013781-bbs2-0020" title="KodalliRK , SundarAS , VakamudiM , RavulapaliH , NandipatiS , ChandrasekaranN , et al. Effect of levosimendan on hemodynamic changes in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled study. Annals of Cardiac Anaesthesia2013;16:94-9. [DOI: 10.4103/0971-9784.109737]">Kodalli 2013</a>, and <a href="./references#CD013781-bbs2-0024" title="MehtaRH , LeimbergerJD , vanDiepenS , MezaJ , WangA , JankowichR , et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. New England Journal of Medicine2017;376:2032-42. [DOI: 10.1056/NEJMoa1616218]">Mehta 2017</a>, but the relative effect was only provided by <a href="./references#CD013781-bbs2-0004" title="CholleyB , CarubaT , GrosjeanS , AmourJ , OuattaraA , VillacortaJ , et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA2017;318:548-56. [DOI: 10.1001/jama.2017.9973]">Cholley 2017</a> and <a href="./references#CD013781-bbs2-0024" title="MehtaRH , LeimbergerJD , vanDiepenS , MezaJ , WangA , JankowichR , et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. New England Journal of Medicine2017;376:2032-42. [DOI: 10.1056/NEJMoa1616218]">Mehta 2017</a>, while the risk ratio from <a href="./references#CD013781-bbs2-0020" title="KodalliRK , SundarAS , VakamudiM , RavulapaliH , NandipatiS , ChandrasekaranN , et al. Effect of levosimendan on hemodynamic changes in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled study. Annals of Cardiac Anaesthesia2013;16:94-9. [DOI: 10.4103/0971-9784.109737]">Kodalli 2013</a> was not estimable due to no events being observed in either group. Information on atrial fibrillation was provided by 11 studies (<a href="./references#CD013781-bbs2-0002" title="AnastasiadisK , AntonitsisP , VranisK , KleontasA , AsteriouC , GrosomanidisV , et al. Effectiveness of prophylactic levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting: a randomized pilot study. Interactive Cardiovascular and Thoracic Surgery2016;23:740-8. [DOI: 10.1093/icvts/ivw213]">Anastasiadis 2016</a>; <a href="./references#CD013781-bbs2-0004" title="CholleyB , CarubaT , GrosjeanS , AmourJ , OuattaraA , VillacortaJ , et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA2017;318:548-56. [DOI: 10.1001/jama.2017.9973]">Cholley 2017</a>; <a href="./references#CD013781-bbs2-0017" title="Juhl-OlsenP , Jakobsen C-J, RasmussenLA , BhavsarR , Klaaborg K-E, FrederiksenCA , et al. Effects of levosimendan in patients with left ventricular hypertrophy undergoing aortic valve replacement. Acta Anaesthesiologica Scandinavica2015;59:65-77. [DOI: 10.1111/aas.12425]">Juhl‐Olsen 2015</a>; <a href="./references#CD013781-bbs2-0020" title="KodalliRK , SundarAS , VakamudiM , RavulapaliH , NandipatiS , ChandrasekaranN , et al. Effect of levosimendan on hemodynamic changes in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled study. Annals of Cardiac Anaesthesia2013;16:94-9. [DOI: 10.4103/0971-9784.109737]">Kodalli 2013</a>; <a href="./references#CD013781-bbs2-0021" title="LahtinenP , PitkänenO , PölönenP , TurpeinenA , KiviniemiV , UusaroA . Levosimendan reduces heart failure after cardiac surgery: a prospective, randomized, placebo-controlled trial. Criítical Care Medicine2011;39:2263-70. [DOI: 10.1097/CCM.0b013e3182227b97]">Lahtinen 2011</a>; <a href="./references#CD013781-bbs2-0023" title="LevinR , DegrangeM , Del MazoC , TanusE , PorcileR . Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Experimental and Clinical Cardiology2012;17:125-30. [PMID: 23620700]">Levin 2012</a>; <a href="./references#CD013781-bbs2-0024" title="MehtaRH , LeimbergerJD , vanDiepenS , MezaJ , WangA , JankowichR , et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. New England Journal of Medicine2017;376:2032-42. [DOI: 10.1056/NEJMoa1616218]">Mehta 2017</a>; <a href="./references#CD013781-bbs2-0026" title="ShahB , SharmaP , BrahmbhattA , ShahR , RathodB , ShastriN , et al. Study of levosimendan during off-pump coronary artery bypass grafting in patients with LV dysfunction: a double-blind randomized study. Indian Journal of Pharmacology2014;46:29-34. [DOI: 10.4103/0253-7613.125161]">Shah 2014</a>; <a href="./references#CD013781-bbs2-0027" title="SharmaP , MalhotraA , GandhiS , GargP , BishnoiA , GandhiH . Preoperative levosimendan in ischemic mitral valve repair. Asian Cardiovascular and Thoracic Annals2014;22:539-45. [DOI: 10.1177/0218492313499352]">Sharma 2014</a>; <a href="./references#CD013781-bbs2-0028" title="TritapepeL , De SantisV , VitaleD , SantulliM , MorelliA , NofroniI , et al. Preconditioning effects of levosimendan in coronary artery bypass grafting - a pilot study. British Journal of Anaesthesia2006;96:694-700. [DOI: 10.1093/bja/ael082]">Tritapepe 2006</a>; <a href="./references#CD013781-bbs2-0029" title="TritapepeL , De SantisV , VitaleD , GuarracinoF , PellegriniF , PietropaoliP , et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. British Journal of Anaesthesia2009;102:198-204. [DOI: 10.1093/bja/aen367]">Tritapepe 2009</a>). However, the relative effect was only generated from 10 included studies (<a href="./references#CD013781-bbs2-0002" title="AnastasiadisK , AntonitsisP , VranisK , KleontasA , AsteriouC , GrosomanidisV , et al. Effectiveness of prophylactic levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting: a randomized pilot study. Interactive Cardiovascular and Thoracic Surgery2016;23:740-8. [DOI: 10.1093/icvts/ivw213]">Anastasiadis 2016</a>; <a href="./references#CD013781-bbs2-0004" title="CholleyB , CarubaT , GrosjeanS , AmourJ , OuattaraA , VillacortaJ , et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA2017;318:548-56. [DOI: 10.1001/jama.2017.9973]">Cholley 2017</a>; <a href="./references#CD013781-bbs2-0017" title="Juhl-OlsenP , Jakobsen C-J, RasmussenLA , BhavsarR , Klaaborg K-E, FrederiksenCA , et al. Effects of levosimendan in patients with left ventricular hypertrophy undergoing aortic valve replacement. Acta Anaesthesiologica Scandinavica2015;59:65-77. [DOI: 10.1111/aas.12425]">Juhl‐Olsen 2015</a>; <a href="./references#CD013781-bbs2-0021" title="LahtinenP , PitkänenO , PölönenP , TurpeinenA , KiviniemiV , UusaroA . Levosimendan reduces heart failure after cardiac surgery: a prospective, randomized, placebo-controlled trial. Criítical Care Medicine2011;39:2263-70. [DOI: 10.1097/CCM.0b013e3182227b97]">Lahtinen 2011</a>; <a href="./references#CD013781-bbs2-0023" title="LevinR , DegrangeM , Del MazoC , TanusE , PorcileR . Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Experimental and Clinical Cardiology2012;17:125-30. [PMID: 23620700]">Levin 2012</a>; <a href="./references#CD013781-bbs2-0024" title="MehtaRH , LeimbergerJD , vanDiepenS , MezaJ , WangA , JankowichR , et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. New England Journal of Medicine2017;376:2032-42. [DOI: 10.1056/NEJMoa1616218]">Mehta 2017</a>; <a href="./references#CD013781-bbs2-0026" title="ShahB , SharmaP , BrahmbhattA , ShahR , RathodB , ShastriN , et al. Study of levosimendan during off-pump coronary artery bypass grafting in patients with LV dysfunction: a double-blind randomized study. Indian Journal of Pharmacology2014;46:29-34. [DOI: 10.4103/0253-7613.125161]">Shah 2014</a>; <a href="./references#CD013781-bbs2-0027" title="SharmaP , MalhotraA , GandhiS , GargP , BishnoiA , GandhiH . Preoperative levosimendan in ischemic mitral valve repair. Asian Cardiovascular and Thoracic Annals2014;22:539-45. [DOI: 10.1177/0218492313499352]">Sharma 2014</a>; <a href="./references#CD013781-bbs2-0028" title="TritapepeL , De SantisV , VitaleD , SantulliM , MorelliA , NofroniI , et al. Preconditioning effects of levosimendan in coronary artery bypass grafting - a pilot study. British Journal of Anaesthesia2006;96:694-700. [DOI: 10.1093/bja/ael082]">Tritapepe 2006</a>; <a href="./references#CD013781-bbs2-0029" title="TritapepeL , De SantisV , VitaleD , GuarracinoF , PellegriniF , PietropaoliP , et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. British Journal of Anaesthesia2009;102:198-204. [DOI: 10.1093/bja/aen367]">Tritapepe 2009</a>), while the risk ratio from <a href="./references#CD013781-bbs2-0020" title="KodalliRK , SundarAS , VakamudiM , RavulapaliH , NandipatiS , ChandrasekaranN , et al. Effect of levosimendan on hemodynamic changes in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled study. Annals of Cardiac Anaesthesia2013;16:94-9. [DOI: 10.4103/0971-9784.109737]">Kodalli 2013</a> was not estimable due to no events being observed in either group. Information on perioperative myocardial infarction was found in eight studies (<a href="./references#CD013781-bbs2-0002" title="AnastasiadisK , AntonitsisP , VranisK , KleontasA , AsteriouC , GrosomanidisV , et al. Effectiveness of prophylactic levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting: a randomized pilot study. Interactive Cardiovascular and Thoracic Surgery2016;23:740-8. [DOI: 10.1093/icvts/ivw213]">Anastasiadis 2016</a>; <a href="./references#CD013781-bbs2-0004" title="CholleyB , CarubaT , GrosjeanS , AmourJ , OuattaraA , VillacortaJ , et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA2017;318:548-56. [DOI: 10.1001/jama.2017.9973]">Cholley 2017</a>; <a href="./references#CD013781-bbs2-0020" title="KodalliRK , SundarAS , VakamudiM , RavulapaliH , NandipatiS , ChandrasekaranN , et al. Effect of levosimendan on hemodynamic changes in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled study. Annals of Cardiac Anaesthesia2013;16:94-9. [DOI: 10.4103/0971-9784.109737]">Kodalli 2013</a>; <a href="./references#CD013781-bbs2-0021" title="LahtinenP , PitkänenO , PölönenP , TurpeinenA , KiviniemiV , UusaroA . Levosimendan reduces heart failure after cardiac surgery: a prospective, randomized, placebo-controlled trial. Criítical Care Medicine2011;39:2263-70. [DOI: 10.1097/CCM.0b013e3182227b97]">Lahtinen 2011</a>; <a href="./references#CD013781-bbs2-0023" title="LevinR , DegrangeM , Del MazoC , TanusE , PorcileR . Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Experimental and Clinical Cardiology2012;17:125-30. [PMID: 23620700]">Levin 2012</a>; <a href="./references#CD013781-bbs2-0024" title="MehtaRH , LeimbergerJD , vanDiepenS , MezaJ , WangA , JankowichR , et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. New England Journal of Medicine2017;376:2032-42. [DOI: 10.1056/NEJMoa1616218]">Mehta 2017</a>; <a href="./references#CD013781-bbs2-0027" title="SharmaP , MalhotraA , GandhiS , GargP , BishnoiA , GandhiH . Preoperative levosimendan in ischemic mitral valve repair. Asian Cardiovascular and Thoracic Annals2014;22:539-45. [DOI: 10.1177/0218492313499352]">Sharma 2014</a>; <a href="./references#CD013781-bbs2-0029" title="TritapepeL , De SantisV , VitaleD , GuarracinoF , PellegriniF , PietropaoliP , et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. British Journal of Anaesthesia2009;102:198-204. [DOI: 10.1093/bja/aen367]">Tritapepe 2009</a>). However, the relative effect was only generated from six included studies (<a href="./references#CD013781-bbs2-0004" title="CholleyB , CarubaT , GrosjeanS , AmourJ , OuattaraA , VillacortaJ , et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA2017;318:548-56. [DOI: 10.1001/jama.2017.9973]">Cholley 2017</a>; <a href="./references#CD013781-bbs2-0021" title="LahtinenP , PitkänenO , PölönenP , TurpeinenA , KiviniemiV , UusaroA . Levosimendan reduces heart failure after cardiac surgery: a prospective, randomized, placebo-controlled trial. Criítical Care Medicine2011;39:2263-70. [DOI: 10.1097/CCM.0b013e3182227b97]">Lahtinen 2011</a>; <a href="./references#CD013781-bbs2-0023" title="LevinR , DegrangeM , Del MazoC , TanusE , PorcileR . Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Experimental and Clinical Cardiology2012;17:125-30. [PMID: 23620700]">Levin 2012</a>; <a href="./references#CD013781-bbs2-0024" title="MehtaRH , LeimbergerJD , vanDiepenS , MezaJ , WangA , JankowichR , et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. New England Journal of Medicine2017;376:2032-42. [DOI: 10.1056/NEJMoa1616218]">Mehta 2017</a>; <a href="./references#CD013781-bbs2-0027" title="SharmaP , MalhotraA , GandhiS , GargP , BishnoiA , GandhiH . Preoperative levosimendan in ischemic mitral valve repair. Asian Cardiovascular and Thoracic Annals2014;22:539-45. [DOI: 10.1177/0218492313499352]">Sharma 2014</a>; <a href="./references#CD013781-bbs2-0029" title="TritapepeL , De SantisV , VitaleD , GuarracinoF , PellegriniF , PietropaoliP , et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. British Journal of Anaesthesia2009;102:198-204. [DOI: 10.1093/bja/aen367]">Tritapepe 2009</a>), while the risk ratio from <a href="./references#CD013781-bbs2-0002" title="AnastasiadisK , AntonitsisP , VranisK , KleontasA , AsteriouC , GrosomanidisV , et al. Effectiveness of prophylactic levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting: a randomized pilot study. Interactive Cardiovascular and Thoracic Surgery2016;23:740-8. [DOI: 10.1093/icvts/ivw213]">Anastasiadis 2016</a> and <a href="./references#CD013781-bbs2-0020" title="KodalliRK , SundarAS , VakamudiM , RavulapaliH , NandipatiS , ChandrasekaranN , et al. Effect of levosimendan on hemodynamic changes in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled study. Annals of Cardiac Anaesthesia2013;16:94-9. [DOI: 10.4103/0971-9784.109737]">Kodalli 2013</a> was not estimable due to no events being observed in either group. Eight studies reported on non‐embolic stroke/transient ischaemic attack (<a href="./references#CD013781-bbs2-0002" title="AnastasiadisK , AntonitsisP , VranisK , KleontasA , AsteriouC , GrosomanidisV , et al. Effectiveness of prophylactic levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting: a randomized pilot study. Interactive Cardiovascular and Thoracic Surgery2016;23:740-8. [DOI: 10.1093/icvts/ivw213]">Anastasiadis 2016</a>; <a href="./references#CD013781-bbs2-0004" title="CholleyB , CarubaT , GrosjeanS , AmourJ , OuattaraA , VillacortaJ , et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA2017;318:548-56. [DOI: 10.1001/jama.2017.9973]">Cholley 2017</a>; <a href="./references#CD013781-bbs2-0020" title="KodalliRK , SundarAS , VakamudiM , RavulapaliH , NandipatiS , ChandrasekaranN , et al. Effect of levosimendan on hemodynamic changes in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled study. Annals of Cardiac Anaesthesia2013;16:94-9. [DOI: 10.4103/0971-9784.109737]">Kodalli 2013</a>; <a href="./references#CD013781-bbs2-0021" title="LahtinenP , PitkänenO , PölönenP , TurpeinenA , KiviniemiV , UusaroA . Levosimendan reduces heart failure after cardiac surgery: a prospective, randomized, placebo-controlled trial. Criítical Care Medicine2011;39:2263-70. [DOI: 10.1097/CCM.0b013e3182227b97]">Lahtinen 2011</a>; <a href="./references#CD013781-bbs2-0023" title="LevinR , DegrangeM , Del MazoC , TanusE , PorcileR . Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Experimental and Clinical Cardiology2012;17:125-30. [PMID: 23620700]">Levin 2012</a>; <a href="./references#CD013781-bbs2-0024" title="MehtaRH , LeimbergerJD , vanDiepenS , MezaJ , WangA , JankowichR , et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. New England Journal of Medicine2017;376:2032-42. [DOI: 10.1056/NEJMoa1616218]">Mehta 2017</a>; <a href="./references#CD013781-bbs2-0026" title="ShahB , SharmaP , BrahmbhattA , ShahR , RathodB , ShastriN , et al. Study of levosimendan during off-pump coronary artery bypass grafting in patients with LV dysfunction: a double-blind randomized study. Indian Journal of Pharmacology2014;46:29-34. [DOI: 10.4103/0253-7613.125161]">Shah 2014</a>; <a href="./references#CD013781-bbs2-0027" title="SharmaP , MalhotraA , GandhiS , GargP , BishnoiA , GandhiH . Preoperative levosimendan in ischemic mitral valve repair. Asian Cardiovascular and Thoracic Annals2014;22:539-45. [DOI: 10.1177/0218492313499352]">Sharma 2014</a>). Similar to atrial fibrillation and cardiogenic shock, only <a href="./references#CD013781-bbs2-0020" title="KodalliRK , SundarAS , VakamudiM , RavulapaliH , NandipatiS , ChandrasekaranN , et al. Effect of levosimendan on hemodynamic changes in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled study. Annals of Cardiac Anaesthesia2013;16:94-9. [DOI: 10.4103/0971-9784.109737]">Kodalli 2013</a> was unable to provide the risk ratio due to no events being observed in either group. <a href="./references#CD013781-bbs2-0008" title="ErbJ , BeutlhauserT , FeldheiserA , SchusterB , TreskatschS , GrubitzschH , et al. Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery. Journal of International Medical Research2014;42:750-64. [DOI: 10.1177/0300060513516293]">Erb 2014</a> narratively reported that the rates of any serious adverse events were significantly reduced in the levosimendan group compared with the placebo group. </p> <p>When levosimendan was compared to the control group, there was little to no difference in all four adverse events. Twenty‐five out of 610 participants suffered from cardiogenic shock in the levosimendan group compared to 38 out of 602 in the control group (RR 0.65, 95% CI 0.40 to 1.05; 1212 participants, 3 studies; high‐certainty evidence; low heterogeneity) (<a href="./references#CD013781-fig-0077" title="">Analysis 7.3</a>; <a href="./full#CD013781-tbl-0002">summary of findings Table 2</a>). There were 375 out of 971 patients suffering from atrial fibrillation in the levosimendan intervention group compared with 356 out of 963 in the placebo control group (RR 1.02, 95% CI 0.82 to 1.27; 1934 participants, 11 studies; low‐certainty evidence; substantial heterogeneity, indication of reporting bias) (<a href="./references#CD013781-fig-0078" title="">Analysis 7.4</a>; <a href="#CD013781-fig-0005">Figure 5</a>). Eighty‐six out 924 participants were afflicted with perioperative myocardial infarction in the levosimendan group compared to 94 out of 914 participants in the control group (RR 0.89, 95% CI 0.61 to 1.31; 1838 participants, 8 studies; moderate‐certainty evidence; low heterogeneity) (<a href="./references#CD013781-fig-0079" title="">Analysis 7.5</a>). There were 36 out of 897 participants suffering from non‐embolic stroke/transient ischaemic attack in the levosimendan group compared to 44 out of 889 participants in the control group (RR 0.89, 95% CI 0.58 to 1.38; 1786 participants, 8 studies; moderate‐certainty evidence; low heterogeneity) (<a href="./references#CD013781-fig-0080" title="">Analysis 7.6</a>). </p> <div class="figure" id="CD013781-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="original image" data-id="CD013781-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> </section> </section> <section id="CD013781-sec-0151"> <h5 class="title">Secondary outcomes</h5> <section id="CD013781-sec-0152"> <h6 class="title">Length of in‐hospital and intensive care unit stay</h6> <p>There were six studies reporting the mean length of stay in hospital (<a href="./references#CD013781-bbs2-0002" title="AnastasiadisK , AntonitsisP , VranisK , KleontasA , AsteriouC , GrosomanidisV , et al. Effectiveness of prophylactic levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting: a randomized pilot study. Interactive Cardiovascular and Thoracic Surgery2016;23:740-8. [DOI: 10.1093/icvts/ivw213]">Anastasiadis 2016</a>; <a href="./references#CD013781-bbs2-0021" title="LahtinenP , PitkänenO , PölönenP , TurpeinenA , KiviniemiV , UusaroA . Levosimendan reduces heart failure after cardiac surgery: a prospective, randomized, placebo-controlled trial. Criítical Care Medicine2011;39:2263-70. [DOI: 10.1097/CCM.0b013e3182227b97]">Lahtinen 2011</a>; <a href="./references#CD013781-bbs2-0022" title="LeppikangasH , JärveläK , SistoT , MaaranenP , VirtanenM , LehtoP , et al. Preoperative levosimendan infusion in combined aortic valve and coronary bypass surgery. British Journal of Anaesthesia2011;106:298-304. [DOI: 10.1093/bja/aeq402]">Leppikangas 2011</a>; <a href="./references#CD013781-bbs2-0027" title="SharmaP , MalhotraA , GandhiS , GargP , BishnoiA , GandhiH . Preoperative levosimendan in ischemic mitral valve repair. Asian Cardiovascular and Thoracic Annals2014;22:539-45. [DOI: 10.1177/0218492313499352]">Sharma 2014</a>; <a href="./references#CD013781-bbs2-0028" title="TritapepeL , De SantisV , VitaleD , SantulliM , MorelliA , NofroniI , et al. Preconditioning effects of levosimendan in coronary artery bypass grafting - a pilot study. British Journal of Anaesthesia2006;96:694-700. [DOI: 10.1093/bja/ael082]">Tritapepe 2006</a>; <a href="./references#CD013781-bbs2-0029" title="TritapepeL , De SantisV , VitaleD , GuarracinoF , PellegriniF , PietropaoliP , et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. British Journal of Anaesthesia2009;102:198-204. [DOI: 10.1093/bja/aen367]">Tritapepe 2009</a>). All showed a similar trend of an observed lower mean length of stay in hospital among patients in the levosimendan group compared to the control group. Altogether, the meta‐analysis revealed a difference in the mean length of stay in hospital between groups, favouring the levosimendan intervention group (mean difference ‐1.80, 95% CI ‐3.27 to ‐0.33; 422 participants, 6 studies; considerable heterogeneity) (<a href="./references#CD013781-fig-0081" title="">Analysis 7.7</a>). IQR data were reported by <a href="./references#CD013781-bbs2-0004" title="CholleyB , CarubaT , GrosjeanS , AmourJ , OuattaraA , VillacortaJ , et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA2017;318:548-56. [DOI: 10.1001/jama.2017.9973]">Cholley 2017</a> and <a href="./references#CD013781-bbs2-0008" title="ErbJ , BeutlhauserT , FeldheiserA , SchusterB , TreskatschS , GrubitzschH , et al. Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery. Journal of International Medical Research2014;42:750-64. [DOI: 10.1177/0300060513516293]">Erb 2014</a>. While <a href="./references#CD013781-bbs2-0004" title="CholleyB , CarubaT , GrosjeanS , AmourJ , OuattaraA , VillacortaJ , et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA2017;318:548-56. [DOI: 10.1001/jama.2017.9973]">Cholley 2017</a> reported identical lengths of hospital stay for both groups (7 (IQR 5 to 10) days), <a href="./references#CD013781-bbs2-0008" title="ErbJ , BeutlhauserT , FeldheiserA , SchusterB , TreskatschS , GrubitzschH , et al. Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery. Journal of International Medical Research2014;42:750-64. [DOI: 10.1177/0300060513516293]">Erb 2014</a> observed a lower median length of stay in hospital in the levosimendan group compared to the placebo group (12 (IQR 10.25 to 21.75) versus 13.5 (IQR 10.25 to 21.5) days). </p> <p>The relative effect of levosimendan compared to placebo on length of intensive care stay was generated from seven included studies (<a href="./references#CD013781-bbs2-0002" title="AnastasiadisK , AntonitsisP , VranisK , KleontasA , AsteriouC , GrosomanidisV , et al. Effectiveness of prophylactic levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting: a randomized pilot study. Interactive Cardiovascular and Thoracic Surgery2016;23:740-8. [DOI: 10.1093/icvts/ivw213]">Anastasiadis 2016</a>; <a href="./references#CD013781-bbs2-0014" title="HuX , XuQ . Application of levosimendan in severe patients after cardiac surgery. Chinese Journal of Clinical Pharmacology and Therapeutics2020;25:1027-32. [DOI: 10.12092/j.issn.1009-2501.2020.09.010]">Hu 2020</a>; <a href="./references#CD013781-bbs2-0020" title="KodalliRK , SundarAS , VakamudiM , RavulapaliH , NandipatiS , ChandrasekaranN , et al. Effect of levosimendan on hemodynamic changes in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled study. Annals of Cardiac Anaesthesia2013;16:94-9. [DOI: 10.4103/0971-9784.109737]">Kodalli 2013</a>; <a href="./references#CD013781-bbs2-0022" title="LeppikangasH , JärveläK , SistoT , MaaranenP , VirtanenM , LehtoP , et al. Preoperative levosimendan infusion in combined aortic valve and coronary bypass surgery. British Journal of Anaesthesia2011;106:298-304. [DOI: 10.1093/bja/aeq402]">Leppikangas 2011</a>; <a href="./references#CD013781-bbs2-0027" title="SharmaP , MalhotraA , GandhiS , GargP , BishnoiA , GandhiH . Preoperative levosimendan in ischemic mitral valve repair. Asian Cardiovascular and Thoracic Annals2014;22:539-45. [DOI: 10.1177/0218492313499352]">Sharma 2014</a>; <a href="./references#CD013781-bbs2-0028" title="TritapepeL , De SantisV , VitaleD , SantulliM , MorelliA , NofroniI , et al. Preconditioning effects of levosimendan in coronary artery bypass grafting - a pilot study. British Journal of Anaesthesia2006;96:694-700. [DOI: 10.1093/bja/ael082]">Tritapepe 2006</a>; <a href="./references#CD013781-bbs2-0029" title="TritapepeL , De SantisV , VitaleD , GuarracinoF , PellegriniF , PietropaoliP , et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. British Journal of Anaesthesia2009;102:198-204. [DOI: 10.1093/bja/aen367]">Tritapepe 2009</a>). In these studies, the mean length of stay in intensive care varied from 1.07 to 8.15 days in the placebo control group. All reported a lower mean length of stay observed in the levosimendan intervention group compared to the control group. Accordingly, the meta‐analysis revealed a difference in the mean length of stay in intensive care between groups, favouring the levosimendan group (mean difference ‐1.00, 95% CI ‐1.63 to ‐0.37; 572 participants, 7 studies; very low‐certainty evidence; considerable heterogeneity) (<a href="./references#CD013781-fig-0082" title="">Analysis 7.8</a>; <a href="./full#CD013781-tbl-0002">summary of findings Table 2</a>). In five studies, information on length of stay in intensive care was restricted to IQR data. For this, <a href="./references#CD013781-bbs2-0004" title="CholleyB , CarubaT , GrosjeanS , AmourJ , OuattaraA , VillacortaJ , et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA2017;318:548-56. [DOI: 10.1001/jama.2017.9973]">Cholley 2017</a>, <a href="./references#CD013781-bbs2-0009" title="RikssonHI , JalonenJR , HeikkinenLO , KivikkoM , LaineM , LeinoKA , et al. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Cardiothoracic Anesthesiology2009;87:448-54. [DOI: 10.1016/j.athoracsur.2008.10.029]">Eriksson 2009</a>, and <a href="./references#CD013781-bbs2-0024" title="MehtaRH , LeimbergerJD , vanDiepenS , MezaJ , WangA , JankowichR , et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. New England Journal of Medicine2017;376:2032-42. [DOI: 10.1056/NEJMoa1616218]">Mehta 2017</a> reported a similar length of stay in both study groups (<a href="./references#CD013781-bbs2-0004" title="CholleyB , CarubaT , GrosjeanS , AmourJ , OuattaraA , VillacortaJ , et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA2017;318:548-56. [DOI: 10.1001/jama.2017.9973]">Cholley 2017</a>: 4 (IQR 2 to 7) versus 4 (IQR 3 to 6) days; <a href="./references#CD013781-bbs2-0009" title="RikssonHI , JalonenJR , HeikkinenLO , KivikkoM , LaineM , LeinoKA , et al. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Cardiothoracic Anesthesiology2009;87:448-54. [DOI: 10.1016/j.athoracsur.2008.10.029]">Eriksson 2009</a>: 2 (IQR 1 to 33) versus 2 (IQR 1 to 31) days; <a href="./references#CD013781-bbs2-0024" title="MehtaRH , LeimbergerJD , vanDiepenS , MezaJ , WangA , JankowichR , et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. New England Journal of Medicine2017;376:2032-42. [DOI: 10.1056/NEJMoa1616218]">Mehta 2017</a>: 2.8 (IQR 1.6 to 4.8) versus 2.9 (IQR 1.8 to 4.9) days). However, <a href="./references#CD013781-bbs2-0008" title="ErbJ , BeutlhauserT , FeldheiserA , SchusterB , TreskatschS , GrubitzschH , et al. Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery. Journal of International Medical Research2014;42:750-64. [DOI: 10.1177/0300060513516293]">Erb 2014</a> observed a length of stay in intensive care of 3.0 (IQR 1.5 to 7.0) days in the levosimendan group compared with 5.0 (IQR 4.0 to 13.8) days in the placebo group, and <a href="./references#CD013781-bbs2-0017" title="Juhl-OlsenP , Jakobsen C-J, RasmussenLA , BhavsarR , Klaaborg K-E, FrederiksenCA , et al. Effects of levosimendan in patients with left ventricular hypertrophy undergoing aortic valve replacement. Acta Anaesthesiologica Scandinavica2015;59:65-77. [DOI: 10.1111/aas.12425]">Juhl‐Olsen 2015</a> reported a length of stay in intensive care of 0.79 (IQR 0.65 to 1.28) days in the levosimendan group compared with 0.83 (IQR 0.75 to 5.80) days in the placebo group. <a href="./references#CD013781-bbs2-0015" title="JärveläK , MaaranenP , SistoT , RuokonenE . Levosimendan in aortic valve surgery: cardiac performance and recovery. Journal of Cardiothoracic and Vascular Anesthesia2008;22:693-8. [DOI: 10.1053/j.jvca.2008.01.024]">Jävelä 2008</a> narratively stated that length of stay was similar between study groups. </p> </section> <section id="CD013781-sec-0153"> <h6 class="title">Haemodynamics (cardiac index, MAP, PCWP)</h6> <p>Quantitative information on mean cardiac index was provided by <a href="./references#CD013781-bbs2-0002" title="AnastasiadisK , AntonitsisP , VranisK , KleontasA , AsteriouC , GrosomanidisV , et al. Effectiveness of prophylactic levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting: a randomized pilot study. Interactive Cardiovascular and Thoracic Surgery2016;23:740-8. [DOI: 10.1093/icvts/ivw213]">Anastasiadis 2016</a>, <a href="./references#CD013781-bbs2-0014" title="HuX , XuQ . Application of levosimendan in severe patients after cardiac surgery. Chinese Journal of Clinical Pharmacology and Therapeutics2020;25:1027-32. [DOI: 10.12092/j.issn.1009-2501.2020.09.010]">Hu 2020</a>, <a href="./references#CD013781-bbs2-0015" title="JärveläK , MaaranenP , SistoT , RuokonenE . Levosimendan in aortic valve surgery: cardiac performance and recovery. Journal of Cardiothoracic and Vascular Anesthesia2008;22:693-8. [DOI: 10.1053/j.jvca.2008.01.024]">Jävelä 2008</a>, <a href="./references#CD013781-bbs2-0020" title="KodalliRK , SundarAS , VakamudiM , RavulapaliH , NandipatiS , ChandrasekaranN , et al. Effect of levosimendan on hemodynamic changes in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled study. Annals of Cardiac Anaesthesia2013;16:94-9. [DOI: 10.4103/0971-9784.109737]">Kodalli 2013</a>, and <a href="./references#CD013781-bbs2-0026" title="ShahB , SharmaP , BrahmbhattA , ShahR , RathodB , ShastriN , et al. Study of levosimendan during off-pump coronary artery bypass grafting in patients with LV dysfunction: a double-blind randomized study. Indian Journal of Pharmacology2014;46:29-34. [DOI: 10.4103/0253-7613.125161]">Shah 2014</a>. Little to no difference in mean cardiac index between the levosimendan intervention group and the placebo control group was reported by these studies at baseline with ‐0.04 (95% CI ‐0.17 to 0.10; 456 participants, 5 studies; moderate heterogeneity) and at end of surgery with 0.67 (95% CI ‐0.20 to 1.53; 74 participants, 2 studies; considerable heterogeneity) as reported by <a href="./references#CD013781-bbs2-0015" title="JärveläK , MaaranenP , SistoT , RuokonenE . Levosimendan in aortic valve surgery: cardiac performance and recovery. Journal of Cardiothoracic and Vascular Anesthesia2008;22:693-8. [DOI: 10.1053/j.jvca.2008.01.024]">Jävelä 2008</a> and <a href="./references#CD013781-bbs2-0026" title="ShahB , SharmaP , BrahmbhattA , ShahR , RathodB , ShastriN , et al. Study of levosimendan during off-pump coronary artery bypass grafting in patients with LV dysfunction: a double-blind randomized study. Indian Journal of Pharmacology2014;46:29-34. [DOI: 10.4103/0253-7613.125161]">Shah 2014</a> (<a href="./references#CD013781-fig-0083" title="">Analysis 7.9</a>). However, there were differences in mean cardiac index between groups at 6 hours, 12 hours, and 24 hours after surgery that were all favourable to levosimendan (<a href="./references#CD013781-fig-0083" title="">Analysis 7.9</a>). For example, <a href="./references#CD013781-bbs2-0015" title="JärveläK , MaaranenP , SistoT , RuokonenE . Levosimendan in aortic valve surgery: cardiac performance and recovery. Journal of Cardiothoracic and Vascular Anesthesia2008;22:693-8. [DOI: 10.1053/j.jvca.2008.01.024]">Jävelä 2008</a> and <a href="./references#CD013781-bbs2-0020" title="KodalliRK , SundarAS , VakamudiM , RavulapaliH , NandipatiS , ChandrasekaranN , et al. Effect of levosimendan on hemodynamic changes in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled study. Annals of Cardiac Anaesthesia2013;16:94-9. [DOI: 10.4103/0971-9784.109737]">Kodalli 2013</a> reported that the mean difference in cardiac index between groups at 6 hours after surgery was 0.68 (95% CI 0.28 to 1.09; 54 participants, 2 studies; low heterogeneity). In addition, <a href="./references#CD013781-bbs2-0015" title="JärveläK , MaaranenP , SistoT , RuokonenE . Levosimendan in aortic valve surgery: cardiac performance and recovery. Journal of Cardiothoracic and Vascular Anesthesia2008;22:693-8. [DOI: 10.1053/j.jvca.2008.01.024]">Jävelä 2008</a>, <a href="./references#CD013781-bbs2-0020" title="KodalliRK , SundarAS , VakamudiM , RavulapaliH , NandipatiS , ChandrasekaranN , et al. Effect of levosimendan on hemodynamic changes in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled study. Annals of Cardiac Anaesthesia2013;16:94-9. [DOI: 10.4103/0971-9784.109737]">Kodalli 2013</a>, and <a href="./references#CD013781-bbs2-0026" title="ShahB , SharmaP , BrahmbhattA , ShahR , RathodB , ShastriN , et al. Study of levosimendan during off-pump coronary artery bypass grafting in patients with LV dysfunction: a double-blind randomized study. Indian Journal of Pharmacology2014;46:29-34. [DOI: 10.4103/0253-7613.125161]">Shah 2014</a> reported a mean difference in cardiac index between groups at 12 hours after surgery of 0.73 (95% CI 0.23 to 1.23; 104 participants, 3 studies; substantial heterogeneity). Moreover, all included studies reported that the mean difference in cardiac index between groups at 24 hours after surgery was 0.51 (95% CI 0.06 to 0.96; 456 participants, 5 studies; considerable heterogeneity). There was narrative information on cardiac index from <a href="./references#CD013781-bbs2-0008" title="ErbJ , BeutlhauserT , FeldheiserA , SchusterB , TreskatschS , GrubitzschH , et al. Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery. Journal of International Medical Research2014;42:750-64. [DOI: 10.1177/0300060513516293]">Erb 2014</a>, <a href="./references#CD013781-bbs2-0009" title="RikssonHI , JalonenJR , HeikkinenLO , KivikkoM , LaineM , LeinoKA , et al. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Cardiothoracic Anesthesiology2009;87:448-54. [DOI: 10.1016/j.athoracsur.2008.10.029]">Eriksson 2009</a>, <a href="./references#CD013781-bbs2-0017" title="Juhl-OlsenP , Jakobsen C-J, RasmussenLA , BhavsarR , Klaaborg K-E, FrederiksenCA , et al. Effects of levosimendan in patients with left ventricular hypertrophy undergoing aortic valve replacement. Acta Anaesthesiologica Scandinavica2015;59:65-77. [DOI: 10.1111/aas.12425]">Juhl‐Olsen 2015</a>, <a href="./references#CD013781-bbs2-0021" title="LahtinenP , PitkänenO , PölönenP , TurpeinenA , KiviniemiV , UusaroA . Levosimendan reduces heart failure after cardiac surgery: a prospective, randomized, placebo-controlled trial. Criítical Care Medicine2011;39:2263-70. [DOI: 10.1097/CCM.0b013e3182227b97]">Lahtinen 2011</a>, <a href="./references#CD013781-bbs2-0022" title="LeppikangasH , JärveläK , SistoT , MaaranenP , VirtanenM , LehtoP , et al. Preoperative levosimendan infusion in combined aortic valve and coronary bypass surgery. British Journal of Anaesthesia2011;106:298-304. [DOI: 10.1093/bja/aeq402]">Leppikangas 2011</a>, <a href="./references#CD013781-bbs2-0023" title="LevinR , DegrangeM , Del MazoC , TanusE , PorcileR . Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Experimental and Clinical Cardiology2012;17:125-30. [PMID: 23620700]">Levin 2012</a>, <a href="./references#CD013781-bbs2-0027" title="SharmaP , MalhotraA , GandhiS , GargP , BishnoiA , GandhiH . Preoperative levosimendan in ischemic mitral valve repair. Asian Cardiovascular and Thoracic Annals2014;22:539-45. [DOI: 10.1177/0218492313499352]">Sharma 2014</a>, and <a href="./references#CD013781-bbs2-0029" title="TritapepeL , De SantisV , VitaleD , GuarracinoF , PellegriniF , PietropaoliP , et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. British Journal of Anaesthesia2009;102:198-204. [DOI: 10.1093/bja/aen367]">Tritapepe 2009</a>. For this, <a href="./references#CD013781-bbs2-0008" title="ErbJ , BeutlhauserT , FeldheiserA , SchusterB , TreskatschS , GrubitzschH , et al. Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery. Journal of International Medical Research2014;42:750-64. [DOI: 10.1177/0300060513516293]">Erb 2014</a> and <a href="./references#CD013781-bbs2-0022" title="LeppikangasH , JärveläK , SistoT , MaaranenP , VirtanenM , LehtoP , et al. Preoperative levosimendan infusion in combined aortic valve and coronary bypass surgery. British Journal of Anaesthesia2011;106:298-304. [DOI: 10.1093/bja/aeq402]">Leppikangas 2011</a> observed no significant differences between study groups. All other studies described higher values in the levosimendan intervention group compared to the placebo control group, which were said to be significant in <a href="./references#CD013781-bbs2-0009" title="RikssonHI , JalonenJR , HeikkinenLO , KivikkoM , LaineM , LeinoKA , et al. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Cardiothoracic Anesthesiology2009;87:448-54. [DOI: 10.1016/j.athoracsur.2008.10.029]">Eriksson 2009</a> (at end of surgery and at 8 hours after declamping aorta), <a href="./references#CD013781-bbs2-0021" title="LahtinenP , PitkänenO , PölönenP , TurpeinenA , KiviniemiV , UusaroA . Levosimendan reduces heart failure after cardiac surgery: a prospective, randomized, placebo-controlled trial. Criítical Care Medicine2011;39:2263-70. [DOI: 10.1097/CCM.0b013e3182227b97]">Lahtinen 2011</a> (postoperative measurements), <a href="./references#CD013781-bbs2-0023" title="LevinR , DegrangeM , Del MazoC , TanusE , PorcileR . Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Experimental and Clinical Cardiology2012;17:125-30. [PMID: 23620700]">Levin 2012</a> (immediately following administration of the levosimendan loading dose until 48 hours postoperatively) and <a href="./references#CD013781-bbs2-0029" title="TritapepeL , De SantisV , VitaleD , GuarracinoF , PellegriniF , PietropaoliP , et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. British Journal of Anaesthesia2009;102:198-204. [DOI: 10.1093/bja/aen367]">Tritapepe 2009</a> (after surgery). <a href="./references#CD013781-bbs2-0028" title="TritapepeL , De SantisV , VitaleD , SantulliM , MorelliA , NofroniI , et al. Preconditioning effects of levosimendan in coronary artery bypass grafting - a pilot study. British Journal of Anaesthesia2006;96:694-700. [DOI: 10.1093/bja/ael082]">Tritapepe 2006</a> provided IQR data that revealed a higher median cardiac index in the levosimendan group compared to the placebo group after surgery (baseline: 2.3 (IQR 2.0 to 2.6) versus 2.4 (IQR 2.1 to 2.7) mmHg); end of surgery: 2.3 (IQR 2.2 to 2.5) versus 2.1 (IQR 1.9 to 2.3) mmHg; 6 hours after surgery: 2.9 (IQR 2.5 to 3.1) versus 2.4 (IQR 2.3 to 2.8) mmHg; 24 hours after surgery: 3.0 (IQR 2.7 to 3.4) versus 2.7 (IQR 2.3 to 2.8) mmHg). </p> <p>There was a difference in mean MAP between the levosimendan intervention group and the placebo control group at 6 hours after surgery as reported by <a href="./references#CD013781-bbs2-0014" title="HuX , XuQ . Application of levosimendan in severe patients after cardiac surgery. Chinese Journal of Clinical Pharmacology and Therapeutics2020;25:1027-32. [DOI: 10.12092/j.issn.1009-2501.2020.09.010]">Hu 2020</a>, <a href="./references#CD013781-bbs2-0015" title="JärveläK , MaaranenP , SistoT , RuokonenE . Levosimendan in aortic valve surgery: cardiac performance and recovery. Journal of Cardiothoracic and Vascular Anesthesia2008;22:693-8. [DOI: 10.1053/j.jvca.2008.01.024]">Jävelä 2008</a>, and <a href="./references#CD013781-bbs2-0020" title="KodalliRK , SundarAS , VakamudiM , RavulapaliH , NandipatiS , ChandrasekaranN , et al. Effect of levosimendan on hemodynamic changes in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled study. Annals of Cardiac Anaesthesia2013;16:94-9. [DOI: 10.4103/0971-9784.109737]">Kodalli 2013</a> with ‐4.81 (95% CI ‐6.08 to ‐3.55; 374 participants, 3 studies; low heterogeneity) (<a href="./references#CD013781-fig-0084" title="">Analysis 7.10</a>). However, no evidence of a difference was observed between groups at baseline, end of surgery, 12 hours, and 24 hours after surgery (<a href="./references#CD013781-fig-0084" title="">Analysis 7.10</a>). For instance, <a href="./references#CD013781-bbs2-0002" title="AnastasiadisK , AntonitsisP , VranisK , KleontasA , AsteriouC , GrosomanidisV , et al. Effectiveness of prophylactic levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting: a randomized pilot study. Interactive Cardiovascular and Thoracic Surgery2016;23:740-8. [DOI: 10.1093/icvts/ivw213]">Anastasiadis 2016</a>, <a href="./references#CD013781-bbs2-0009" title="RikssonHI , JalonenJR , HeikkinenLO , KivikkoM , LaineM , LeinoKA , et al. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Cardiothoracic Anesthesiology2009;87:448-54. [DOI: 10.1016/j.athoracsur.2008.10.029]">Eriksson 2009</a>, <a href="./references#CD013781-bbs2-0015" title="JärveläK , MaaranenP , SistoT , RuokonenE . Levosimendan in aortic valve surgery: cardiac performance and recovery. Journal of Cardiothoracic and Vascular Anesthesia2008;22:693-8. [DOI: 10.1053/j.jvca.2008.01.024]">Jävelä 2008</a>, and <a href="./references#CD013781-bbs2-0020" title="KodalliRK , SundarAS , VakamudiM , RavulapaliH , NandipatiS , ChandrasekaranN , et al. Effect of levosimendan on hemodynamic changes in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled study. Annals of Cardiac Anaesthesia2013;16:94-9. [DOI: 10.4103/0971-9784.109737]">Kodalli 2013</a> reported that the mean difference between groups at baseline was 2.91 (95% CI ‐3.19 to 9.01; 146 participants, 4 studies; moderate heterogeneity). Moreover, three studies, <a href="./references#CD013781-bbs2-0009" title="RikssonHI , JalonenJR , HeikkinenLO , KivikkoM , LaineM , LeinoKA , et al. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Cardiothoracic Anesthesiology2009;87:448-54. [DOI: 10.1016/j.athoracsur.2008.10.029]">Eriksson 2009</a>, <a href="./references#CD013781-bbs2-0014" title="HuX , XuQ . Application of levosimendan in severe patients after cardiac surgery. Chinese Journal of Clinical Pharmacology and Therapeutics2020;25:1027-32. [DOI: 10.12092/j.issn.1009-2501.2020.09.010]">Hu 2020</a>, and <a href="./references#CD013781-bbs2-0015" title="JärveläK , MaaranenP , SistoT , RuokonenE . Levosimendan in aortic valve surgery: cardiac performance and recovery. Journal of Cardiothoracic and Vascular Anesthesia2008;22:693-8. [DOI: 10.1053/j.jvca.2008.01.024]">Jävelä 2008</a>, reported that the mean difference between groups at end of surgery was ‐2.06 (95% CI ‐6.50 to 2.38; 404 participants, 3 studies; substantial heterogeneity). In addition, <a href="./references#CD013781-bbs2-0014" title="HuX , XuQ . Application of levosimendan in severe patients after cardiac surgery. Chinese Journal of Clinical Pharmacology and Therapeutics2020;25:1027-32. [DOI: 10.12092/j.issn.1009-2501.2020.09.010]">Hu 2020</a>, <a href="./references#CD013781-bbs2-0015" title="JärveläK , MaaranenP , SistoT , RuokonenE . Levosimendan in aortic valve surgery: cardiac performance and recovery. Journal of Cardiothoracic and Vascular Anesthesia2008;22:693-8. [DOI: 10.1053/j.jvca.2008.01.024]">Jävelä 2008</a>, and <a href="./references#CD013781-bbs2-0020" title="KodalliRK , SundarAS , VakamudiM , RavulapaliH , NandipatiS , ChandrasekaranN , et al. Effect of levosimendan on hemodynamic changes in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled study. Annals of Cardiac Anaesthesia2013;16:94-9. [DOI: 10.4103/0971-9784.109737]">Kodalli 2013</a> reported that the mean difference between groups at 12 hours after surgery was ‐4.57 (95% CI ‐9.19 to 0.05; 374 participants, 3 studies; moderate heterogeneity). At 12 hours after surgery, five studies found that the mean difference between groups was ‐2.19 (95% CI ‐5.84 to 1.46; 466 participants, 5 studies; moderate heterogeneity) (<a href="./references#CD013781-bbs2-0002" title="AnastasiadisK , AntonitsisP , VranisK , KleontasA , AsteriouC , GrosomanidisV , et al. Effectiveness of prophylactic levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting: a randomized pilot study. Interactive Cardiovascular and Thoracic Surgery2016;23:740-8. [DOI: 10.1093/icvts/ivw213]">Anastasiadis 2016</a>; <a href="./references#CD013781-bbs2-0009" title="RikssonHI , JalonenJR , HeikkinenLO , KivikkoM , LaineM , LeinoKA , et al. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Cardiothoracic Anesthesiology2009;87:448-54. [DOI: 10.1016/j.athoracsur.2008.10.029]">Eriksson 2009</a>; <a href="./references#CD013781-bbs2-0014" title="HuX , XuQ . Application of levosimendan in severe patients after cardiac surgery. Chinese Journal of Clinical Pharmacology and Therapeutics2020;25:1027-32. [DOI: 10.12092/j.issn.1009-2501.2020.09.010]">Hu 2020</a>; <a href="./references#CD013781-bbs2-0015" title="JärveläK , MaaranenP , SistoT , RuokonenE . Levosimendan in aortic valve surgery: cardiac performance and recovery. Journal of Cardiothoracic and Vascular Anesthesia2008;22:693-8. [DOI: 10.1053/j.jvca.2008.01.024]">Jävelä 2008</a>; <a href="./references#CD013781-bbs2-0020" title="KodalliRK , SundarAS , VakamudiM , RavulapaliH , NandipatiS , ChandrasekaranN , et al. Effect of levosimendan on hemodynamic changes in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled study. Annals of Cardiac Anaesthesia2013;16:94-9. [DOI: 10.4103/0971-9784.109737]">Kodalli 2013</a>). Narrative information on MAP was given by <a href="./references#CD013781-bbs2-0008" title="ErbJ , BeutlhauserT , FeldheiserA , SchusterB , TreskatschS , GrubitzschH , et al. Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery. Journal of International Medical Research2014;42:750-64. [DOI: 10.1177/0300060513516293]">Erb 2014</a>; <a href="./references#CD013781-bbs2-0017" title="Juhl-OlsenP , Jakobsen C-J, RasmussenLA , BhavsarR , Klaaborg K-E, FrederiksenCA , et al. Effects of levosimendan in patients with left ventricular hypertrophy undergoing aortic valve replacement. Acta Anaesthesiologica Scandinavica2015;59:65-77. [DOI: 10.1111/aas.12425]">Juhl‐Olsen 2015</a>; <a href="./references#CD013781-bbs2-0022" title="LeppikangasH , JärveläK , SistoT , MaaranenP , VirtanenM , LehtoP , et al. Preoperative levosimendan infusion in combined aortic valve and coronary bypass surgery. British Journal of Anaesthesia2011;106:298-304. [DOI: 10.1093/bja/aeq402]">Leppikangas 2011</a>; <a href="./references#CD013781-bbs2-0027" title="SharmaP , MalhotraA , GandhiS , GargP , BishnoiA , GandhiH . Preoperative levosimendan in ischemic mitral valve repair. Asian Cardiovascular and Thoracic Annals2014;22:539-45. [DOI: 10.1177/0218492313499352]">Sharma 2014</a>, and <a href="./references#CD013781-bbs2-0029" title="TritapepeL , De SantisV , VitaleD , GuarracinoF , PellegriniF , PietropaoliP , et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. British Journal of Anaesthesia2009;102:198-204. [DOI: 10.1093/bja/aen367]">Tritapepe 2009</a>. Whereas <a href="./references#CD013781-bbs2-0008" title="ErbJ , BeutlhauserT , FeldheiserA , SchusterB , TreskatschS , GrubitzschH , et al. Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery. Journal of International Medical Research2014;42:750-64. [DOI: 10.1177/0300060513516293]">Erb 2014</a>, <a href="./references#CD013781-bbs2-0017" title="Juhl-OlsenP , Jakobsen C-J, RasmussenLA , BhavsarR , Klaaborg K-E, FrederiksenCA , et al. Effects of levosimendan in patients with left ventricular hypertrophy undergoing aortic valve replacement. Acta Anaesthesiologica Scandinavica2015;59:65-77. [DOI: 10.1111/aas.12425]">Juhl‐Olsen 2015</a>, and <a href="./references#CD013781-bbs2-0022" title="LeppikangasH , JärveläK , SistoT , MaaranenP , VirtanenM , LehtoP , et al. Preoperative levosimendan infusion in combined aortic valve and coronary bypass surgery. British Journal of Anaesthesia2011;106:298-304. [DOI: 10.1093/bja/aeq402]">Leppikangas 2011</a> documented no significant difference in MAP between groups during the study period, <a href="./references#CD013781-bbs2-0029" title="TritapepeL , De SantisV , VitaleD , GuarracinoF , PellegriniF , PietropaoliP , et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. British Journal of Anaesthesia2009;102:198-204. [DOI: 10.1093/bja/aen367]">Tritapepe 2009</a> stated that after surgery there were significantly higher values of MAP in those treated with levosimendan. Likewise, <a href="./references#CD013781-bbs2-0027" title="SharmaP , MalhotraA , GandhiS , GargP , BishnoiA , GandhiH . Preoperative levosimendan in ischemic mitral valve repair. Asian Cardiovascular and Thoracic Annals2014;22:539-45. [DOI: 10.1177/0218492313499352]">Sharma 2014</a> noted that the levosimendan group showed better MAP in both intra‐ and postoperative periods, and that the difference was statistically significant at all time points without providing quantitative data. <a href="./references#CD013781-bbs2-0028" title="TritapepeL , De SantisV , VitaleD , SantulliM , MorelliA , NofroniI , et al. Preconditioning effects of levosimendan in coronary artery bypass grafting - a pilot study. British Journal of Anaesthesia2006;96:694-700. [DOI: 10.1093/bja/ael082]">Tritapepe 2006</a> provided IQR data that were similar in dimension between study groups at baseline, end of surgery, and 24 hours after surgery (baseline: 72.5 (IQR 65.2 to 77.7) versus 70.0 (IQR 65.8 to 76.5) mmHg); end of surgery: 69.0 (IQR 65.0 to 76.7) versus 68.0 (IQR 65.0 to 71.5) mmHg; 24 hours after surgery: 78.5 (IQR 73.2 to 84.5) versus 74.5 (IQR 70.0 to 80.0) mmHg)). However, at 6 hours after surgery, median MAP was higher in the levosimendan group compared to the placebo control group (77.5 (IQR 72.2 to 79.7) versus 70.00 (IQR 68.0 to 77.0) mmHg). </p> <p>Little to no difference was reported in mean PCWP between the levosimendan group and the control group at baseline, end of surgery, 6 hours, and 12 hours after surgery (<a href="./references#CD013781-fig-0085" title="">Analysis 7.11</a>). At baseline, five studies reported the mean difference between groups was 0.11 (95% CI ‐1.02 to 1.24; 196 participants, 5 studies; low heterogeneity) (<a href="./references#CD013781-bbs2-0002" title="AnastasiadisK , AntonitsisP , VranisK , KleontasA , AsteriouC , GrosomanidisV , et al. Effectiveness of prophylactic levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting: a randomized pilot study. Interactive Cardiovascular and Thoracic Surgery2016;23:740-8. [DOI: 10.1093/icvts/ivw213]">Anastasiadis 2016</a>; <a href="./references#CD013781-bbs2-0009" title="RikssonHI , JalonenJR , HeikkinenLO , KivikkoM , LaineM , LeinoKA , et al. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Cardiothoracic Anesthesiology2009;87:448-54. [DOI: 10.1016/j.athoracsur.2008.10.029]">Eriksson 2009</a>; <a href="./references#CD013781-bbs2-0015" title="JärveläK , MaaranenP , SistoT , RuokonenE . Levosimendan in aortic valve surgery: cardiac performance and recovery. Journal of Cardiothoracic and Vascular Anesthesia2008;22:693-8. [DOI: 10.1053/j.jvca.2008.01.024]">Jävelä 2008</a>; <a href="./references#CD013781-bbs2-0020" title="KodalliRK , SundarAS , VakamudiM , RavulapaliH , NandipatiS , ChandrasekaranN , et al. Effect of levosimendan on hemodynamic changes in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled study. Annals of Cardiac Anaesthesia2013;16:94-9. [DOI: 10.4103/0971-9784.109737]">Kodalli 2013</a>; <a href="./references#CD013781-bbs2-0026" title="ShahB , SharmaP , BrahmbhattA , ShahR , RathodB , ShastriN , et al. Study of levosimendan during off-pump coronary artery bypass grafting in patients with LV dysfunction: a double-blind randomized study. Indian Journal of Pharmacology2014;46:29-34. [DOI: 10.4103/0253-7613.125161]">Shah 2014</a>). Moreover, <a href="./references#CD013781-bbs2-0009" title="RikssonHI , JalonenJR , HeikkinenLO , KivikkoM , LaineM , LeinoKA , et al. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Cardiothoracic Anesthesiology2009;87:448-54. [DOI: 10.1016/j.athoracsur.2008.10.029]">Eriksson 2009</a>, <a href="./references#CD013781-bbs2-0015" title="JärveläK , MaaranenP , SistoT , RuokonenE . Levosimendan in aortic valve surgery: cardiac performance and recovery. Journal of Cardiothoracic and Vascular Anesthesia2008;22:693-8. [DOI: 10.1053/j.jvca.2008.01.024]">Jävelä 2008</a>, and <a href="./references#CD013781-bbs2-0026" title="ShahB , SharmaP , BrahmbhattA , ShahR , RathodB , ShastriN , et al. Study of levosimendan during off-pump coronary artery bypass grafting in patients with LV dysfunction: a double-blind randomized study. Indian Journal of Pharmacology2014;46:29-34. [DOI: 10.4103/0253-7613.125161]">Shah 2014</a> reported that the mean difference between groups at end of surgery was ‐1.63 (95% CI ‐3.85 to 0.58; 134 participants, 3 studies; considerable heterogeneity). At 6 hours after surgery, <a href="./references#CD013781-bbs2-0015" title="JärveläK , MaaranenP , SistoT , RuokonenE . Levosimendan in aortic valve surgery: cardiac performance and recovery. Journal of Cardiothoracic and Vascular Anesthesia2008;22:693-8. [DOI: 10.1053/j.jvca.2008.01.024]">Jävelä 2008</a> and <a href="./references#CD013781-bbs2-0020" title="KodalliRK , SundarAS , VakamudiM , RavulapaliH , NandipatiS , ChandrasekaranN , et al. Effect of levosimendan on hemodynamic changes in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled study. Annals of Cardiac Anaesthesia2013;16:94-9. [DOI: 10.4103/0971-9784.109737]">Kodalli 2013</a> reported that the mean difference between groups was 0.31 (95% CI ‐0.82 to 1.44; 54 participants, 2 studies; low heterogeneity). At 12 hours after surgery, three studies found that the mean difference between groups was ‐1.35 (95% CI ‐4.05 to 1.36; 104 participants, 3 studies; considerable heterogeneity) (<a href="./references#CD013781-bbs2-0015" title="JärveläK , MaaranenP , SistoT , RuokonenE . Levosimendan in aortic valve surgery: cardiac performance and recovery. Journal of Cardiothoracic and Vascular Anesthesia2008;22:693-8. [DOI: 10.1053/j.jvca.2008.01.024]">Jävelä 2008</a>; <a href="./references#CD013781-bbs2-0020" title="KodalliRK , SundarAS , VakamudiM , RavulapaliH , NandipatiS , ChandrasekaranN , et al. Effect of levosimendan on hemodynamic changes in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled study. Annals of Cardiac Anaesthesia2013;16:94-9. [DOI: 10.4103/0971-9784.109737]">Kodalli 2013</a>; <a href="./references#CD013781-bbs2-0026" title="ShahB , SharmaP , BrahmbhattA , ShahR , RathodB , ShastriN , et al. Study of levosimendan during off-pump coronary artery bypass grafting in patients with LV dysfunction: a double-blind randomized study. Indian Journal of Pharmacology2014;46:29-34. [DOI: 10.4103/0253-7613.125161]">Shah 2014</a>). However, there was a difference in mean PCWP between groups at 24 hours after surgery as reported by <a href="./references#CD013781-bbs2-0002" title="AnastasiadisK , AntonitsisP , VranisK , KleontasA , AsteriouC , GrosomanidisV , et al. Effectiveness of prophylactic levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting: a randomized pilot study. Interactive Cardiovascular and Thoracic Surgery2016;23:740-8. [DOI: 10.1093/icvts/ivw213]">Anastasiadis 2016</a>, <a href="./references#CD013781-bbs2-0009" title="RikssonHI , JalonenJR , HeikkinenLO , KivikkoM , LaineM , LeinoKA , et al. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Cardiothoracic Anesthesiology2009;87:448-54. [DOI: 10.1016/j.athoracsur.2008.10.029]">Eriksson 2009</a>, <a href="./references#CD013781-bbs2-0015" title="JärveläK , MaaranenP , SistoT , RuokonenE . Levosimendan in aortic valve surgery: cardiac performance and recovery. Journal of Cardiothoracic and Vascular Anesthesia2008;22:693-8. [DOI: 10.1053/j.jvca.2008.01.024]">Jävelä 2008</a>, <a href="./references#CD013781-bbs2-0020" title="KodalliRK , SundarAS , VakamudiM , RavulapaliH , NandipatiS , ChandrasekaranN , et al. Effect of levosimendan on hemodynamic changes in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled study. Annals of Cardiac Anaesthesia2013;16:94-9. [DOI: 10.4103/0971-9784.109737]">Kodalli 2013</a>, and <a href="./references#CD013781-bbs2-0026" title="ShahB , SharmaP , BrahmbhattA , ShahR , RathodB , ShastriN , et al. Study of levosimendan during off-pump coronary artery bypass grafting in patients with LV dysfunction: a double-blind randomized study. Indian Journal of Pharmacology2014;46:29-34. [DOI: 10.4103/0253-7613.125161]">Shah 2014</a>, with ‐1.33 (95% CI ‐2.50 to ‐0.17; 196 participants, 5 studies; moderate heterogeneity) (<a href="./references#CD013781-fig-0085" title="">Analysis 7.11</a>). <a href="./references#CD013781-bbs2-0028" title="TritapepeL , De SantisV , VitaleD , SantulliM , MorelliA , NofroniI , et al. Preconditioning effects of levosimendan in coronary artery bypass grafting - a pilot study. British Journal of Anaesthesia2006;96:694-700. [DOI: 10.1093/bja/ael082]">Tritapepe 2006</a> provided IQR data that were similar in dimension between study groups at baseline, end of surgery, 6 hours, and 24 hours after surgery (baseline: 14.0 (IQR 12.0 to 15.7) versus 12.5 (IQR 11.2 to 15.7) mmHg); end of surgery: 14.5 (IQR 12.2 to 17.5) versus 15.5 (IQR 13.2 to 17.0) mmHg; 6 hours after surgery: 13.0 (IQR 10.5 to 15.0) versus 14.0 (IQR 11.2 to 15.0) mmHg; 24 hours after surgery: 11.0 (IQR 10.0 to 13.7) versus 13.0 (IQR 11.0 to 14.0) mmHg)). <a href="./references#CD013781-bbs2-0027" title="SharmaP , MalhotraA , GandhiS , GargP , BishnoiA , GandhiH . Preoperative levosimendan in ischemic mitral valve repair. Asian Cardiovascular and Thoracic Annals2014;22:539-45. [DOI: 10.1177/0218492313499352]">Sharma 2014</a> narratively reported that there was a significant reduction in mean PCWP in the levosimendan group, which started after the infusion and was sustained postoperatively. </p> </section> <section id="CD013781-sec-0154"> <h6 class="title">Duration of mechanical ventilation</h6> <p>The mean duration of mechanical ventilation was reported by <a href="./references#CD013781-bbs2-0002" title="AnastasiadisK , AntonitsisP , VranisK , KleontasA , AsteriouC , GrosomanidisV , et al. Effectiveness of prophylactic levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting: a randomized pilot study. Interactive Cardiovascular and Thoracic Surgery2016;23:740-8. [DOI: 10.1093/icvts/ivw213]">Anastasiadis 2016</a>, <a href="./references#CD013781-bbs2-0014" title="HuX , XuQ . Application of levosimendan in severe patients after cardiac surgery. Chinese Journal of Clinical Pharmacology and Therapeutics2020;25:1027-32. [DOI: 10.12092/j.issn.1009-2501.2020.09.010]">Hu 2020</a>, <a href="./references#CD013781-bbs2-0020" title="KodalliRK , SundarAS , VakamudiM , RavulapaliH , NandipatiS , ChandrasekaranN , et al. Effect of levosimendan on hemodynamic changes in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled study. Annals of Cardiac Anaesthesia2013;16:94-9. [DOI: 10.4103/0971-9784.109737]">Kodalli 2013</a>, <a href="./references#CD013781-bbs2-0022" title="LeppikangasH , JärveläK , SistoT , MaaranenP , VirtanenM , LehtoP , et al. Preoperative levosimendan infusion in combined aortic valve and coronary bypass surgery. British Journal of Anaesthesia2011;106:298-304. [DOI: 10.1093/bja/aeq402]">Leppikangas 2011</a>, <a href="./references#CD013781-bbs2-0027" title="SharmaP , MalhotraA , GandhiS , GargP , BishnoiA , GandhiH . Preoperative levosimendan in ischemic mitral valve repair. Asian Cardiovascular and Thoracic Annals2014;22:539-45. [DOI: 10.1177/0218492313499352]">Sharma 2014</a>, <a href="./references#CD013781-bbs2-0028" title="TritapepeL , De SantisV , VitaleD , SantulliM , MorelliA , NofroniI , et al. Preconditioning effects of levosimendan in coronary artery bypass grafting - a pilot study. British Journal of Anaesthesia2006;96:694-700. [DOI: 10.1093/bja/ael082]">Tritapepe 2006</a>, and <a href="./references#CD013781-bbs2-0029" title="TritapepeL , De SantisV , VitaleD , GuarracinoF , PellegriniF , PietropaoliP , et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. British Journal of Anaesthesia2009;102:198-204. [DOI: 10.1093/bja/aen367]">Tritapepe 2009</a> with 572 participants. <a href="./references#CD013781-bbs2-0002" title="AnastasiadisK , AntonitsisP , VranisK , KleontasA , AsteriouC , GrosomanidisV , et al. Effectiveness of prophylactic levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting: a randomized pilot study. Interactive Cardiovascular and Thoracic Surgery2016;23:740-8. [DOI: 10.1093/icvts/ivw213]">Anastasiadis 2016</a> reported that the mean duration of mechanical ventilation in the control group was 29.9 ± 54.3 hours. The mean duration of mechanical ventilation in the intervention group receiving levosimendan was 17.80 hours lower (mean difference ‐17.80, 95% CI ‐44.63 to 9.03). <a href="./references#CD013781-bbs2-0014" title="HuX , XuQ . Application of levosimendan in severe patients after cardiac surgery. Chinese Journal of Clinical Pharmacology and Therapeutics2020;25:1027-32. [DOI: 10.12092/j.issn.1009-2501.2020.09.010]">Hu 2020</a> reported that the mean duration of mechanical ventilation in the control group was 157.44 ± 58.56 hours. The mean duration of mechanical ventilation in the intervention group receiving levosimendan was 53.76 hours lower (mean difference ‐53.76, 95% CI ‐63.79 to ‐43.73). <a href="./references#CD013781-bbs2-0020" title="KodalliRK , SundarAS , VakamudiM , RavulapaliH , NandipatiS , ChandrasekaranN , et al. Effect of levosimendan on hemodynamic changes in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled study. Annals of Cardiac Anaesthesia2013;16:94-9. [DOI: 10.4103/0971-9784.109737]">Kodalli 2013</a> observed a mean duration of mechanical ventilation in the control group of 7.1 ± 1.5 hours. The mean duration of mechanical ventilation in the intervention group receiving levosimendan was 0.10 hours lower (mean difference ‐0.10, 95% CI ‐1.33 to 1.13). <a href="./references#CD013781-bbs2-0022" title="LeppikangasH , JärveläK , SistoT , MaaranenP , VirtanenM , LehtoP , et al. Preoperative levosimendan infusion in combined aortic valve and coronary bypass surgery. British Journal of Anaesthesia2011;106:298-304. [DOI: 10.1093/bja/aeq402]">Leppikangas 2011</a> found the mean duration of mechanical ventilation in the control group was 5.67 ± 1.47 hours. The mean duration of mechanical ventilation in the intervention group receiving levosimendan was 4.10 hours higher (mean difference 4.10, 95% CI ‐1.76 to 9.96). <a href="./references#CD013781-bbs2-0027" title="SharmaP , MalhotraA , GandhiS , GargP , BishnoiA , GandhiH . Preoperative levosimendan in ischemic mitral valve repair. Asian Cardiovascular and Thoracic Annals2014;22:539-45. [DOI: 10.1177/0218492313499352]">Sharma 2014</a> reported that the mean duration of mechanical ventilation in the control group was 37.65 ± 3.48 hours. The mean duration of mechanical ventilation in the intervention group receiving levosimendan was 9.55 hours lower (mean difference ‐9.55, 95% CI ‐11.47 to ‐7.63). <a href="./references#CD013781-bbs2-0028" title="TritapepeL , De SantisV , VitaleD , SantulliM , MorelliA , NofroniI , et al. Preconditioning effects of levosimendan in coronary artery bypass grafting - a pilot study. British Journal of Anaesthesia2006;96:694-700. [DOI: 10.1093/bja/ael082]">Tritapepe 2006</a> documented a mean duration of mechanical ventilation in the control group of 11 ± 3 hours. The mean duration of mechanical ventilation in the intervention group receiving levosimendan was 1.00 hours lower (mean difference ‐1.00, 95% CI ‐3.40 to 1.40). <a href="./references#CD013781-bbs2-0029" title="TritapepeL , De SantisV , VitaleD , GuarracinoF , PellegriniF , PietropaoliP , et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. British Journal of Anaesthesia2009;102:198-204. [DOI: 10.1093/bja/aen367]">Tritapepe 2009</a> reported the mean duration of mechanical ventilation in the control group was 13.6 ± 4.5 hours. The mean duration of mechanical ventilation in the intervention group receiving levosimendan was 2.30 hours lower (mean difference ‐2.30, 95% CI ‐3.72 to ‐0.88). In summary, there was a difference in the mean duration of mechanical ventilation between groups, favouring the levosimendan group (mean difference ‐8.03, 95% CI ‐13.17 to ‐2.90; 572 participants, 7 studies; very low‐certainty evidence; considerable heterogeneity) (<a href="./references#CD013781-fig-0086" title="">Analysis 7.12</a>; <a href="./full#CD013781-tbl-0002">summary of findings Table 2</a>). IQR data were reported by <a href="./references#CD013781-bbs2-0004" title="CholleyB , CarubaT , GrosjeanS , AmourJ , OuattaraA , VillacortaJ , et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA2017;318:548-56. [DOI: 10.1001/jama.2017.9973]">Cholley 2017</a>, <a href="./references#CD013781-bbs2-0008" title="ErbJ , BeutlhauserT , FeldheiserA , SchusterB , TreskatschS , GrubitzschH , et al. Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery. Journal of International Medical Research2014;42:750-64. [DOI: 10.1177/0300060513516293]">Erb 2014</a>; <a href="./references#CD013781-bbs2-0009" title="RikssonHI , JalonenJR , HeikkinenLO , KivikkoM , LaineM , LeinoKA , et al. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Cardiothoracic Anesthesiology2009;87:448-54. [DOI: 10.1016/j.athoracsur.2008.10.029]">Eriksson 2009</a>, and <a href="./references#CD013781-bbs2-0017" title="Juhl-OlsenP , Jakobsen C-J, RasmussenLA , BhavsarR , Klaaborg K-E, FrederiksenCA , et al. Effects of levosimendan in patients with left ventricular hypertrophy undergoing aortic valve replacement. Acta Anaesthesiologica Scandinavica2015;59:65-77. [DOI: 10.1111/aas.12425]">Juhl‐Olsen 2015</a>. All but <a href="./references#CD013781-bbs2-0017" title="Juhl-OlsenP , Jakobsen C-J, RasmussenLA , BhavsarR , Klaaborg K-E, FrederiksenCA , et al. Effects of levosimendan in patients with left ventricular hypertrophy undergoing aortic valve replacement. Acta Anaesthesiologica Scandinavica2015;59:65-77. [DOI: 10.1111/aas.12425]">Juhl‐Olsen 2015</a> observed a lower median duration of mechanical ventilation in the levosimendan group compared to the placebo group (<a href="./references#CD013781-bbs2-0004" title="CholleyB , CarubaT , GrosjeanS , AmourJ , OuattaraA , VillacortaJ , et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA2017;318:548-56. [DOI: 10.1001/jama.2017.9973]">Cholley 2017</a>: 17 (IQR 12 to 20) versus 18 (IQR 14 to 20) hours; <a href="./references#CD013781-bbs2-0008" title="ErbJ , BeutlhauserT , FeldheiserA , SchusterB , TreskatschS , GrubitzschH , et al. Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery. Journal of International Medical Research2014;42:750-64. [DOI: 10.1177/0300060513516293]">Erb 2014</a>: 20 (IQR 16 to 63) versus 45 (IQR 18 to 115) hours; <a href="./references#CD013781-bbs2-0009" title="RikssonHI , JalonenJR , HeikkinenLO , KivikkoM , LaineM , LeinoKA , et al. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Cardiothoracic Anesthesiology2009;87:448-54. [DOI: 10.1016/j.athoracsur.2008.10.029]">Eriksson 2009</a>: 21 (IQR 10 to 792) versus 23 (IQR 10 to 580) hours). <a href="./references#CD013781-bbs2-0017" title="Juhl-OlsenP , Jakobsen C-J, RasmussenLA , BhavsarR , Klaaborg K-E, FrederiksenCA , et al. Effects of levosimendan in patients with left ventricular hypertrophy undergoing aortic valve replacement. Acta Anaesthesiologica Scandinavica2015;59:65-77. [DOI: 10.1111/aas.12425]">Juhl‐Olsen 2015</a> reported a duration of mechanical ventilation of 7.93 (IQR 4.77 to 15.4) hours in the levosimendan group compared with 6.77 (IQR 4.82 to 13.27) hours in the placebo control group. </p> </section> <section id="CD013781-sec-0155"> <h6 class="title">Proportion of weaning failure within 48 hours of extubation</h6> <p>There were five studies with 1233 participants reporting on the proportion of weaning failure within 48 hours of extubation (<a href="./references#CD013781-bbs2-0002" title="AnastasiadisK , AntonitsisP , VranisK , KleontasA , AsteriouC , GrosomanidisV , et al. Effectiveness of prophylactic levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting: a randomized pilot study. Interactive Cardiovascular and Thoracic Surgery2016;23:740-8. [DOI: 10.1093/icvts/ivw213]">Anastasiadis 2016</a>; <a href="./references#CD013781-bbs2-0009" title="RikssonHI , JalonenJR , HeikkinenLO , KivikkoM , LaineM , LeinoKA , et al. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Cardiothoracic Anesthesiology2009;87:448-54. [DOI: 10.1016/j.athoracsur.2008.10.029]">Eriksson 2009</a>; <a href="./references#CD013781-bbs2-0023" title="LevinR , DegrangeM , Del MazoC , TanusE , PorcileR . Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Experimental and Clinical Cardiology2012;17:125-30. [PMID: 23620700]">Levin 2012</a>; <a href="./references#CD013781-bbs2-0024" title="MehtaRH , LeimbergerJD , vanDiepenS , MezaJ , WangA , JankowichR , et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. New England Journal of Medicine2017;376:2032-42. [DOI: 10.1056/NEJMoa1616218]">Mehta 2017</a>; <a href="./references#CD013781-bbs2-0027" title="SharmaP , MalhotraA , GandhiS , GargP , BishnoiA , GandhiH . Preoperative levosimendan in ischemic mitral valve repair. Asian Cardiovascular and Thoracic Annals2014;22:539-45. [DOI: 10.1177/0218492313499352]">Sharma 2014</a>). <a href="./references#CD013781-bbs2-0002" title="AnastasiadisK , AntonitsisP , VranisK , KleontasA , AsteriouC , GrosomanidisV , et al. Effectiveness of prophylactic levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting: a randomized pilot study. Interactive Cardiovascular and Thoracic Surgery2016;23:740-8. [DOI: 10.1093/icvts/ivw213]">Anastasiadis 2016</a> reported that none out of 16 participants in the levosimendan intervention group had weaning failure within 48 hours of extubation compared to 1 out of 16 in the control group (RR 0.33, 95% CI 0.01 to 7.62). <a href="./references#CD013781-bbs2-0009" title="RikssonHI , JalonenJR , HeikkinenLO , KivikkoM , LaineM , LeinoKA , et al. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Cardiothoracic Anesthesiology2009;87:448-54. [DOI: 10.1016/j.athoracsur.2008.10.029]">Eriksson 2009</a> found that 8 out of 30 patients in the levosimendan group had weaning failure within 48 hours of extubation compared to 20 out of 30 in the control group (RR 0.40, 95% CI 0.21 to 0.76). Also, <a href="./references#CD013781-bbs2-0023" title="LevinR , DegrangeM , Del MazoC , TanusE , PorcileR . Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Experimental and Clinical Cardiology2012;17:125-30. [PMID: 23620700]">Levin 2012</a> reported that 3 out of 127 participants in the levosimendan group had weaning failure within 48 hours of extubation compared to 12 out of 125 in the control group (RR 0.25, 95% CI 0.07 to 0.85). In contrast, <a href="./references#CD013781-bbs2-0024" title="MehtaRH , LeimbergerJD , vanDiepenS , MezaJ , WangA , JankowichR , et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. New England Journal of Medicine2017;376:2032-42. [DOI: 10.1056/NEJMoa1616218]">Mehta 2017</a> found that 1 out of 428 patients in the levosimendan group had weaning failure within 48 hours of extubation compared to none out of 421 in the control group (RR 2.95, 95% CI 0.12 to 72.24). <a href="./references#CD013781-bbs2-0027" title="SharmaP , MalhotraA , GandhiS , GargP , BishnoiA , GandhiH . Preoperative levosimendan in ischemic mitral valve repair. Asian Cardiovascular and Thoracic Annals2014;22:539-45. [DOI: 10.1177/0218492313499352]">Sharma 2014</a> reported that 2 out of 20 participants in the levosimendan group had weaning failure within 48 hours of extubation compared to 4 out of 20 in the control group (RR 0.50, 95% CI 0.10 to 2.43). Altogether, there was a difference in the proportion of weaning failure within 48 hours of extubation between groups, favouring the levosimendan group (RR 0.39, 95% CI 0.23 to 0.67; 1233 participants, 5 studies; low heterogeneity) (<a href="./references#CD013781-fig-0087" title="">Analysis 7.13</a>). </p> </section> <section id="CD013781-sec-0156"> <h6 class="title">Number of patients requiring mechanical circulatory support (IABP)</h6> <p>Information on the number of patients requiring mechanical circulatory support was found in 10 studies with 1881 participants (<a href="./references#CD013781-bbs2-0002" title="AnastasiadisK , AntonitsisP , VranisK , KleontasA , AsteriouC , GrosomanidisV , et al. Effectiveness of prophylactic levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting: a randomized pilot study. Interactive Cardiovascular and Thoracic Surgery2016;23:740-8. [DOI: 10.1093/icvts/ivw213]">Anastasiadis 2016</a>; <a href="./references#CD013781-bbs2-0004" title="CholleyB , CarubaT , GrosjeanS , AmourJ , OuattaraA , VillacortaJ , et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA2017;318:548-56. [DOI: 10.1001/jama.2017.9973]">Cholley 2017</a>; <a href="./references#CD013781-bbs2-0008" title="ErbJ , BeutlhauserT , FeldheiserA , SchusterB , TreskatschS , GrubitzschH , et al. Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery. Journal of International Medical Research2014;42:750-64. [DOI: 10.1177/0300060513516293]">Erb 2014</a>; <a href="./references#CD013781-bbs2-0009" title="RikssonHI , JalonenJR , HeikkinenLO , KivikkoM , LaineM , LeinoKA , et al. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Cardiothoracic Anesthesiology2009;87:448-54. [DOI: 10.1016/j.athoracsur.2008.10.029]">Eriksson 2009</a>; <a href="./references#CD013781-bbs2-0020" title="KodalliRK , SundarAS , VakamudiM , RavulapaliH , NandipatiS , ChandrasekaranN , et al. Effect of levosimendan on hemodynamic changes in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled study. Annals of Cardiac Anaesthesia2013;16:94-9. [DOI: 10.4103/0971-9784.109737]">Kodalli 2013</a>; <a href="./references#CD013781-bbs2-0021" title="LahtinenP , PitkänenO , PölönenP , TurpeinenA , KiviniemiV , UusaroA . Levosimendan reduces heart failure after cardiac surgery: a prospective, randomized, placebo-controlled trial. Criítical Care Medicine2011;39:2263-70. [DOI: 10.1097/CCM.0b013e3182227b97]">Lahtinen 2011</a>; <a href="./references#CD013781-bbs2-0023" title="LevinR , DegrangeM , Del MazoC , TanusE , PorcileR . Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Experimental and Clinical Cardiology2012;17:125-30. [PMID: 23620700]">Levin 2012</a>; <a href="./references#CD013781-bbs2-0024" title="MehtaRH , LeimbergerJD , vanDiepenS , MezaJ , WangA , JankowichR , et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. New England Journal of Medicine2017;376:2032-42. [DOI: 10.1056/NEJMoa1616218]">Mehta 2017</a>; <a href="./references#CD013781-bbs2-0026" title="ShahB , SharmaP , BrahmbhattA , ShahR , RathodB , ShastriN , et al. Study of levosimendan during off-pump coronary artery bypass grafting in patients with LV dysfunction: a double-blind randomized study. Indian Journal of Pharmacology2014;46:29-34. [DOI: 10.4103/0253-7613.125161]">Shah 2014</a>; <a href="./references#CD013781-bbs2-0027" title="SharmaP , MalhotraA , GandhiS , GargP , BishnoiA , GandhiH . Preoperative levosimendan in ischemic mitral valve repair. Asian Cardiovascular and Thoracic Annals2014;22:539-45. [DOI: 10.1177/0218492313499352]">Sharma 2014</a>). However, the relative effect was only generated from <a href="./references#CD013781-bbs2-0002" title="AnastasiadisK , AntonitsisP , VranisK , KleontasA , AsteriouC , GrosomanidisV , et al. Effectiveness of prophylactic levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting: a randomized pilot study. Interactive Cardiovascular and Thoracic Surgery2016;23:740-8. [DOI: 10.1093/icvts/ivw213]">Anastasiadis 2016</a>, <a href="./references#CD013781-bbs2-0004" title="CholleyB , CarubaT , GrosjeanS , AmourJ , OuattaraA , VillacortaJ , et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA2017;318:548-56. [DOI: 10.1001/jama.2017.9973]">Cholley 2017</a>, <a href="./references#CD013781-bbs2-0008" title="ErbJ , BeutlhauserT , FeldheiserA , SchusterB , TreskatschS , GrubitzschH , et al. Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery. Journal of International Medical Research2014;42:750-64. [DOI: 10.1177/0300060513516293]">Erb 2014</a>, <a href="./references#CD013781-bbs2-0009" title="RikssonHI , JalonenJR , HeikkinenLO , KivikkoM , LaineM , LeinoKA , et al. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Cardiothoracic Anesthesiology2009;87:448-54. [DOI: 10.1016/j.athoracsur.2008.10.029]">Eriksson 2009</a>, <a href="./references#CD013781-bbs2-0021" title="LahtinenP , PitkänenO , PölönenP , TurpeinenA , KiviniemiV , UusaroA . Levosimendan reduces heart failure after cardiac surgery: a prospective, randomized, placebo-controlled trial. Criítical Care Medicine2011;39:2263-70. [DOI: 10.1097/CCM.0b013e3182227b97]">Lahtinen 2011</a>, <a href="./references#CD013781-bbs2-0023" title="LevinR , DegrangeM , Del MazoC , TanusE , PorcileR . Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Experimental and Clinical Cardiology2012;17:125-30. [PMID: 23620700]">Levin 2012</a>, <a href="./references#CD013781-bbs2-0024" title="MehtaRH , LeimbergerJD , vanDiepenS , MezaJ , WangA , JankowichR , et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. New England Journal of Medicine2017;376:2032-42. [DOI: 10.1056/NEJMoa1616218]">Mehta 2017</a>, <a href="./references#CD013781-bbs2-0026" title="ShahB , SharmaP , BrahmbhattA , ShahR , RathodB , ShastriN , et al. Study of levosimendan during off-pump coronary artery bypass grafting in patients with LV dysfunction: a double-blind randomized study. Indian Journal of Pharmacology2014;46:29-34. [DOI: 10.4103/0253-7613.125161]">Shah 2014</a>, and <a href="./references#CD013781-bbs2-0027" title="SharmaP , MalhotraA , GandhiS , GargP , BishnoiA , GandhiH . Preoperative levosimendan in ischemic mitral valve repair. Asian Cardiovascular and Thoracic Annals2014;22:539-45. [DOI: 10.1177/0218492313499352]">Sharma 2014</a>, while the risk ratio from <a href="./references#CD013781-bbs2-0020" title="KodalliRK , SundarAS , VakamudiM , RavulapaliH , NandipatiS , ChandrasekaranN , et al. Effect of levosimendan on hemodynamic changes in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled study. Annals of Cardiac Anaesthesia2013;16:94-9. [DOI: 10.4103/0971-9784.109737]">Kodalli 2013</a> was not estimable due to no events being observed in either group. <a href="./references#CD013781-bbs2-0014" title="HuX , XuQ . Application of levosimendan in severe patients after cardiac surgery. Chinese Journal of Clinical Pharmacology and Therapeutics2020;25:1027-32. [DOI: 10.12092/j.issn.1009-2501.2020.09.010]">Hu 2020</a> narratively reported a significantly longer IABP support in the placebo control group compared with the levosimendan intervention group without specifying the number of patients in need of this support. </p> <p>There were 92 out of 944 participants in the levosimendan group requiring mechanical circulatory support compared to 136 out of 937 in the control group. When levosimendan was compared to the control group, there was a difference in the number of patients requiring mechanical circulatory support and this effect was favourable to levosimendan (RR 0.47, 95% CI 0.24 to 0.91; 1881 participants, 10 studies; low‐certainty evidence; substantial heterogeneity) (<a href="./references#CD013781-fig-0088" title="">Analysis 7.14</a>; <a href="./full#CD013781-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD013781-sec-0157"> <h6 class="title">Number of patients requiring additional inotropic drugs</h6> <p>Need for overall additional inotropic drugs was reported by six studies (<a href="./references#CD013781-bbs2-0004" title="CholleyB , CarubaT , GrosjeanS , AmourJ , OuattaraA , VillacortaJ , et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA2017;318:548-56. [DOI: 10.1001/jama.2017.9973]">Cholley 2017</a>; <a href="./references#CD013781-bbs2-0023" title="LevinR , DegrangeM , Del MazoC , TanusE , PorcileR . Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Experimental and Clinical Cardiology2012;17:125-30. [PMID: 23620700]">Levin 2012</a>; <a href="./references#CD013781-bbs2-0024" title="MehtaRH , LeimbergerJD , vanDiepenS , MezaJ , WangA , JankowichR , et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. New England Journal of Medicine2017;376:2032-42. [DOI: 10.1056/NEJMoa1616218]">Mehta 2017</a>; <a href="./references#CD013781-bbs2-0026" title="ShahB , SharmaP , BrahmbhattA , ShahR , RathodB , ShastriN , et al. Study of levosimendan during off-pump coronary artery bypass grafting in patients with LV dysfunction: a double-blind randomized study. Indian Journal of Pharmacology2014;46:29-34. [DOI: 10.4103/0253-7613.125161]">Shah 2014</a>; <a href="./references#CD013781-bbs2-0028" title="TritapepeL , De SantisV , VitaleD , SantulliM , MorelliA , NofroniI , et al. Preconditioning effects of levosimendan in coronary artery bypass grafting - a pilot study. British Journal of Anaesthesia2006;96:694-700. [DOI: 10.1093/bja/ael082]">Tritapepe 2006</a>; <a href="./references#CD013781-bbs2-0029" title="TritapepeL , De SantisV , VitaleD , GuarracinoF , PellegriniF , PietropaoliP , et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. British Journal of Anaesthesia2009;102:198-204. [DOI: 10.1093/bja/aen367]">Tritapepe 2009</a>), which found that 338 out of 811 patients required additional inotropic drugs in the intervention group with levosimendan compared to 433 out of 801 patients in the placebo control group. There was a difference in the risk ratio between groups favouring levosimendan (RR 0.49, 95% CI 0.28 to 0.88; 1612 participants, 6 studies; considerable heterogeneity) (<a href="./references#CD013781-fig-0089" title="">Analysis 7.15</a>). </p> <p>Within this outcome category, specific inotropic drugs, i.e. epinephrine, norepinephrine, dopamine, dobutamine, enoximone, milrinone, nitroprusside, ephedrine, and phenylephrine were also reported. Except for dobutamine, there was little to no difference in risk ratio between groups. Five studies, <a href="./references#CD013781-bbs2-0004" title="CholleyB , CarubaT , GrosjeanS , AmourJ , OuattaraA , VillacortaJ , et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA2017;318:548-56. [DOI: 10.1001/jama.2017.9973]">Cholley 2017</a>, <a href="./references#CD013781-bbs2-0008" title="ErbJ , BeutlhauserT , FeldheiserA , SchusterB , TreskatschS , GrubitzschH , et al. Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery. Journal of International Medical Research2014;42:750-64. [DOI: 10.1177/0300060513516293]">Erb 2014</a>, <a href="./references#CD013781-bbs2-0009" title="RikssonHI , JalonenJR , HeikkinenLO , KivikkoM , LaineM , LeinoKA , et al. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Cardiothoracic Anesthesiology2009;87:448-54. [DOI: 10.1016/j.athoracsur.2008.10.029]">Eriksson 2009</a>, <a href="./references#CD013781-bbs2-0020" title="KodalliRK , SundarAS , VakamudiM , RavulapaliH , NandipatiS , ChandrasekaranN , et al. Effect of levosimendan on hemodynamic changes in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled study. Annals of Cardiac Anaesthesia2013;16:94-9. [DOI: 10.4103/0971-9784.109737]">Kodalli 2013</a>, and <a href="./references#CD013781-bbs2-0021" title="LahtinenP , PitkänenO , PölönenP , TurpeinenA , KiviniemiV , UusaroA . Levosimendan reduces heart failure after cardiac surgery: a prospective, randomized, placebo-controlled trial. Criítical Care Medicine2011;39:2263-70. [DOI: 10.1097/CCM.0b013e3182227b97]">Lahtinen 2011</a>, reported that 30 out of 328 patients in the levosimendan group required additional epinephrine compared to 47 out of 330 patients in the control group (RR 0.61, 95% CI 0.26 to 1.45; 658 participants, 5 studies; substantial heterogeneity) (<a href="./references#CD013781-fig-0090" title="">Analysis 7.16</a>). Regarding norepinephrine, <a href="./references#CD013781-bbs2-0004" title="CholleyB , CarubaT , GrosjeanS , AmourJ , OuattaraA , VillacortaJ , et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA2017;318:548-56. [DOI: 10.1001/jama.2017.9973]">Cholley 2017</a>, <a href="./references#CD013781-bbs2-0008" title="ErbJ , BeutlhauserT , FeldheiserA , SchusterB , TreskatschS , GrubitzschH , et al. Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery. Journal of International Medical Research2014;42:750-64. [DOI: 10.1177/0300060513516293]">Erb 2014</a>, <a href="./references#CD013781-bbs2-0009" title="RikssonHI , JalonenJR , HeikkinenLO , KivikkoM , LaineM , LeinoKA , et al. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Cardiothoracic Anesthesiology2009;87:448-54. [DOI: 10.1016/j.athoracsur.2008.10.029]">Eriksson 2009</a>, <a href="./references#CD013781-bbs2-0017" title="Juhl-OlsenP , Jakobsen C-J, RasmussenLA , BhavsarR , Klaaborg K-E, FrederiksenCA , et al. Effects of levosimendan in patients with left ventricular hypertrophy undergoing aortic valve replacement. Acta Anaesthesiologica Scandinavica2015;59:65-77. [DOI: 10.1111/aas.12425]">Juhl‐Olsen 2015</a>, <a href="./references#CD013781-bbs2-0020" title="KodalliRK , SundarAS , VakamudiM , RavulapaliH , NandipatiS , ChandrasekaranN , et al. Effect of levosimendan on hemodynamic changes in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled study. Annals of Cardiac Anaesthesia2013;16:94-9. [DOI: 10.4103/0971-9784.109737]">Kodalli 2013</a>, and <a href="./references#CD013781-bbs2-0021" title="LahtinenP , PitkänenO , PölönenP , TurpeinenA , KiviniemiV , UusaroA . Levosimendan reduces heart failure after cardiac surgery: a prospective, randomized, placebo-controlled trial. Criítical Care Medicine2011;39:2263-70. [DOI: 10.1097/CCM.0b013e3182227b97]">Lahtinen 2011</a> reported that 166 out of 338 participants in the levosimendan group received this additional inotropic support compared to 117 out of 340 participants in the control group (RR 1.31, 95% CI 1.00 to 1.71; 678 participants, 6 studies; moderate heterogeneity) (<a href="./references#CD013781-fig-0091" title="">Analysis 7.17</a>). Narratively, both <a href="./references#CD013781-bbs2-0015" title="JärveläK , MaaranenP , SistoT , RuokonenE . Levosimendan in aortic valve surgery: cardiac performance and recovery. Journal of Cardiothoracic and Vascular Anesthesia2008;22:693-8. [DOI: 10.1053/j.jvca.2008.01.024]">Jävelä 2008</a> and <a href="./references#CD013781-bbs2-0022" title="LeppikangasH , JärveläK , SistoT , MaaranenP , VirtanenM , LehtoP , et al. Preoperative levosimendan infusion in combined aortic valve and coronary bypass surgery. British Journal of Anaesthesia2011;106:298-304. [DOI: 10.1093/bja/aeq402]">Leppikangas 2011</a> stated that the levosimendan group required more norepinephrine compared with the control group. <a href="./references#CD013781-bbs2-0029" title="TritapepeL , De SantisV , VitaleD , GuarracinoF , PellegriniF , PietropaoliP , et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. British Journal of Anaesthesia2009;102:198-204. [DOI: 10.1093/bja/aen367]">Tritapepe 2009</a> reported that 9 out of 52 patients in the levosimendan group required additional dopamine compared to 17 out of 50 patients in the control group (RR 0.51, 95% CI 0.25 to 1.03; 102 participants, 1 study; heterogeneity not applicable) (<a href="./references#CD013781-fig-0092" title="">Analysis 7.18</a>). Four studies, <a href="./references#CD013781-bbs2-0008" title="ErbJ , BeutlhauserT , FeldheiserA , SchusterB , TreskatschS , GrubitzschH , et al. Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery. Journal of International Medical Research2014;42:750-64. [DOI: 10.1177/0300060513516293]">Erb 2014</a>, <a href="./references#CD013781-bbs2-0017" title="Juhl-OlsenP , Jakobsen C-J, RasmussenLA , BhavsarR , Klaaborg K-E, FrederiksenCA , et al. Effects of levosimendan in patients with left ventricular hypertrophy undergoing aortic valve replacement. Acta Anaesthesiologica Scandinavica2015;59:65-77. [DOI: 10.1111/aas.12425]">Juhl‐Olsen 2015</a>, <a href="./references#CD013781-bbs2-0021" title="LahtinenP , PitkänenO , PölönenP , TurpeinenA , KiviniemiV , UusaroA . Levosimendan reduces heart failure after cardiac surgery: a prospective, randomized, placebo-controlled trial. Criítical Care Medicine2011;39:2263-70. [DOI: 10.1097/CCM.0b013e3182227b97]">Lahtinen 2011</a>, and <a href="./references#CD013781-bbs2-0028" title="TritapepeL , De SantisV , VitaleD , SantulliM , MorelliA , NofroniI , et al. Preconditioning effects of levosimendan in coronary artery bypass grafting - a pilot study. British Journal of Anaesthesia2006;96:694-700. [DOI: 10.1093/bja/ael082]">Tritapepe 2006</a>, stated that 23 out of 138 patients in the levosimendan group required additional dobutamine compared to 72 out of 139 patients in the control group and there was a difference in the risk ratio between groups favouring levosimendan (RR 0.33, 95% CI 0.22 to 0.50; 277 participants, 4 studies; low heterogeneity) (<a href="./references#CD013781-fig-0093" title="">Analysis 7.19</a>). <a href="./references#CD013781-bbs2-0008" title="ErbJ , BeutlhauserT , FeldheiserA , SchusterB , TreskatschS , GrubitzschH , et al. Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery. Journal of International Medical Research2014;42:750-64. [DOI: 10.1177/0300060513516293]">Erb 2014</a> reported that 7 out of 17 patients in the levosimendan group required additional enoximone compared to 11 out of 16 patients in the control group (RR 0.60, 95% CI 0.31 to 1.16; 33 participants, 1 study; heterogeneity not applicable) (<a href="./references#CD013781-fig-0094" title="">Analysis 7.20</a>). Regarding milrinone, <a href="./references#CD013781-bbs2-0009" title="RikssonHI , JalonenJR , HeikkinenLO , KivikkoM , LaineM , LeinoKA , et al. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Cardiothoracic Anesthesiology2009;87:448-54. [DOI: 10.1016/j.athoracsur.2008.10.029]">Eriksson 2009</a> and <a href="./references#CD013781-bbs2-0021" title="LahtinenP , PitkänenO , PölönenP , TurpeinenA , KiviniemiV , UusaroA . Levosimendan reduces heart failure after cardiac surgery: a prospective, randomized, placebo-controlled trial. Criítical Care Medicine2011;39:2263-70. [DOI: 10.1097/CCM.0b013e3182227b97]">Lahtinen 2011</a> documented that 2 out of 129 participants in the levosimendan group received this additional inotropic support compared to 13 out of 131 participants in the control group (RR 0.22, 95% CI 0.03 to 1.41; 260 participants, 2 studies; low heterogeneity) (<a href="./references#CD013781-fig-0095" title="">Analysis 7.21</a>). <a href="./references#CD013781-bbs2-0017" title="Juhl-OlsenP , Jakobsen C-J, RasmussenLA , BhavsarR , Klaaborg K-E, FrederiksenCA , et al. Effects of levosimendan in patients with left ventricular hypertrophy undergoing aortic valve replacement. Acta Anaesthesiologica Scandinavica2015;59:65-77. [DOI: 10.1111/aas.12425]">Juhl‐Olsen 2015</a> reported that 1 out of 10 patients in the levosimendan group required additional nitroprusside compared to 6 out of 10 patients in the control group (RR 0.17, 95% CI 0.02 to 1.14; 20 participants, 1 study; heterogeneity not applicable) (<a href="./references#CD013781-fig-0096" title="">Analysis 7.22</a>). <a href="./references#CD013781-bbs2-0015" title="JärveläK , MaaranenP , SistoT , RuokonenE . Levosimendan in aortic valve surgery: cardiac performance and recovery. Journal of Cardiothoracic and Vascular Anesthesia2008;22:693-8. [DOI: 10.1053/j.jvca.2008.01.024]">Jävelä 2008</a> narratively noted that the levosimendan group received less nitroprusside postoperatively compared with the control group. <a href="./references#CD013781-bbs2-0004" title="CholleyB , CarubaT , GrosjeanS , AmourJ , OuattaraA , VillacortaJ , et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA2017;318:548-56. [DOI: 10.1001/jama.2017.9973]">Cholley 2017</a> reported that 53 out of 167 patients in the levosimendan group required additional ephedrine compared to 48 out of 168 patients in the control group (RR 1.11, 95% CI 0.80 to 1.54; 335 participants, 1 study; heterogeneity not applicable) (<a href="./references#CD013781-fig-0097" title="">Analysis 7.23</a>). In addition, <a href="./references#CD013781-bbs2-0004" title="CholleyB , CarubaT , GrosjeanS , AmourJ , OuattaraA , VillacortaJ , et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA2017;318:548-56. [DOI: 10.1001/jama.2017.9973]">Cholley 2017</a> reported that 34 out of 167 patients in the levosimendan group required additional phenylephrine compared to 24 out of 168 patients in the control group (RR 1.43, 95% CI 0.88 to 2.30; 335 participants, 1 study; heterogeneity not applicable) (<a href="./references#CD013781-fig-0098" title="">Analysis 7.24</a>). </p> </section> <section id="CD013781-sec-0158"> <h6 class="title">Number of patients requiring cardiac transplantation, ventricular assist device (VAD) implantation or cardiopulmonary resuscitation </h6> <p>Information on the number of patients requiring cardiac transplantation or VAD implantation was restricted to <a href="./references#CD013781-bbs2-0004" title="CholleyB , CarubaT , GrosjeanS , AmourJ , OuattaraA , VillacortaJ , et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA2017;318:548-56. [DOI: 10.1001/jama.2017.9973]">Cholley 2017</a>, <a href="./references#CD013781-bbs2-0008" title="ErbJ , BeutlhauserT , FeldheiserA , SchusterB , TreskatschS , GrubitzschH , et al. Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery. Journal of International Medical Research2014;42:750-64. [DOI: 10.1177/0300060513516293]">Erb 2014</a>, <a href="./references#CD013781-bbs2-0020" title="KodalliRK , SundarAS , VakamudiM , RavulapaliH , NandipatiS , ChandrasekaranN , et al. Effect of levosimendan on hemodynamic changes in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled study. Annals of Cardiac Anaesthesia2013;16:94-9. [DOI: 10.4103/0971-9784.109737]">Kodalli 2013</a>, and <a href="./references#CD013781-bbs2-0023" title="LevinR , DegrangeM , Del MazoC , TanusE , PorcileR . Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Experimental and Clinical Cardiology2012;17:125-30. [PMID: 23620700]">Levin 2012</a>. However, the relative effect was only generated from <a href="./references#CD013781-bbs2-0004" title="CholleyB , CarubaT , GrosjeanS , AmourJ , OuattaraA , VillacortaJ , et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA2017;318:548-56. [DOI: 10.1001/jama.2017.9973]">Cholley 2017</a>, <a href="./references#CD013781-bbs2-0008" title="ErbJ , BeutlhauserT , FeldheiserA , SchusterB , TreskatschS , GrubitzschH , et al. Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery. Journal of International Medical Research2014;42:750-64. [DOI: 10.1177/0300060513516293]">Erb 2014</a>, and <a href="./references#CD013781-bbs2-0023" title="LevinR , DegrangeM , Del MazoC , TanusE , PorcileR . Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Experimental and Clinical Cardiology2012;17:125-30. [PMID: 23620700]">Levin 2012</a>, while the risk ratio from <a href="./references#CD013781-bbs2-0020" title="KodalliRK , SundarAS , VakamudiM , RavulapaliH , NandipatiS , ChandrasekaranN , et al. Effect of levosimendan on hemodynamic changes in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled study. Annals of Cardiac Anaesthesia2013;16:94-9. [DOI: 10.4103/0971-9784.109737]">Kodalli 2013</a> was not estimable due to no events being observed in either group. There were none out of 326 patients in the levosimendan group requiring cardiac transplantation/VAD implantation compared to 8 out of 322 in the control group and the risk ratio between groups differed in this, favouring levosimendan (RR 0.16, 95% CI 0.03 to 0.91; 648 participants, 4 studies; low heterogeneity) (<a href="./references#CD013781-fig-0099" title="">Analysis 7.25</a>). </p> <p>Information on the number of patients requiring cardiopulmonary resuscitation was restricted to <a href="./references#CD013781-bbs2-0020" title="KodalliRK , SundarAS , VakamudiM , RavulapaliH , NandipatiS , ChandrasekaranN , et al. Effect of levosimendan on hemodynamic changes in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled study. Annals of Cardiac Anaesthesia2013;16:94-9. [DOI: 10.4103/0971-9784.109737]">Kodalli 2013</a> with 30 participants. However, the relative effect for the outcome was not estimable due to no events being observed in either group (<a href="./references#CD013781-fig-0100" title="">Analysis 7.26</a>). </p> </section> <section id="CD013781-sec-0159"> <h6 class="title">Proportion of renal failure</h6> <p>Nine studies reported this outcome (<a href="./references#CD013781-bbs2-0002" title="AnastasiadisK , AntonitsisP , VranisK , KleontasA , AsteriouC , GrosomanidisV , et al. Effectiveness of prophylactic levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting: a randomized pilot study. Interactive Cardiovascular and Thoracic Surgery2016;23:740-8. [DOI: 10.1093/icvts/ivw213]">Anastasiadis 2016</a>; <a href="./references#CD013781-bbs2-0004" title="CholleyB , CarubaT , GrosjeanS , AmourJ , OuattaraA , VillacortaJ , et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA2017;318:548-56. [DOI: 10.1001/jama.2017.9973]">Cholley 2017</a>; <a href="./references#CD013781-bbs2-0008" title="ErbJ , BeutlhauserT , FeldheiserA , SchusterB , TreskatschS , GrubitzschH , et al. Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery. Journal of International Medical Research2014;42:750-64. [DOI: 10.1177/0300060513516293]">Erb 2014</a>; <a href="./references#CD013781-bbs2-0020" title="KodalliRK , SundarAS , VakamudiM , RavulapaliH , NandipatiS , ChandrasekaranN , et al. Effect of levosimendan on hemodynamic changes in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled study. Annals of Cardiac Anaesthesia2013;16:94-9. [DOI: 10.4103/0971-9784.109737]">Kodalli 2013</a>; <a href="./references#CD013781-bbs2-0021" title="LahtinenP , PitkänenO , PölönenP , TurpeinenA , KiviniemiV , UusaroA . Levosimendan reduces heart failure after cardiac surgery: a prospective, randomized, placebo-controlled trial. Criítical Care Medicine2011;39:2263-70. [DOI: 10.1097/CCM.0b013e3182227b97]">Lahtinen 2011</a>; <a href="./references#CD013781-bbs2-0023" title="LevinR , DegrangeM , Del MazoC , TanusE , PorcileR . Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Experimental and Clinical Cardiology2012;17:125-30. [PMID: 23620700]">Levin 2012</a>; <a href="./references#CD013781-bbs2-0024" title="MehtaRH , LeimbergerJD , vanDiepenS , MezaJ , WangA , JankowichR , et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. New England Journal of Medicine2017;376:2032-42. [DOI: 10.1056/NEJMoa1616218]">Mehta 2017</a>; <a href="./references#CD013781-bbs2-0026" title="ShahB , SharmaP , BrahmbhattA , ShahR , RathodB , ShastriN , et al. Study of levosimendan during off-pump coronary artery bypass grafting in patients with LV dysfunction: a double-blind randomized study. Indian Journal of Pharmacology2014;46:29-34. [DOI: 10.4103/0253-7613.125161]">Shah 2014</a>; <a href="./references#CD013781-bbs2-0027" title="SharmaP , MalhotraA , GandhiS , GargP , BishnoiA , GandhiH . Preoperative levosimendan in ischemic mitral valve repair. Asian Cardiovascular and Thoracic Annals2014;22:539-45. [DOI: 10.1177/0218492313499352]">Sharma 2014</a>). However, the relative effect was only generated from <a href="./references#CD013781-bbs2-0002" title="AnastasiadisK , AntonitsisP , VranisK , KleontasA , AsteriouC , GrosomanidisV , et al. Effectiveness of prophylactic levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting: a randomized pilot study. Interactive Cardiovascular and Thoracic Surgery2016;23:740-8. [DOI: 10.1093/icvts/ivw213]">Anastasiadis 2016</a>, <a href="./references#CD013781-bbs2-0004" title="CholleyB , CarubaT , GrosjeanS , AmourJ , OuattaraA , VillacortaJ , et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA2017;318:548-56. [DOI: 10.1001/jama.2017.9973]">Cholley 2017</a>, <a href="./references#CD013781-bbs2-0008" title="ErbJ , BeutlhauserT , FeldheiserA , SchusterB , TreskatschS , GrubitzschH , et al. Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery. Journal of International Medical Research2014;42:750-64. [DOI: 10.1177/0300060513516293]">Erb 2014</a>, <a href="./references#CD013781-bbs2-0021" title="LahtinenP , PitkänenO , PölönenP , TurpeinenA , KiviniemiV , UusaroA . Levosimendan reduces heart failure after cardiac surgery: a prospective, randomized, placebo-controlled trial. Criítical Care Medicine2011;39:2263-70. [DOI: 10.1097/CCM.0b013e3182227b97]">Lahtinen 2011</a>, <a href="./references#CD013781-bbs2-0023" title="LevinR , DegrangeM , Del MazoC , TanusE , PorcileR . Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Experimental and Clinical Cardiology2012;17:125-30. [PMID: 23620700]">Levin 2012</a>, <a href="./references#CD013781-bbs2-0024" title="MehtaRH , LeimbergerJD , vanDiepenS , MezaJ , WangA , JankowichR , et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. New England Journal of Medicine2017;376:2032-42. [DOI: 10.1056/NEJMoa1616218]">Mehta 2017</a>, <a href="./references#CD013781-bbs2-0026" title="ShahB , SharmaP , BrahmbhattA , ShahR , RathodB , ShastriN , et al. Study of levosimendan during off-pump coronary artery bypass grafting in patients with LV dysfunction: a double-blind randomized study. Indian Journal of Pharmacology2014;46:29-34. [DOI: 10.4103/0253-7613.125161]">Shah 2014</a>, and <a href="./references#CD013781-bbs2-0027" title="SharmaP , MalhotraA , GandhiS , GargP , BishnoiA , GandhiH . Preoperative levosimendan in ischemic mitral valve repair. Asian Cardiovascular and Thoracic Annals2014;22:539-45. [DOI: 10.1177/0218492313499352]">Sharma 2014</a>, while the risk ratio from <a href="./references#CD013781-bbs2-0020" title="KodalliRK , SundarAS , VakamudiM , RavulapaliH , NandipatiS , ChandrasekaranN , et al. Effect of levosimendan on hemodynamic changes in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled study. Annals of Cardiac Anaesthesia2013;16:94-9. [DOI: 10.4103/0971-9784.109737]">Kodalli 2013</a> was not estimable due to no events being observed in either group. There were 43 out of 914 patients in the levosimendan group suffering renal failure compared to 61 out of 905 in the control group, with little to no difference in the risk ratio between groups (RR 0.71, 95% CI 0.43 to 1.16; 1819 participants, 9 studies; low heterogeneity) (<a href="./references#CD013781-fig-0101" title="">Analysis 7.27</a>). </p> </section> <section id="CD013781-sec-0160"> <h6 class="title">Quality of life</h6> <p>Overall, eight studies gave information on quality of life (<a href="./references#CD013781-bbs2-0008" title="ErbJ , BeutlhauserT , FeldheiserA , SchusterB , TreskatschS , GrubitzschH , et al. Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery. Journal of International Medical Research2014;42:750-64. [DOI: 10.1177/0300060513516293]">Erb 2014</a>; <a href="./references#CD013781-bbs2-0017" title="Juhl-OlsenP , Jakobsen C-J, RasmussenLA , BhavsarR , Klaaborg K-E, FrederiksenCA , et al. Effects of levosimendan in patients with left ventricular hypertrophy undergoing aortic valve replacement. Acta Anaesthesiologica Scandinavica2015;59:65-77. [DOI: 10.1111/aas.12425]">Juhl‐Olsen 2015</a>; <a href="./references#CD013781-bbs2-0021" title="LahtinenP , PitkänenO , PölönenP , TurpeinenA , KiviniemiV , UusaroA . Levosimendan reduces heart failure after cardiac surgery: a prospective, randomized, placebo-controlled trial. Criítical Care Medicine2011;39:2263-70. [DOI: 10.1097/CCM.0b013e3182227b97]">Lahtinen 2011</a>; <a href="./references#CD013781-bbs2-0023" title="LevinR , DegrangeM , Del MazoC , TanusE , PorcileR . Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Experimental and Clinical Cardiology2012;17:125-30. [PMID: 23620700]">Levin 2012</a>; <a href="./references#CD013781-bbs2-0024" title="MehtaRH , LeimbergerJD , vanDiepenS , MezaJ , WangA , JankowichR , et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. New England Journal of Medicine2017;376:2032-42. [DOI: 10.1056/NEJMoa1616218]">Mehta 2017</a>; <a href="./references#CD013781-bbs2-0026" title="ShahB , SharmaP , BrahmbhattA , ShahR , RathodB , ShastriN , et al. Study of levosimendan during off-pump coronary artery bypass grafting in patients with LV dysfunction: a double-blind randomized study. Indian Journal of Pharmacology2014;46:29-34. [DOI: 10.4103/0253-7613.125161]">Shah 2014</a>; <a href="./references#CD013781-bbs2-0027" title="SharmaP , MalhotraA , GandhiS , GargP , BishnoiA , GandhiH . Preoperative levosimendan in ischemic mitral valve repair. Asian Cardiovascular and Thoracic Annals2014;22:539-45. [DOI: 10.1177/0218492313499352]">Sharma 2014</a>; <a href="./references#CD013781-bbs2-0029" title="TritapepeL , De SantisV , VitaleD , GuarracinoF , PellegriniF , PietropaoliP , et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. British Journal of Anaesthesia2009;102:198-204. [DOI: 10.1093/bja/aen367]">Tritapepe 2009</a>). <a href="./references#CD013781-bbs2-0008" title="ErbJ , BeutlhauserT , FeldheiserA , SchusterB , TreskatschS , GrubitzschH , et al. Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery. Journal of International Medical Research2014;42:750-64. [DOI: 10.1177/0300060513516293]">Erb 2014</a> used the EuroQol 5‐D questionnaire and reported that according to this, quality of life was comparable between levosimendan and control groups six months after surgery (levosimendan group: 6.5 ± 2.1 versus placebo group: 7.4 ± 1.2). Similarly, <a href="./references#CD013781-bbs2-0021" title="LahtinenP , PitkänenO , PölönenP , TurpeinenA , KiviniemiV , UusaroA . Levosimendan reduces heart failure after cardiac surgery: a prospective, randomized, placebo-controlled trial. Criítical Care Medicine2011;39:2263-70. [DOI: 10.1097/CCM.0b013e3182227b97]">Lahtinen 2011</a> used EuroQol 5‐D to assess the quality of life status and found that the quality of life was comparable between groups preoperatively. Six months after surgery, both groups had substantially improved quality of life compared to preoperative values with no difference reported between groups (no quantitative data given). <a href="./references#CD013781-bbs2-0017" title="Juhl-OlsenP , Jakobsen C-J, RasmussenLA , BhavsarR , Klaaborg K-E, FrederiksenCA , et al. Effects of levosimendan in patients with left ventricular hypertrophy undergoing aortic valve replacement. Acta Anaesthesiologica Scandinavica2015;59:65-77. [DOI: 10.1111/aas.12425]">Juhl‐Olsen 2015</a> stated that no patient developed headache or nausea. <a href="./references#CD013781-bbs2-0023" title="LevinR , DegrangeM , Del MazoC , TanusE , PorcileR . Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Experimental and Clinical Cardiology2012;17:125-30. [PMID: 23620700]">Levin 2012</a> narratively pointed out that there were no significant differences in adverse events (hypotension, headache, nausea and vomiting) during the 24‐hour preoperative infusion period between study groups. <a href="./references#CD013781-bbs2-0024" title="MehtaRH , LeimbergerJD , vanDiepenS , MezaJ , WangA , JankowichR , et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. New England Journal of Medicine2017;376:2032-42. [DOI: 10.1056/NEJMoa1616218]">Mehta 2017</a> reported on reasons for premature permanent discontinuation of infusion, i.e. hypotension (26 of 428 in levosimendan group versus 21 of 421 in placebo group) and tachycardia or arrhythmia (2 of 428 in levosimendan group versus 3 of 421 in placebo group). <a href="./references#CD013781-bbs2-0026" title="ShahB , SharmaP , BrahmbhattA , ShahR , RathodB , ShastriN , et al. Study of levosimendan during off-pump coronary artery bypass grafting in patients with LV dysfunction: a double-blind randomized study. Indian Journal of Pharmacology2014;46:29-34. [DOI: 10.4103/0253-7613.125161]">Shah 2014</a> stated that the adverse events occurring during the 24 hours preoperative infusion were hypotension (7 of 25 in levosimendan group versus 2 of 25 in placebo group), need for vasopressors (2 of 25 in levosimendan group versus 1 of 25 in placebo group), headache (3 of 25 in levosimendan group, versus 1 of 25 in placebo group), nausea (2 of 25 in levosimendan group versus 0 of 25 in placebo group), and vomiting (2 of 25 in levosimendan group versus 0 of 25 in placebo group). <a href="./references#CD013781-bbs2-0027" title="SharmaP , MalhotraA , GandhiS , GargP , BishnoiA , GandhiH . Preoperative levosimendan in ischemic mitral valve repair. Asian Cardiovascular and Thoracic Annals2014;22:539-45. [DOI: 10.1177/0218492313499352]">Sharma 2014</a> pointed out that the adverse events occurring during the 24 hours preoperative infusion were hypotension (5 of 20 in levosimendan group versus 3 of 20 in placebo group), need for vasopressors (3 of 20 in levosimendan group versus 2 of 20 in placebo group), headache (2 of 20 in levosimendan group versus 1 of 20 in placebo group), and vomiting (1 of 20 in levosimendan group versus 2 of 20 in placebo group). Regarding quality of life, <a href="./references#CD013781-bbs2-0029" title="TritapepeL , De SantisV , VitaleD , GuarracinoF , PellegriniF , PietropaoliP , et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. British Journal of Anaesthesia2009;102:198-204. [DOI: 10.1093/bja/aen367]">Tritapepe 2009</a> documented that 4 out of 52 patients in the levosimendan group developed hypotension. </p> </section> </section> </section> <section id="CD013781-sec-0161"> <h4 class="title">Subgroup analyses</h4> <p>Due to the small number of studies in most comparisons, subgroup analyses were limited to levosimendan. </p> <section id="CD013781-sec-0162"> <h5 class="title">Regimen of the control group</h5> <p>We had planned to analyse the influence of the control group regimen (placebo‐controlled versus active control). However, only a minority of the included studies investigated levosimendan compared with an active control, so no interpretable results could be obtained based on the available data. There was only one feasible analysis that addressed the impact of control group regimens on atrial fibrillation, and no subgroup interaction was found (<a href="./references#CD013781-fig-0102" title="">Analysis 8.1</a>). </p> </section> <section id="CD013781-sec-0163"> <h5 class="title">Timing of the administration</h5> <p>Given the time points reported in the included studies, it was possible to perform subgroup analyses on all primary endpoints distinguishing between levosimendan administration before surgery (4 to 24 hours in advance) and in the operating room (at induction of anaesthesia, before skin incision or before initiation of the cardiopulmonary bypass machine). Subgroup analyses show evidence of a difference between the placebo group and the levosimendan group favouring levosimendan with respect to 30‐day mortality when the drug was given in the preoperative period (RR 0.30, 95% CI 0.14 to 0.67; <a href="./references#CD013781-fig-0103" title="">Analysis 9.1</a>). However, there was little to no difference between the placebo group and the levosimendan group when the drug was given in the operating room (RR 0.92, 95% CI 0.60 to 1.41; <a href="./references#CD013781-fig-0103" title="">Analysis 9.1</a>). No subgroup interaction was found regarding the incidence of LCOS or adverse events (<a href="./references#CD013781-fig-0104" title="">Analysis 9.2</a>; <a href="./references#CD013781-fig-0105" title="">Analysis 9.3</a>; <a href="./references#CD013781-fig-0106" title="">Analysis 9.4</a>; <a href="./references#CD013781-fig-0107" title="">Analysis 9.5</a>). </p> </section> <section id="CD013781-sec-0164"> <h5 class="title">Administration protocol of levosimendan</h5> <p>Levosimendan can be administered with or without an initial bolus. Therefore, subgroup analyses were performed to assess the potential impact of the administration protocol. These analyses revealed no subgroup interaction for any of the primary endpoints investigated (30‐day mortality, LCOS, adverse events) (<a href="./references#CD013781-fig-0108" title="">Analysis 10.1</a>; <a href="./references#CD013781-fig-0109" title="">Analysis 10.2</a>; <a href="./references#CD013781-fig-0110" title="">Analysis 10.3</a>; <a href="./references#CD013781-fig-0111" title="">Analysis 10.4</a>; <a href="./references#CD013781-fig-0112" title="">Analysis 10.5</a>). </p> </section> <section id="CD013781-sec-0165"> <h5 class="title">Type of cardiac surgery</h5> <p>We aimed to analyse the influence of the type of cardiac surgery performed. However, there were too many mixed surgical intervention studies to have any meaningful comparisons. </p> </section> <section id="CD013781-sec-0166"> <h5 class="title">Participants with versus without pre‐existing LV dysfunction</h5> <p>We aimed to analyse the influence of the severity of the participants' disease (with or without pre‐existing LV dysfunction). However, no subgroup analysis was possible since virtually no events were reported in the limited studies that included participants without LV dysfunction. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013781-sec-0167" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013781-sec-0167"></div> <section id="CD013781-sec-0168"> <h3 class="title" id="CD013781-sec-0168">Summary of main results</h3> <p>This systematic review comprised 29 RCTs involving 3307 participants. Of these, 24 studies addressed levosimendan and compared its efficacy and safety with dobutamine, milrinone, standard cardiac care, or placebo. Another four studies estimated the efficacy and safety of milrinone compared with placebo; one of these studies was designed as a three‐arm intervention study that also evaluated amrinone. An individual study evaluated dopamine versus placebo. </p> <p>In general, confidence in the results of analysed studies was reduced due to relevant risk of bias, imprecision, or inconsistency. Domains of concern encompassed inadequate methods of sequence generation (selection bias) and lack of blinding (performance and detection bias). The majority of trials were small with only a few included participants (high imprecision of results). An acknowledgement of funding by the pharmaceutical industry or missing conflict of interest statements occurred in 19 of 29 trials. </p> <p>Our meta‐analyses showed that levosimendan may reduce the risk of LCOS and probably reduces all‐cause mortality compared to placebo but not compared to standard cardiac care or milrinone (<a href="./full#CD013781-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD013781-tbl-0002">summary of findings Table 2</a>). Subgroup analyses revealed that the beneficial effects of levosimendan were predominantly observed in preoperative drug administration. Our meta‐analyses further indicated that levosimendan compared to placebo, dobutamine, or milrinone but not compared to standard cardiac care may shorten the length of ICU stay and the duration of mechanical ventilation (<a href="./full#CD013781-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD013781-tbl-0002">summary of findings Table 2</a>), but the evidence is very uncertain. There was no conclusive evidence on the effect of dopamine compared to placebo on LCOS and duration of mechanical ventilation, or on the effect of milrinone compared to placebo on all‐cause mortality, length of ICU stay, and duration of mechanical ventilation. For all further comparisons, no data on all‐cause mortality, LCOS, length of ICU stay, or duration of mechanical ventilation were available. The risk of adverse events and the number of participants requiring mechanical circulatory support, if reported, did not clearly differ between study groups for all comparisons. </p> </section> <section id="CD013781-sec-0169"> <h3 class="title" id="CD013781-sec-0169">Overall completeness and applicability of evidence</h3> <p>The available evidence was not sufficient to fully address the objectives of the review. In clinical practice, there are a variety of inotropic drugs. In the identified studies, this diversity was not reflected. A majority of the studies examined levosimendan. An assessment of the efficacy and safety of other inotropic agents was thus not possible or only to a very limited extent. Further limitations related to study size and the availability of relevant outcomes. In most studies, the number of included participants was small. Not all outcomes pre‐specified in the protocol for this review article were reported in all studies, and in some cases, quantitative data were not available. For valid estimation of the efficacy and safety of the prophylactic use of inotropic agents to prevent LCOS and mortality during elective cardiac surgery, it is important to consider relevant influential factors. This comprises the regimen of the control group, the timing and, in the case of levosimendan, the type of inotropic administration, the type of cardiac surgery, and the severity of cardiac disease. However, due to the small number of studies and the lack of quantitative outcome data, the evidence base for the required subgroup analyses was limited. Therefore, the findings of the subgroup analyses, insofar as they were feasible at all, should be viewed with caution. </p> </section> <section id="CD013781-sec-0170"> <h3 class="title" id="CD013781-sec-0170">Quality of the evidence</h3> <p>We downgraded GRADE certainty assessment of RCT outcomes due to imprecision, risk of bias, and inconsistency. Overall, we assessed the certainty of evidence for our primary outcomes as moderate to low for all‐cause mortality, low to very low for incidence of LCOS, and high to very low for adverse events. With the exception of the comparison of levosimendan versus placebo, the criterion of optimal information size was not met for any of the interventions being evaluated. Accordingly, we downgraded the certainty of all outcomes in these comparisons for imprecision. For all‐cause mortality in the comparison of milrinone versus placebo, there was also imprecision due to methodological heterogeneity. We applied downgrading due to risk of bias to outcomes in the comparisons levosimendan versus milrinone, levosimendan versus standard cardiac care, levosimendan versus placebo, and dopamine versus placebo. We downgraded outcomes in the dopamine versus placebo comparison as reasons for exclusion of study participants related to true outcome. In the other comparisons, we downgraded outcomes due to inadequate methods of sequence generation and/or lack of blinding. For inconsistency, we downgraded the outcomes incidence of LCOS, adverse events: atrial fibrillation, length of ICU stay, and duration of mechanical ventilation in the comparisons of levosimendan versus dobutamine, levosimendan versus standard cardiac care, and levosimendan versus placebo. </p> </section> <section id="CD013781-sec-0171"> <h3 class="title" id="CD013781-sec-0171">Potential biases in the review process</h3> <p>Our review has limitations primarily related to a lack of data availability. Although we searched key databases and study registries in collaboration with Cochrane Heart, we cannot exclude the possibility that we may have missed relevant publications. We contacted corresponding authors of the included studies to obtain missing quantitative outcome data, if possible. However, we received an adequate response only in the case of one study (<a href="./references#CD013781-bbs2-0003" title="BaysalA , YanartasM , DogukanM , GundogusN , KocakT , Koksal C. Levosimendan improves renal outcome in cardiac surgery: a randomized trial. Journal of Cardiothoracic and Vascular Anesthesia2014;28:586-94. [DOI: 10.1053/j.jvca.2013.09.004]">Baysal 2014</a>). Bias may have resulted merely from the relatively small total number of studies available and participants included. For most of the outcomes, there were too few studies to create a funnel plot, so we were not able to assess the possibility of publication bias. The limited evidence base also had a negative impact on the feasibility of relevant subgroup analyses. </p> </section> <section id="CD013781-sec-0172"> <h3 class="title" id="CD013781-sec-0172">Agreements and disagreements with other studies or reviews</h3> <p>The prophylactic use of inotropic agents in adult patients undergoing cardiac surgery to prevent LCOS and associated mortality and morbidity has been evaluated in two meta‐analyses so far (<a href="./references#CD013781-bbs2-0060" title="ElbadawiA , ElgendyIY , SaadM , MegalyM , MentiasA , AbuzaidAS , et al. Meta-analysis of trials on prophylactic use of levosimendan in patients undergoing cardiac surgery. Annals of Thoracic Surgery2018;105(5):1403-10.">Elbadawi 2018</a>; <a href="./references#CD013781-bbs2-0095" title="WangW , ZhouX , LiaoX , LiuB , YuH . The efficacy and safety of prophylactic use of levosimendan on patients undergoing coronary artery bypass graft. Journal of Anesthesia2019;33(4):543-50.">Wang 2019a</a>). Both review articles focused on the potential benefit of levosimendan. Meta‐analyses on the safety and efficacy of strictly prophylactic administration of other inotropic agents are not available. </p> <p><a href="./references#CD013781-bbs2-0060" title="ElbadawiA , ElgendyIY , SaadM , MegalyM , MentiasA , AbuzaidAS , et al. Meta-analysis of trials on prophylactic use of levosimendan in patients undergoing cardiac surgery. Annals of Thoracic Surgery2018;105(5):1403-10.">Elbadawi 2018</a> included participants undergoing cardiac surgery (CABG and/or valve surgery) who received levosimendan before, during, or after surgery for prophylactic reasons. Only RCTs were included. There were no restrictions regarding the type of control group. A total of 16 studies with 2273 participants were analysed. No statistically significant differences were found between levosimendan and control groups with regard to 30‐day mortality, incidence of perioperative myocardial infarction or postoperative cerebrovascular events, or the need for additional inotropic agents, postoperative dialysis or mechanical assist devices. In contrast, the levosimendan group showed a significant reduction in the duration of ventilation time and ICU stay as well as the incidence of postoperative acute kidney disease on the one hand, and a significantly increased incidence of atrial fibrillation on the other. Concerning the primary outcome of the meta‐analysis, 30‐day mortality, a subgroup analysis was performed to examine the potential influence of pre‐existing LV dysfunction (LVEF &lt; 40% versus LVEF &gt; 40%), the regimen of the control group (placebo‐controlled versus active control), and the timing of administration (preoperative versus postoperative). Here, a subgroup interaction was found solely for the regimen of the control group. This suggested that a prophylactic administration of levosimendan was associated with improved 30‐day mortality compared to active control, but not compared to placebo control. </p> <p><a href="./references#CD013781-bbs2-0095" title="WangW , ZhouX , LiaoX , LiuB , YuH . The efficacy and safety of prophylactic use of levosimendan on patients undergoing coronary artery bypass graft. Journal of Anesthesia2019;33(4):543-50.">Wang 2019a</a> focused on the prophylactic administration of levosimendan compared with any control in adult participants undergoing CABG. Twenty‐one RCTs with 1727 participants were included. The meta‐analysis showed a statistically significant reduction in mortality, the need for IABP and additional inotropic agents, and the incidence of atrial fibrillation, myocardial infarction or renal dysfunction in the levosimendan group compared to the control group. Furthermore, a statistically significant increased incidence of hypotension and associated need for vasoactive medication was found with levosimendan administration. Subgroup analyses showed that the beneficial effects of levosimendan were predominantly observed in isolated on‐pump CABG and preoperative bolus drug administration. Interestingly, the subgroup analysis also indicated that a reduction in mortality with levosimendan was limited to the comparison with placebo control. </p> <p>Our meta‐analyses showed that levosimendan may reduce the risk of LCOS and and probably reduces associated all‐cause mortality as well as the need for IABP when compared to placebo, but not when compared to standard cardiac care, dobutamine, or milrinone. Our meta‐analyses further indicated that levosimendan compared to placebo, dobutamine, or milrinone but not compared to standard cardiac care may shorten the length of ICU stay and the duration of mechanical ventilation, but the evidence is very uncertain. We did not find a significant effect of levosimendan on the incidence of adverse events or the need for additional inotropic medication. Our data, as do the findings of <a href="./references#CD013781-bbs2-0060" title="ElbadawiA , ElgendyIY , SaadM , MegalyM , MentiasA , AbuzaidAS , et al. Meta-analysis of trials on prophylactic use of levosimendan in patients undergoing cardiac surgery. Annals of Thoracic Surgery2018;105(5):1403-10.">Elbadawi 2018</a> and <a href="./references#CD013781-bbs2-0095" title="WangW , ZhouX , LiaoX , LiuB , YuH . The efficacy and safety of prophylactic use of levosimendan on patients undergoing coronary artery bypass graft. Journal of Anesthesia2019;33(4):543-50.">Wang 2019a</a>, provide some indications of the possible efficacy and safety of prophylactic use of levosimendan in elective cardiac surgery. Consistent with <a href="./references#CD013781-bbs2-0095" title="WangW , ZhouX , LiaoX , LiuB , YuH . The efficacy and safety of prophylactic use of levosimendan on patients undergoing coronary artery bypass graft. Journal of Anesthesia2019;33(4):543-50.">Wang 2019a</a>, our subgroup analyses showed that a favourable effect of prophylactic levosimendan on LCOS incidence and mortality was limited to preoperative administration. However, the quality and validity of the data are very poor. Given the limited evidence available, there is an unmet need for large‐scale, well‐designed randomised trials. Notably, future studies of levosimendan should be designed to determine the potential benefit in specific patient groups (with/without left ventricular dysfunction) and surgery types, as well as the optimal administration protocol. </p> <p>There are two meta‐analyses in the scientific literature dealing with the prophylactic administration of levosimendan during heart surgery in children due to congenital heart disease (<a href="./references#CD013781-bbs2-0065" title="HummelJ , RückerG , StillerB . Prophylactic levosimendan for the prevention of low cardiac output syndrome and mortality in paediatric patients undergoing surgery for congenital heart disease. Cochrane Database of Systematic Reviews2017, Issue 8. Art. No: CD011312. [DOI: 10.1002/14651858.CD011312.pub3]">Hummel 2017</a>; <a href="./references#CD013781-bbs2-0096" title="WangH , LuoQ , LiY , ZhangL , WuX , YanF . Effect of prophylactic levosimendan on all-cause mortality in pediatric patients undergoing cardiac surgery—an updated systematic review and meta-analysis. Frontiers in Pediatrics2020;8:456. [DOI: 10.3389/fped.2020.00456]">Wang 2020</a>). Both studies found no effect on mortality rates. However, only a very limited number of RCTs and participants could be included in both reviews, so no firm conclusions were drawn by the study authors. </p> <p>There are several meta‐analyses that investigated the safety and efficacy of the inotropic agents milrinone or levosimendan in cardiac surgery, though without distinguishing between prophylactic use and treatment of acute LCOS. Regarding milrinone, all but one meta‐analyses found no effect on mortality rates (<a href="./references#CD013781-bbs2-0071" title="MajureDT , GrecoT , GrecoM , PonschabM , Biondi-ZoccaiG , ZangrilloA , et al. Meta-analysis of randomized trials of effect of milrinone on mortality in cardiac surgery: an update. Journal of Cardiothoracic and Vascular Anesthesia2013;27(2):220-9.">Majure 2013</a>; <a href="./references#CD013781-bbs2-0080" title="Ren Y-S, Li L-F, PengT , Tan Y-J, SunY , Cheng G-L, et al. The effect of milrinone on mortality in adult patients who underwent CABG surgery: a systematic review of randomized clinical trials with a meta-analysis and trialsequential analysis. BMC Cardiovascular Disorders2020;20:328. [DOI: 10.1186/s12872-020-01598-8]">Ren 2020</a>; <a href="./references#CD013781-bbs2-0082" title="RongLQ , RahoumaM , AbouarabA , Di FrancoA , CalauttiNM , FitzgeraldMM , et al. Intravenous and inhaled milrinone in adult cardiac surgery patients: a pairwise and network meta-analysis. Journal of Cardiothoracic and Vascular Anesthesia2019;33:663673.">Rong 2019</a>; <a href="./references#CD013781-bbs2-0089" title="UshioM , EgiM , WakabayashiJ , NishimuraT , MiyatakeY , ObataN , et al. Impact of milrinone administration in adult cardiac surgery patients: updated meta-analysis. Journal of Cardiothoracic and Vascular Anesthesia2016;30(6):1454-60.">Ushio 2016</a>; <a href="./references#CD013781-bbs2-0100" title="YouZ , HuangL , ChengX , WuQ , JiangX , WuY . Effect of milrinone on cardiac functions in patients undergoing coronary artery bypass graft: a meta-analysis of randomized clinical trials. Drug Design, Development and Therapy2016;10:53-8.">You 2016</a>; <a href="./references#CD013781-bbs2-0102" title="ZangrilloA , Biondi-ZoccaiG , PonschabM , GrecoM , CornoL , CovelloRD , et al. Milrinone and mortality in adult cardiac surgery: a meta-analysis. Journal of Cardiothoracic and Vascular Anesthesia2012;26(1):70-7.">Zangrillo 2012</a>). Regarding levosimendan, the majority of reviews reported a reduction in mortality rates in the intervention group compared to the control (<a href="./references#CD013781-bbs2-0062" title="HarrisonRW , HasselbladV , MehtaRH , LevinR , HarringtonRA , AlexanderJH . Effect of levosimendan on survival and adverse events after cardiac surgery: a meta-analysis. Journal of Cardiothoracic and Vascular Anesthesia2013;27(6):1224-32.">Harrison 2013</a>; <a href="./references#CD013781-bbs2-0066" title="LandoniG , Biondi-ZoccaiG , GrecoM , GrecoT , BignamiE , MorelliA , et al. Effects of levosimendan on mortality and hospitalization: a meta-analysis of randomized controlled studies. Critical Care Medicine2012;40(2):634-46.">Landoni 2012</a>; <a href="./references#CD013781-bbs2-0068" title="LeeCT , LinYC , YehYC , ChenTL , ChenCY . Effects of levosimendan for perioperative cardiovascular dysfunction in patients receiving cardiac surgery. Intensive Care Medicine2017;43(12):1929-30. [DOI: 10.1007/s00134-017-4927-5]">Lee 2017</a>; <a href="./references#CD013781-bbs2-0073" title="NgKT , ChanXL , TanW , WangCY . Levosimendan use in patients with preoperative low ejection fraction undergoing cardiac surgery: a systematic review with meta-analysis and trial sequential analysis. Journal of Clinical Anesthesia2019;52:37-47.">Ng 2019</a>; <a href="./references#CD013781-bbs2-0074" title="OliverosH , GarcíaH , RubioC , NavarreteJ . Perioperative use of levosimendan in patients undergoing cardiac surgery: systematic review and meta-analysis. Colombian Journal of Anesthesiology2019;47(3):142-53.">Oliveros 2019</a>; <a href="./references#CD013781-bbs2-0077" title="PutzuA , ClivioS , BellettiA , CassinaT . Perioperative levosimendan in cardiac surgery: a systematic review with meta-analysis and trial sequential analysis. International Journal of Cardiology2018;251:22-31.">Putzu 2018</a>; <a href="./references#CD013781-bbs2-0079" title="QiangH , LuoX , Huo J-H, Wang Z-Q. Perioperative use of levosimendan improves clinical outcomes in patients after cardiac surgery: a systematic review and meta-analysis. Journal of Cardiovascular Pharmacology2018;72(1):11-8.">Qiang 2018</a>; <a href="./references#CD013781-bbs2-0088" title="TenaMA , UrsoS , GonzálezJM , SantanaL , SadabaR , JuarezP , et al. Levosimendan versus placebo in cardiac surgery: a systematic review and meta-analysis. Interactive Cardiovascular and Thoracic Surgery2018;27(5):677-85.">Tena 2018</a>; <a href="./references#CD013781-bbs2-0093" title="WangB , HeX , GongY , ChengB . Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery: an update meta-analysis and trial sequential analysis. BioMed Research International2018;2018:7563083.">Wang 2018</a>; <a href="./references#CD013781-bbs2-0098" title=" XingZ , TangL , ChenP , HuangJ , PengX , HuX . Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery: a meta-analysisand trial sequential analysis of randomized trials. Scientific Reports2018;8:7775. [DOI: 10.1038/s41598-018-26206-w]">Xing 2018</a>; <a href="./references#CD013781-bbs2-0101" title="ZangrilloA , Biondi-ZoccaiG , MizziA , BrunoG , BignamiA , GerliC , et al. Levosimendan reduces cardiac troponin release after cardiac surgery: a meta-analysis of randomized controlled studies. Journal of Cardiothoracic and Vascular Anesthesia2009;23(4):474-8.">Zangrillo 2009</a>; <a href="./references#CD013781-bbs2-0103" title="ZhouX , HuC , XuZ , LiuP , ZhangY , SunL , et al. Effect of levosimendan on clinical outcomes in adult patients undergoing cardiac surgery: a meta-analysis of randomized controlled trials. Interactive Cardiovascular and Thoracic Surgery2018;26(6):1016-26.">Zhou 2018</a>). However, several of these meta‐analyses also stressed the limited quality of this evidence. In two meta‐analyses, a trial sequential analysis (TSA) was performed, stating that the effect was not reliable (<a href="./references#CD013781-bbs2-0093" title="WangB , HeX , GongY , ChengB . Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery: an update meta-analysis and trial sequential analysis. BioMed Research International2018;2018:7563083.">Wang 2018</a>; <a href="./references#CD013781-bbs2-0098" title=" XingZ , TangL , ChenP , HuangJ , PengX , HuX . Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery: a meta-analysisand trial sequential analysis of randomized trials. Scientific Reports2018;8:7775. [DOI: 10.1038/s41598-018-26206-w]">Xing 2018</a>). In three meta‐analyses, a subgroup analysis regarding the trials' risk of bias was performed. In this analysis, the levosimendan effect was lost if only studies with high quality were included (<a href="./references#CD013781-bbs2-0073" title="NgKT , ChanXL , TanW , WangCY . Levosimendan use in patients with preoperative low ejection fraction undergoing cardiac surgery: a systematic review with meta-analysis and trial sequential analysis. Journal of Clinical Anesthesia2019;52:37-47.">Ng 2019</a>; <a href="./references#CD013781-bbs2-0074" title="OliverosH , GarcíaH , RubioC , NavarreteJ . Perioperative use of levosimendan in patients undergoing cardiac surgery: systematic review and meta-analysis. Colombian Journal of Anesthesiology2019;47(3):142-53.">Oliveros 2019</a>; <a href="./references#CD013781-bbs2-0077" title="PutzuA , ClivioS , BellettiA , CassinaT . Perioperative levosimendan in cardiac surgery: a systematic review with meta-analysis and trial sequential analysis. International Journal of Cardiology2018;251:22-31.">Putzu 2018</a>). According to <a href="./references#CD013781-bbs2-0103" title="ZhouX , HuC , XuZ , LiuP , ZhangY , SunL , et al. Effect of levosimendan on clinical outcomes in adult patients undergoing cardiac surgery: a meta-analysis of randomized controlled trials. Interactive Cardiovascular and Thoracic Surgery2018;26(6):1016-26.">Zhou 2018</a>, the publication date could also play a role, since according to their subgroup analysis, the levosimendan effect could only be observed in studies conducted before the year 2015. Most authors of the above‐mentioned review articles thus concluded that there is not enough evidence of high quality to support the systematic use of levosimendan in cardiac surgery. The lack of high‐quality evidence is also evident in the present meta‐analysis. In future, special care should be taken to carefully differentiate the indications for the use of inotropics in cardiac surgery when evaluating them. A valid and meaningful assessment can only be achieved if prophylactic and acute use are considered separately. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013781-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-FIG-01" target="_blank"><b></b></a></p> </div><img alt="PRISMA study flow diagram" data-id="CD013781-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/full#CD013781-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD013781-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/full#CD013781-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013781-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/full#CD013781-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-FIG-04" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD013781-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/full#CD013781-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-FIG-05" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD013781-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/full#CD013781-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Comparison 1: Amrinone versus placebo, Outcome 1: Secondary outcome: cardiac index (postoperative nadir)" data-id="CD013781-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Comparison 1: Amrinone versus placebo, Outcome 1: Secondary outcome: cardiac index (postoperative nadir) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Comparison 2: Dopamine versus placebo, Outcome 1: Primary outcome: incidence of LCOS" data-id="CD013781-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Comparison 2: Dopamine versus placebo, Outcome 1: Primary outcome: incidence of LCOS </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Comparison 2: Dopamine versus placebo, Outcome 2: Primary outcome: adverse events ‐ atrial fibrillation" data-id="CD013781-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Comparison 2: Dopamine versus placebo, Outcome 2: Primary outcome: adverse events ‐ atrial fibrillation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Comparison 2: Dopamine versus placebo, Outcome 3: Primary outcome: adverse events ‐ perioperative myocardial infarction" data-id="CD013781-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Comparison 2: Dopamine versus placebo, Outcome 3: Primary outcome: adverse events ‐ perioperative myocardial infarction </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Comparison 2: Dopamine versus placebo, Outcome 4: Secondary outcome: length of hospital stay (days)" data-id="CD013781-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Comparison 2: Dopamine versus placebo, Outcome 4: Secondary outcome: length of hospital stay (days) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Comparison 2: Dopamine versus placebo, Outcome 5: Secondary outcome: mean arterial pressure (24 hours after surgery)" data-id="CD013781-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Comparison 2: Dopamine versus placebo, Outcome 5: Secondary outcome: mean arterial pressure (24 hours after surgery) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Comparison 2: Dopamine versus placebo, Outcome 6: Secondary outcome: duration of mechanical ventilation (hours)" data-id="CD013781-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Comparison 2: Dopamine versus placebo, Outcome 6: Secondary outcome: duration of mechanical ventilation (hours) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Comparison 2: Dopamine versus placebo, Outcome 7: Secondary outcome: number of participants requiring additional inotropic drugs ‐ dopamine" data-id="CD013781-fig-0013" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Comparison 2: Dopamine versus placebo, Outcome 7: Secondary outcome: number of participants requiring additional inotropic drugs ‐ dopamine </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Comparison 2: Dopamine versus placebo, Outcome 8: Secondary outcome: proportion of renal failure" data-id="CD013781-fig-0014" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Comparison 2: Dopamine versus placebo, Outcome 8: Secondary outcome: proportion of renal failure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Comparison 3: Milrinone versus placebo, Outcome 1: Primary outcome: all‐cause mortality" data-id="CD013781-fig-0015" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Comparison 3: Milrinone versus placebo, Outcome 1: Primary outcome: all‐cause mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Comparison 3: Milrinone versus placebo, Outcome 2: Primary outcome: adverse events ‐ cardiogenic shock" data-id="CD013781-fig-0016" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Comparison 3: Milrinone versus placebo, Outcome 2: Primary outcome: adverse events ‐ cardiogenic shock </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Comparison 3: Milrinone versus placebo, Outcome 3: Primary outcome: adverse events ‐ atrial fibrillation" data-id="CD013781-fig-0017" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Comparison 3: Milrinone versus placebo, Outcome 3: Primary outcome: adverse events ‐ atrial fibrillation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Comparison 3: Milrinone versus placebo, Outcome 4: Primary outcome: adverse events ‐ perioperative myocardial infarction" data-id="CD013781-fig-0018" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Comparison 3: Milrinone versus placebo, Outcome 4: Primary outcome: adverse events ‐ perioperative myocardial infarction </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Comparison 3: Milrinone versus placebo, Outcome 5: Primary outcome: adverse events ‐ non‐embolic stroke or transient ischaemic attack" data-id="CD013781-fig-0019" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Comparison 3: Milrinone versus placebo, Outcome 5: Primary outcome: adverse events ‐ non‐embolic stroke or transient ischaemic attack </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Comparison 3: Milrinone versus placebo, Outcome 6: Secondary outcome: length of ICU stay (days)" data-id="CD013781-fig-0020" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Comparison 3: Milrinone versus placebo, Outcome 6: Secondary outcome: length of ICU stay (days) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Comparison 3: Milrinone versus placebo, Outcome 7: Secondary outcome: cardiac index" data-id="CD013781-fig-0021" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Comparison 3: Milrinone versus placebo, Outcome 7: Secondary outcome: cardiac index </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-003.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Comparison 3: Milrinone versus placebo, Outcome 8: Secondary outcome: mean arterial pressure" data-id="CD013781-fig-0022" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-003.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-003.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3: Comparison 3: Milrinone versus placebo, Outcome 8: Secondary outcome: mean arterial pressure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-003.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-003.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Comparison 3: Milrinone versus placebo, Outcome 9: Secondary outcome: PCWP" data-id="CD013781-fig-0023" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-003.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-003.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3: Comparison 3: Milrinone versus placebo, Outcome 9: Secondary outcome: PCWP </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-003.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-003.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Comparison 3: Milrinone versus placebo, Outcome 10: Secondary outcome: duration of mechanical ventilation (hours)" data-id="CD013781-fig-0024" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-003.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-003.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3: Comparison 3: Milrinone versus placebo, Outcome 10: Secondary outcome: duration of mechanical ventilation (hours) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-003.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-003.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Comparison 3: Milrinone versus placebo, Outcome 11: Secondary outcome: proportion of weaning failure within 48 hours of extubation" data-id="CD013781-fig-0025" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-003.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-003.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3: Comparison 3: Milrinone versus placebo, Outcome 11: Secondary outcome: proportion of weaning failure within 48 hours of extubation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-003.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-003.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Comparison 3: Milrinone versus placebo, Outcome 12: Secondary outcome: number of participants requiring mechanical circulatory support" data-id="CD013781-fig-0026" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-003.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-003.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3: Comparison 3: Milrinone versus placebo, Outcome 12: Secondary outcome: number of participants requiring mechanical circulatory support </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-003.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-003.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Comparison 3: Milrinone versus placebo, Outcome 13: Secondary outcome: number of participants requiring additional inotropic drugs" data-id="CD013781-fig-0027" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-003.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-003.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3: Comparison 3: Milrinone versus placebo, Outcome 13: Secondary outcome: number of participants requiring additional inotropic drugs </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-003.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-003.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Comparison 3: Milrinone versus placebo, Outcome 14: Secondary outcome: number of participants requiring additional inotropic drugs ‐ epinephrine" data-id="CD013781-fig-0028" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-003.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-003.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.14</div> <div class="figure-caption"> <p>Comparison 3: Comparison 3: Milrinone versus placebo, Outcome 14: Secondary outcome: number of participants requiring additional inotropic drugs ‐ epinephrine </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-003.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-003.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Comparison 3: Milrinone versus placebo, Outcome 15: Secondary outcome: number of participants requiring additional inotropic drugs ‐ norepinephrine" data-id="CD013781-fig-0029" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-003.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-003.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.15</div> <div class="figure-caption"> <p>Comparison 3: Comparison 3: Milrinone versus placebo, Outcome 15: Secondary outcome: number of participants requiring additional inotropic drugs ‐ norepinephrine </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-003.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-003.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Comparison 3: Milrinone versus placebo, Outcome 16: Secondary outcome: number of participants requiring additional inotropic drugs ‐ dobutamine" data-id="CD013781-fig-0030" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-003.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-003.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.16</div> <div class="figure-caption"> <p>Comparison 3: Comparison 3: Milrinone versus placebo, Outcome 16: Secondary outcome: number of participants requiring additional inotropic drugs ‐ dobutamine </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-003.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-003.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Comparison 3: Milrinone versus placebo, Outcome 17: Secondary outcome: number of participants requiring additional inotropic drugs ‐ phenylephrine" data-id="CD013781-fig-0031" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-003.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-003.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.17</div> <div class="figure-caption"> <p>Comparison 3: Comparison 3: Milrinone versus placebo, Outcome 17: Secondary outcome: number of participants requiring additional inotropic drugs ‐ phenylephrine </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-003.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-003.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Comparison 3: Milrinone versus placebo, Outcome 18: Secondary outcome: proportion of renal failure" data-id="CD013781-fig-0032" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-003.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-003.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.18</div> <div class="figure-caption"> <p>Comparison 3: Comparison 3: Milrinone versus placebo, Outcome 18: Secondary outcome: proportion of renal failure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-003.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Comparison 4: Levosimendan versus dobutamine, Outcome 1: Primary outcome: adverse events ‐ atrial fibrillation" data-id="CD013781-fig-0033" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Comparison 4: Levosimendan versus dobutamine, Outcome 1: Primary outcome: adverse events ‐ atrial fibrillation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Comparison 4: Levosimendan versus dobutamine, Outcome 2: Secondary outcome: length of hospital stay (days)" data-id="CD013781-fig-0034" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Comparison 4: Levosimendan versus dobutamine, Outcome 2: Secondary outcome: length of hospital stay (days) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Comparison 4: Levosimendan versus dobutamine, Outcome 3: Secondary outcome: length of ICU stay (days)" data-id="CD013781-fig-0035" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Comparison 4: Levosimendan versus dobutamine, Outcome 3: Secondary outcome: length of ICU stay (days) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Comparison 4: Levosimendan versus dobutamine, Outcome 4: Secondary analysis: cardiac index" data-id="CD013781-fig-0036" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Comparison 4: Levosimendan versus dobutamine, Outcome 4: Secondary analysis: cardiac index </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Comparison 4: Levosimendan versus dobutamine, Outcome 5: Secondary outcome: mean arterial pressure" data-id="CD013781-fig-0037" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Comparison 4: Levosimendan versus dobutamine, Outcome 5: Secondary outcome: mean arterial pressure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-004.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Comparison 4: Levosimendan versus dobutamine, Outcome 6: Secondary analysis: PCWP" data-id="CD013781-fig-0038" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-004.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-004.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4: Comparison 4: Levosimendan versus dobutamine, Outcome 6: Secondary analysis: PCWP </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-004.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-004.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Comparison 4: Levosimendan versus dobutamine, Outcome 7: Secondary outcome: duration of mechanical ventilation (hours)" data-id="CD013781-fig-0039" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-004.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-004.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4: Comparison 4: Levosimendan versus dobutamine, Outcome 7: Secondary outcome: duration of mechanical ventilation (hours) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-004.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-004.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Comparison 4: Levosimendan versus dobutamine, Outcome 8: Secondary outcome: number of participants requiring mechanical circulatory support" data-id="CD013781-fig-0040" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-004.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-004.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4: Comparison 4: Levosimendan versus dobutamine, Outcome 8: Secondary outcome: number of participants requiring mechanical circulatory support </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-004.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-004.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Comparison 4: Levosimendan versus dobutamine, Outcome 9: Secondary outcome: number of participants requiring additional inotropic drugs" data-id="CD013781-fig-0041" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-004.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-004.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4: Comparison 4: Levosimendan versus dobutamine, Outcome 9: Secondary outcome: number of participants requiring additional inotropic drugs </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-004.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-004.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Comparison 4: Levosimendan versus dobutamine, Outcome 10: Secondary outcome: number of participants requiring additional inotropic drugs ‐ epinephrine" data-id="CD013781-fig-0042" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-004.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-004.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4: Comparison 4: Levosimendan versus dobutamine, Outcome 10: Secondary outcome: number of participants requiring additional inotropic drugs ‐ epinephrine </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-004.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-004.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Comparison 4: Levosimendan versus dobutamine, Outcome 11: Secondary outcome: number of participants requiring additional inotropic drugs ‐ norepinephrine" data-id="CD013781-fig-0043" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-004.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-004.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.11</div> <div class="figure-caption"> <p>Comparison 4: Comparison 4: Levosimendan versus dobutamine, Outcome 11: Secondary outcome: number of participants requiring additional inotropic drugs ‐ norepinephrine </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-004.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Comparison 5: Levosimendan versus standard cardiac care, Outcome 1: Primary outcome: all‐cause mortality" data-id="CD013781-fig-0044" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Comparison 5: Levosimendan versus standard cardiac care, Outcome 1: Primary outcome: all‐cause mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Comparison 5: Levosimendan versus standard cardiac care, Outcome 2: Primary outcome: incidence of LCOS" data-id="CD013781-fig-0045" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Comparison 5: Levosimendan versus standard cardiac care, Outcome 2: Primary outcome: incidence of LCOS </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Comparison 5: Levosimendan versus standard cardiac care, Outcome 3: Primary outcome: adverse events ‐ cardiogenic shock" data-id="CD013781-fig-0046" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Comparison 5: Levosimendan versus standard cardiac care, Outcome 3: Primary outcome: adverse events ‐ cardiogenic shock </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Comparison 5: Levosimendan versus standard cardiac care, Outcome 4: Primary outcome: adverse events ‐ atrial fibrillation" data-id="CD013781-fig-0047" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Comparison 5: Levosimendan versus standard cardiac care, Outcome 4: Primary outcome: adverse events ‐ atrial fibrillation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Comparison 5: Levosimendan versus standard cardiac care, Outcome 5: Primary outcome: adverse events ‐ perioperative myocardial infarction" data-id="CD013781-fig-0048" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: Comparison 5: Levosimendan versus standard cardiac care, Outcome 5: Primary outcome: adverse events ‐ perioperative myocardial infarction </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-005.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Comparison 5: Levosimendan versus standard cardiac care, Outcome 6: Primary outcome: adverse events ‐ non‐embolic stroke or transient ischaemic attack" data-id="CD013781-fig-0049" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-005.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-005.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5: Comparison 5: Levosimendan versus standard cardiac care, Outcome 6: Primary outcome: adverse events ‐ non‐embolic stroke or transient ischaemic attack </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-005.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-005.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Comparison 5: Levosimendan versus standard cardiac care, Outcome 7: Secondary outcome: length of hospital stay (days)" data-id="CD013781-fig-0050" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-005.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-005.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5: Comparison 5: Levosimendan versus standard cardiac care, Outcome 7: Secondary outcome: length of hospital stay (days) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-005.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-005.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Comparison 5: Levosimendan versus standard cardiac care, Outcome 8: Secondary outcome: length of ICU stay (days)" data-id="CD013781-fig-0051" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-005.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-005.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5: Comparison 5: Levosimendan versus standard cardiac care, Outcome 8: Secondary outcome: length of ICU stay (days) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-005.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-005.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Comparison 5: Levosimendan versus standard cardiac care, Outcome 9: Secondary outcome: cardiac index" data-id="CD013781-fig-0052" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-005.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-005.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.9</div> <div class="figure-caption"> <p>Comparison 5: Comparison 5: Levosimendan versus standard cardiac care, Outcome 9: Secondary outcome: cardiac index </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-005.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-005.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Comparison 5: Levosimendan versus standard cardiac care, Outcome 10: Secondary outcome: mean arterial pressure" data-id="CD013781-fig-0053" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-005.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-005.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.10</div> <div class="figure-caption"> <p>Comparison 5: Comparison 5: Levosimendan versus standard cardiac care, Outcome 10: Secondary outcome: mean arterial pressure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-005.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-005.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Comparison 5: Levosimendan versus standard cardiac care, Outcome 11: Secondary outcome: PCWP" data-id="CD013781-fig-0054" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-005.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-005.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.11</div> <div class="figure-caption"> <p>Comparison 5: Comparison 5: Levosimendan versus standard cardiac care, Outcome 11: Secondary outcome: PCWP </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-005.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-005.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Comparison 5: Levosimendan versus standard cardiac care, Outcome 12: Secondary outcome: duration of mechanical ventilation (hours)" data-id="CD013781-fig-0055" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-005.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-005.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.12</div> <div class="figure-caption"> <p>Comparison 5: Comparison 5: Levosimendan versus standard cardiac care, Outcome 12: Secondary outcome: duration of mechanical ventilation (hours) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-005.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-005.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Comparison 5: Levosimendan versus standard cardiac care, Outcome 13: Secondary outcome: proportion of weaning failure within 48 hours of extubation" data-id="CD013781-fig-0056" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-005.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-005.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.13</div> <div class="figure-caption"> <p>Comparison 5: Comparison 5: Levosimendan versus standard cardiac care, Outcome 13: Secondary outcome: proportion of weaning failure within 48 hours of extubation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-005.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-005.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Comparison 5: Levosimendan versus standard cardiac care, Outcome 14: Secondary outcome: number of participants requiring mechanical circulatory support" data-id="CD013781-fig-0057" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-005.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-005.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.14</div> <div class="figure-caption"> <p>Comparison 5: Comparison 5: Levosimendan versus standard cardiac care, Outcome 14: Secondary outcome: number of participants requiring mechanical circulatory support </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-005.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-005.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Comparison 5: Levosimendan versus standard cardiac care, Outcome 15: Secondary outcome: number of participants requiring additional inotropic drugs" data-id="CD013781-fig-0058" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-005.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-005.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.15</div> <div class="figure-caption"> <p>Comparison 5: Comparison 5: Levosimendan versus standard cardiac care, Outcome 15: Secondary outcome: number of participants requiring additional inotropic drugs </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-005.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-005.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Comparison 5: Levosimendan versus standard cardiac care, Outcome 16: Secondary outcome: number of participants requiring additional inotropic drugs ‐ epinephrine" data-id="CD013781-fig-0059" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-005.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-005.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.16</div> <div class="figure-caption"> <p>Comparison 5: Comparison 5: Levosimendan versus standard cardiac care, Outcome 16: Secondary outcome: number of participants requiring additional inotropic drugs ‐ epinephrine </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-005.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-005.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Comparison 5: Levosimendan versus standard cardiac care, Outcome 17: Secondary outcome: number of participants requiring additional inotropic drugs ‐ norepinephrine" data-id="CD013781-fig-0060" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-005.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-005.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.17</div> <div class="figure-caption"> <p>Comparison 5: Comparison 5: Levosimendan versus standard cardiac care, Outcome 17: Secondary outcome: number of participants requiring additional inotropic drugs ‐ norepinephrine </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-005.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-005.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Comparison 5: Levosimendan versus standard cardiac care, Outcome 18: Secondary outcome: number of participants requiring additional inotropic drugs ‐ dopamine" data-id="CD013781-fig-0061" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-005.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-005.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.18</div> <div class="figure-caption"> <p>Comparison 5: Comparison 5: Levosimendan versus standard cardiac care, Outcome 18: Secondary outcome: number of participants requiring additional inotropic drugs ‐ dopamine </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-005.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-005.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Comparison 5: Levosimendan versus standard cardiac care, Outcome 19: Secondary outcome: number of participants requiring additional inotropic drugs ‐ dobutamine" data-id="CD013781-fig-0062" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-005.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-005.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.19</div> <div class="figure-caption"> <p>Comparison 5: Comparison 5: Levosimendan versus standard cardiac care, Outcome 19: Secondary outcome: number of participants requiring additional inotropic drugs ‐ dobutamine </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-005.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-005.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Comparison 5: Levosimendan versus standard cardiac care, Outcome 20: Secondary outcome: number of participants requiring cardiac transplantation" data-id="CD013781-fig-0063" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-005.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-005.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.20</div> <div class="figure-caption"> <p>Comparison 5: Comparison 5: Levosimendan versus standard cardiac care, Outcome 20: Secondary outcome: number of participants requiring cardiac transplantation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-005.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-005.21" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Comparison 5: Levosimendan versus standard cardiac care, Outcome 21: Secondary outcome: number of participants requiring cardiopulmonary resuscitation" data-id="CD013781-fig-0064" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-005.21.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-005.21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.21</div> <div class="figure-caption"> <p>Comparison 5: Comparison 5: Levosimendan versus standard cardiac care, Outcome 21: Secondary outcome: number of participants requiring cardiopulmonary resuscitation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-005.21.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-005.22" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Comparison 5: Levosimendan versus standard cardiac care, Outcome 22: Secondary outcome: proportion of renal failure" data-id="CD013781-fig-0065" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-005.22.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-005.22.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.22</div> <div class="figure-caption"> <p>Comparison 5: Comparison 5: Levosimendan versus standard cardiac care, Outcome 22: Secondary outcome: proportion of renal failure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-005.22.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Comparison 6: Levosimendan versus milrinone, Outcome 1: Primary outcome: all‐cause mortality" data-id="CD013781-fig-0066" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Comparison 6: Levosimendan versus milrinone, Outcome 1: Primary outcome: all‐cause mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Comparison 6: Levosimendan versus milrinone, Outcome 2: Primary outcome: adverse events ‐ atrial fibrillation" data-id="CD013781-fig-0067" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Comparison 6: Levosimendan versus milrinone, Outcome 2: Primary outcome: adverse events ‐ atrial fibrillation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Comparison 6: Levosimendan versus milrinone, Outcome 3: Primary outcome: adverse events ‐ perioperative myocardial infarction" data-id="CD013781-fig-0068" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: Comparison 6: Levosimendan versus milrinone, Outcome 3: Primary outcome: adverse events ‐ perioperative myocardial infarction </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-006.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Comparison 6: Levosimendan versus milrinone, Outcome 4: Secondary outcome: length of ICU stay (days)" data-id="CD013781-fig-0069" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-006.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-006.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6: Comparison 6: Levosimendan versus milrinone, Outcome 4: Secondary outcome: length of ICU stay (days) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-006.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-006.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Comparison 6: Levosimendan versus milrinone, Outcome 5: Secondary outcome: mean arterial pressure" data-id="CD013781-fig-0070" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-006.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-006.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6: Comparison 6: Levosimendan versus milrinone, Outcome 5: Secondary outcome: mean arterial pressure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-006.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-006.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Comparison 6: Levosimendan versus milrinone, Outcome 6: Secondary outcome: duration of mechanical ventilation (hours)" data-id="CD013781-fig-0071" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-006.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-006.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6: Comparison 6: Levosimendan versus milrinone, Outcome 6: Secondary outcome: duration of mechanical ventilation (hours) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-006.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-006.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Comparison 6: Levosimendan versus milrinone, Outcome 7: Secondary outcome: number of participants requiring mechanical circulatory support" data-id="CD013781-fig-0072" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-006.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-006.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6: Comparison 6: Levosimendan versus milrinone, Outcome 7: Secondary outcome: number of participants requiring mechanical circulatory support </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-006.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-006.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Comparison 6: Levosimendan versus milrinone, Outcome 8: Secondary outcome: number of participants requiring additional inotropic drugs ‐ norepinephrine" data-id="CD013781-fig-0073" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-006.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-006.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.8</div> <div class="figure-caption"> <p>Comparison 6: Comparison 6: Levosimendan versus milrinone, Outcome 8: Secondary outcome: number of participants requiring additional inotropic drugs ‐ norepinephrine </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-006.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-006.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Comparison 6: Levosimendan versus milrinone, Outcome 9: Secondary outcome: number of participants requiring additional inotropic drugs ‐ dobutamine" data-id="CD013781-fig-0074" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-006.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-006.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.9</div> <div class="figure-caption"> <p>Comparison 6: Comparison 6: Levosimendan versus milrinone, Outcome 9: Secondary outcome: number of participants requiring additional inotropic drugs ‐ dobutamine </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-006.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 1: Primary outcome: all‐cause mortality" data-id="CD013781-fig-0075" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 1: Primary outcome: all‐cause mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 2: Primary outcome: incidence of LCOS" data-id="CD013781-fig-0076" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 2: Primary outcome: incidence of LCOS </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-007.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 3: Primary outcome: adverse events ‐ cardiogenic shock" data-id="CD013781-fig-0077" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-007.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 3: Primary outcome: adverse events ‐ cardiogenic shock </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-007.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 4: Primary outcome: adverse events ‐ atrial fibrillation" data-id="CD013781-fig-0078" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-007.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 4: Primary outcome: adverse events ‐ atrial fibrillation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-007.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 5: Primary outcome: adverse events ‐ perioperative myocardial infarction" data-id="CD013781-fig-0079" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-007.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 5: Primary outcome: adverse events ‐ perioperative myocardial infarction </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-007.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 6: Primary outcome: adverse events ‐ non‐embolic stroke or transient ischaemic attack" data-id="CD013781-fig-0080" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-007.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.6</div> <div class="figure-caption"> <p>Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 6: Primary outcome: adverse events ‐ non‐embolic stroke or transient ischaemic attack </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-007.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 7: Secondary outcome: length of hospital stay (days)" data-id="CD013781-fig-0081" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-007.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.7</div> <div class="figure-caption"> <p>Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 7: Secondary outcome: length of hospital stay (days) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-007.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 8: Secondary outcome: length of ICU stay (days)" data-id="CD013781-fig-0082" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-007.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.8</div> <div class="figure-caption"> <p>Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 8: Secondary outcome: length of ICU stay (days) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-007.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 9: Secondary outcome: cardiac index" data-id="CD013781-fig-0083" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-007.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.9</div> <div class="figure-caption"> <p>Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 9: Secondary outcome: cardiac index </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-007.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 10: Secondary outcome: mean arterial pressure" data-id="CD013781-fig-0084" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-007.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.10</div> <div class="figure-caption"> <p>Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 10: Secondary outcome: mean arterial pressure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-007.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 11: Secondary outcome: PCWP" data-id="CD013781-fig-0085" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-007.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.11</div> <div class="figure-caption"> <p>Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 11: Secondary outcome: PCWP </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-007.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 12: Secondary outcome: duration of mechanical ventilation (hours)" data-id="CD013781-fig-0086" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-007.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.12</div> <div class="figure-caption"> <p>Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 12: Secondary outcome: duration of mechanical ventilation (hours) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-007.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 13: Secondary outcome: proportion of weaning failure within 48 hours after extubation" data-id="CD013781-fig-0087" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-007.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.13</div> <div class="figure-caption"> <p>Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 13: Secondary outcome: proportion of weaning failure within 48 hours after extubation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-007.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 14: Secondary outcome: number of participants requiring mechanical circulatory support" data-id="CD013781-fig-0088" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-007.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.14</div> <div class="figure-caption"> <p>Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 14: Secondary outcome: number of participants requiring mechanical circulatory support </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-007.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 15: Secondary outcome: number of participants requiring additional inotropic drugs" data-id="CD013781-fig-0089" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-007.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.15</div> <div class="figure-caption"> <p>Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 15: Secondary outcome: number of participants requiring additional inotropic drugs </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-007.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 16: Secondary outcome: number of participants requiring additional inotropic drugs ‐ epinephrine" data-id="CD013781-fig-0090" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-007.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.16</div> <div class="figure-caption"> <p>Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 16: Secondary outcome: number of participants requiring additional inotropic drugs ‐ epinephrine </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-007.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 17: Secondary outcome: number of participants requiring additional inotropic drugs ‐ norepinephrine" data-id="CD013781-fig-0091" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-007.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.17</div> <div class="figure-caption"> <p>Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 17: Secondary outcome: number of participants requiring additional inotropic drugs ‐ norepinephrine </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-007.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 18: Secondary outcome: number of participants requiring additional inotropic drugs ‐ dopamine" data-id="CD013781-fig-0092" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-007.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.18</div> <div class="figure-caption"> <p>Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 18: Secondary outcome: number of participants requiring additional inotropic drugs ‐ dopamine </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-007.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 19: Secondary outcome: number of participants requiring additional inotropic drugs ‐ dobutamine" data-id="CD013781-fig-0093" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-007.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.19</div> <div class="figure-caption"> <p>Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 19: Secondary outcome: number of participants requiring additional inotropic drugs ‐ dobutamine </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-007.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 20: Secondary outcome: number of participants requiring additional inotropic drugs ‐ enoximone" data-id="CD013781-fig-0094" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-007.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.20</div> <div class="figure-caption"> <p>Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 20: Secondary outcome: number of participants requiring additional inotropic drugs ‐ enoximone </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0095"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-007.21" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 21: Secondary outcome: number of participants requiring additional inotropic drugs ‐ milrinone" data-id="CD013781-fig-0095" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.21.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-007.21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.21</div> <div class="figure-caption"> <p>Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 21: Secondary outcome: number of participants requiring additional inotropic drugs ‐ milrinone </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0095">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.21.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0096"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-007.22" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 22: Secondary outcome: number of participants requiring additional inotropic drugs ‐ nitroprusside" data-id="CD013781-fig-0096" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.22.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-007.22.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.22</div> <div class="figure-caption"> <p>Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 22: Secondary outcome: number of participants requiring additional inotropic drugs ‐ nitroprusside </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0096">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.22.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0097"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-007.23" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 23: Secondary outcome: number of participants requiring additional inotropic drugs ‐ ephedrine" data-id="CD013781-fig-0097" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.23.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-007.23.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.23</div> <div class="figure-caption"> <p>Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 23: Secondary outcome: number of participants requiring additional inotropic drugs ‐ ephedrine </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0097">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.23.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0098"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-007.24" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 24: Secondary outcome: number of participants requiring additional inotropic drugs ‐ phenylephrine" data-id="CD013781-fig-0098" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.24.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-007.24.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.24</div> <div class="figure-caption"> <p>Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 24: Secondary outcome: number of participants requiring additional inotropic drugs ‐ phenylephrine </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0098">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.24.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0099"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-007.25" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 25: Secondary outcome: number of participants requiring cardiac transplantation" data-id="CD013781-fig-0099" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.25.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-007.25.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.25</div> <div class="figure-caption"> <p>Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 25: Secondary outcome: number of participants requiring cardiac transplantation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0099">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.25.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0100"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-007.26" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 26: Secondary outcome: number of participants requiring cardiopulmonary resuscitation" data-id="CD013781-fig-0100" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.26.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-007.26.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.26</div> <div class="figure-caption"> <p>Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 26: Secondary outcome: number of participants requiring cardiopulmonary resuscitation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0100">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.26.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-007.27" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 27: Secondary outcome: proportion of renal failure" data-id="CD013781-fig-0101" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.27.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-007.27.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.27</div> <div class="figure-caption"> <p>Comparison 7: Comparison 7: Levosimendan versus placebo, Outcome 27: Secondary outcome: proportion of renal failure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-007.27.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Subgroup analysis: Regimen of the control group ‐ primary outcomes, Outcome 1: Adverse event: atrial fibrillation" data-id="CD013781-fig-0102" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Subgroup analysis: Regimen of the control group ‐ primary outcomes, Outcome 1: Adverse event: atrial fibrillation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Subgroup analysis: Timing of the drug administration ‐ primary outcomes, Outcome 1: All‐cause mortality" data-id="CD013781-fig-0103" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: Subgroup analysis: Timing of the drug administration ‐ primary outcomes, Outcome 1: All‐cause mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-009.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Subgroup analysis: Timing of the drug administration ‐ primary outcomes, Outcome 2: Incidence of LCOS" data-id="CD013781-fig-0104" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-009.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-009.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9: Subgroup analysis: Timing of the drug administration ‐ primary outcomes, Outcome 2: Incidence of LCOS </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-009.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0105"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-009.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Subgroup analysis: Timing of the drug administration ‐ primary outcomes, Outcome 3: Adverse events: atrial fibrillation" data-id="CD013781-fig-0105" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-009.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-009.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9: Subgroup analysis: Timing of the drug administration ‐ primary outcomes, Outcome 3: Adverse events: atrial fibrillation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0105">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-009.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0106"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-009.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Subgroup analysis: Timing of the drug administration ‐ primary outcomes, Outcome 4: Adverse events: perioperative myocardial infarction" data-id="CD013781-fig-0106" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-009.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-009.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.4</div> <div class="figure-caption"> <p>Comparison 9: Subgroup analysis: Timing of the drug administration ‐ primary outcomes, Outcome 4: Adverse events: perioperative myocardial infarction </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0106">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-009.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0107"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-009.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Subgroup analysis: Timing of the drug administration ‐ primary outcomes, Outcome 5: Adverse events: non‐embolic stroke or transient ischaemic attack" data-id="CD013781-fig-0107" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-009.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-009.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.5</div> <div class="figure-caption"> <p>Comparison 9: Subgroup analysis: Timing of the drug administration ‐ primary outcomes, Outcome 5: Adverse events: non‐embolic stroke or transient ischaemic attack </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0107">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-009.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0108"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-010.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Subgroup analysis: Effect of the administration protocol ‐ primary outcomes, Outcome 1: All‐cause mortality" data-id="CD013781-fig-0108" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-010.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-010.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10: Subgroup analysis: Effect of the administration protocol ‐ primary outcomes, Outcome 1: All‐cause mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0108">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-010.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0109"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-010.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Subgroup analysis: Effect of the administration protocol ‐ primary outcomes, Outcome 2: Incidence of LCOS" data-id="CD013781-fig-0109" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-010.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-010.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10: Subgroup analysis: Effect of the administration protocol ‐ primary outcomes, Outcome 2: Incidence of LCOS </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0109">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-010.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0110"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-010.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Subgroup analysis: Effect of the administration protocol ‐ primary outcomes, Outcome 3: Adverse events: atrial fibrillation" data-id="CD013781-fig-0110" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-010.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-010.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10: Subgroup analysis: Effect of the administration protocol ‐ primary outcomes, Outcome 3: Adverse events: atrial fibrillation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0110">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-010.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0111"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-010.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Subgroup analysis: Effect of the administration protocol ‐ primary outcomes, Outcome 4: Adverse events: Perioperative myocardial infarction" data-id="CD013781-fig-0111" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-010.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-010.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.4</div> <div class="figure-caption"> <p>Comparison 10: Subgroup analysis: Effect of the administration protocol ‐ primary outcomes, Outcome 4: Adverse events: Perioperative myocardial infarction </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0111">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-010.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013781-fig-0112"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/urn:x-wiley:14651858:media:CD013781:CD013781-CMP-010.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Subgroup analysis: Effect of the administration protocol ‐ primary outcomes, Outcome 5: Adverse events: non‐embolic stroke or transient ischaemic attack" data-id="CD013781-fig-0112" src="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-010.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_t/tCD013781-CMP-010.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.5</div> <div class="figure-caption"> <p>Comparison 10: Subgroup analysis: Effect of the administration protocol ‐ primary outcomes, Outcome 5: Adverse events: non‐embolic stroke or transient ischaemic attack </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-fig-0112">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/media/CDSR/CD013781/image_n/nCD013781-CMP-010.05.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013781-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Levosimendan compared to standard cardiac care</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patients/population:</b> adults (&gt; 18 years) undergoing cardiac surgery </p> <p><b>Intervention:</b> levosimendan (started for preventive reasons) </p> <p><b>Comparison:</b> standard cardiac care </p> <p><b>Setting of interest:</b> hospital‐based randomised controlled trials conducted in Turkey or India </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with standard cardiac care</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with levosimendan</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> (number of deaths within 30 days) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>115 per 1000<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>42 per 1000</b> </p> <p>(15 to 120)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.37</b><br/>(0.13 to 1.04) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>208 (3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>low<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of LCOS</b> (number of events within 48 hours post surgery) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>192 per 1000<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>94 per 1000</b> </p> <p>(27 to 332)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.49</b><br/>(0.14 to 1.73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>208 (3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>very low<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events: cardiogenic shock</b> (number of events within hospital stay) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>125 per 1000<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>79 per 1000</b> </p> <p>(27 to 226)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.62</b><br/>(0.22 to 1.81) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>128 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>very low<sup>e</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Length of ICU stay</b> (in days within ICU care) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean length of ICU stay across control groups was from 1.40 to 3.67 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean length of ICU stay in the intervention group was 0.33 higher (1.16 lower to 1.83 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>very low<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of mechanical ventilation</b> (in hours within ICU care) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean duration of mechanical ventilation in the control group was 83.2 hours</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean duration of mechanical ventilation in the intervention group was 3.40 hours lower (11.50 lower to 4.70 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>128 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>very low<sup>e</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants requiring mechanical circulatory support</b> (number of events within hospital stay) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>192 per 1000<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>169 per 1000</b> </p> <p>(96 to 298)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.88</b><br/>(0.50 to 1.55) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>208 (3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>low<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI</b> : confidence interval; <b>LCOS:</b> low cardiac output syndrome; <b>ICU:</b> intensive care unit; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE working group grades of evidence</p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Control group risk estimate comes from the control group risk in included studies.<br/><sup>b</sup>Control group risk estimate comes from the control group risk in a small included study.<br/><sup>c</sup>Downgraded 1 level for risk of bias due to inadequate methods of sequence generation and lack of blinding, and 1 level for imprecision due to the optimal information size criterion not being met.<br/><sup>d</sup>Downgraded 1 level for risk of bias due to inadequate methods of sequence generation and lack of blinding, 1 level for imprecision due to the optimal information size criterion not being met, and 1 level for inconsistency due to heterogeneity according to the I<sup>2</sup> statistic.<br/><sup>e</sup>Downgraded 1 level for risk of bias due to inadequate methods of sequence generation and lack of blinding, and 2 levels for imprecision due to the optimal information size criterion not being met (data based on a single small study). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Levosimendan compared to standard cardiac care</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/full#CD013781-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013781-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Levosimendan compared to placebo</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="bottom"> <p><b>Patients/population:</b> adults (&gt; 18 years) undergoing cardiac surgery </p> <p><b>Intervention:</b> levosimendan (started for preventive reasons) </p> <p><b>Comparison:</b> placebo </p> <p><b>Setting of interest:</b> hospital‐based randomised controlled trials conducted in Europe, China, or India </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with levosimendan</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> (number of deaths within 30 days) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66 per 1000<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>43 per 1000</b> </p> <p>(28 to 64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.65</b><br/>(0.43 to 0.97) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2347 (14 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>moderate<sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of LCOS</b> (number of events within 48 hours post surgery) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>238 per 1000<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>102 per 1000</b> </p> <p>(60 to 176)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.43</b><br/>(0.25 to 0.74) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1724 (6 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>low<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events: cardiogenic shock</b> (number of events within hospital stay) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>63 per 1000<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>41 per 1000</b> </p> <p>(25 to 66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.65</b><br/>(0.40 to 1.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1212 (3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>high</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Length of ICU stay</b> (in days within ICU care) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean length of ICU stay across control groups was from 1.07 to 8.15 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean length of ICU stay in the intervention group was 1.00 lower (1.63 lower to 0.37 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>572 (7 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>very low<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of mechanical ventilation</b> (in hours within ICU care) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean duration of mechanical ventilation across control groups was between 5.67 and 157.44 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean duration of mechanical ventilation in the intervention group was 8.03 lower (13.17 lower to 2.90 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>572 (7 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>very low<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants requiring mechanical circulatory support</b> (number of events within hospital stay) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>145 per 1000<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>68 per 1000</b> (35 to 132) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.47</b><br/>(0.24 to 0.91) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1881 (10 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>low<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI</b> : confidence interval; <b>LCOS:</b> low cardiac output syndrome; <b>ICU:</b> intensive care unit; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE working group grades of evidence</p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Control group risk estimate comes from the control group risk in included studies.<br/><sup>b</sup>Downgraded 1 level for risk of bias due to inadequate methods of sequence generation and lack of blinding.<br/><sup>c</sup>Downgraded 1 level for risk of bias due to inadequate methods of sequence generation and 1 level for inconsistency due to heterogeneity according to the I<sup>2</sup> statistic.<br/><sup>d</sup>Downgraded 1 level for risk of bias due to inadequate methods of sequence generation and lack of blinding, and 2 levels for inconsistency due to heterogeneity according to the I<sup>2</sup> statistic. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Levosimendan compared to placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/full#CD013781-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013781-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Comparison 1: Amrinone versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Secondary outcome: cardiac index (postoperative nadir) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.33, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Comparison 1: Amrinone versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013781-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Comparison 2: Dopamine versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Primary outcome: incidence of LCOS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Primary outcome: adverse events ‐ atrial fibrillation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.44, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Primary outcome: adverse events ‐ perioperative myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Secondary outcome: length of hospital stay (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐1.54, 1.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Secondary outcome: mean arterial pressure (24 hours after surgery) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [‐1.36, 7.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Secondary outcome: duration of mechanical ventilation (hours) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐1.11, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Secondary outcome: number of participants requiring additional inotropic drugs ‐ dopamine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.01, 1.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Secondary outcome: proportion of renal failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.01, 1.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Comparison 2: Dopamine versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013781-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Comparison 3: Milrinone versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Primary outcome: all‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.06, 15.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Primary outcome: adverse events ‐ cardiogenic shock <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.06, 15.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Primary outcome: adverse events ‐ atrial fibrillation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.12, 3.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Primary outcome: adverse events ‐ perioperative myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.15, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Primary outcome: adverse events ‐ non‐embolic stroke or transient ischaemic attack <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Secondary outcome: length of ICU stay (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.15 [‐0.40, 0.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Secondary outcome: cardiac index <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.1 End of surgery cardiac index</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.22, 0.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.2 Cardiac index 6 hours after surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.29, 0.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.3 Cardiac index 12 hours after surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.25, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.8 Secondary outcome: mean arterial pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.1 Baseline mean arterial pressure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [‐2.23, 6.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.2 End of surgery mean arterial pressure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.66 [‐5.43, 2.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.3 Mean arterial pressure 6 hours after surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.00 [‐9.82, 3.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.4 Mean arterial pressure 12 hours after surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.00 [‐8.19, 6.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.9 Secondary outcome: PCWP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9.1 End of surgery PCWP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.00 [‐6.74, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9.2 PCWP 6 hours after surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.00 [‐7.16, ‐0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9.3 PCWP 12 hours after surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.00 [‐8.00, 2.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.10 Secondary outcome: duration of mechanical ventilation (hours) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.98 [‐7.28, ‐0.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.11 Secondary outcome: proportion of weaning failure within 48 hours of extubation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.37, 3.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.12 Secondary outcome: number of participants requiring mechanical circulatory support <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>204</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.13, 1.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.13 Secondary outcome: number of participants requiring additional inotropic drugs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>204</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.65, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.14 Secondary outcome: number of participants requiring additional inotropic drugs ‐ epinephrine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.49, 3.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.15 Secondary outcome: number of participants requiring additional inotropic drugs ‐ norepinephrine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.39, 2.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.16 Secondary outcome: number of participants requiring additional inotropic drugs ‐ dobutamine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.94 [0.18, 20.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.17 Secondary outcome: number of participants requiring additional inotropic drugs ‐ phenylephrine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 7.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.18 Secondary outcome: proportion of renal failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.08, 2.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Comparison 3: Milrinone versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013781-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Comparison 4: Levosimendan versus dobutamine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Primary outcome: adverse events ‐ atrial fibrillation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.16, 1.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Secondary outcome: length of hospital stay (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.97 [‐1.28, ‐0.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Secondary outcome: length of ICU stay (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.29 [‐0.51, ‐0.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Secondary analysis: cardiac index <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.1 Baseline cardiac index</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.08, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.2 Cardiac index after 6 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.15, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.3 Cardiac index after 12 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [‐0.02, 0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.4 Cardiac index after 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.35, 0.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Secondary outcome: mean arterial pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.1 Baseline mean arterial pressure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐2.11, 2.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.2 Mean arterial pressure after 6 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.27 [‐14.18, ‐4.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.3 Mean arterial pressure after 12 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.17 [‐10.85, ‐7.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.4 Mean arterial pressure after 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.42 [‐12.52, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.6 Secondary analysis: PCWP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.1 Baseline PCWP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [‐0.07, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.2 PCWP after 6 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.47 [‐3.04, ‐1.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.3 PCWP after 12 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.42 [‐2.90, ‐1.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.4 PCWP after 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.45 [‐1.92, ‐0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.7 Secondary outcome: duration of mechanical ventilation (hours) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.04 [‐1.72, ‐0.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.8 Secondary outcome: number of participants requiring mechanical circulatory support <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.06, 15.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.9 Secondary outcome: number of participants requiring additional inotropic drugs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.25 [2.05, 13.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.10 Secondary outcome: number of participants requiring additional inotropic drugs ‐ epinephrine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [0.32, 8.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.11 Secondary outcome: number of participants requiring additional inotropic drugs ‐ norepinephrine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.52 [1.21, 10.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Comparison 4: Levosimendan versus dobutamine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013781-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Comparison 5: Levosimendan versus standard cardiac care</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Primary outcome: all‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.13, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Primary outcome: incidence of LCOS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.14, 1.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Primary outcome: adverse events ‐ cardiogenic shock <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.22, 1.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Primary outcome: adverse events ‐ atrial fibrillation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.11, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 Primary outcome: adverse events ‐ perioperative myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.22, 1.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.6 Primary outcome: adverse events ‐ non‐embolic stroke or transient ischaemic attack <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.27, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.7 Secondary outcome: length of hospital stay (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [‐1.50, 2.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.8 Secondary outcome: length of ICU stay (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [‐1.16, 1.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.9 Secondary outcome: cardiac index <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.9.1 Baseline cardiac index</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.10, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.9.2 End‐of‐surgery cardiac index</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.32, 0.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.9.3 Cardiac index 6 hours after surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.64, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.9.4 Cardiac index 12 hours after surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.34, 0.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.9.5 Cardiac index 24 hours after surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.35, 0.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.10 Secondary outcome: mean arterial pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.10.1 Baseline mean arterial pressure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [‐0.78, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.10.2 End of surgery mean arterial pressure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.39 [‐8.74, 13.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.10.3 Mean arterial pressure 6 hours after surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.11 [‐2.36, 0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.10.4 Mean arterial pressure 12 hours after surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.07 [1.03, 7.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.10.5 Mean arterial pressure 24 hours after surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.54 [‐0.06, 7.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.11 Secondary outcome: PCWP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.11.1 Baseline PCWP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [‐0.63, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.11.2 End of surgery PCWP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.07 [‐3.06, ‐1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.11.3 PCWP 6 hours after surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.21 [‐2.22, ‐0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.11.4 PCWP 12 hours after surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.04 [‐1.69, ‐0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.11.5 PCWP 24 hours after surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.73 [‐1.48, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.12 Secondary outcome: duration of mechanical ventilation (hours) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.40 [‐11.50, 4.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.13 Secondary outcome: proportion of weaning failure within 48 hours of extubation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.36, 1.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.14 Secondary outcome: number of participants requiring mechanical circulatory support <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.50, 1.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.15 Secondary outcome: number of participants requiring additional inotropic drugs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [1.13, 2.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.16 Secondary outcome: number of participants requiring additional inotropic drugs ‐ epinephrine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.41, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.17 Secondary outcome: number of participants requiring additional inotropic drugs ‐ norepinephrine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.58, 2.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.18 Secondary outcome: number of participants requiring additional inotropic drugs ‐ dopamine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.56, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.19 Secondary outcome: number of participants requiring additional inotropic drugs ‐ dobutamine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.89, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.20 Secondary outcome: number of participants requiring cardiac transplantation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.21 Secondary outcome: number of participants requiring cardiopulmonary resuscitation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.13, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.22 Secondary outcome: proportion of renal failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.22, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Comparison 5: Levosimendan versus standard cardiac care</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013781-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Comparison 6: Levosimendan versus milrinone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Primary outcome: all‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.01, 2.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Primary outcome: adverse events ‐ atrial fibrillation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.38, 1.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Primary outcome: adverse events ‐ perioperative myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.4 Secondary outcome: length of ICU stay (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.69 [‐1.31, ‐0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.5 Secondary outcome: mean arterial pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5.1 Baseline mean arterial pressure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [‐4.60, 8.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5.2 End of surgery mean arterial pressure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [‐1.53, 7.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5.3 Mean arterial pressure 6 hours after surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.00 [‐10.16, 4.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5.4 Mean arterial pressure 12 hours after surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐6.48, 6.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5.5 Mean arterial pressure 24 hours after surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.00 [‐7.01, 3.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.6 Secondary outcome: duration of mechanical ventilation (hours) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.06 [‐10.19, ‐3.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.7 Secondary outcome: number of participants requiring mechanical circulatory support <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.09, 3.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.8 Secondary outcome: number of participants requiring additional inotropic drugs ‐ norepinephrine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.88, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.9 Secondary outcome: number of participants requiring additional inotropic drugs ‐ dobutamine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.88, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Comparison 6: Levosimendan versus milrinone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013781-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Comparison 7: Levosimendan versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Primary outcome: all‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2347</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.43, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Primary outcome: incidence of LCOS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1724</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.25, 0.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.3 Primary outcome: adverse events ‐ cardiogenic shock <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.40, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.4 Primary outcome: adverse events ‐ atrial fibrillation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1934</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.82, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.5 Primary outcome: adverse events ‐ perioperative myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1838</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.61, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.6 Primary outcome: adverse events ‐ non‐embolic stroke or transient ischaemic attack <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1786</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.58, 1.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.7 Secondary outcome: length of hospital stay (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>422</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.80 [‐3.27, ‐0.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.8 Secondary outcome: length of ICU stay (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>572</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.00 [‐1.63, ‐0.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.9 Secondary outcome: cardiac index <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.9.1 Baseline cardiac index</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>456</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.17, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.9.2 End of surgery cardiac index</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [‐0.20, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.9.3 Cardiac index 6 hours after surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.28, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.9.4 Cardiac index 12 hours after surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.23, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.9.5 Cardiac index 24 hours after surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>456</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.06, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.10 Secondary outcome: mean arterial pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.10.1 Baseline mean arterial pressure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.91 [‐3.19, 9.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.10.2 End of surgery mean arterial pressure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>404</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.06 [‐6.50, 2.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.10.3 Mean arterial pressure 6 hours after surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>374</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.81 [‐6.08, ‐3.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.10.4 Mean arterial pressure 12 hours after surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>374</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.57 [‐9.19, 0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.10.5 Mean arterial pressure 24 hours after surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>466</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.19 [‐5.84, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.11 Secondary outcome: PCWP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.11.1 Baseline PCWP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [‐1.02, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.11.2 End of surgery PCWP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.63 [‐3.85, 0.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.11.3 PCWP 6 hours after surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [‐0.82, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.11.4 PCWP 12 hours after surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.35 [‐4.05, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.11.5 PCWP 24 hours after surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.33 [‐2.50, ‐0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.12 Secondary outcome: duration of mechanical ventilation (hours) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>572</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.03 [‐13.17, ‐2.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.13 Secondary outcome: proportion of weaning failure within 48 hours after extubation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.23, 0.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.14 Secondary outcome: number of participants requiring mechanical circulatory support <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1881</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.24, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.15 Secondary outcome: number of participants requiring additional inotropic drugs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1612</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.28, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.16 Secondary outcome: number of participants requiring additional inotropic drugs ‐ epinephrine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>658</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.26, 1.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.17 Secondary outcome: number of participants requiring additional inotropic drugs ‐ norepinephrine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>678</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [1.00, 1.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.18 Secondary outcome: number of participants requiring additional inotropic drugs ‐ dopamine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.25, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.19 Secondary outcome: number of participants requiring additional inotropic drugs ‐ dobutamine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.22, 0.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.20 Secondary outcome: number of participants requiring additional inotropic drugs ‐ enoximone <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.31, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.21 Secondary outcome: number of participants requiring additional inotropic drugs ‐ milrinone <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.03, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.22 Secondary outcome: number of participants requiring additional inotropic drugs ‐ nitroprusside <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.02, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.23 Secondary outcome: number of participants requiring additional inotropic drugs ‐ ephedrine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.80, 1.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.24 Secondary outcome: number of participants requiring additional inotropic drugs ‐ phenylephrine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.88, 2.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.25 Secondary outcome: number of participants requiring cardiac transplantation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>648</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.03, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.26 Secondary outcome: number of participants requiring cardiopulmonary resuscitation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.27 Secondary outcome: proportion of renal failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1819</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.43, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Comparison 7: Levosimendan versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013781-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Subgroup analysis: Regimen of the control group ‐ primary outcomes</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Adverse event: atrial fibrillation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.1 Levosimendan vs active controlled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.38, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.2 Levosimendan vs passive controlled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.75, 1.19]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Subgroup analysis: Regimen of the control group ‐ primary outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013781-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Subgroup analysis: Timing of the drug administration ‐ primary outcomes</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.1 Preoperative period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.14, 0.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.2 Perioperative/anaesthesia induction period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1633</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.60, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.2 Incidence of LCOS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2.1 Preoperative period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>342</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.22, 0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2.2 Perioperative/anaesthesia induction period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1382</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.17, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.3 Adverse events: atrial fibrillation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3.1 Preoperative period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.37, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3.2 Perioperative/anaesthesia induction period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1540</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [1.02, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.4 Adverse events: perioperative myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4.1 Preoperative period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>324</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.04, 2.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4.2 Perioperative/anaesthesia induction period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1514</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.75, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.5 Adverse events: non‐embolic stroke or transient ischaemic attack <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5.1 Preoperative period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>374</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.34, 1.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5.2 Perioperative/anaesthesia induction period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1412</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.34, 2.08]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Subgroup analysis: Timing of the drug administration ‐ primary outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013781-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Subgroup analysis: Effect of the administration protocol ‐ primary outcomes</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1.1 With bolus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>802</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.26, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1.2 Without bolus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1823</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.44, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.2 Incidence of LCOS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.1 With bolus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>600</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.21, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.2 Without bolus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.52, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.3 Adverse events: atrial fibrillation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3.1 With bolus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>706</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.49, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3.2 Without bolus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1586</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.74, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.4 Adverse events: Perioperative myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4.1 With bolus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>682</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.34, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4.2 Without bolus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.75, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.5 Adverse events: non‐embolic stroke or transient ischaemic attack <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5.1 With bolus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>580</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.43, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5.2 Without bolus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.34, 1.84]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Subgroup analysis: Effect of the administration protocol ‐ primary outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013781.pub2/references#CD013781-tbl-0012">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013781.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD013781-note-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD013781-note-0011">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013781-note-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013781-note-0010">Français</a> </li> <li class="section-language"> <a class="" href="ru#CD013781-note-0008">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013781-note-0007">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013781\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013781\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013781\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013781\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013781\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013781\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013781\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013781\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013781\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013781\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013781\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013781\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013781\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013781\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013781\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013781\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013781\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013781\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=xNbeAU8n&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013781.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013781.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013781.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013781.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013781.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716759944"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013781.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716759947"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013781.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918da75c6c7c1be3',t:'MTc0MDcxNjc2MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 